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ABSTRACT SUMMARY 
The aim of this thesis is to investigate the diagnosis and management of endometriosis 
amongst women with pain or subfertility through a series of systematic reviews and 
primary studies. I will also evaluate the quality of information available to researchers, 
clinicians and patients on the management of endometriosis. 
Endometriosis is the presence of endometrial like cells outside the uterus, commonly 
within the pelvis. The disease is characterised by benign fibrosis and tissue invasion of 
endometrial like cells in surrounding structures such as the peritoneum, ovary, bowel, 
and bladder. The commonest symptoms reported by women with endometriosis are pain 
and subfertility. Non-invasive diagnostic tools have poor accuracy with the current gold 
standard diagnosis of laparoscopic surgery, biopsy and histological confirmation.  
I performed a diagnostic meta-analysis of the most researched diagnostic marker, 
Cancer Antigen125 (CA-125), establishing a cut-off value that had limited sensitivity but 
high specificity with potential as a rule-in test. I tested this in a multicentre cohort study of 
patients with pain and subfertility to assess the accuracy (CA-125) at the newly 
established cut off value. 
A systematic review assessing the reporting of outcomes and outcome measures 
identified 3 commonly reported outcomes: dysmenorrhoea, dyspareunia and pregnancy. 
There was heterogeneous outcome reporting across all Randomised control trials (RCT). 
A systematic review of international and national endometriosis guidelines revealed poor 
evidence synthesis from treatment effectiveness studies into guideline formation.   
A systematic and literature review of treatment effectiveness highlighted significant 
harms associated with ovarian surgery and oophorectomy.  
There is need for further research to develop accurate non-invasive diagnostic tests for 
endometriosis. The development of a collection of well-defined prioritised clinical 
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outcomes will augment the usefulness of research to enhance the care for patients with 
endometriosis.  
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AIMS / PROGRESS 
 
1. To review the current non-invasive diagnostic strategies for endometriosis  
2. To assess the diagnostic accuracy of CA-125 for the detection of histologically 
confirmed endometriosis  
3. To assess the diagnostic accuracy of CA-125 for the detection of endometriosis 
in a cohort of women with pain or subfertility 
4. To assess the relationship between quality of outcomes reported, study quality 
and journal impact factor in trials of endometriosis  
5. To assess the online information available to patients regarding Endometriosis  
6. To assess the quality and variation of national and international endometriosis 
guidelines.  
7. To review the risks of surgery for women with endometrioma. 
8. To assess the long-term risks of female surgical castration for the management 
of endometriosis. 
9. To assess the role of music in the recovery following endometriosis surgery 
10. Discussion 
METHODS 
- Literature reviews to meet objective 1 & 7 
- Systematic review 2,4,5,6,8,9 
- Prospective observational study to meet objective 3 
 
 
 
 12. 
RESULTS 
1. There is no highly sensitive and specific non-invasive diagnostic marker for 
endometriosis. The most commonly reported non-invasive diagnostic test was 
CA-125.  
2. 21 Studies met criteria for inclusion. Thirteen studies produced a summary of 
pooled estimates based on a cut-off value ≥ 30 iu/ml. The sensitivity and 
specificity of CA-125 ≥ 30 iu/ml for the detection of histologically confirmed 
endometriosis was 52% (CI 38–66%) and 93% (CI 89–95%). 
3. 58 participants with pelvic pain and or subfertility were recruited. Using a pre-
defined cut-off value of CA-125 ≥ 30 iu/ml the sensitivity and specificity were 
57% (95% CI 37.4 – 74.5%) and 96% (95% CI 81.7 – 99.9%). The area under 
the curve for positive CA-125 test was 0.85 demonstrating high test accuracy.  
4. 54 Randomised controlled trials evaluating surgical interventions for the 
treatment of endometriosis were identified. These studies reported a total of 
164 outcomes using 113 outcome measures. The 3 most commonly reported 
primary outcomes were dysmenorrhea (10 outcome measures; 23 trials), 
dyspareunia (11 outcome measures; 21 trials), and pregnancy (3 outcome 
measures; 26 trials). The median quality of outcome reporting was 3 
(interquartile range 4 - 2) and methodological quality 3 (interquartile range 5 - 
2). Multivariate linear regression demonstrated a correlation between 
outcome reporting quality with methodological quality (β=0.325; p=0.038) and 
year of publication (β=0.067; p=0.040). No relationship was demonstrated 
between outcome reporting quality with journal impact factor (Rho=0.190; 
p=0.212) or commercial funding (p=0.370) 
5. We identified 750 websites, of which 54 were included in the quantitative 
analysis. The median values with interquartile ranges are: accuracy 5 (IQR 2 
- 8.8); quality 44 (IQR 37.3 - 51); readability 38.2 (IQR 30.7 – 48.0), and 
credibility 5 (IQR 4 - 7).  No website scored highly across all four domains. 
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6. We include two international and five national guidelines.  No guideline 
followed the standardised guideline development methods (AGREE-II). 
Guidelines performed poorly in the domains of stakeholder involvement and 
rigor of development and very poorly in the domains of applicability and 
editorial independence. The European Society of Human Reproduction and 
Embryology (ESHRE) was objectively evaluated as the highest quality 
guideline (methodological quality score: 88/100).  One hundred and fifty-two 
different recommendations were made, 10 (7%) recommendations were 
comparable across guidelines. 
7. Studies reported the risks of ovarian surgery for future fertility using surrogate 
markers including: antral follicle count; follicular stimulating hormone; anti-
Müllerian hormone (AMH); and dosage of gonadotropins. Surgery for ovarian 
endometriomas can increase spontaneous conception however, it can also 
reduce ovarian reserve with increasing numbers of procedures. 
8. No studies examined women with endometriosis. The criteria were extended 
to all benign gynaecological disease. Of 13,470 citations, there were 48 
relevant studies (1,272,071 women). Hysterectomy with bilateral 
oophorectomy (498,603 women) vs without (773,468 women) was associated 
with increase in stroke (RR 1.09, 95% CI 1.03 – 1.16; baseline risk = 35%; 
number needed to harm [NNH] = 32) and anxiety (RR 1.26, 95% CI 1.06 – 
1.51; baseline risk =5.9%; NNH = 65); and decrease in ovarian cancer (RR 
0.09, 95% CI 0.04 – 0.19; baseline risk = 2.5%; number needed to treat [NNT] 
= 44); and breast cancer (hazard ratio 0.85, 95% CI 0.73 – 0.99; baseline risk 
= 12%; NNT = 55).  
9. No studies assessed endometriosis surgery and the criteria was expanded to 
include all gynaecological surgery. Ten studies were included assessing 1056 
participants with size varying between 26 - 372 participants.  Choice of music, 
timing and duration varied. Comparators included routine care, headphones 
with no music, and recording of operating room noise. Postoperatively music 
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reduced anxiety (Standard mean Difference (SMD) -0.56 (95% CIs (95%CI) -
1.02 to -0.02). There were non-significant improvements in pain SMD -0.37 
(95%CI -0.80 to 0.06), and analgesia use SMD -0.32 (95%CI -0.96 to 0.33) 
and increased patient satisfaction SMD 0.52 (95%CI -0.98 to 2.03), and 
length of stay (MD -0.19 (95%CI –0.71 to 0.32)).  
 
 
CONCLUSIONS 
 
1. There is currently no single or multi-tiered, non-invasive, diagnostic test for 
the detection of endometriosis. CA-125 is the most commonly evaluated 
marker with limited sensitivity. This has been evaluated against a historic 
reference standard (visual diagnosis at surgery) associated with significant 
diagnostic inaccuracy. 
2. CA-125 ≥ 30 iu/ml has a high specificity for the detection of histologically 
confirmed endometriosis. This enables its use as a rule-in test for 
endometriosis. The sensitivity is poor and a negative test does not exclude 
disease. 
3. Amongst women with pelvic pain and or subfertility in the absence of imaging 
or historical gynaecological disease, there is a very high positive predictive 
value for CA-125 ≥ 30 iu/ml. This demonstrates a role for CA-125 as a rule-in 
test. The sensitivity is poor and a negative test does not exclude disease.  
4. There is wide variation in the outcomes reported within endometriosis trials. 
This prohibits the combination and analysis of results limiting usefulness of 
research to improve patient care. There is need for a core outcome set within 
endometriosis trials. 
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5. Websites providing information for patients typically perform poorly across the 
domains of quality, accuracy, credibility and readability. Healthcare 
professionals, and the wider community, should inform women with 
endometriosis of the risk of outdated, inaccurate, or even dangerous 
information online. 
6. There is substantial variation in the methodological quality of endometriosis 
guidelines. Future guidelines should be developed with reference to high 
quality methods, in consultation with key stakeholders including women with 
endometriosis, ensuring their scope can truly inform clinical practice and 
eliminate unwarranted and unjustified variation in clinical practice.  
7. There are significant risks to ovarian reserve associated with repeated or 
bilateral ovarian surgery for endometrioma. The decision should be made on 
a case-by-case basis after fully informed consent with the risks to ovarian 
reserve being discussed clearly. There is a shift towards performing In Vitro 
Fertilisation (IVF) without removing ovarian endometrioma amongst women 
with subfertility. 
8. There are significant cardiovascular and psychiatric risks associated with 
hysterectomy and bilateral oophorectomy compared to hysterectomy alone. 
The rate of breast and ovarian cancer is reduced. 
9.  Listening to music following gynaecological surgery offers a significant 
improvement in pain. There are non-significant improvements in anxiety, 
satisfaction, and length of stay compared with controls. This is likely to be the 
case for endometriosis surgery. 
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SYNOPSIS 
This thesis investigates the diagnostic, therapeutic and methodological challenges faced 
by clinicians, researchers, and importantly, patients managing endometriosis. It 
evaluates the diagnostic value of the commonest current non-invasive biomarker marker; 
CA-125. I assess the impact of intra and post-operative surgical treatment options for the 
management of endometriosis along with quantifying the quality of current research and 
information readily available to patients, researchers, and clinicians.  
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CHAPTER 1: 
BACKGROUND  
1.1 THE HISTORY AND ORIGINS OF ENDOMETRIOSIS 
The discovery of endometriosis in 1860 was preceded by the changes brought about by 
a little known poet turned scientist, Johann Wolfgang von Goethe (1749-1832). This 
German artist and poet took the principles he learnt in studying works of art and 
translated these to become principles of science. He was described as observing 
science through the eye of an artist. His strength in the field of observational science 
inspired others including Johannes Peter Müller. Müller followed the medical path to 
become a pathologist and most notably writing and describing the embryological origins 
of the eponymously named Müllerian ducts and their malformations (1). At the same time 
Carl von Rokitansky was working in the pathology department of Vienna’s largest 
hospital for Johann Wagner. Rokitansky collected, analysed and correlated pathological 
observations from the many thousands of autopsies he were to perform over the 
subsequent two decades. He was the first to accurately describe diseases and their 
processes, including that of Müllerian agenesis which would over time become known as 
Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome (Figure 1). The absence of 
Müllerian tissue was well described when in 1860 Rokitansky were to observe the 
presence of ectopic Müllerian tissue within the pelvis and the ovaries in association with 
a normally developed uterus. Rokitansky observed three subtle forms of ectopic 
Müllerian tissue. The first description is that of lesions invading the myometrial tissue 
which he named ‘Sarcoma adenoids uterinium’. Secondly, he noted that abnormal 
lesions would invade into endometrial cavity forming a polyp he described ‘cystosarcoma 
adenoids uterinium polyposum’. Finally he described a lesion of Müllerian tissue invasion 
within the ovary called ‘ovarian cystosarcom’ (2). His opponents, primarily Von 
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Recklinghausen, hypothesised that these abnormally sited lesions were merely 
displaced mesonephric or Wolffian ducts (3).  
 
Figure 1 - Mayer-Rokitansky-Kuster-Hauser syndrome 
 
 
 
It was the surgeon Thomas Stephen Cullen (1868-1953) who noted similarities between 
the myometrial invasion and those seen in extra-uterine locations such as the recto-
vaginal septum, uterosacral ligaments, ovary, bowels, and abdominal wall termed 
adenomyosis externa. He grouped all these areas of ectopic endometrial cells under the 
description of adenomyomas (figure 2). In 1923 an established Canadian Gynaecologist 
John A Sampson observed that during operations timed to occur with menstruation, 
lesions of the peritoneum would be bleeding similar to that of the shedding eutopic 
endometrium (4). His initial theories of peritoneal endometriosis surrounded the 
dissemination of endometrial cells from ruptured endometriomas. However, with closer 
inspection Sampson hypothesised that endometrial cells refluxed in a retrograde fashion 
at the time of menstruation developing the now long held theory of causation: retrograde 
menstruation (5).  
 31. 
Figure 2 Thomas Stephen Cullen’s description of adenomyomas from 1920 - Diagram 
showing locations of ectopic endometrial tissue (indicated as adenomyomas):  
1, uterine wall; 2, recto-vaginal septum; 3, fallopian tubes; 4, round ligament; 5, hilum of 
ovary; 6, utero-ovarian ligament; 7, utero-sacral ligament; 8, colon; 9, musculus rectus; 
10, umbilicus. From Cullen (6) with permission. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
With the arrival of laparoscopic surgery in the 1960’s onwards, direct visualisation of the 
pelvis during a chosen cycle stage could be achieved more easily and with less 
morbidity. The notion that retrograde menstruation only happened to those women 
suffering from endometriosis was dispelled in 1984 when a study team published 
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findings that over 90% of women with patent tubes had retrograde menstruation around 
the time of their menses (7).  
The American Fertility Society developed the first quantitative classification system of 
endometriosis in 1979, this, less than perfect, classification has been revised and 
incorporated into international standards for describing disease morphology (8). This was 
followed by a classification system of anomalies of the Müllerian duct (Figure 3). 
 
Figure 3 - Classification of the different anomalies of Müllerian duct development by 
American Fertility Society (1988) (9) 
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Figure 4 - Images of aforementioned Scientists 
Johann Wolfgang von Groethe (1749-1832) 
 
 
 
 
 
 
 
 
Johannes Peter Müller (1801-1858)            Carl von Rokitansky (1804-1878)  
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Thomas Stephen Cullen (1868-1953)              John A Sampson (1873-1946)                     
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1.2 AETIOLOGY OF ENDOMETRIOSIS 
 
1. Retrograde menstruation 
2. Coelomic Metaplasia 
3. Immune system dysregulation 
4. Life style 
5. Familial linkage 
6. Endometrial abnormalities 
7. Haematological / Lymphatic spread 
8. Inflammation 
 
 
1.2.1 RETROGRADE MENSTRUATION  
 
The original theory proposed by Sampson et al in 1920’s describes the reflux of 
menstrual debris from the uterus backwards through the fallopian tubes and into the 
peritoneal cavity at the time of a women’s menses. This provides a conceptually sound 
and logical theory as to how cells from the endometrium get to their common sites such 
as the ovary, the ovarian fossa, the pouch of Douglas, and the uterosacral ligaments. 
Support for this theory grew with the discovery of higher rates of endometriosis in women 
with hereditary genital outflow obstruction, iatrogenic outflow obstruction (primates), 
cervical stenosis and the presence of a uterine septum (10–13). The notion that this only 
happened to those women suffering from endometriosis was dispelled in 1984 by Halme 
et al who published findings that over 90% of women with patent tubes had retrograde 
menstruation around the time of their menses (7). 
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1.2.2 COELOMIC METAPLASIA 
 
Retrograde menstruation can account for the majority of women diagnosed with 
endometriosis. There are however a group of men, women and children who fall outside 
this category. The theory centres on aberrant differentiation of mesothelial cells. 
Mesothelial cells are simple squamous cells found on cavity linings such as those in the 
abdomen (peritoneum), brain (arachnoid membrane), and chest (pleura and 
mediastinum). Under the influence of endogenous or exogenous hormone exposure, 
mesothelial cells can auto transform into endometrial cells. This has been demonstrated 
to be the case in in-vitro models (14). Case studies have demonstrated endometriosis 
deposits in all areas known to contain mesothelial cells such as the peritoneum, the 
pleural lining of the lungs, the diaphragm, liver, umbilicus and brain (15–20).  These 
theories could be explained through haematogenous or lymphatic spread of endometrial 
cells while case studies of men presenting with endometriosis following exogenous 
hormone therapy (HT) or fetuses of female infants with peritoneal endometrial cells adds 
merit to this theory (21,22).  
 
1.2.3 IMMUNODEFICIENCY  
 
Theories of defective immunodeficiency suggest the survival and development of 
abnormally located endometrial tissue, in locations such as the rectum or vagina is 
similar to a foetus evading maternal immunity pathways. This immuno-tolerance in the 
case of endometriosis allows for reduced menstrual debris recognition and removal 
providing increased contact time between retrograde menstrual effluent and the pelvic 
peritoneum (23). There is associated persistence of macrophages noted within the pelvic 
peritoneum. These macrophages present foreign material including retrograde menstrual 
effluent to T-lymphocytes for destruction and removal. In patients with endometriosis pro-
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inflammatory markers are released disturbing this important balance between 
macrophages and T-lymphocytes (24). These inflammatory cytokines contribute to 
ectopic endometrial survival and reduced menstrual debris removal.  The resultant 
environment favours implantation and proliferation of endometrial cells into the lining of 
the peritoneum and other structures.  
 
1.2.4 LIFE STYLE / ETHNICITY 
 
The prospect of controllable reversible lifestyle choices or exposures affecting the 
development of endometriosis has been examined. Early epidemiological analysis had 
thought the disease to be confined to Caucasian women (25) and rare amongst women 
of African descent (26,27). A more recent and significantly larger longitudinal study of 
90,000 American women where those with a diagnosis of endometriosis or infertility were 
excluded initially revealed that Black African and Hispanic women were 20-40% less 
likely to go on and get diagnosed with endometriosis than Caucasians. Despite the 
known linkage between adiposity and oestrogen secretion there appears to be an 
inverse relationship between weight and risk of endometriosis with patients who have a 
lower body mass index (BMI) being at greater risk (28).  Phenotypical features of 
ethnicity and life style choices such as hip : waist ration, height or caffeine intake had no 
relationship with disease prevalence (28). Endometriosis was historically termed “the 
disease of the rich” (29) but recent studies have failed to address this variable (30). 
 
1.2.5 FAMILIAL LINKAGE 
 
Endometriosis has been shown to have a high degree of hereditability since it was first 
investigated in 1970 (31).  Numerous subsequent twin and family studies have 
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demonstrated a 5 to 7-fold increase risk in an individual with a family history of the 
disease (32–34). Two small twin studies of mono-zygotic twins with one twin affected by 
endometriosis demonstrated a 75-87% concordance rate (35,36). A large Genome Wide 
Association study evaluation of single-nucleotide polymorphism has highlighted an 
association between a gene (WNT4) located on chromosome 1. WNT4 is important for 
steroidogenesis, ovarian follicle development and the natural development of the female 
reproductive tract and a very plausible candidate for endometriosis based on its 
biological functions (37). 
 
1.2.6 ENDOMETRIAL ABNORMALITIES 
 
The endometrium is a complex structure that changes throughout a normal menstrual 
cycle under the influence of circulating hormones. The role of apoptosis in normal 
endometrium is to eliminate senescent or dysfunctional cells, as a way for tissue repair 
at each menstrual cycle. Apoptosis is a fundamental physiological process that allows 
the body to maintain homeostasis by eliminating dysfunctional cells. In women with 
endometriosis, endometrial cells regurgitated into the peritoneal cavity lack the 
appropriate mechanisms of programmed cell death and can therefore escape clearance 
and survive to invade pelvic structures through concomitant overexpression of anti-
apoptotic factors and reduced expression of pro-apoptotic factors (38,39). 
 
1.2.7 HAEMATOLOGICAL / LYMPHATIC SPREAD 
 
Endometriosis has been found during histopathological examination of pericolic lymph 
nodes removed during bowel surgery for endometriosis (40,41). Further studies have 
found the prevalence of isolated endometriosis like cells (IELCs) in pelvic sentinel lymph 
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nodes in 11% of women with ovarian or peritoneal endometriosis (42). Recent studies 
using cell filtering technology, commonly used for the detection of circulating tumour 
cells, have demonstrated the presence of peripherally circulating serum endometrial like 
cells (43). 
 
1.2.8 INFLAMMATION   
 
Inflammation is believed to play a fundamental role in the development and progression 
of endometriosis(44,45).  
Endometriotic tissue, unlike endometrial tissue, is associated with the overproduction of 
inflammatory markers; prostaglandins, metalloproteinases, cytokines, and chemokines 
(46–49). Overexpression of prostaglandin E2 in endometriotic tissue is sustained by 
overexpression of cyclooxygenase (COX) 2 and CYP19A1. Prostaglandin E2 released 
following the inflammatory response stimulates the expression of all steroidogenic genes 
necessary to enable the endometriotic stromal cell to synthesise estradiol from 
cholesterol (50). Oestrogen enhances the survival or persistence of endometriotic tissue, 
prostaglandins and cytokines mediate pain, inflammation, and infertility (51,52).  
Pro-inflammatory cytokines such as tumour necrosis factor α (TNFα) and IL-1b initiate 
the development and progression of endometriosis via: pleiotropic, cytostatic, 
chemoattractant, or angiogenic effects (53). The presence of peritoneal TNFα and serum 
levels of Inter-Leukin-1b  have been associated with endometriosis suffers (54), 
dysmenorrhoea (55), and severe endometriosis (45).  
The inflammatory process of oxidative stress occurs when there is an imbalance 
between reactive oxygen species (ROS) production and the antioxidant defence (56). 
Oxidative stress has been associated with several chronic inflammatory diseases 
including endometriosis (44). As a result, ROS promote the growth and adhesion of 
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endometrial cells within the peritoneal cavity, leading to disease establishment and 
symptoms of pain and infertility (57,58).  
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1.3 THE CLASSIFICATION OF ENDOMETRIOSIS 
 
1.3.1 DISEASE CLASSIFICATION 
 
Since endometriosis was first recognised, a classification has been necessary to 
describe this disease. Early classification scores were based on locality of the disease 
and had little correlation with disease severity or the clinical manifestations. Initial 
attempts to produce a classification scale for the disease originated with Sampson et al 
in 1921 (59) and followed some years later by Albrecht et al (60).  Acosta et al (61) were 
the first group to link the disease severity and clinical pregnancy rates. The use of 
classification tools in Endometriosis has become widespread and unified since the 
revised American Fertility Society published their points based score system in 1986 
following its original publication in 1979 (8,62) This established classification tool, is not 
without its limitations and was again revised and renamed in 1996 to form the revised 
American Fertility and Reproductive Medicine (rAFRM) score (63). 
The disease has had 5 classification tools, the revised American Fertility Society (rAFS), 
Buttram, Kistner, Acousta and Enzian classification method. The rAFS is widely used, in 
comparison to the Enzian classification which is limited to German speaking countries. 
The remaining classification systems have had historic use and are no longer widely 
accepted.  
The purpose of a classification system is to provide a reproducible set of symptom or 
prognostic markers that can be accurately translated to patients. The classification and 
diagnosis of the disease should be simple and accurate regardless of clinician and 
country.  
The difficulties of producing a classification system for endometriosis are numerous.  The 
visual appearance of lesions varies widely resulting in significant intra-observer and 
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inter-observer variability. There is up to 50% false positive rate with visual diagnosis of 
endometriosis given its varied appearances (64). The revised American Society 
Classification tool will be used during this thesis. 
 
1.3.2 REVISED AMERICAN FERTILITY SOCIETY CLASSIFICATION (RAFS) 
 
The American Fertility and Reproductive Medicine society’s classification tool is used 
most widely for both clinical and academic practice. Values are assigned to 
endometriotic lesions of the ovary and peritoneum according to size and depth of 
infiltration, either superficial or deep. Additionally, points are awarded for adhesions on 
the fallopian tubes and ovary along with partial or complete obliteration of the posterior 
cul-de-sac. After a full assessment the points are totalled to provide an overall score, 
staging and lay description; 1-5 Stage 1 (minimal), 6-15 Stage 2 (mild), 16-40 Stage 3 
(moderate), >40 stage 4 (severe) (Figure 5)  
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Figure 5 – The revised American Fertility Society Classification   
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This scale has many advantages. It the most widely used and validated assessment tool 
available. The simplistic scoring system used provides ease of use for the clinician and 
an uncomplicated lay description available to the patient. 
Limitations 
This classification has limitations and the scoring system does not account for the 
disease morphology or its penetration to surrounding structures. The numerous points 
available for lesion size reduces the reliability of its reproducibility with intraobserver and 
interobserver reliability accounting for a change in the disease score in 38% and 52% of 
patients respectively. The score ranges from 0-90 and greatest intraobserver and 
interobserver variability was seen in ovarian endometriosis and endometriosis effecting 
the posterior cul-du-sac (65). 
With the exception of invasive disease the rAFS correlates poorly with, fertility (66,67), 
dysmenorrhea, dyspareunia, and pelvic pain (68). It is because of this poor association 
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with rAFRM score and fertility that Adamson and Pasta developed the Endometriosis 
Fertility Index (69) which includes clinical information on fertility and sterility.  
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1.4 ENDOMETRIOSIS SYMPTOMS 
 
 1.4.1 PAIN 
 
Endometriosis can be associated with a variety of different pain symptoms without 
correlation to disease severity (70,71).  These symptoms include dysmenorrhoea, 
dyspareunia, dyschezia, dysuria, and chronic pelvic pain (71). The precise aetiological 
origins of endometriosis associated pain remain poorly understood. Theories include: 1) 
bleeding from active endometriosis lesions, 2) release of pro-inflammatory markers from 
the endometriosis lesions, and 3) direct invasion or irritation of the pelvic peritoneal 
nerves (72). Pain is both subjective and difficult to measure. Pelvic pain is not diagnostic 
of endometriosis and there are no associated patterns of pain presentation that can be 
accurately linked to the disease making the decision for laparoscopic investigation 
difficult. Pain mapping of those women with and without endometriosis suggest that 
symptoms of chronic pelvic pain, dyschezia, and dyspareunia were much more likely to 
be reported amongst women with endometriosis than without (73).   
 
1.4.2 INFERTILITY  
 
Endometriosis is increased amongst women with infertility. The disease prevalence is 
believed to be up to 50% of infertile women(74). Estimates suggest around 50% of 
women with surgically confirmed endometriosis will not achieve a spontaneous 
pregnancy (69,75–77). The monthly fecundity rate is significantly less for those with 
confirmed endometriosis (2-10%) compared to those fertile couples (78).  
Large retrospective analyses have shown non-significant differences in IVF outcomes 
between those women with endometriosis to either tubal factor controls or all other 
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causes (79,80). The concerns that IVF may prompt a deterioration in endometriosis 
symptoms or disease progression has not been demonstrated (81).    
 
 1.4.3 QUALITY OF LIFE 
 
Quality of life is affected in a complex way by each individuals’ physical health, 
psychological state, level of independence, social relationships, personal beliefs, and 
their relationship to salient features of their environment (82). 
In addition to physical symptoms, women with endometriosis have a higher prevalence 
of non-physical symptoms such as depression (83,84). Many different studies have 
aimed to assess quality of life but have had limited validity owing to low study size, 
poorly selected controls or non-validated assessment tools (85–87). Recently validated 
assessment tools include the Short Form 36, a questionnaire designed to measure the 
impact of endometriosis on quality of life research(88). 
Psychological quality of life in 479 endometriosis patients was significantly reduced 
compared to patients with serious chronic diseases such as cancer (89). 
 
 
 
1.5 DIAGNOSIS 
1.5.1 Background  
1.5.2 Current guidance 
1.5.3 Blood markers 
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1.5.4 Endometrial markers 
1.5.5 Urinary markers 
1.5.6 Clinical symptom prediction models 
1.5.7 Imaging prediction  
1.5.8 Conclusions 
 
1.5.1 BACKGROUND 
 
Endometriosis is a varied and enigmatic disease. It is histologically characterised by the 
presence of ectopic endometrial glands and stroma distant to the uterus. Common sites 
include the pelvic organs and the peritoneum surrounding the uterus (90). Endometriosis 
is a chronic benign oestrogen-dependent disease affecting 10% of women during their 
reproductive years (91). The prevalence increases to 35–50% amongst women with 
pelvic pain and or subfertility (25,92–94). Endometriosis is often undiagnosed, and 
average delays from symptom onset to diagnosis are 6–11 years (95–97). Endometriosis 
is characterised clinically by noncyclical pelvic pain, dysmenorrhoea, dyspareunia and 
subfertility (71,98–100). The disease has estimated annual costs of 9579 Euro per 
patient, comprising one-third of the direct healthcare costs with two-thirds attributed to 
loss of productivity (101). The disease manifests itself in three distinct visually and 
pathological forms: superficial peritoneal, ovarian endometrioma and DIE. There is 
significant heterogeneity between these three disease forms and debate is ongoing 
whether despite their similar histopathological appearance they are in fact separate 
processes (102). The surgical findings are widely classified according to the revised 
American Fertility Society (rAFS) despite this having very poor correlation with 
postoperative outcomes, symptomatology and high intra-user variability (103–105). The 
development of a screening test for endometriosis relies on several critical properties 
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including high specificity, high sensitivity, reproducibility simplicity and patient 
acceptability or minimal invasiveness. A marker or test must provide consistent results 
among a varied geographical and ethnically varied population. This marker or test has 
not been able to meet these criteria nor has it been validated and as a result this has 
been highlighted as an endometriosis research priority (106). 
1.5.2 CURRENT GUIDANCE 
To date, we have been unable to accurately predict the presence of endometriosis with 
symptom, clinical, blood, urine nor image-based screening tests. The combination of 
laparoscopy and histopathological confirmation is currently the gold standard for 
diagnostic confirmation of endometriosis (107). Endometriosis has a myriad of 
macroscopic appearances that can lead to false-negative and false-positive diagnosis 
via visualisation alone (108). This is more evident in peritoneal endometriosis than 
ovarian and DIE; nonetheless, the visual diagnosis of endometriosis has been 
demonstrated to be unreliable  (64,109). The European Society of Human Reproduction 
and Embryology (ESHRE) committee of endometriosis experts set up a guideline 
development group that stated visually confirmed endometriosis at laparoscopy is of 
limited value without a biopsy confirming histological presence (90)  . A study supporting 
this excised 122 visually confirmed endometriosis lesions from 54 patients and found 
that only 54% of these lesions were histopathologically confirmed endometriosis (110). 
This limited diagnostic accuracy of visualisation was compounded by a meta-analysis of 
studies demonstrating close to 50% misdiagnosis in rAFS stage I–II with visualisation 
alone (64). The combination of poor diagnostic accuracy and poor prognostic capabilities 
of disease presence and quantity makes for challenging consultations with patients when 
discussing the management of the disease.  
There is consensus in the World Endometriosis Society (WES) that the development of a 
reliable non-invasive test is one of the top research priorities in endometriosis (106,111). 
The development of biomarker test for the detection of any disease is long, difficult and 
riddled with uncertainty. The development can be broadly broken down 4 phases: 
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1) Pre-clinical discovery phase: preclinical studies identifying potential biomarkers  
2) Retrospective Validation: those known to have the disease are tested to assess 
the accuracy in a preclinical setting. 
3) Prospective validation: this establishes the diagnostic accuracy and both positive 
and negative predictive value. 
4) Commercialisation: industry development of the test for widespread distribution. 
The development and implementation of a reliable non-invasive test for endometriosis 
will have a profound impact on reducing the health care burden, current costs (112) while 
improving the quality of life for an estimate 10% of the female reproductive population 
(101,113,114). 
1.5.3 BLOOD MARKERS 
 
The chronic inflammatory nature of endometriosis further challenges the specificity of 
tests based on mediators of inflammation. The most commonly used biomarker for 
preoperative assessment is CA-125 (CA-125). This is a glycoprotein found within the 
cells lining the female genital tract and is raised in both epithelial ovarian cancer and 
other gynaecological diseases (115–117). This was systematically reviewed with a meta-
analysis finding insignificant sensitivities and specificities to justify its use as a predictive 
marker (116) though serum levels appear to rise with increasing disease severity (118). 
CA-125 along with other glycoproteins has been analysed by research teams in Leuven 
who have kept a bank of frozen blood samples from patients since 1999. The team were 
able to demonstrate the accuracy of CA-125 with sensitivity and specificity of 78 and 
51% (119). There are significant data to suggest that CA-125 has a limited role in the 
assessment and follow-up of endometriosis (120) with limited studies suggesting that 
vascular endothelial growth factor (VEGF) could potentially provide a more accurate 
means of diagnosis with sensitivities and specificities of 93.3 and 96.7%, respectively 
(121). There are limited studies including diagnostic data to support the use of VEGF 
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hence this thesis explored the use of CA125.  
Inflammatory markers such as IL-8 [44] and high-sensitivity C-reactive protein (hs-CRP) 
(122) have been analysed in large studies. The use of CRP in the detection of many 
inflammatory conditions is widely recognised, yet its use in endometriosis is uncertain. 
Previous studies have demonstrated hs-CRP as a more useful marker than CRP but 
without conclusively demonstrating its use as a marker in its own right (123–126). 
Thubert et al. (122) examined the significance of hs-CRP in 370 women with 
histopathological confirmed endometriosis compared with those patients (n.464) who 
had had negative laparoscopies. Over a study period of 4 years, the authors 
demonstrated no significant difference in this marker between the case and control group 
(122). 
Endometriosis is widely considered an inflammatory process of unclear aetiology. The 
inflammation pathway is associated with oxidative stress (127) which results in the 
production of free radicals and reactive oxygen species (127). When these by products 
are not adequately metabolised and removed, they may cause oxidative alteration in 
proteins, lipids, carbohydrates, nucleic acids and their sequential signalling pathways. 
This cascade of events that follows oxidative stress requires several key components 
including thiols and carbonyls that have become the focus of biomarker analysis (128) 
and have been linked to endometriosis and subfertility (44,56). In the quantitative 
analysis of serum thiols in 67 cases of histologically confirmed endometriosis compared 
with 41 controls, quantitative analysis demonstrated significantly lower levels of thiols 
and carbonyls amongst endometriosis cases compared with controls. Receiver operating 
curve analysis provided cut-off levels at 396.44mM and 14.9 mM for thiols and 
carbonyls, respectively, and sensitivity of 73.1% and specificity of 80.5% for thiols and 94 
and 51.2% with carbonyls (129). This finding was contradicted by several studies 
demonstrating no association between endometriosis and markers of oxidative stress 
(130,131). More recent areas of biomarker development have included micro RNAs 
(miRNAs). These circulating lengths of 19–25 nucleotides have been demonstrated to 
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influence mRNA translation and degradation resulting in a sequential impact on gene 
and proteomic expression (132–134). The aberrant expression of miRNA has been 
linked to chronic diseases including endometriosis [60]. Variation between miRNA levels 
in eutopic and ectopic endometrium of controls and those patients with endometriosis 
has led to further analysis of serum miRNA profiles (135–138). A quantitative analysis of 
miRNA levels in women with stage III–IV endometriosis demonstrated high levels of 
accuracy with sensitivities and specificities up to 90% for miRNA-17- 5p, miRNA-20a, 
miRNA-22 (139). This contrasts to Suryawanshi et al. (140) who found differentiation 
between endometriosis patients and controls with miRNA-16, miRNA-191 and miRNA-
195 at sensitivity and specificity of 88 and 60%, respectively. The most promising study 
yet from Wang et al. (141) compared 60 patients with histopathological confirmed 
endometriosis to 25 patients with a negative laparoscopy. This study found 
discriminatory sensitivities and specificities of 93.2 and 96% when combining miR-199a, 
miR-122, miR-542-3p and miR-145. We were unable to combine this data for meta-
analysis due to the multitude of different miRNA markers evaluated, however, this field of 
endometriosis research appears to be a growing area of interest. 
 
1.5.4 ENDOMETRIAL MARKERS 
The hormonal variation in ovulatory women throughout their menstrual cycle results in 
endometrial molecular signature change depending on the stage in the cycle. This 
presents a significant challenge with regard to endometrial-based biomarker 
development. Although a cycle phase specific test may be acceptable to optimise 
sensitivities and specificities, this may not be practical with women having irregular 
menstrual cycles. This is particularly relevant in studies analysing eutopic mRNA 
expression (142).  
Recent studies have found that aberrant neuronal growth may contribute to abnormal 
fertility and uterine disorders including endometriosis. The hypothesis that increased 
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neuronal innervation to endometrial cells (eutopic and ectopic) could be reflected in an 
endometrial biopsy to detect a neuronal protein called protein gene product 9.5. The 
association between protein gene product 9.5 in the functional layer of the endometrium 
and the presence of endometriosis in the pelvis has, like many markers, shown promise 
(142–148). This C-terminal hydrolase dissociates ubiquitin peptide bonds and thus 
regulates proteolysis (149). The use of this semi-invasive biomarker has sensitivities 
ranging from 80 to 81% with specificity 92–100% and did not appear to vary by phase of 
the menstrual cycle (148,150). Protein expression correlated with the presence of 
endometriosis, whereas the gene expression did not; this discordance between genomic 
expression and proteomic expression suggests that expression of these proteins is 
influenced by mechanisms taking place in the post-transcription period (150). We chose 
not to perform a meta-analysis as this was being performed by the Cochrane 
gynaecology and fertility group (151). 
 
1.5.5 URINARY MARKERS 
In a recent evaluation of urinary proteomics amongst 11 women with endometriosis and 
6 women without, cytokeratin 19 (CK19) was found to be significantly upregulated 
amongst those women with endometriosis (152). The authors of this scoping study 
detected 917 protein spots of which 130 were statistically significant with urinary 
cytokeratin 19 as the most accurate of urinary protein markers for endometriosis (152). 
The authors did not set out to test this specific biomarker and little is known about the 
role of CK19 in endometriosis. Further studies have continued to demonstrate a high 
specificity (94%) but a low sensitivity (11%) in a population of 98 women with pelvic pain. 
In the group which had a negative index test (CK19), 56 of the 89 (62%) were found to 
have histologically confirmed endometriosis compared with two patients from nine who 
had a false-positive result exposing many women to unnecessary interventions (153). A 
Study of Chinese women undergoing gynaecological investigation examined the role of 
urinary proteomic expression as a screening tool. The significance of urinary angiogenic 
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markers and cytokines has previously been demonstrated in both systemic and 
urogenital diseases such as nephrotic syndrome, hypertension and cardiac failure (154–
158). ELISA analysis of creatinine-adjusted urinary vitamin-D binding protein for 57 
women with endometriosis compared with control group of 38 women without 
endometriosis produced a sensitivity of 58% and specificity of 76% (159). A diagnostic 
review performed by Cochrane subfertility and menstrual disorders group revealed only 8 
eligible studies concluding that there is insufficient evidence to recommend a urinary 
biomarker for use in the diagnosis of endometriosis (160).  
 
 
1.5.6 CLINICAL SYMPTOM PREDICTION MODELS 
Endometriosis is known for a triad of pain symptoms: dysmenorrhoea, dyspareunia and 
pelvic pain; however, multiple symptom-based predictive tools have failed to accurately 
predict endometriosis from those without endometriosis. A detailed pelvic examination 
has previously been unable to accurately predict the presence of endometriosis as many 
women have normal findings (161,162). The ill-defined relationship between clinical 
stage (rAFS) and symptom severity provides clinicians with further challenges. Several 
systematic reviews and studies of endometriosis have attempted to develop predictive 
analysis with a combination of examination, symptoms and ultrasound to add diagnostic 
accuracy to tools which are individually imprecise (163–165). Despite the low individual 
clinical accuracy, pelvic examination remains a crucial component to the preoperative 
assessment. 
 
1.5.7 IMAGING PREDICTION 
Imaging modalities have a major role in the investigation and diagnosis of gynaecological 
disease. Ultrasound alone provides high sensitivities of up to 97% in stage three or four 
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endometriosis but consistently low sensitivities of 10% in stage I & II endometriosis. This 
demonstrates an ability for a positive scan result to diagnose the disease but not exclude 
the disease when it is negative (166). Ultrasound imaging has a historic use in identifying 
ovarian endometrioma. The diagnosis of endometrioma with ultrasound has moderate 
sensitivities but high specificities, using three commonly reported ultrasound signs: 
ground glass appearance, septations 1–4, papillaries without blood flow. When 
premenopausal status is added, the sensitivities range from 62 to 73%. The experience 
and subjective assessment of a senior trained sonographer increases sensitivities to 
81% (167,168). Endometriosis is a disease characterised by inflammation and fibrosis 
more commonly causing adhesions rather than ovarian endometrioma (169). Several 
ultrasound studies have tried to address this as a potential area for non-invasive 
diagnosis. Adhesions are not well visualised on ultrasound and in the absence of 
endometriosis or other inflammatory processes, the uterus and ovaries can move freely. 
However, when endometriosis is coexistent, adhesions commonly form between the 
ovary and the uterus increasing in frequency and severity with advancing disease 
preventing this movement (170). Several studies have looked to assess the diagnostic 
accuracy of adhesions or pelvic immobility at ultrasound to predict endometriosis 
presence at surgery (171–174). The diagnostic accuracies are variable with a potential 
use in the diagnosis of deep infiltrating disease, pouch of Douglas obliteration (173,174) 
and ovarian adhesions. MRI is now more commonly used in the preoperative setting for 
women with known or suspected endometriosis. This modality is not effective in 
detecting superficial endometriosis but more beneficial in assessing moderate to severe 
disease stages III–IV. The ability for MRI to diagnose endometriosis depends on the 
stromal to glandular consistency of the lesion, the extent of haemorrhage and 
inflammatory response (175). Haemorrhage within the ovary is a key feature of 
endometriomas and MRI is commonly used to assess complex ovarian cysts found 
during ultrasound in which a diagnosis is not certain. This has been shown to have high 
specificities of 92% but lower sensitivities of 67%, suggesting alternative pathologies 
share similar MRI characteristics (176). The preoperative assessment and diagnosis of 
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endometriosis stage III–IV is crucial for surgical planning to minimise the risk of 
complications in moderate to severe disease (177). The identification of solid 
endometriotic nodules together with adhesions is well documented with MRI. In those 
lesions with pure fibrous components, images will elicit low signal intensity with T-1 and 
T-2-weighted images, whereas those with a heavy glandular component demonstrate 
high signal intensity with T-1 and T-2- weighted images. The commonest lesions found 
are a mixture of fibrous and glandular endometriosis but with stromal/fibrous 
predominance. These demonstrate low signal attenuation from the fibrous element, 
irregular speculated edges and cystic components with internal high signal intensity from 
areas of haemorrhage on T-1 images (178,179). The specificities appeared to be 
consistently high (176,179–181), whereas sensitivities varied from 23% to 100% 
(179,182,183) depending on the location of endometriosis deposit. The commonest 
location for DIE to be found was the recto–cervical junction with high sensitivities (95%) 
and specificities (100%). We chose not to combine biomarkers with imaging as this has 
been the subject of several previous studies evaluating the use of ultrasound or MRI with 
biomarkers to improve diagnostic accuracy (184–190).  
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1.5.8 CONCLUSION 
The non-invasive diagnosis of endometriosis remains a challenge for both patients and 
healthcare professionals. The annual healthcare costs are comparable to diabetes for 
this chronic disease affecting 10% of the female reproductive population (101). With the 
average age of first live birth increasing (191), it is likely that gynaecologists we will see 
an increase in disease progression and symptomatic patients. This will have an 
associated increase in health economic costs from surgery and fertility treatments unless 
accurate non-invasive diagnostic tests are developed. The development of a robust non-
invasive test for endometriosis is of great clinical importance (106), yet it has many 
inherent difficulties related to cyclical hormonal fluctuations. The pathway that leads from 
a theory to the development of a diagnostic test is long, complicated and difficult (192). 
Further understanding of the aetiology and basic science processes involved in the 
development of this disease will aid in the development of a non-invasive test. The 
commonest biomarker that has been evaluated is serum CA-125. Previous studies have 
been meta-analysed demonstrating poor sensitivity and moderate specificity. This was 
performed over ten years ago with a historic reference standard (visual diagnosis). There 
is need for re-evaluation of the accuracy of CA-125 for the diagnosis of histologically 
confirmed endometriosis. 
 
 
 
This section (1.5) of Chapter 1 was based on the following publication: 
Preoperative assessment and diagnosis of endometriosis: are we any closer? 
Hirsch M, Davis CJ. 
Curr Opin Obstet Gynecol. 2015 Aug;27(4):284-90. 
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  1.6 ENDOMETRIOSIS TREATMENTS  
 1.6.1 Medical Treatments 
 1.6.2 Alternative Treatments 
 1.6.3 Surgical Treatments 
 1.6.4 Assisted Reproductive Techniques  
 
1.6.1 MEDICAL TREATMENTS  
 
ANALGESIA 
Non-Steroidal Anti-Inflammatory drugs (NSAIDs) are a common initial treatment modality 
for women presenting to their doctor with symptoms suggestive of endometriosis. 
However, there is minimal evidence for the use of NSAIDs as analgesia for 
endometriosis related pain (193). 
 
HORMONAL TREATMENTS FOR PAIN 
LEVONORGESTREL RELEASING INTRA-UTERINE SYSTEM (IUS)  
The Trade name Mirena is a drug releasing intra-uterine system (IUS) which secretes 20 
mcg Levonorgestrel from the coil into the uterine cavity every 24 hours. The synthetic 
progestogens have local effects on the surrounding tissue (endometrium) causing 
suppression of endometrial thickening, reduced menstrual loss, and reduced 
endometriosis associated pain (194–196). There are other levonorgestrel releasing 
systems available without the evidence base to support their use in the treatment of 
endometriosis associated pain. 
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OVULATION SUPPRESSION 
COMBINED ORAL CONTRACEPTIVE PILL (COCP) 
The use of the combined oral contraceptive pill (COCP) is widely considered a first line 
of treatment for a patient with suspected endometriosis related pain. They act by 
inhibiting ovulation and reducing the risk of endometrioma formation (197), inducing 
atrophy of endometriosis, enhance apoptosis of endometriotic tissue and reduce 
growth/spread of the disease (198,199). The post-operative use of the COCP leads to an 
80% risk reduction of endometrioma recurrence and dysmenorrhoea (200–203). 
 
GONADAOTROPIN RELEASING HORMONE AGONISTS (GNRHA) 
The use of Gonadotrophin releasing hormone agonists (GnRHa) is common for the 
treatment of endometriosis. This treatment causes central pituitary down regulation 
following repeated agonist stimulation inhibiting the production of ovarian hormones 
essential for the development, maintenance and progression of endometriosis. The use 
of GnRHa has been shown to reduce pain and recurrence of endometriosis (204–206). If 
a GnRHa is chosen, add-back HRT is recommended to prevent bone loss and 
hypoestrogenic side effects. Add back HRT therapy is not known to affect the treatment 
efficacy of GnRHa (207–210). The use of HRT is recommended to be continuous and 
combined as unopposed oestrogen therapy is believed to carry a greater risk of 
endometriosis symptom recurrence. There is limited high quality evidence to support this 
treatment recommendation. Comparisons of continuous combined HRT have 
demonstrated the symptom recurrence risk is lowest with Tibolone, a synthetic HRT 
(107,211). 
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PROGESTOGENS 
The use of progestogens is believed to induce decidualisation and atrophy of lesions. It was the 
observation of improved clinical symptoms during pregnancy that led to the evaluation of 
progestogens in the medical treatment of endometriosis associated pain (212,213). 
ORAL PROGESTOGENS 
Several small randomised control trials have evaluated the efficacy of oral progestogens. These 
small studies have shown non-significant benefits compared to placebo in the outcomes of: 
change in pain at 12 months and AFS score. There were significant improvements demonstrated 
in: pelvic pain and sum of all symptoms at both six and twelve months when compared to 
placebo but these were not seen when compared to other treatments. There were significantly 
greater patient reported in efficacy of treatment associated with other treatments when 
compared to oral progestogens (214).  
INJECTABLE PROGESTOGENS 
The use of depot progestogens is associated with significant improvement in dysmenorrhoea at 
6 months. The use of injectable progestogens compared to other treatments is associated with 
significant increase in adverse effects, including: injection site reactions, bloating, intermentrual 
bleedings, weight gain, amenorrhoea, and nausea (214). 
PROGESTOGEN IMPLANTS 
The use of implantable progestogens for the treatment of endometriosis associated pain has 
undergone limited evaluation. A single non-inferiority randomized control trial has found 
implantable progestogens to be non-inferior to levonorgestrel releasing intra-uterine system in 
pelvic pain, dysmenorrhoea, and quality of life (215). 
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1.6.2 ALTERNATIVE TREATMENTS  
 
ACUPUNCTURE 
Acupuncture is a very commonly used form of Traditional Chinese Medicine (TCM) 
which has been practiced for over a thousand years (216). Western culture has 
increasingly adopted this form treatment since the start of the twentieth century. The 
single randomised controlled trial included in analysis by Cochrane reviewers found that 
auricular acupuncture significantly reduced severe dysmenorrhoea compared to a 
separate TCM (217). 
  
CHINESE MEDICINE 
Chinese Herbal Medicine (CHM) has traditional use dating back over 2000 years. 
Chinese medical theories believe the symptoms of pain associated with endometriosis 
originate from stagnation in the blood leading to a blockade in the blood flow to an area 
and subsequent pain. The hypothesised mechanism of action for CHM for endometriosis 
centres on the regulation of endocrine, immunological, circulatory and inflammatory 
pathways (218,219).  
Two RCTs exist comparing the use CHM with western medicine. CHM demostrated 
improvement when compared to danazol use for the treatment of dysmenorrhoea, 
adenexal mass shrinkage, vaginal nodularity, lumbosacral pain and rectal pain but no 
significant differences in reduction of dysmenorrhoea nor pregnancy rate against 
gestrinone (220).   
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1.6.3 SURGICAL TREATMENTS 
 
Surgery aims to remove endometriosis lesions and restore normally anatomy. When 
endometriosis is found or suspected at the time of surgery, clinicians are recommended 
to surgically treat the disease in a “see and treat” approach as this is effective for 
reducing pain (221). Both laparotomy and laparoscopy are effective however, 
laparoscopy is associated with reduced recovery time and hospital stay (222). The 
excision or ablation of endometriosis are effective for stages I&II disease while excision 
is preferential for treatment of pain associated with advanced diseased (223,224). 
Excision also allows the surgeon and patient a possibility to retrieve a sample for 
histological analysis and confirmation (223,224). 
 
SURGERY FOR PAIN WITH ENDOMETRIOSIS 
The treatment of pain associated with endometriosis surrounds three general 
techniques; removal or destruction of endometriotic lesions, interruption of nerve 
pathways, and division of adhesions. All of these techniques have moved from open 
laparotomy to minimally invasive laparoscopic or robotic procedures. The efficacy of 
laparoscopy compared to laparotomy has not been proven but the morbidity and 
recovery time following surgery is significantly less with laparoscopy (222).  
Techniques to interrupt the nerve pathways supplying the pelvic organs have evaluated 
Laparoscopic Uterosacral Nerve Ablation (LUNA) and Pre-sacral neurectomy (PSN). 
These interrupt the uterosacral nerves severing the nerve pathways from the central 
nervous system along the uterosacral nerve leading to the uterus (LUNA) or pre-sacral 
nerve plexus overlying the sacral promontory. LUNA has been demonstrated to add no 
additional benefit at 1 year following surgery while the additional use of PSN is beneficial 
at 6 months and 1 year postoperatively. There are increased complications associated 
with PSN compared to LUNA including; bleeding, constipation, urgency of urination, and 
painless first stage of labour (225).  
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SEVERE ENDOMETRIOSIS 
Deep infiltrating endometriosis (DIE) is the presence of endometriosis at 5mm or greater 
depth from the peritoneal surface and can involve the uterosacral ligaments, vagina, 
bowel, bladder or ureters (226). Pain is the cardinal symptom of DIE (227) with studies 
suggesting increasing intensity with severity of disease (228). Surgical treatments of DIE 
reduce pain and improves QOL (77,229,230) but this was not found to be more 
efficacious when compared to medical treatment (231). Different surgical techniques 
have been identified including shaving of endometriotic nodule, disc excision, and 
segmental bowel resection with end-to-end anastomosis or stoma formation. All 
treatments appear to significantly improve outcomes of pain with higher complication 
rates associated with bowel resection (232,233). The fertility outcomes following surgery 
for deep infiltrating endometriosis are less clear with no robust evidence to suggest 
significant benefit (234). Hysterectomy with bilateral salpingoophorectomy is advised 
when women have completed their families and failed other forms of more conservative 
treatment (235). The long-term outcomes of premature iatrogenic ovarian failure are 
poorly understood and therefore covered in chapter 8. 
 
SURGERY FOR OVARIAN ENDOMETRIOSIS ASSOCIATED WITH PAIN AND INFERTILITY. 
There are many different surgical techniques for the management of ovarian 
endometrioma including, cystectomy, fenestration, drainage, fenestration and ablation. 
Cystectomy is historically the surgical technique of choice. This involves opening the 
ovarian cortex, identifying the cyst wall and stripping this from the healthy ovarian tissue. 
In the presence of endometrioma, surgical treatment has been advocated as the 
treatment choice of pelvic pain, dyspareunia, improved sexual function, and enhanced 
spontaneous conception (236,237).  
The benefits associated with IVF outcomes are less clear. A Cochrane review assessed 
multiple spontaneous and assisted fertility outcomes following cystectomy vs fenestration 
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and electro-cautery. The results favoured cystectomy with increased spontaneous 
conception rates, reduced recurrence, and increased ovarian response to gonadotrophin 
use during assisted reproductive technology (ART) (238). Subsequent meta-analyses 
have shown no significant improvement in pregnancy outcomes associated with surgery 
vs no surgery for ovarian endometrioma prior to ART (239–242). Please see chapter 7 
for further discussion on the surgical management of endometrioma amongst patients 
with subfertility. 
 
SURGERY FOR INFERTILITY WITH ENDOMETRIOSIS 
There is a relationship between endometriosis and infertility as discussed previously 
(1.4.2) (243,244). Surgery for peritoneal disease has been assessed with two 
randomised controlled trials where combined meta-analysis demonstrated a benefit for 
spontaneous conception (221,245). There is no known pathway to explain this process 
(245). 
 
MENOPAUSE IN WOMEN WITH ENDOMETRIOSIS 
 
Oestrogen with or without progestagens are common hormonal treatments for women 
with menopausal symptoms arising from a physiological change to a hypoestrogenic 
environment. Endometriosis is an oestrogen dependent disease raising concern that 
post menopausal administration of exogenous oestrogen may result in recurrence or 
reactivation of endometriosis. Recurrence of endometriosis symptoms and active lesions 
has been observed in those having had a hysterectomy, bilateral oophorectomy and HT 
(211). The use of tibolone is recommended for the treatment of menopausal symptoms 
for those women who undergo the surgical menopause until they reach the mean age of 
menopause (211). 
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1.7 ENDOMETRIOSIS RESEARCH 
 
Endometriosis is currently managed with both surgical and medical modalities often in 
combination. Where combined medical and surgical strategies meet, accurate 
measurement and reporting of outcomes relevant to both treatments, clinicians, 
researchers, and patients is critical. Endometriosis remains a poorly understood disease 
and the lack of aetiological clarity can lead to multidirectional research that prevents 
comparability and threatens the advancement of patient care.  Across all diseases there 
is a desire to generate patient centred clinically meaningful outcomes while basic 
science researchers further the understanding of this enigmatic disease.   
Randomised controlled trials and systematic reviews evaluate interventions by 
comparing outcomes chosen to reflect beneficial and harmful effects. A systematic 
review cannot perform meta-analysis if the outcomes reported are diverse and 
heterogeneous.  A scoping exercise of RCTs published in endometriosis between 
January 2013- October 2014 revealed 6 published trials reporting 37 separate outcomes, 
averaging 6 outcomes reported per article. Three studies reported dysmenorrhea, 
dyspareunia (246–248), two trials reported post-operative pain (246,249) two trials 
reported pregnancy and ectopic pregnancy (247,250) two trials reported irregular vaginal 
bleeding (246,250). The remaining 31 outcomes were assessed by individual trials. This 
limited search and scoping exercise suggests that only 16% of all outcomes reported in 
Endometriosis RCTs are comparable while those commonly reported outcomes of 
dysmenorrhea, dyspareunia and pregnancy are reported by only 50% or less of all trials. 
Such heterogeneity, if reflective of all trials, results in substantial outcome reporting bias 
and an inability to synthesise results across studies in systematic reviews. Outcome 
reporting bias is the selection for publication of a subset of the original recorded outcome 
variables on the basis of the results and/or incomplete reporting of outcome data. A 
recent study examined the prevalence of outcome reporting bias and its impact on 
Cochrane reviews (251). When adjusting for outcome reporting bias the treatment effect 
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estimate became non-significant in 19% of reviews and 26% would have overestimated 
the treatment effect by 20% or more.  
This diversity in peer-reviewed publications can have a knock-on effect with guideline 
generation and interpretation of research for public dissemination. This is a small number 
of trials from a limited period of time, and provided the basis for chapters 3,4, & 5.  
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1.8 AREAS OF UNCERTAINTY 
 
There remains great uncertainty within the diagnosis and management of endometriosis. 
The generalisability and non-specific nature of many of the symptoms together with the 
lack of a non-invasive diagnostic test can account for delays in disease diagnosis, 
treatment and symptom control. The variation in published research prohibits 
comparison, restricting the development of guidelines and use of structured treatment 
pathways. This allows for discrepancies and variation in the provision of practice, formal 
guidance and patient information internationally.   
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1.9 AIMS OF THE THESIS  
Section 1. Diagnostic evaluation 
1. To review the current non-invasive diagnostic strategies for endometriosis 
(Chapter 1) 
2. To assess the diagnostic accuracy of CA-125 for the detection of histologically 
confirmed endometriosis (chapter 2)  
3. To assess the diagnostic accuracy of CA-125 for the detection of endometriosis 
in a cohort of women with pain or subfertility (Chapter 3) 
Section 2. Methodology evaluation 
4. To assess the quality of published trials for researchers working in the field of 
endometriosis (Chapter 4) 
5. To assess the quality of online information available to patients suffering with 
symptoms suggestive of Endometriosis (Chapter 5) 
6. To assess the quality of national and international endometriosis guidelines for 
clinicians working with patients suffering from endometriosis. (Chapter 6) 
Section 3. Therapeutic evaluation 
7. To review the risks of surgery for women with endometrioma (Chapter 7) 
8. To assess the risks of female surgical castration for the management of 
endometriosis. (Chapter 8) 
9. To assess the role of music in the recovery from endometriosis surgery (Chapter 
9)  
 69. 
Table 1 - Framing the research question 
Chapter 
Number 
Population Intervention/test Outcome  Study design 
     
 
2 
Women with 
endometriosis 
symptoms 
Serum CA-125  Histological 
endometriosis  
Systematic 
review and 
Diagnostic 
meta-analysis 
 
3 
Women with 
pain and/or 
subfertility 
Serum CA-125 Histological 
endometriosis 
Prospective 
observation 
study 
 
4 
Patients with 
endometriosis 
Outcomes and 
outcome measures for 
endometriosis 
Quality of outcome 
reporting 
Systematic 
review 
 
5 
Websites with 
information on 
endometriosis 
Quality 
Readability 
Accuracy 
Credibility 
Quality assessment 
of online 
information 
Systematic 
review 
 
6 
National 
Guidelines on 
the 
management of 
endometriosis  
AGREE II assessment 
tool 
Quality and 
variation within 
national guidelines 
Systematic 
review 
 
7 
Patients with 
ovarian 
endometriosis 
and subfertility  
Surgical treatment 
options 
Fertility  Literature 
review 
 
8 
Patients 
undergoing 
hysterectomy 
and bilateral 
Surgical techniques Chronic health 
outcomes 
Systematic 
review and 
meta-analysis 
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oophorectomy 
 
9 
Patients 
undergoing 
endometriosis 
surgery 
Music Pain, Anxiety, 
Satisfaction, 
analgesia 
requirements. 
Systematic 
review and 
meta-analysis 
 
 
 
 
Figure 6 – Outlining the research question 
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Chapter 1
Evaluating and testing
diagnostic modalities
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Background of Endometriosis (1). 
Evidence quality 
appraisal
Chapters 4, 5, & 6
Systematic reviews on variation within published research 
(4), online information(5), and national guidelines (6) for the 
management of endometriosis.
Diagnostic meta-analysis (2) with primary observational study (3) assessing 
the diagnostic accuracy of CA 125 for histologically confirmed endometriosis.
Systematic reviews 
of therapeutic
Interventions for 
endometriosis
Chapter 7, 8, & 9
Systematic reviews evaluating the 
effectiveness and risks of surgical treatment 
strategies for the management of 
endometriosis (7, 8, & 9). 
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Chapter 10
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CHAPTER 2: 
THE DIAGNOSTIC ACCURACY 
OF THE CA-125 FOR 
ENDOMETRIOSIS IN 
SYMPTOMATIC WOMEN – A 
SYSTEMATIC REVIEW AND 
META-ANALYSIS  
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This chapter focuses on assessing the diagnostic accuracy of the most commonly used 
serum test for the histological presence of endometriosis. There is significant verification 
bias associated with the visual diagnosis of endometriosis as discussed in chapter 1. 
The evaluation of non-invasive diagnostic biomarkers has not identified an accurate test 
for the detection of endometriosis. 
 
3.1 ABSTRACT 
Objective: To assess the diagnostic accuracy of serum CA-125 (CA-125) for the 
presence of histologically confirmed pelvic endometriosis in reproductive aged women. 
Data Sources: The following databases were searched from inception to February 2015: 
1) EMBASE (1980-2015), 2) Medline (1954-2015), and 3) Web of Science (1900-2015). 
There were no language restrictions and bibliographies were manually searched by 
hand.   
Study Selection: Observational studies evaluating the accuracy of serum CA-125 (index 
test) for the diagnosis of histologically confirmed endometriosis (reference standard) 
were included. Exclusion criteria were studies comparing the accuracy of CA-125 for the 
detection of malignancy. Study selection, data extraction, and quality assessment was 
performed by two authors independently. The assessment of methodological quality was 
undertaken using Quality Assessment of Comparative Diagnostic Accuracy Studies 
(QUADAS-2) checklist. A bivariate hierarchical model was used to pool accuracy of data.                      
Result(s): Nineteen observational studies (15 cohort, four case-control), 3163 
participants, met the inclusion criteria. 13 of 19 studies (2611 participants) included data 
eligible for meta-analysis and were entered into a bivariate hierarchical model. This 
produce pooled accuracy data of CA-125 ≥30 unit / milliliter for the detection of 
histological endometriosis. The pooled specificity was 91% (95% CI 89% - 94%) and 
sensitivity 51% (95% CI 35% - 66%).  Positive likelihood ratio was 5.9 (95% CI 3.7 - 9.5); 
negative likelihood ratio was 0.5 (95% CI 0.4 - 0.7). The post-test probability of CA125 
≥30 unit / milliliter rises to 86%-95% in women experiencing pain or subfertility symptoms 
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associated with endometriosis. CA-125 was significantly more sensitive for the diagnosis 
of moderate and severe endometriosis, using all cut-off values, compared to minimal and 
mild disease (62.6% 95% CI 44.6 - 77.6 vs. 24.8% 95%CI 18.8 - 32.1, p value=0.003).  
Conclusions: CA-125 continues to play an important role as a diagnostic serum 
biomarker in women with symptoms suggestive of endometriosis. Due to the poor 
sensitivity, we recommend limiting the use of this, rule-in, test to women with symptoms 
suggestive of endometriosis. The use of CA-125 ≥ 30 unit / milliliter has a high specificity 
for the detection of endometriosis when used amongst a symptomatic population.  
 
Key words: endometriosis, non-invasive diagnosis, CA-125, biomarkers  
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3.2 BACKGROUND: 
Endometriosis is a chronic oestrogen dependent disease defined by the presence of 
endometrial glands and stroma located outside the uterus. The disease is characterised 
by symptoms of pain and subfertility. Estimates of disease prevalence vary but are 
thought to be as high as 10% in the general female population and up to 75% of 
symptomatic women, yet it is commonly under-diagnosed (96). The current gold 
standard for diagnosis is laparoscopic visualisation, biopsy and histological confirmation. 
The invasive and time-consuming nature of referral for and performance of surgery 
accounts for a delay of 6-9 years from symptom onset to formal diagnosis (95–97). This 
time allows for disease progression, symptom deterioration and an annual societal cost 
of $49.6 Billion in the USA (101). The identification of an accurate non-invasive test for 
the detection of endometriosis is still ongoing (112,252). Women presenting to their 
General practitioner or gynaecologist with symptoms cannot receive a non-invasive test 
to include or exclude endometriosis. The discovery of a test which can rule-in 
endometriosis will reduce time to diagnosis, reduce disease progression, provide 
psychological reassurance, and offer additional treatment options (253). CA-125 (CA-
125) is a well-established marker for epithelial cell ovarian cancer. This glycoprotein is 
derived from coelomic epithelia including the endometrium, fallopian tube, ovary, and 
peritoneum (117). CA-125 can be raised in endometriosis through direct stimulation of 
coelomic epithelia though its accuracy as a biomarker has been doubted (254). Studies 
evaluating the diagnostic accuracy of CA--125 for endometriosis have methodological 
limitations in patient selection (119,255–268), conduct of the index test 
(118,119,121,255,260–264,269–276), and verification of diagnosing the reference test 
(125,256–259,277–301). Two diagnostic reviews exists, however, one is over fifteen 
years old with a high risk of verification bias (116) and the second is low methodological 
quality (302).  
In this chapter I aimed to perform a meta-analysis to assess the diagnostic accuracy of 
CA-125 for endometriosis.  
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3.3 METHODS: 
A protocol with explicitly defined objectives, criteria for study selection, approaches to 
assessing study quality, and statistical methods was developed and prospectively 
registered with the International Prospective Register of Systematic Reviews 
(PROSPERO), registration number CRD42015017630, available online 
www.crd.york.ac.uk/prospero.  We have reported the systematic review and meta-
analysis in accordance with the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement (303).  
Search Strategy: 
We performed a comprehensive and systematic literature review searching: 1) EMBASE, 
2) MEDLINE, and 3) Web of Science for relevant citations from the date of inception to 
February 2015.   
We used MeSH and free text combinations with Boolean logic of the following search 
terms: endometrio*, test*, diagnos*, accura*, marker, screen*, detect*, CA-125, CA-125, 
CA-125, CA125. There were no language or date restrictions. We searched the 
bibliographies of relevant articles by hand. 
Study Selection 
We included prospective and retrospective observational studies (cohort and case-
control) assessing the diagnostic accuracy of pre-operative serum CA-125 to detect 
endometriosis confirmed by histology collected at robotic, laparoscopic, or open surgery. 
Exclusion criteria were malignancy. The patients were women undergoing surgery for the 
diagnosis or treatment of benign gynaecological diseases.  
Data extraction and quality assessment 
Titles and abstracts were screened independently by two reviewers (MH and JD).  Full 
text of selective studies were critically reviewed the to assess eligibility.  Any 
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discrepancies between the reviewers were resolved by discussion with a third author 
(KK).  
Two reviewers (MH and JD) used a pilot-tested data extraction sheet to independently 
extract the data.  The characteristics collected from each study included study design, 
setting, and participants. Where possible we extracted all relevant raw data from each 
study. Independent assessment of each study's methodological quality was performed in 
duplicate using the QUADAS-2 checklist.  This checklist assessed: patient selection, 
conduct of the index test, conduct of the reference test, and patient flow. Studies were 
considered to be of high quality if they used consecutive recruitment to sample an 
appropriate patient spectrum using the index test before the reference standard, and all 
participants underwent the same reference standard (>85% histological analysis) (304). 
The following were considered study qualities with potential to introduce bias; patients 
with a pre-operative ultrasound diagnosis of endometriosis, case-control studies, and 
control groups that did not undergo the reference standard. These were assessed with 
subgroup and sensitivity analysis. 
Outcomes: 
We independently extracted data for the number of true positives, true negatives, false 
positives, and false negatives for the index test at the documented threshold in each 
individual study.  Where raw data was unavailable in the text, the authors used the 
published sensitivities and specificities to calculate these data necessary to complete a 2 
x 2 table.  We actively contacted authors by email to seek clarification and requested 
missing data or additional data to complete our analysis (118,255,305,306). All 
discrepancies between the reviewers (MH and JD) were resolved through discussion 
with a third author (KK) or by contacting the authors. 
Data synthesis:  
We constructed 2 x 2 tables for the detection of endometriosis for individual studies 
included in the review. Where studies reported multiple cut off values for CA-125 we 
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selected the closest value to the laboratory upper limit of normality (35 unit / milliliter) for 
our analysis (307). We explored variation in accuracy indices graphically using forests 
plots of sensitivity and specificity and receiver operative characteristics (ROC) plane 
plots of sensitivity against 1- specificity. As the studies used different cut-offs we grouped 
them in order to isolate subsets of studies using the same cut-off. In the case of no 
evidence of threshold effect within these subsets of studies, we fitted hierarchical 
bivariate random effects model (308) and obtained the following summary accuracy 
measures with corresponding 95% confidence intervals (CI): sensitivity, specificity, 
positive likelihood ratio, and negative likelihood ratio. Post-test probabilities were 
calculated based on pooled estimates of likelihood ratios and overall pre-test odds based 
on published prevalence studies of endometriosis by clinical symptoms or signs. In case 
of evidence of threshold effects we summarised the analyses with the summary receiver 
operating characteristics curve. To investigate sources of heterogeneity, we performed 
subgroup analysis on the following: 1) comparison of study design (cohort vs. case-
control), 2) comparison of positive ultrasound findings for endometriosis and negative or 
no ultrasound prior to test, 3) comparison of revised American Fertility Score (62,63) 
disease stage 1-2 versus 3-4. Sensitivity analyses were performed to evaluate the 
impact on accuracy of excluding studies that had elements of verification bias including 
87% histological confirmation of endometriosis (119) and controls that did not undergo 
the reference standard (262). We checked differences in sensitivity and specificity 
between subgroups by adding covariates to the bivariate model. Stata software was 
used for statistical analyses. (StataCorp. 2013. Stata Statistical Software: Release 13. 
College Station, TX: StataCorp LP).    
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3.4 RESULTS:  
Twenty-one studies recruited 3317 participants (7) (118–121,255,260–265,269–
276,305,309,310). Two retrospective observational studies (119,262), and nineteen 
prospective observational studies (118,120,121,255,261,263–265,269–
276,305,309,310) were included for analysis.  Two studies did not include data that was 
analysable. The authors were contacted but did not respond, these studies were not 
included in the final analysis (255,305). A summary of the included studies is shown in 
figure 7.  
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Figure 7 - Flow of included studies 
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With the exception of Kitawaki 2005 (261), Cho 2008 (262), and Santulli 2015 (118) 
(Table 2), the studies were relatively small (n<300 participants). In accordance with 
World Health Organisation classification, all studies were conducted in high-resource 
settings (311). Recruitment occurred in a variety of settings including infertility clinics, 
fifteen studies (118–121,255,263–265,269,271,272,274,276,305,309) and general 
gynaecology clinic or elective gynaecological theatre sessions, seven studies 
(118,261,263,264,269,271,274). Twelve studies reported including patients with pain 
symptoms (118,120,121,261,264,265,269,271,274–276,305).  Twelve studies recruited 
patients with pre-operative imaging available indicating an ovarian cyst (118,120,261–
265,269–271,273,305).  Endometriosis was confirmed by histology collected at either 
laparoscopic (63,118–121,263,265,269,272–276,305), laparoscopy or open 
(63,255,261,264,271) or did not specify the route of surgery (262,270).  The staging of 
endometriosis was classified using the revised American Fertility Society classification 
1985 (62) or the revised American Fertility Society classification 1997 (63). Nine studies 
(954 participants) included participants with minimal to mild endometriosis (255,262–
265,271,272,305,309) and thirteen studies (1282 participants) included participants with 
moderate to severe endometriosis (121,255,262–265,271–273,275,305,309,310).
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Table 2 - Characteristics of included studies  
Author Year Country Participants Cut Off 
(iu/ml) 
Study Design Participant Characteristics Ovarian 
Cysts 
Endometriosis 
staging criteria 
    
 
    
Wild 1991 USA 93 16 cohort infertility  no rAFS 1985 
Adamyan 1993 USSR 49 35 case - control cysts yes rAFS 1985 
Molo 1994 USA 35 35 cohort Infertility no rAFS 1985 
Abrao 1997 Brazil 50 n/a case - control Not specified / tubal reanastomosis yes rAFS 1985 
Chen 1998 Taiwan 99 35 cohort pain no rAFS 1985 
Kitawaki  2005 Japan 350 30 cohort gynaecology referral / pain / cysts yes rAFS 1997 
Amaral 2006 Brazil 52 25 cohort infertility / pain / tubal ligation no rAFS 1997 
Cho 2008 South 
Korea 
760 35 case - control elective gynaecological surgery / cysts yes rAFS 1997 
Gajbhiye 2008 India 77 35 cohort infertility department / cysts  yes rAFS 1997 
Jing 2008 Japan 61 16.3 case - control pain / Infertility / cysts yes rAFS 1997 
Salahpour 2009 Iran 60 14.7 cohort pain / infertility / miscarriage no rAFS 1997 
Kurdoglu 2009 Turkey 127 35 cohort pain / infertility / general gynaecology / cysts yes rAFS 1997 
Florio 2009 Italy 99 32 cohort endometrioma vs other cysts yes rAFS 1997 
Tokmak 2011 Turkey 88 21.3 cohort cysts yes rAFS 1997 
Vodolazkaia 2012 Belgium 296 12.5 cohort infertility / biobank no rAFS 1997 
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Ramos 2012 Brazil 104 n/a cohort pain / infertility / tubal ligation / cysts yes rAFS 1997 
Mohammed 2013 Egypt 60 35 cohort pain / Infertility no rAFS 1997 
Sayan  2013 Turkey 100 29.9 cohort pain / infertility / general gynaecology / tubal 
ligation / cysts 
yes rAFS 1997 
Kubatova 2013 Turkey 73 35 cohort Pain / infertility / cysts yes rAFS 1997 
Bilibio 2014 Brazil 97 35 case - control pain / infertility / tubal ligation no rAFS 1997 
Santulli 2015 France 685 35 cohort pain / infertility / tubal surgery / cysts yes rAFS 1997 
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Risk of bias was assessed by two authors using the revised assessment tool: QUADAS2 
and is represented in figure 8. 
Figure 8 - Quality Assessment using QUADAS2 Assessment tool 
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undergo surgery. A low risk of bias attributed to the reference standard for all studies as 
this was deemed an objective histological assessment.  One study analysed the index 
test after the reference standard (119), while a further study performed the index test 
following the reference standard (255) and were deemed high risk of bias. A diagnostic 
cut off level for CA-125 was not specified a priori in 15/21 studies, these were classified 
as an unclear risk of bias (118,121,261–264,269–276,297). Fourteen studies had a low 
risk of bias owing to patient selection; five were high risk owing to case-control design 
(119,261–265) and the remaining two were unclear (119,264). Blinding of the surgeon to 
the index test prior to the conduct of the reference standard was reported in eight studies 
(119,255,263,265,269,276,305,309), thirteen studies were unclear in their description. 
CA-125 is an objective laboratory test result however, bias could be introduced to the 
conduct of the reference standard if the surgeon is aware of the CA-125 result. All 
studies were low risk for the index and reference standard with regard to applicability 
concerns. Twelve studies were low risk for patient selection and nine studies unclear 
owing to case-control design and inclusion of patients for tubal surgery, as this group 
may not routinely be screened for endometriosis (118,255,261–263,265,271,274,305). 
The variation in sensitivity and specificity between individual studies for the detection of 
pelvic endometriosis with serum CA-125 measurement is illustrated well in forest plots 
(figure 9). Individual study sensitivities ranged from 0% (272) to 87% (275) and 
specificity from 51% (119) and 100% (120). 
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Figure 9 - Forest plots of sensitivity and specificity sorted in descending order of sensitivity, stratified by cut-off (CA-125 > 30 or <30 iu/ml).  
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Thirteen studies, 2611 participants (1387 with endometriosis, 1224 controls) were 
meta-analysed to assess the accuracy of CA-125 ≥ 30 unit / milliliter for the 
presence of endometriosis (121,261–265,270–272,275,279,309,310). Pooled 
sensitivities and specificities for the 13 studies is summarised in figure 10 (right 
panel). Serum CA-125 ≥ 30 unit / milliliter had a pooled sensitivity of 50.6% (95% 
35.3-65.8) and specificity 91.4% (95% 88.6-93.6). There was no apparent 
correlation between sensitivity and specificity. A sensitivity analysis which 
excluded an outlier study with 0% sensitivity (272) did not significantly alter 
results. This data is not shown. When we analysed a mix of cut-off points for CA-
125, a high variation in both sensitivity and specificity was observed (Figure 10, 
left panel). There was a clear threshold effect which made the accuracy 
estimates of this subgroup less useful.   
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Figure 10 - Summary Receiver Operating Characteristic Curves (CA-125 < 30 or ≥ 30 
iu/ml) 
 
 
 
 
 
 
 
 
 
 
For the detection of endometriosis, the positive likelihood ratio was 5.9 (95% 3.7-9.5) 
and the negative likelihood ratio was 0.5 (95% 0.4-0.7). Fagan’s Nomogram was used to 
calculate post-test probabilities and the likelihood of a positive test reflecting disease 
presence. This predictive tool is used to test the accuracy of a positive test amongst a 
disease with varied prevalence depending on clinical symptoms. For illustrative purposes 
Table 3 has split data into three groups, the general female reproductive population 
(10% pretest probability), women with subfertility (50% pretest probability) and those 
women with treatment resistant chronic pelvic pain (70-90% pretest probability) 
(91,96,312). Patients with a pretest probability of 75% and CA-125 ≥ 30 unit / milliliter will 
have a 95% likelihood of pelvic endometriosis.
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Table 3 - Pre and post-test probability of disease presence. 
 
* Derived from Fagan’s Nomogram. 
 
Clinical Characteristics Pre-test Probability Positive 
Likelihood 
Ratio 
Positive Post-test Probability* Negative 
Likelihood 
Ratio 
Negative Post-test 
Probability* 
            
General population 10% 5.9 40% 0.5 5%       
Subfertility 50% 5.9 86% 0.5 33%       
Chronic Pelvic Pain 75% 5.9 95% 0.5 60% 
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We highlighted sources of heterogeneity as study design (case-control versus cohort), 
the pre-operative ultrasound diagnosis of ovarian endometrioma and disease stage. 
Table 4 summarises these sources of heterogeneity. CA-125 showed higher sensitivity 
with increasing disease severity, 24.8% (95% 18.8-32.1 stage I-II) versus 62.6% (95% 
44.6-77.6 stage III-IV). No significant differences were noted in pooled sensitivity and 
specificity for the detection of endometriosis in the presence or absence of ovarian cysts 
or change in study design. Sensitivity and specificity depend on the clinical situation in 
which the test is being applied. This varies between studies and results in clinical 
heterogeneity. Due to this clinical heterogeneity and the threshold effect, sensitivity and 
specificity are very heterogeneous in diagnostic meta-analyses. This limits the useful of 
testing for heterogeneity or using the I-square statistic to indicate the degree of 
heterogeneity (313).  
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Table 4 - Sub-group analysis
 
 Studies 
(n) 
overall 
p value 
Sensitivity 
 (95% CI) 
p value 
 (relative 
sensitivity)  
Specificity  
(95% CI) 
p value 
 (relative 
specificity) 
LR+ 
(95% CI) 
LR- 
(95% 
CI) 
DOR  
(95% CI) 
CYSTS with 11 p=0.928 56.4  
(44 - 68) 
p=0.538 90.0  
(84.3 - 
93.8) 
p=0.991 5.6  
(3.4 - 
9.4) 
0.5  
(0.4 - 
0.6) 
11.6  
(5.7 - 
23.6) 
without 9 48.9  
(28.9 - 
69.2) 
91.5  
(79.0 - 
96.9) 
5.8  
(2.7 - 
12.3) 
0.6  
(0.4 - 
0.8) 
10.3  
(4.5 - 
23.6) 
STUDY 
DESIGN 
cohort  15 p=0.595 57.9  
(43.2 - 
71.3) 
p=0.210 89.4  
(81.7 - 
94.1) 
p=0.639 5.5  
(3.2 - 
9.3) 
0.5  
(0.3 - 
0.6) 
11.6  
(5.9 - 
23.0) 
case-
control 
4 38.2  
(25.3 - 
53.1) 
90.9  
(85.7 - 
94.4) 
4.2  
(2.1 - 
8.3) 
0.7  
(0.5 - 
0.9) 
6.2  
(2.5 - 
15.3) 
DISEASE  
STAGE 
stages III-
IV  
10 p=0.006 62.6  
(44.6 - 
77.6) 
p=0.003 90.3  
(83 - 94.7) 
p=0.513 6.5  
(4.0 - 
10.4) 
0.4  
(0.3 - 
0.6) 
15.6  
(8.4 - 
29.0) 
stages I-II 6 24.8  
(18.8 - 
32.1) 
92.2  
(89.9 - 
94.0) 
3.2  
(2.2 - 
4.6) 
0.8  
(0.7 - 
0.9) 
3.9  
(2.5 - 
6.2) 
Overall p-value refers to the likelihood ratio test of including in the model variation in both sensitivity and specificity. 
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We performed sensitivity analyses excluding studies with verification limitations 
(119,262) and this did not change accuracy estimates of CA-125 for detecting the 
presence of endometriosis (Table 5). 
Table 5 - Sensitivity analyses 
  
 
Studies Diseased
/ 
Non 
diseased 
Sensitivity 
 (95% CI) 
Specificity 
(95% CI) 
Positive 
Likelihood 
Ratio 
(95% CI) 
Negative 
Likelihood 
Ratio  
(95% CI) 
Diagnostic 
Odds 
Ratio  
(95% CI) 
Cutoff 
Level 
≥ 30 
Total 
 
13 1387/ 
1224 
50.6  
(35.3-65.8) 
91.4  
(88.6-93.6) 
5.9  
(3.7-9.5) 
0.5  
(0.4-0.7) 
10.9  
(5.0-23.7) 
Sensitivity 
analysis* 
 
12 1156/ 695 49.9  
(33.1-66.7) 
91.3  
(87.5-94) 
5.7  
(3.3-9.9) 
0.5  
(0.4-0.8) 
10.4  
(4.4-24.8) 
*(Without Cho & Vodolazkaia studies) 
*(Without Cho & Vodolazkaia studies)  
  Studies Diseased
/ 
Non 
diseased 
Sensitivity 
 (95% CI) 
Specificity 
(95% CI) 
Positive 
Likelihood 
Ratio 
(95% CI) 
Negative 
Likeloihoo
d Ratio 
(95% CI) 
Diagnostic 
Odds 
Ratio  
(95% CI) 
Cutoff  
Level 
< 30 
Total 
 
6 331/ 221 58.1  
(39.7-74.5) 
79.4  
(60.1-90.8) 
2.8  
(1.6-4.8) 
0.5  
(0.4-0.7) 
5.3  
(3.0-9.5) 
Sensitivity 
analysis* 
5 214/ 140 54.6  
(33.6-74.2) 
83.2  
(67.8-92.1) 
3.3  
(2.0-5.4) 
0.5  
(0.4-0.8) 
6  
(3.1-11.3) 
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3.5 DISCUSSION: 
This chapter has been able to demonstrate that the use of serum CA-125 ≥ 30 unit / 
milliliter is highly specific for the detection of histologically confirmed pelvic endometriosis 
amongst symptomatic women. The high levels of specificity achieved in symptomatic 
women provides the possibility of using CA-125 > 30 unit / milliliter as a rule-in test. This 
would minimise unnecessary instigation of hormonal or surgical treatments. The index 
test does have a poor sensitivity for the detection of endometriosis and only 51% of 
those suffering having a CA-125 ≥ 30 unit / milliliter. A CA-125 test result of < 30 units / 
milliliter is unable to rule out the disease, optimising its use amongst a high risk 
symptomatic population. 
This chapter is a summary of the first prospectively registered review comparing the 
accuracy of CA-125 with the histological presence of endometriosis. We conducted a 
comprehensive search strategy, robust methodology, and statistical analysis. All studies 
included reported the primary endpoint using the reference standard of histologically 
confirmed endometriosis. While the sensitivity is poor, the high specificity indicates a low 
risk of false positive result. This minimises patient harm through unnecessary surgical 
procedures or hormonal treatments. This offers specialist and generalist clinicians 
confidence in a positive test providing a diagnosis and instigating management of this 
enigmatic disease. This has potential for providing a resource to diagnosis and medical 
management in countries without access to safe laparoscopic surgery. There are several 
other gynaecological diseases that cause a rise in CA-125 these include, ovarian 
epithelial carcinoma, leiomyoma, and pelvic inflammatory disease. A previous systematic 
review was published over 15 years ago with associated verification bias (116). Our 
meta-analysis addresses these methodological inadequacies. 
Methodological inadequacies include the use of case-control studies (121,256–
259,262,265–268,276). These studies have large discrepancies between the anticipated 
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prevalence of the groups. To analyse the effect of these sources of bias on 
heterogeneity, we performed sub-group analysis with case-control studies and found a 
non-significant change in sensitivity and specificity (Table 4). There was variation in CA-
125 assay assessment which could introduce bias.  
To counter the previously observed verification bias, our selection criteria excluded many 
high quality studies that did not use histological confirmation of endometriosis as the 
reference standard. This leads to selection and publication bias. Patient recruitment, 
index, and reference standard sampling occurred at various stages within the menstrual 
cycle but whether this influences CA-125 level is not well established (278,314). 
Homogenous secondary outcome sub-group meta-analysis was not possible as only 
three studies assessed infertility or pelvic pain separately.  
There is currently no accurate non-invasive test for the detection of endometriosis. This 
meta-analysis demonstrates a role for the use of CA-125 in women presenting with pain 
or infertility. Diagnosis allows women relief, liberation and legitimisation of their 
symptoms including access to support and an opportunity to discuss medical or surgical 
management (253). CA-125 could play a role in both surgical and family care settings. In 
the surgical setting, CA-125 can aid physician-patient decision making in symptomatic 
women where laparoscopy would confer benefit. In family care practices, CA-125 should 
be offered to symptomatic women who would benefit from hormonal use or referral to a 
gynaecologist. For positive post-test probability by pretest risk see table 3. CA-125 has 
limitations with a poor sensitivity of 51%. This limits the use of CA125 to women with 
symptoms of endometriosis where there is high suspicion of disease. The indiscriminate 
use of CA-125 should be avoided in favour of a targeted rule-in test for symptomatic 
women and their clinicians wishing for further confidence in diagnosis prior to delivering 
a therapeutic intervention.  
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In the absence of a more accurate test, this readily accessible and specific test can, 
when positive, provide additional treatment options, reduce time to diagnosis, and 
anxiety amongst endometriosis sufferers. We recommended further research assessing 
cost, quality of life, pain and fertility outcomes following the use of CA-125 to triage 
treatment modality for women in a pelvic pain or fertility clinic. 
3.6 CONCLUSIONS: 
In symptomatic women, the use of CA-125 > 30 unit / milliliter is highly specific for 
diagnosing endometriosis. CA-125 < 30 unit / milliliter does not exclude endometriosis 
and further investigation is required. CA-125 has an important role as a diagnostic 
biomarker in women with symptoms suggestive of endometriosis. 
 
 
This Chapter was based on the following peer reviewed publication (315): 
Diagnostic accuracy of cancer antigen 125 for endometriosis: a systematic review 
and meta-analysis. 
Hirsch M, Duffy J, Davis CJ, Nieves Plana M, Khan KS; International Collaboration to 
Harmonise Outcomes and Measures for Endometriosis. 
BJOG. 2016 Oct;123(11):1761-8. 
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CHAPTER 3:  
THE DIAGNOSTIC ACCURACY 
OF CA-125 – A PRIMARY 
DIAGNOSTIC STUDY  
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This chapter addresses the recommendations from chapter 1. We conducted a 
prospective observational cohort study assessing the diagnostic accuracy of CA-125 for 
the presence or absence of histological endometriosis in women with pelvic pain and or 
subfertility. This study aims to assess the sensitivity, specificity, positive, and negative 
likelihood ratios of a CA-125 ³ 30 iu/ml predicting histologically confirmed endometriosis. 
The analysis of this chapter was informed and performed following the development of a 
cut off value of CA-125 ³ 30 iu/ml generated in chapter 2. This was developed following 
commencement of recruitment for this study. The standardised cut off CA-125 ³ 30 iu/ml 
will promote homogeneity of published research and the future synthesis of meta-
analyses. 
 
4.1 ABSTRACT 
 
Study Objective: Endometriosis is associated with pelvic pain and subfertility affecting 
10% of reproductive age women. There is currently no widely used non-invasive 
diagnostic marker. We aimed to assess the diagnostic accuracy of serum CA-125 > 30 
iu/ml for predicting histological endometriosis in women with pelvic pain or subfertility. 
Design: Prospective observational cohort study. 58 women with pelvic pain or subfertility 
were prospectively evaluated with questionnaires and serum CA-125 immunoassay.  
Setting: Tertiary referral university hospital 
Patients: Patients were included if they were scheduled for laparoscopic investigation of 
pain and or subfertility in the absence of other imaging or history assessed 
gynaecological pathology. We evaluated the accuracy of CA-125 (index test) with 
histological endometriosis (reference standard). 
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Interventions: Laparoscopic investigation of the abdomen and pelvis. 
Measurements and Main Results: We recruited 58 patients with pelvic pain and or 
subfertility undergoing laparoscopy investigation. Women with endometriosis had a 
mean higher CA-125 level than those without endometriosis (54.7 +/-71.6 vs 16.2 +/- 8.0 
p=0.006). The sensitivity of CA-125 ³ 30 U/ml was 0.57 and the specificity was 0.96. The 
positive likelihood ratio for the histological presence of endometriosis with a CA-125 ³ 30 
U/ml was 15.8 providing a post-test probability of 94% in women with pain and or 
subfertility. 
Conclusions: 
This study demonstrates that CA-125 > 30 iu/ml is highly predictive of endometriosis in 
women with symptoms of pain or sub-fertility and no evidence of concomitant 
gynaecological pathology.  
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4.2 INTRODUCTION 
Endometriosis is defined as the presence of endometrial glands and stroma located 
outside the uterus. It is a disease characterised by pain and subfertility. Disease 
estimates suggest a prevalence of 10% of reproductive age women and up to 75% of 
symptomatic women yet it is commonly under-diagnosed (315). The gold standard 
diagnostic test is surgery, visualisation, biopsy and histological confirmation. Evaluation 
of non-invasive diagnostic biomarkers has not identified an accurate test for the 
detection of endometriosis (316,317). Women presenting to their primary care physician 
or gynaecologist are unable to receive a non-invasive test that can include or exclude 
endometriosis. A rule in test can reduce time to diagnosis, provide psychological 
reassurance, offer treatment options, and reduce disease progression (253). Cancer 
Antigen-125 (CA-125), a well-established marker for epithelial cell ovarian cancer, is 
derived from coelomic epithelia including the endometrium, fallopian tube, ovary, and 
peritoneum (318). CA-125 is raised in endometriosis through stimulation of coelomic 
epithelia (254). Previous diagnostic accuracy studies have suffered from verification bias 
(visual diagnosis) or design bias (all case control). 
The aim of this present study is to assess the diagnostic accuracy of preoperative serum 
CA-125 levels in a cohort of women with pain or subfertility for the diagnosis of 
histologically confirmed endometriosis.   
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4.3 METHODS 
Study Design 
The local ethics committee approval was sought for the study protocol. This study was 
conducted as a prospective observational cohort study. The cohort included women with 
pelvic pain and or subfertility undergoing laparoscopic investigation. 
Patient selection and data collection 
All included patients signed a written informed consent form. The study commenced in 
October 2013 and we prospectively collected consecutive clinical data from women 
referred for investigation of pelvic pain and or subfertility under the care of the benign / 
reproductive gynaecological teams at The Royal London and St Bartholomew’s Hospital. 
The definition used for pelvic pain was a visual analogue score (VAS) of > 50 on a VAS 
0-100 for dysmenorrhea, dyspareunia or chronic pelvic pain. The definition used for 
subfertility was unexplained failed conception after 12 months of regular (>twice/week) 
unprotected vaginal intercourse (319). Patients were excluded if they were believed to 
have or previously had a condition other than endometriosis which can cause a raised 
CA-125. These conditions included previous or suspected; leiomyoma, adenomyosis, 
pelvic inflammatory disease, mature cystic teratoma, mucinous cystadenoma, and 
hydrosalpinges. They were evaluated with either ultrasound, MRI, or medical history. 
Women with a history of any malignancy or those who did not consent were excluded 
from analysis.  
Participants were recruited consecutively and consented prior to surgery and serum 
samples were collected preoperatively for CA-125 immunoassay measurement. The 
participants underwent routine operative surgical management from surgeons working 
within a national endometriosis centre with over ten years’ experience of diagnosing and 
managing endometriosis. The surgeons performing the procedures were blinded to the 
result of the CA-125 test that was processed in a NHS quality controlled laboratory within 
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4 hours of sampling. Laparoscopy was performed and all recognisable endometriosis 
lesions were biopsied and then treated by bipolar coagulation, resection of endometriosis 
nodules or ovarian cystectomy. In accordance with ESHRE guidance (107), histological 
confirmation of disease was attempted but not possible in all cases of suspected 
endometriosis. As the diagnosis of endometriosis stage 1 / 2 has poor accuracy based 
on visual diagnosis alone (64), the authors decided to exclude those patients without 
histological confirmation of disease. Those patients with visually confirmed 
endometriosis or other pelvic pathology at the time of surgery were excluded from the 
primary analysis. 
Data was collected during face-to-face interviews with each patient by a single 
researcher (MH) in the preoperative assessment area. We collected demographic 
information for all patients including age, gravidity, parity, age at menarche, stage of 
menstrual cycle, smear history, previous surgery, medication, infertility duration, smoking 
status, alcohol status, and contraceptive use. Pain symptoms were assessed 
prospectively using a visual analogue scale (VAS) 0-100mm for dysmenorrhoea, deep 
dyspareunia, dysuria, dyschezia, chronic pelvic pain, and mid cycle pain. We did not 
confound for hormonal use or stage of menstrual cycle.  
The primary outcome was the diagnostic accuracy of CA-125 ³ 30 iu/ml to detect the 
presence of histologically confirmed endometriosis. Secondary outcomes included 
assessing the association between CA-125 level and pain.  
Statistical analysis 
Statistical data were collected in a computerised database and analysed by SPSS 
software 18.0.0 (SPSS Inc., Chicago, Illinois). We compared the clinical characteristics 
between those with endometriosis and those without, summarising the characteristics of 
the two groups using standard statistics. These two groups were classified as either 
reference standard (histological endometriosis) positive or negative. We then calculated 
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the area under the receiver operating curve (ROC), which quantifies the ability of the 
index test (CA 125) to distinguish between patients with and without endometriosis. Our 
sample size was chosen so that if the true AUC was 0.85, we would be able to estimate 
it to within 0.15 using a 95% CI [13]. This was performed retrospectively. Positive 
likelihood ratios and negative likelihood ratios were calculated and post-test probability 
was evaluated using these likelihood ratios and Fagan’s Nomogram (320) based on a 
pre-test prevalence estimate of 50% in this group of symptomatic women (312). 
 
4.4 RESULTS 
 
Primary study 
A total of 141 participants undergoing laparoscopic investigation of pelvic pain or 
subfertility were approached for recruitment. 102 met the previously described inclusion 
criteria. We prospectively recruited 67 women without evidence of PID, fibroids, ovarian 
cysts, (other than endometrioma), adenomyosis, or hydrosalpinges. Nine patients were 
excluded at the time of surgery: biopsy of suspected lesions was not possible (n=7); 
additional disease was noted (n=1); and failed laparoscopic entry (=1). One study 
participant who did not undergo the procedure due to failed laparoscopic entry 
secondary to insufflation of the pre-peritoneal space. This prohibited safe primary trocar 
insertion. The patient was observed overnight and followed up in clinic without 
complication. Fifty-eight women were included in the primary analysis (figure 11). Of 
those included, 28 had no macroscopic pathology and 30 were found to have 
histologically confirmed endometriosis (figure 11).   
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Figure 11 - flow of included patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Approached 
Patients referred for surgery for benign / reproductive 
gynaecological disease 
n= 141 
Excluded 
Ultrasound evidence of exclusion criteria n=22 
History of exclusion criteria: n=19 
Did not meet inclusion criteria: n=33 
 
 
 
 
 
Included 
Histological evidence of endometriosis 
n= 30 
Excluded  
Endometriosis not biopsied: n=7 
Pelvic inflammatory disease: n=1 
Failed laparoscopic entry: n=1 
 
 
 
 
 
Surgery 
n= 67 
 
 
 
 
 Included 
No evidence of pelvic pathology 
n= 28 
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Clinical characteristics 
Between October 2013 and October 2015, 141 patients were approached for entry into 
this study. We excluded 84 for the following reasons; suspected adenomyosis, 
suspected leiomyoma, previous pelvic inflammatory disease or sexually transmitted 
infection, previous malignancy, and visually suspected endometriosis. A total of 58 were 
included for analysis. The clinical characteristics of the patients are summarised in table 
6. The patients were staged according the revised American Fertility Scoring for 
endometriosis and were classified as follows: 7 stage 1, 9 stage 2, 10 stage 3, 4 stage 4 
(63). Twenty six patients were recruited during the follicular phase and 22 during the 
luteal phase of the menstrual cycle. We were unable to determine the phase of the 
menstrual in 10 patients due to hormonal contraceptive use.  
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Table 6 - Participant Characteristics  
 
Baseline Characteristics Endometriosis 
(n=30) 
Controls  
(n=28) 
Age, yrs 34.1 32.2 
Primary Infertility, n (%) 14 (47%) 8 (29%) 
Secondary Infertility, n (%) 3 (10%) 6 (21%) 
Endometriosis Stage I-II, n (%) 16 (53%) - 
Endometriosis Stage III-IV, n (%) 14 (47%) - 
Mean CA-125 value u/ml 54.7 (SD 71.6) 16.2 (SD 7.97) 
Hormonal contraceptive use, n (%) 5 (17%) 4 (14%) 
Mean VAS (0-10cm) Dysmenorrhea 8.10 (SD 1.41) 6.49 (SD 2.97) 
Mean VAS (0-10cm) Dyspareunia 5.26 (SD 3.31) 4.53 (SD 3.79) 
Mean VAS (0-10cm) Dsychezia 3.77 (SD 3.41) 1.91 (SD 2.81) 
Mean VAS (0-10cm) Chronic pelvic pain 3.81 (SD 3.80) 4.24 (SD 3.82) 
Mean VAS (0-10cm) Dysuria 1.25 (SD 1.99) 0.73 (SD 1.72) 
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Primary results  
The two groups were comparable for age. The mean age for those with confirmed 
endometriosis was 34.1 (SD +/- 5.9) and without endometriosis 32.2 (SD +/- 8.6). 
Mean CA-125 values 
Thirty patients diagnosed with endometriosis had a mean CA-125 level was 54.7 (SD 
71.6). Twenty eight participants with no macroscopic pathology had a mean CA-125 of 
16.2 (SD 8.0). One patient had a CA-125 > 30 iu/ml without macroscopic gynaecological 
disease while 17 had both a CA-125 > 30 iu/ml and histological endometriosis. Thirteen 
patients had a CA-125 < 30 iu/ml in the presence of histological endometriosis while 
27patients had a CA-125 < 30 iu/ml in the absence of macroscopic endometriosis.  
Diagnostic accuracy  
Receiver operating characteristic curve (figure 12) demonstrates the accuracy of CA-125 
as a diagnostic test for endometriosis. The area under the curve, 0.85 (CI 0.74 – 0.96) 
indicates high test accuracy. The use of a predefined cut-off, CA-125 ³ 30 iu/ml is based 
on a previously published meta-analysis (315). This will enable further data-synthesis in 
the future with a comparable cut off. The chosen cut-off value (30 iu/ml) demonstrated 
57% (95% CI 37.4 – 74.5%) test sensitivity and 96% (95% CI 81.7 – 99.9%) specificity, 
and 76% diagnostic accuracy. The positive likelihood ratio of CA ³ 30 iu/ml was 15.8 
(2.3-112) producing a positive post-test probability of 94% amongst women with pain or 
subfertility in the absence of other gynaecological disease (table 7, figure 13). The 
negative likelihood ratio is 0.45 (95% CI 0.30-0.68) producing a negative post-test 
probability of 33% in women with CA < 30 u/ml and common gynaecological symptoms. 
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Figure 12 - Receiver Operating Characteristics Curve  
 
 
Area Under the Curve 
Test Result Variable(s):   CA-125 iu/ml 
Area Std. Errora Asymptotic Sig.b 
Asymptotic 95% CI 
Lower Bound Upper Bound 
.850 .054 .000 .744 .956 
The test result variable(s): CA125 has at least one tie between the positive actual state group 
and the negative actual state group. Statistics may be biased. 
a. Under the nonparametric assumption 
 b. Null hypothesis: true area = 0.5 
 
  
 107. 
Table 7 - Coordinates of the Curve Test Result Variable: CA-125 iu/ml 
 
Positive if greater than or equal 
to 
Sensitivity Specificity 
4.00 1.000 0 
6.00 0.967 0 
8.00 0.967 0.071 
9.50 0.933 0.143 
10.50 0.933 0.179 
11.50 0.933 0.25 
12.50 0.933 0.321 
13.50 0.933 0.5 
14.50 0.933 0.571 
15.50 0.933 0.607 
16.50 0.933 0.643 
17.50 0.900 0.643 
18.50 0.867 0.75 
19.50 0.833 0.786 
20.50 0.733 0.786 
21.50 0.667 0.786 
22.50 0.633 0.786 
23.50 0.633 0.857 
25.00 0.633 0.893 
26.50 0.633 0.964 
28.00 0.600 0.964 
30.00 0.567 0.964 
34.00 0.533 0.964 
37.50 0.467 0.964 
38.50 0.433 0.964 
39.50 0.400 0.964 
40.50 0.367 0.964 
43.00 0.267 0.964 
45.50 0.233 0.964 
51.00 0.233 1 
63.00 0.200 1 
80.00 0.167 1 
90.50 0.133 1 
111.50 0.100 1 
161.00 0.067 1 
282.00 0.033 1 
375.00 0.000 1 
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Secondary results 
Pain symptoms 
We compared pain symptoms between those with endometriosis and those without 
endometriosis. Individual patient values were combined to produce means with standard 
deviations (SD) calculated. The mean VAS for dysmenorrhea amongst those women 
with endometriosis was 8.10cm (SD 1.41cm), and for women without endometriosis was 
6.49cm (SD 2.97cm). The mean VAS for dyspareunia amongst those women with 
endometriosis was 5.26cm (SD 3.31cm), and for women without endometriosis was 
4.53cm (SD 3.79cm). The mean VAS for chronic, non-cyclical pelvic pain amongst those 
women with endometriosis was 3.81cm (SD 3.8cm), and for those women without 
endometriosis was 4.24cm (SD 3.82cm).  
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Figure 13 - Fagan's Normogram 
 
POSITIVE TEST: 
Positive Likelihood ratio: 15.75 
95% CI: [2.26,112] 
Post-test probability (odds): 94% (17.1) 
95% CI: [71%,99%] 
 
NEGATIVE TEST: 
Negative Likelihood ratio: 0.45 
95% CI: [0.30,0.68] 
Post-test probability (odds): 33% (0.5) 
95% CI: [24%,42%] 
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4.5 DISCUSSION 
 
Main Findings 
This primary cohort study indicates that CA-125 ³ 30 iu/ml has a high accuracy for the 
detection of endometriosis in symptomatic women without evidence of other concurrent 
gynaecological disease. CA-125 provides limited sensitivity for the detection of 
endometriosis and a negative test cannot exclude endometriosis. In the absence of other 
accurate biomarkers, CA-125 > 30 iu/ml provides diagnostic confidence to both clinicians 
and patients.  
Strengths 
Strengths of this study include its robust design. We prospectively recruited a 
homogenous cohort of women with pain or subfertility. We blinded a select group of 
surgeons working at an endometriosis specialist centre to the outcome of the index test 
result.  We reduced recruitment bias by limiting recruitment to be performed by a single 
individual and assay bias was minimised by the use of a single quality controlled NHS 
laboratory. We limited interpretation bias by using a pre-defined validated cut-off for the 
analysis. We minimised clinical heterogeneity by excluding participants with other 
diseases known to cause a raised CA-125. 
Limitations 
This study has limitations by its small sample size. We sampled the index and reference 
standard at varied times during the menstrual cycle, including those women on hormonal 
modulators. Although there is no clear influence of menstrual timing (314)  nor hormones 
(321) altering CA-125 levels this introduces clinical heterogeneity. CA-125 is known to be 
raised in other benign and malignant gynaecological pathology. We attempted to 
confound for this by excluding all those patients with prior ultrasonographic or MRI 
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evidence of leiomyoma, adenomyosis, and hydrosalpinges, benign non-endometriotic 
cysts. We excluded those patients with a previous history of pelvic inflammatory or 
sexually transmitted disease. This study is limited by the small number included 
participants. There are ongoing limitations associated with the reference standard 
(visualisation, biopsy, and histological confirmation) used in this and many other studies. 
The presence of occult microscopic endometriosis endometriosis lesions has been 
confirmed on visually normal peritoneum, this introduces verification bias to this and all 
diagnostic accuracy studies(322).  
Comparison with existing literature 
Previous primary studies and systematic reviews have demonstrated a limited role for 
the use of CA-125 in the detection of endometriosis. These studies suffered from 
significant verification bias (visual detection), design bias (case-control studies) and 
cohort heterogeneity (varied recruitment strategies) (315). The sensitivity of CA-125 has 
repeatedly been demonstrated as poor with increasing accuracy associated with 
advancing stage of disease (315). The search for an accurate non-invasive biomarker for 
endometriosis remains elusive (252,323) despite it being highlighted a research priority 
in 2009 (106).  
Interpretation 
As confirmed by Mol et al 1998, CA-125 is an important biomarker with a role as a rule-in 
test for women with pain or subfertility (116). The sensitivity of this test remains poor, 
limiting its use to cohorts of symptomatic women with a high pre-test prevalence. The 
diagnosis of women with pain or subfertility and a normal ultrasound remains difficult. 
This study has attempted to address these difficulties.  
This study demonstrates that when CA-125 ³ 30 iu/ml is used amongst a defined 
population with a narrow inclusion criteria for testing, a positive result provides a very 
high post-test probability. The high specificity minimises false positive results and 
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unnecessary treatment exposure from hormonal therapies or surgical procedures. The 
implementation of CA 125 in primary care or hospital settings as a point of care test for 
women with pain or subfertility and a normal USS may decrease delays in the diagnostic 
pathway, allowing women relief, liberation and legitimisation of their symptoms, together 
with access to support and an opportunity to discuss individualised medical or surgical 
management. 
Further research is required amongst a population of women with pelvic pain or 
subfertility and a negative pelvic ultrasound to assess its role in triaging treatment, 
access to specialist services and time to diagnosis and symptom control. We 
recommend a new treatment pathway for those women presenting to their family 
practitioner with pelvic pain or subfertility which promotes patients’ autonomy, speed of 
diagnosis, and access to treatment or specialist advice. 
 
4.6 CONCLUSION 
In the absence of a more accurate, non-invasive diagnostic test, CA-125 ³ 30 iu/ml can 
act as a rule-in test for women with pain or subfertility.  
 
This chapter is based on the following publication: 
Diagnostic accuracy of CA-125 for endometriosis in symptomatic women: A multi-
center study.  
Hirsch M, Duffy J, Deguara C, Davis C, Khan K.  
Eur J Obstet Gynecol Reprod Biol. 2017 Mar;210:102-107.  
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CHAPTER 4: 
VARIATION IN OUTCOME 
REPORTING IN 
ENDOMETRIOSIS TRIALS – A 
SYSTEMATIC REVIEW  
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In this chapter I will discuss the most commonly reported outcomes and outcome 
measures used in treatment effectiveness trials in endometriosis. I will describe their 
quality and associations with journal impact factor, methodological quality, year of 
publication, journal type and funding source. 
5.1 ABSTRACT 
Background: The reporting of outcomes within systematic reviews is dependent upon 
the quality and homogeneity of those reported within trials. Variation in outcome 
reporting leads to difficulty in comparing, contrasting and analysing data to generate 
clinical guidelines and improve patient care. 
 
Objective: To reviewed the outcomes and outcome measures reported in randomised 
controlled trials (RCTs) of surgical interventions for endometriosis. To assess the 
relationship of the outcome quality with methodological quality, year of publication, 
commercial funding, and journal impact factor.  
 
Data Sources: The following databases were searched from inception to November 
2014: Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and 
MEDLINE  
 
Methods of Study Selection: We included randomised controlled trials which evaluated 
a surgical intervention with or without an adjuvant medical therapy for the treatment of 
endometriosis. Two authors worked independently to select trials, assess methodological 
quality (Jadad score; range one to five), outcome reporting quality (MOMENT criteria; 
range one to six), year of publication, impact factor in the year of publication, and 
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presence or absence of commercial funding. Univariate and bivariate analysis were 
performed using both Spearman Rho and Mann-Whitney U tests. Multivariate linear 
regression models were used to assess the relationship associations between outcome 
reporting quality and other variables. 
 
Results:  
A total of 54 RCTs with 5427 participants reported 164 outcomes and 113 outcome 
measures.  The three most reported primary outcomes were dysmenorrhea (10 outcome 
measures; 23 trials), dyspareunia (11 outcome measures; 21 trials), and pregnancy (3 
outcome measures; 26 trials). The quality of outcome reporting was measured and the 
median score was 3 (interquartile range 4-2) and methodological quality 3 (interquartile 
range 5-2). Multivariate linear regression demonstrated a correlation between outcome 
reporting quality with methodological quality (β=0.325; p=0.038) and year of publication 
(β=0.067; p=0.040). No relationship was demonstrated between outcome reporting 
quality with journal impact factor (Rho=0.190; p=0.212) or commercial funding (p=0.370)  
 
Conclusion: There is variation in outcome reporting within endometriosis trials. This 
prohibits comparison, combination, and synthesis of data, limiting the usefulness of 
research to inform clinical practice, enhance patient care, and improve patient outcomes. 
This demonstrates the need to generate an international consensus among stakeholders 
to standardise outcome reporting through the development of a core outcome set for 
endometriosis trials.  
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5.2 INTRODUCTION 
Endometriosis is a common disease affecting 1 in 10 women impairing health related 
quality of life in the domains of fertility, pain, psychological, and social functioning. 
Endometriosis is a poorly understood disease and is managed with alternative, holistic, 
medical, and surgical therapies. There is currently no consensus amongst stakeholders 
(patients, healthcare professionals, and researchers) regarding the most important 
outcomes and outcome measures which should be collected and reported in 
endometriosis effectiveness trials. The factors leading to outcome reporting variation are 
unclear. Without stakeholder generated consensus, the variation in outcome reporting 
within effectiveness trials will continue to produce misleading results as these individual 
studies cannot be compared or combined. This can lead to the favouring of ineffective 
interventions or underestimating harms (324,325). The accurate measurement and 
reporting of consistent comparable outcomes is crucial to developing the highest level of 
evidence.  
In line with a statement from the US Congress established Patient-Centered Outcomes 
Research Institute (PCORI) we hope that this review will help towards ensuring the 
selection of ‘‘outcomes that people in the population of interest notice and care about’’ 
(326). 
In this chapter I aimed to systematically organise and describe the outcomes, their 
measurement instruments and definitions reported by RCTs evaluating surgical 
interventions for endometriosis. I assessed other publication features, such as journal 
impact factor, year of publication, methodological quality, and publication location 
(general or women’s health specific journal) are correlated to outcome reporting or 
methodological quality.   
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5.3 METHODS 
 
A protocol with clearly defined objectives, criteria for study selection, and approaches 
assessing outcomes selection was developed. This study was prospectively registered 
with the Core Outcome Measures in Effectiveness Trials (COMET) (327) Initiative and 
reported in accordance with the PRISMA guidelines (328). 
Sources 
We searched CENTRAL, Embase, and Medline for relevant citations from database 
inception to November 2014 with no language restrictions. We reviewed the Cochrane 
Register of Systematic reviews to identify any additional systematic reviews then 
searching their bibliography for eligible trials (329). 
Study Selection 
Two independent reviewers (MH & JMND) screened titles and abstracts.  The full text of 
selected studies were critically reviewed to assess eligibility by both MH & JMND.  
Discrepancies between the two reviewers were resolved by discussion with a more 
senior third author (KSK).  We included only randomised control trials (RCTs) assessing 
the effectiveness of any surgical procedure with or without an adjuvant medical therapy 
for the treatment of endometriosis.  We excluded, non-randomised, quasi-randomised, 
diagnostic and analytical studies. 
Two reviewers (MH and JMND) extracted data independently using a piloted data 
extraction sheet. We extracted study characteristics including the publishing journal, 
setting, study design, sample size calculation, interventions, participants, and 
pharmaceutical funding.  The study characteristics were summarised in tabular form 
(Table 8). We used the online platform, Researchgate, to assess the impact factor in the 
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year of publication. We systematically reviewed primary and secondary outcomes and 
their definitions and instruments.   
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Table 8 - Study Characteristics 
Study IF Method. 
quality 
Outcome 
quality 
Intervention group one Intervention group two Intervention group 
three 
Abbott  
2004 
3.17 5 4 Diagnostic laparoscopy 
+ delayed surgical treatment 
Surgical treatment 
+ repeat surgery 
  
       
Abu Hashim 2012 1.85 5 6 Surgical treatment  
+ superovualtion with letrozole  
+ intrauterine inseminiation (IUI) 
Surgical treatment 
+ superovulation with clomiphene 
citrate  
+ IUI 
  
              
Acien  
2002 
3.202 2 2 Surgical treatment  
+ interferon α-2b  
Surgical treatment  
+ saline  
  
              
Alborzi  
2004 
3.17 2 5 Surgical treatment  
+ ovarian fenestration and 
coagulation 
Surgical treatment  
+ovarian cystectomy 
  
  
 
          
 
Alborzi  3.168 2 2  Surgical Treatment Surgical treatment Surgical treatment 
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2007 + ovarian fenestration and 
coagulation 
+ ovarian cystectomy + ovarian fenestration and 
cystectomy  
              
Alborzi 2011 1.072 2 2 Surgical treatment  
+ GnRHa 
Surgical treatment  
+ aromatase inhibitor 
Surgical treatment  
 
              
Alkatout 2013 1.575 2 2 Surgical treatment 
 
HT 
 
Surgical treatment  
+ HT 
              
Audebert 1998 0.745 2 2 Surgery treatment  
+ GnRHa  
GnRHa  
+ Surgical treatment 
  
              
Ballester 2011 3.468 2 4 Laparoscopy 
+ colorectal resection 
Laparotomy 
+ colorectal resection 
  
              
Beretta 1998 3.344 2 2 Surgical treatment  
+ ovarian cystectomy 
Surgical treatment 
+ ovarian fenestration and 
coagulation 
  
              
Bianchi 1999 3.643 3 2 Surgical treatment  Surgical treatment 
 
  
  
 121. 
+ Danocrine 
              
Busacca 2001 2.751 3 2 Surgical treatment  
+ GnRH agonist 
Surgical treatment   
              
Candiani 1992 1.982 3 3 Surgical treatment  
+ presacral neurectomy 
Surgical treatment 
 
  
              
Cobellis 2011 1.974 5 3 Surgery treatment  
+ Fatty acid amide 
Surgical treatment  
+ selective COX2 NSAID 
Surgical treatment 
 
              
Cosson 2002 3.202 3 4 Surgical treatment  
+ Progestin 
Surgical treatment  
+ GnRHa 
  
              
Costello 2010 3.122 5 6 Surgical treatment  
+ multimodal intraoperative 
analgesia 
Surgical treatment  
+ placebo 
  
  
 
            
Creus 2008 2.537 5 0 Surgical treatment  
+ Xanthine derivative 
Surgical treatment  
+ placebo 
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Darai 2010 7.474 3 5 Laparoscopy 
+ colorectal resection 
Laparotomy 
+ colorectal resection 
  
              
Darai 2011 3.564 3 2 Laparoscopy 
+ colorectal resection 
Laparotomy 
+ colorectal resection 
  
              
diZerega 2007 3.168 5 3 Surgical treatment  
+ Adhesion barrier gel 
Surgical treatment 
 
  
              
Healey 2010 3.122 5 3 Surgical treatment  
+ ablation 
Surgical treatment 
+ excision 
  
              
Hoo 2014 3.483 5 6 Surgical treatment 
+ ovarian suspension 
Surgical treatment 
 
  
              
Jarrell 2005 - 5 2 Surgical treatment 
 
Diagnostic Laparoscopy  
+ biopsy 
  
              
Kamencic 2008 - 3 2 Surgical treatment  Surgical treatment 
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+ Xanthine derivative 
              
Koninckx 2013 2.03 5 6 Surgical treatment  
+ humidified CO2 
pneumoperitoneum   
Surgical treatment  
+ peritoneal full conditioning and 
barrier gel 
  
              
Lalchandani 2005 - 2 3 Diagnostic laparoscopy  
+ GnRHa + HT 
Sugical treatment  
+ helium thermal coagulator 
  
              
Loverro 2008 1.565 5 2 Surgical treatment  
+ GnRHa 
Surgical treatment  
+ placebo 
  
              
Mais 1995 - 2 5 Surgical treatment  
+ adhesion barrier 
Surgical treatment 
 
  
              
Marcoux 1997 27.766 5 6 Surgical treatment  
+ ablation 
Surgical treatment  
+ excision 
  
              
Matorras 2002 3.202 2 2 Bilateral salpingo-oophrectomy  
+ HT 
Bilateral salpingo-oophrectomy 
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Moini 2012 0.471 5 4 Surgical treatment 
 
Diagnostic Laparoscopy 
 
  
              
Morgante 1999 3.643 2 3 Surgical treatment  
+ GnRHa + Danocrine 
Surgical treatment  
+ GnRHa 
  
              
Nowroozi  1987 - 3 1 Surgical treatment  
+ ablation 
Diagnostic Laparoscopy 
 
  
              
Parazzini 1994 2.247 5 3 Surgical treatment  
+ GnRHa 
Surgical treatment 
 
  
              
Parazzini 1999 3.643 3 2 Surgical treatment  
+ ablation 
Surgical treatment  
+ excision 
Diagnostic Laparoscopy 
 
              
Seiler 1986 - 3 0 Surgical treatment   
+ ablation 
Treatment with Danocrine   
              
Soysal 2004 3.072 5 4 Surgical treatment  
+ GnRHa 
Surgical treatment  
+ GnRHa + aromatase inhibitor 
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Surrey 1994 - 2 3 Gamete Intra-fallopian tube transfer 
(GIFT) 
+ Surgical treatment 
GIFT 
 
  
              
Sutton 1994 2.464 5 3 Surgical treatment  
+ presacral neurectomy 
Diagnostic Laparoscopy 
 
  
              
Sutton 1997 2.612 4 2 Surgical treatment  
+ presacral neurectomy 
Diagnostic Laparoscopy 
 
  
              
Sutton 2001 0.63 5 2 Surgical treatment  
+ presacral neurectomy 
Surgical treatment  
 
  
              
Tanmahasamut 
2012 
4.798 5 5 Surgical treatment  
+ Mirena IUS 
Surgical treatment 
 
  
  
 
            
Telimaa 1988 - 4 1 Surgical treatment  
+ Danocrine 
Surgical treatment  
+ progestin 
Surgical treatment  
+ placebo 
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Tsai 2004 0.778 5 2 Surgical treatment  
+ GnRHa 
Surgical treatment  
+ Danocrine 
Surgical treatment 
 
              
Vercellini 1999 2.657 3 4 Surgical treatment  
+ GnRHa 
Surgical treatment 
 
  
              
Vercellini 2002 3.202 3 4 Surgical treatment  
+ Progestin 
Surgical treatment  
+ COCP 
  
              
Vercellini 2003A 3.483 5 5 Surgical treatment  
+ presacral neurectomy 
Surgical treatment 
 
  
              
Vercellini 2003B 3.483 3 3 Surgical treatment  
+ Mirena IUS 
Surgical treatment 
 
  
              
Wickstrom 2012 4.542 5 3 Tubal pertubation  
+ lidocaine 
Tubal pertubation  
+ placebo 
  
              
Wright 2005 3.114 4 2 Surgical treatment  
+ ablation 
Surgical treatment  
+ excision 
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Zhao 2013 1.401 1 2 Surgical treatment  
+ chinese medicine 
Surgical treatment  
+ GnRHa + HT 
Surgical treatment  
+ progestin 
              
Zhao  2013B 1.401 3 6 Surgical treatment  
+ chinese medicine 
Surgical treatment  
+ GnRHa + HT 
Surgical treatment  
+ progestin 
              
Zhu 2014 1.877 3 2 Surgical treatment  
+ COCP 
Surgical treatment  
+ COCP + Chinese medicine 
Surgical treatment  
 
              
Zullo 2003 2.518 5 4 Surgical treatment 
+ presacral neurectomy 
 
Surgical treatment 
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Quality Assessment 
All included studies were assessed by two reviewers (MH and JD) independently 
evaluating each study's methodological and outcome reporting quality. 
We used the internationally recognised JADAD criteria for assessment of methodological 
quality. The five point validated scoring system assesses the following: 1. Was the trial 
described as randomised? (1-point); 2. Did the trial use an appropriate method of 
randomisation?  (1-point); 3. Was the trial blinded? (1-point), 4. Did the trial use an 
appropriate method of blinding? (1-point), 5. Did the trial account for all patients 
randomised? (1-point) (330). 
Two reviewers (MH and JD) independently assessed each study's outcome reporting 
using the six point MOMENT scoring system which had been previously validated for the 
development of a core outcome set (331): 1. Was a primary outcome stated? (1-point), 
2. Was the primary outcome clearly defined for reproducible measures? (1-point), 3. 
Were the secondary outcomes clearly stated? (1-pojnt), 4. Were the secondary 
outcomes clearly defined for reproducible measures? (1-point), 5. Do the authors explain 
the choice of outcome? (1-point), 6. Are the methods used designed to enhance quality 
of measures appropriate? (1-point). There is no well-defined rating score associated with 
this criteria, therefore a previously used cut off of ≥ 4 was used to represent ‘high’ quality 
trials (331).  
Data synthesis 
Non-parametric correlation coefficient (Spearman rho) was used to assess univariate 
association between continuous factors. The comparison of outcome reporting quality 
was assessed between groups according to funding source (commercial or other), year 
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of publication, type of journal (general vs. specialist), and impact factor in the year of 
publication. A specialist journal within obstetrics and gynaecology was defined by those 
found listed by www.scimagojr.com. Articles were reviewed closely for funding status. 
Those trials receiving commercial funding or the donation of equipment, which had 
facilitated the trial were classed pharmaceutically funded. The univariate analysis 
between non-continuous factors was performed using non-parametric Mann Whitney U 
tests. We used a multivariate linear regression model to assess the multivariate 
relationship of outcome reporting quality. We included journal type, impact factor in the 
year of publication, year of publication and methodological quality as independent 
variables and outcome reporting as the dependent variable. We only included significant 
predictors within the final model. We checked linear regression assumptions by exploring 
residuals versus predicted plot. The analyses were all performed using Stata program 
(StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp 
LP).  
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5.4 RESULTS 
The study selection is summarised in figure 14. There were 1570 titles and abstracts 
identified from the search strategy.  We found 161 duplicate records, which we excluded, 
and screened 1409 titles and abstracts (figure 14). We included 54 RCTs 
(204,206,223,224,246–250,332–376) (Table 8). The included trials collected and 
reported 164 separate primary and secondary outcomes together with 113 outcome 
measures (Table 9). The outcome measurement or definition was not described within 
the trial report for 110 outcomes.  
Outcomes were grouped by domain and the commonest outcome domains were pain 
29/54 trials (53%), subfertility 22/54 trials (41%), and quality of life 9/54 trials (17%).  
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Figure 14 - Flow of included studies. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through database search  
n= 1570  
EMBASE: 496 
Medline: 464 
CENTRAL: 610 
         
Records screened (titles and abstract)  
n= 1409 
Duplicates removed  
n= 161 
Records excluded 
n= 1061 
Studies included in quantitative synthesis  
n= 54 
Excluded studies (n= 294)  
No surgical intervention: n= 101 
Not RCT: n= 142 
Not exclusively endometriosis: n= 
51 
 
 
 
  
Records screened (full text)  
n= 348 
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Table 9 - Outcome and outcome measures reported 
Domain RCTs  Outcomes* Outcome measure*  
Pain 37 32 24 
Subfertility 32 28 11 
Quality of life 9 10 10 
Surgical adverse events 14 34 5 
Medical adverse events 8 22 0 
*Not an exhaustive list 
 
 
Pain is a hallmark symptom of endometriosis and within the domain, the three most 
commonly reported outcomes were dysmenorrhea (23/54 RCTs, 10 outcome measures), 
dyspareunia (21/54 RCTs, 11 outcome measures), and pelvic pain (15/54 RCTs, 9 
outcome measures). Three trials assessing pain did not specify the outcome measure 
used (337,347,348) (table 9, table 10, and table 11). Dysmenorrhea was measured with 
ten different outcome measures. Listed in order of frequency of use; visual analogue 
scale anchored between 0-10cm; visual analogue scale anchored between 0-100mm; 
visual analogue scale anchored between 0 (no pain) and 10 (severe pain); a visual 
analogue scale with no specified parameters; a questionnaire including three domains 
activities of daily living, coexistence of systemic symptoms, and analgesic requirement; a 
questionnaire with ranked symptoms; a questionnaire with no further description 
available; a ranked ordinal scale (1 to 5); number of episodes; and not specified.   
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Table 10 - Reported pain and fertility outcomes 
Outcome domain Outcome* Trials (n) 
Fertility outcomes Pregnancy 26 
Miscarriage  7 
Live birth 5 
Estradiol 5 
Ectopic pregnancy 4 
Endometrial thickness 2 
Number of follicles >18mm 3 
Ampoules of gonadotropin 1 
Days of stimulation 1 
Early fetal loss 1 
Embryos per cycle 1 
Follicular Stimulating Hormone 1 
Luteinising Hormone 1 
Number of oocytes per cycle 1 
Pregnancy Interval 1 
Pregnancy subsequent cycle 1 
Reproductive outcome 1 
Singleton delivery 1 
Still birth 1 
Term delivery 2 
Twin delivery 1 
Twin pregnancy 1 
Vaginal delivery 1 
Pain Outcomes Dysmenorrhea 23 
Dyspareunia 21 
Pelvic pain 15 
Non-menstrual pelvic pain 6 
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Dyschezia 6 
Overall pain 5 
Postop pain  3 
Abdominal pain  2 
Back Pain 2 
Aggregate pain 1 
Analgesia use 3 
Analgesic requirement 2 
Chest discomfort 1 
General Discomfort 1 
General pain 1 
Global intensity of pain 1 
Lateral menstrual pain 1 
Painless first stage of labor 1 
Postop opioid analgesia 1 
Rectal pain 1 
Shoulder pain 1 
Thigh pain  1 
Voiding pain  1 
n= number of randomised trials reporting individual outcome measure. 
*Not an exhaustive list  
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Table 11 - Outcome measures for commonly reported outcomes 
 
Outcome Outcome measure* n 
Dysmenorrhea Visual analogue scale (0-10) 8 
	
Visual analogue scale (0-100) 7 
Visual analogue scale (0-10 with 
description) 
3 
Visual analogue scale (no 
description) 
1 
Ranked rdinal scale (1 to 5) 1 
Likert scale (0-10) 3 
Questionnaire (with description) 2 
Questionnaire (ranked symptoms) 1 
Questionnaire (no description) 1 
Number of episodes 1 
Not specified	 2 
Pregnancy Serum βHCG  4 
	
Ultrasound (visualizing fetal heart) 4 
Ultrasound (growth scan) 2 
Pregnancy greater than 20 weeks 
gestation 
1 
Not specified 19 
Quality of Life World Health Organisation Quality 
of Life-BREF 
1 
 
EuroQol-5D 1 
Short Form Health Survey 12 1 
Short Form Health Survey 36 6 
Hospital Anxiety and Depression 
Scale 
2 
Greene Climateric Scale 1 
Blatt Kupperman Menopausal Index 1 
Sabbatsberg Sexual Rating Scale 1 
Revised Sabbatsberg Sexual 
Rating Scale 
2 
Sexual Activity Questionnaire 1 
n= number of randomised trials reporting individual outcome measure. 
*Not an exhaustive list 
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Endometriosis is one of the largest causes for sub-fertility and is implicated as a cause in 
up to 50% of IVF cycles. The three most frequently reported fertility outcomes were 
pregnancy (26/54 RCTs, 5 outcome measures), miscarriage (7/54 RCTs, 2 outcome 
measures), and live birth (5/54 RCTs, 2 outcome measures). The following outcome 
measures were used to assess pregnancy in order of reducing frequency: serum beta 
HCG; ultrasound scan visualising fetal heart; ultrasound growth scan; pregnancy greater 
than 20 weeks gestation; not specified (table 11, figure 15).  
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Figure 15 -Outcome reporting in Endometriosis trials: Largest 25 studies listed by study size showing pain and fertility outcomes. 
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Alkatout  2013 450  X X  X      X X X  X      
Marcoux 1997 348           X X         
Zhao 2013 320           X          
Vercellini 1999 269    X            X     
Vercellini 2003A 180  X X    X    X          
Healey 2010 178 X X X X X  X X             
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Zhao 2013B 176                     
Matorras 2002 172                     
Zhu 2014 156  X X X     X   X X    X    
Moini 2012 146           X          
Alborzi 2010 144  X X    X    X          
Cosson 2002 142    X       X          
Zullo 2003 141  X X    X              
Abu Hashim 2012 136           X  X X  X  X X  
Nowroozi 1987 123      X     X          
Creus 2008 104           X  X        
Parazzini 1999 101           X  X  X      
Alborzi 2004 100    X       X          
Vercellini 2002 90  X X    X              
Seiler 1986 90           X          
Busacca 2001 89  X X    X    X          
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*Pelvic pain - This includes non-menstrual pelvic pain   
Alborzi 2007 88           X        X  
Soysal 2004 80                     
Bianchi 1999 77  X     X    X          
Parazzini 1994 75       X    X          
Other studies (29)  1452  5 14 14 0 0 0 13 0 2  9 1 2 0 0 3 0 0 1 1 
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Endometriosis is associated with reduced quality of life and this outcome is the most 
highly predictive assessment tool for direct health care and total annual patient 
associated costs (101). Quality of life was reported by only nine of 54  RCTs using 10 
different outcome measures including World Health Organisation Quality of Life-BREF; 
EuroQol-5D; Short Form Health Survey 12; Short Form Health Survey 36; Hospital 
Anxiety and Depression Scale; Greene Climacteric Scale; Blatt Kupperman Menopausal 
Index; Sabbatsberg Sexual Rating Scale; Revised Sabbatsberg Sexual Rating Scale; 
and Sexual Activity Questionnaire  (204,338,347,348,367,370,371,374,376).  
Intraoperative and postoperative complications were collected and reported by 14 RCTs 
using 34 different outcomes and 5 different outcome measures 
(223,249,334,342,344,347–349,351,354,355,357,359,375).   
The mean outcome reporting quality was 3.15/6 (95% CI 1.65; 4.65) and methodological 
quality 3.61/5 (95% CI 2.35 - 4.88). Table 8 summarises quality assessment. Just over 
half of all trials clearly reported a primary outcome 32/54 (204,206,223,246–
250,333,334,339,342,344,345,347–349,352,354,355,357,361,363,364,367,370–375) 
while just under half, 26/54 (204,206,246,248,249,332,341,342,345,347,348,350–
352,355,357,361,366,367,369–371,373–376) described using a power calculation to 
influence their sample size. The majority of studies, 89% (n=48/54), were published in an 
obstetrics and gynaecology specific journal while 11% (n=6/54) trials were published in 
general medical journals including one trial in The New England Journal of Medicine 
(355). Studies receiving commercial or pharmaceutical funding accounted for 22% of 
trials (n=12/54)(223,248,249,337,345,346,350,355–357,367,373), while 4% of trials 
(n=2/54) (332,351) did not receive funding and 74% of trials (n=40) did not specify 
whether they received private funding (204,206,224,246,247,250,333–336,338–
344,347–349,352–354,358–366,368–372,374–376). 
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We explored the relationship between quality of outcome reporting with impact factor in 
the year of publication, study quality, year of publication, journal type, and commercial 
funding (Table 12). After exploring the data we found one study (355) behaving clearly 
differently to the other studies in terms of impact factor (IF =27.776). This outlier was 
excluded from further analysis. Univariate analysis results are shown in Table 12. Year 
of publication and methodological quality of the paper correlated positively with quality of 
outcome reporting. Neither impact factor nor type of journal nor commercial funding was 
associated with outcome reporting. Multivariate analysis confirmed that both factors 
(year of publication and methodological quality) were independently associated with 
outcome reporting (Table 12). Residual plot did not show any evidence of violating 
assumptions of linear regression. 
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Table 12 -Multiple linear regression analysis to determine factors associated with quality of outcome reporting 
 
 
Factor 
Univariable Multivariable* 
Rho Spearman p β p 
Study quality+ 
Impact factor at publication 
Journal type (specialist/generalist)** 
Year of publication 
Commercial funding** 
 0.379 
0.190 
- 
0.294 
- 
0.010 
0.212 
0.691 
0.050 
0.370 
0.325 
- 
- 
0.067 
- 
0.038 
- 
- 
0.040 
- 
 
+ Measurement details in methodology section 
* Based on best sub-set regression 
** Based on Mann-Whitney test 
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4.5 DISCUSSION 
 
This chapter has found that there is outcome reporting heterogeneity in RCTs evaluating 
treatment effectiveness of surgical interventions for endometriosis. The commonest 
comparable outcome (dysmenorrhea) and its commonest measurement tool (visual 
analogue scale from 1-10) were used synonymously in only eight of 54 RCTs (15%).  
There was a relationship demonstrated between the quality of outcomes reported and 
the methodological quality of a study and year of publication. There was no association 
seen with journal impact factor at publication in a multivariable analysis. It was difficult to 
produce meaningful comparisons relating to ethnicity as the RCTs included were 
conducted from an array of international settings with multiple patient populations. 
The strengths of this prospectively registered review include its originality, robust search 
strategy and methodological design.  This chapter describes the first systematic review 
of outcome reporting variation in endometriosis trials. The search was guided by the 
Cochrane Collaboration handbook in order to prevent bias in the review process. The 
selection and assessment of trials had good reviewer agreement, with discrepancies 
resolved quickly. This review, like others, has limitations we must acknowledge. We 
limited the inclusion of studies to only RCTs, this resulted in missing all those outcomes 
included in observational studies. The use of patient reported questionnaires to generate 
outcomes was widely employed within the included studies. These questionnaires 
introduce methodological inaccuracies as they are difficult to replicate, can lack 
reliability, and demonstrate varied sensitivity for the measurement of their desired 
outcome (377). This can lead to heterogeneity between disease or symptom endpoints. 
This subsequently results in an inability to compare the effectiveness of an intervention 
on a specified outcome (378). 
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Interpretation 
There was a lack of association between journal impact factor and outcome reporting 
quality. This finding may suggest that journal editors prioritise those studies with sound 
methodological quality or favourable results ahead of outcome reporting quality. 
Alternatively, this could be the result of outcome reporting bias. This could involve the 
selection of ‘cherry picked’ attractive results for submission without negative or 
inconclusive results. However, this is difficult to prove or negate without a set of core 
outcomes. 
The high prevalence of outcome reporting bias has been highlighted as a concern and 
can impact on Cochrane reviews (251). A review of outcome reporting bias within 
Cochrane reviews found that following adjusting for outcome reporting bias the 
treatments’ effect estimate became non-significant in 19% of reviews and 26% of their 
reviews would have overestimated the treatment effect by greater than 20%. An analysis 
of research spending found that 85% of research funding is wasted across all aspects of 
the research cycle. Three of the four most common sources of waste were closely 
related to the reporting of outcomes: 1) important outcomes are not assessed, 2) 
published research fails to set the study in the context with all previous similar research 
and, 3) over 50% of planned study outcomes are not reported (379).  
The All Trials initiative has looked to address this and, regardless of findings, all RCTs 
are published. The aims of this initiative is to eliminate publication bias from those 
studies that are withheld from publication where there is negative or no effect 
demonstrated (380).  
The long term effect of outcome reporting variation is the restriction to produce 
meaningful conclusions. This limits the usefulness of research to inform clinical practice 
(381). Systematic reviews and meta-analyses are the highest quality research that can 
be used to implement evidenced based medicine, yet outcome reporting diversity 
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restricts the combination of results for meta-analysis. This is of particular concern to 
health economists as two thirds of the annual health related disease costs for patients 
with endometriosis (€9579) are attributed to loss of productivity (101). This is comparable 
to Crohns disease or Diabetes mellitus (101). Without harmonised outcomes the 
development of new, effective treatment modalities for women with endometriosis will not 
be achieved.   
Recommendation(s) 
The selection of pre-defined appropriate outcomes and outcome measures within 
endometriosis is necessary to limit bias and enhance patient centred care. The 
production and implementation of a core outcome set would help to address these 
concerns (382). A core outcome set is a collection of well-defined, discriminatory, and 
feasible outcomes that are the minimum measured endpoints to be reported by a trial or 
a systematic review. This does not restrict a trial or systematic review to the core 
outcome set however, it is envisaged that in most trials, the primary outcome would be 
selected from the core outcome set. The COMET Initiative was launched in January 
2010.  This aims to address the lack of standardised outcomes by aiding researchers 
with the prospective registration and development of core outcome sets.  
Improving published research is supported by CoRe Outcomes in WomeN’s health 
(CROWN) initiative, led by journal editors, this encourages and promotes the publication 
of studies which, where available, use outcomes from a published core outcome set. 
Implementing core outcome sets will augment and maintain the production of 
homogenous comparable data for improved evidence based patient care (382). The 
World Health Organisation, National Institutes of Health, and the Cochrane Collaboration 
have committed to supporting the development and implementation of core outcome 
sets.   
This study demonstrates that reporting of outcomes following the surgical treatment of 
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endometriosis is inconsistent and requires standardisation. There is no internationally 
agreed selection of outcomes for trials and systematic reviews to evaluate. The 
development and use of core outcome sets routinely in the treatment of endometriosis 
will enable scientific summarising of outcomes from different studies and centres while 
reducing outcome reporting bias (251). In the absence of a core outcome set for 
endometriosis we recommend the use of the three commonest outcomes and their 
outcome measures. This will maximise the contribution of each individual trial to meta-
analysis and clinical guideline development following trial completion (table 10 and table 
11). 
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5.6 CONCLUSION  
Variation in outcome reporting leads to multidirectional research that lacks comparability 
and threatens patient care. There is clear and evident need for the harmonisation of 
patient centered clinical outcomes through the development of a core outcome set in 
endometriosis. 
 
This chapter is based on the following peer-reviewed publication: 
Variation in Outcome Reporting in Endometriosis Trials: A Systematic Review. 
Hirsch M, Duffy JM, Kusznir JO, Davis CJ, Plana MN, Khan KS.  
Am J Obstet Gynecol. 2016 Jan 14. pii: S0002-9378(15)02587-9.  
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CHAPTER 5: 
GOOGLING ENDOMETRIOSIS – 
A SYSTEMATIC REVIEW OF 
INFORMATION AVAILABLE ON 
THE INTERNET  
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6.1 ABSTRACT 
Objective 
We aim to evaluate the credibility, quality, readability, and accuracy of online patient 
information concerning endometriosis. 
Data sources 
We searched the five popular internet search engines: [1] aol.com; [2] ask.com; [3] 
bing.com; [4] google.com; and [5] yahoo.com. We developed a search strategy in 
consultation with patients with endometriosis, to identify relevant websites. 
Website eligibility  
Websites containing information related to endometriosis for women with endometriosis 
or the public. 
Website appraisal and synthesis methods 
Two independent authors screened the search results. Websites were evaluated using 
validated instruments across four domains, including assessments of: [1] credibility 
(White Paper instrument; range 0-10); [2] quality (DISCERN instrument; range 0-85); and 
[3] readability (Flesch-Kincaid instrument; range 0-100). Accuracy was assessed by a 
prioritised criteria developed in consultation with healthcare professionals, researchers, 
and women with endometriosis based upon the European Society of Human 
Reproduction of Endometriosis guidelines (range 0 – 30). We summarised these data in 
diagrams, tables, and narratively.  
Results 
We identified 750 websites, of which 54 were included. Over a third of websites did not 
attribute authorship and almost half the included websites did not report the sources of 
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information or academic references.  No websites provided information assessed as 
being written in plain English. A minority of websites were assessed as high quality. A 
single website provided accurate information, evidentlycochrane.net. Available 
information was, in general, skewed towards the diagnosis of endometriosis.  There were 
16 credible websites, however the content limitations were infrequently discussed. No 
website scored highly across all four domains. 
Comment 
In the unlikely event that a website reports high quality, accurate, and credible health 
information it is typically challenging for a lay audience to comprehend. Healthcare 
professionals, and the wider community, should inform women with endometriosis of the 
risk of outdated, inaccurate, or even dangerous information online. The implementation 
of an Information Standard will incentivise providers of online information to establish 
and adhere to codes of conduct.  
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6.2 INTRODUCTION 
Endometriosis is benign gynaecological disease which affects one in ten women of 
reproductive age, and is characterised by pain and subfertility with associated reduced 
quality of life (383). The economic burden of endometriosis is of a similar magnitude to 
other chronic diseases such as diabetes (101). There is a paucity of high quality 
research to guide clinical practice, this leads to unwarranted and unjustified variations in 
patient care (384). 
The internet is fast becoming the preferred source of health information for patients who 
can access health information quickly, conveniently and privately. There are currently an 
estimated 6.75 million health searches daily in Google. This represents 4.5% of all 
searches performed (385). There has been a swift growth in the number of websites 
providing health information with little or no governance (386) while 7 in ten adults admit 
to regularly search for an explanation and information on a new diagnosis or treatment 
(387–389). Information provided online is commonly written at a high literacy level. This 
is further compounded by the difficulties patients may have establishing whether the 
information is accurate. The exposure to complex language, ungoverned, and unfounded 
health information could negatively affect patient understanding, compliance, and 
decision making. This could lead to poorer health outcomes, including harm (390–394). 
There are no systematic reviews assessing the quality of online patient information 
pertaining to endometriosis. 
 
We systematically assessed the accuracy, quality, readability, and credibility of websites 
providing women with endometriosis and the public information regarding the diagnosis 
and management of endometriosis.   
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6.3 MATERIALS AND METHODS 
Sources 
A protocol with explicitly defined objectives, criteria for website selection, and 
approaches assessing outcome selection was developed and registered with the 
International PROSPERO, Identification number: CRD42016036134. This review was 
performed in accordance with the PRISMA statement (303). 
Website Selection  
We developed a comprehensive search strategy in consultation with healthcare 
professionals, researchers, and women with endometriosis. We used a keyword analytic 
instrument, SEMrush (www.semrush.com), to inform our selection of search terms. 
SEMrush provides analytical information related to search terms.  We are confident we 
identified and selected all search terms commonly used by women with endometriosis. 
We used the following search terms: 1) endometriosis, 4,560,000 searches per annum; 
2) endometriosis symptoms, 325,200 searches per annum; 3) endometriosis treatment, 
64,800 searches per annum; 4) endometriosis pain, 19,200 searches per annum; and 5) 
endometriosis diagnosis, 15,600 searches per annum. We searched the most popular 
search engines including: 1) aol.com; 2) ask.com; 3) bing.com; 4) google.com; and 5) 
yahoo.com, during March 2016. 
Individuals rarely examine more than the first three pages of a search (392). We 
therefore extracted the websites from the first three pages for each search term within 
each search engine.  Location services were disabled to eliminate geographical bias. 
 
We organised the extracted websites and removed duplicates.  Two reviewers (M.H. and 
S.A.) independently screened the full content of websites to assess eligibility. All data 
extraction was performed using piloted data extraction instruments. We pilot tested each 
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instrument using a representative sample of the websites to be reviewed. This testing 
helped identify data that are missing from the form, or likely to be superfluous. This 
allows authors trialing the form to provide feedback that certain coding instructions are 
confusing or incomplete (e.g. a list of options may not cover all situations). Any 
discrepancies between the reviewers were resolved by discussion with a consensus 
required before the form is modified to avoid any misunderstandings or later 
disagreements. We repeated the pilot testing on a new set of websites where no major 
changes were needed after the first pilot testing (395). 
We included websites providing health information about endometriosis greater than 300 
words in length. We excluded websites for the following reasons; 1) non-English 
language; 2) inaccessible, for example password restricted; 3) aimed at a professional 
audience, for example scientific publication; 4) excessive commercial advertising (two or 
more commercial advertisements); and 5) content related solely to the lived experience 
of endometriosis, for example a patient’s diary or blog.  
Those websites which met the criteria for inclusion were saved as a portable document 
format for evaluation and data extraction by two independent authors (M.H & S.A). M.H. 
and J.D. did not assess any websites they had previously contributed too.   
Website Characteristics 
Two reviewers (M.H. and S.A.) extracted the website characteristics independently using 
a piloted data extraction sheet. Information extracted from each website included country 
of origin, disease specific information, listed authors, and privacy statements. Two 
reviewers (M.H. and S.A.) independently assessed each website using validated 
instruments including assessments of 1) credibility assessed using the White instrument 
(396) anchored between 0 (poor) and 10 (excellent) 2) quality assessed using the 
DISCERN (397) instrument anchored between 0 (poor) and 85 (excellent), and 3) 
readability assessed using the Flesch-Kincaid (398) instrument anchored between 0 
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(poor) and 100 (excellent).  Discrepancies were resolved by discussion.  
Quality Assessment 
Two reviewers (MH and SA) underwent training in the use of the quality assessment 
instruments. We assessed accuracy using a prioritised list of recommendations included 
within the ESHRE endometriosis guidelines (107). The ESHRE guideline was selected 
for comparison as this was objectively assessed to represent the highest quality 
endometriosis guideline (399). All recommendations were extracted by two authors 
independently. Discrepancies were resolved by discussion. In consultation with 
healthcare professionals, researchers and women with endometriosis, the 
recommendations were scored as 1) critical for decision making, 2) important but not 
critical for decision making and 3) not critical and not important for decision making. 
Fifteen guideline recommendations were selected as statements critical for decision 
making (Appendix 2). The assessment of accuracy was standardised against selected 
guideline recommendations. This approach has been utilised in similar research studies 
(400). 
Two reviewers (M.H and S.A) independently reviewed each website and using a piloted 
standardised proforma assessing the accuracy of information. Each recommendation 
was scored: 0 (if absent or incorrectly described), one (present and incompletely 
described), or two (present and completely described). Accuracy assessment was 
anchored between zero and 30. Discrepancies were resolved by discussion. We 
classified websites with a score greater than or equal to 20 as accurate.  
The website’s credibility was assessed by two reviewers independently using a validated 
instrument, White (396). This instrument, designed for consumers of health information, 
provides a set of criteria that can be used to accurately and reliably assess the quality of 
health information on the Internet. Credibility was assessed using a ten point criteria: 1) 
source; 2) context; 3) currency; 4) utility; 5) editorial review process; 6) hierarchy of 
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evidence; 7) statement of original source; 8) disclaimer, which included ownership, 
sponsorship, funding and advertising; 9) omissions; and 10) feedback. Each criterion 
was scored 0 (absent) or one (present) giving a score anchored between 0 to 10 (401). 
Discrepancies were resolved by discussion. We classified those websites with a score 
greater than or equal to seven as credible. 
The website’s quality was assessed by two reviewers independently using a validated 
instrument, DISCERN (397), a validated instrument designed to assess the quality of 
written information on treatment choices which can be applied to any disease (388,397). 
The DISCERN instrument offers a framework for the production, evaluation, and 
screening of written consumer health information. This includes 16 questions assessed 
using a Likert scale anchored between one (do not agree) and five (agree) (397). 
Discrepancies were resolved by discussion. We classified those websites as high (>53), 
moderate (27à52), and low (<27) quality. 
The website’s readability was assessed using the Flesch-Kincaid reading-ease test 
(398). This formula presents a score as a U.S. grade level, making it easier for teachers, 
parents, librarians, and consumers of health information to judge the readability level of 
various texts. The Flesch Kincaid score is generated from the following equation: 
206.835 – 1.015 (total words / total sentences) – 84.6 (total syllables / total words) 
(www.readability-score.com) (398).  The scores were anchored between 0 (complex 
language) and 100 (simple language) and can be categorised by reading age or 
educational status: 1) 90-100 (5th grade); 2) 80-90 (6th grade); 3) 70-80 (7th grade); 4) 
60-70 (8th and 9th grade); 5) 50-60 (10th, 11th and 12th grade); 6) 30-50 (college); 7) 0-
30 (college graduate). Discrepancies were resolved by discussion.  
A large-scale national assessment of the average reading level among Americans 
performed by the National Center for Education Statistics found that the typical American 
reads between a 7th and 8th grade level (402). It is recommended that online health 
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information should not exceed the level of American 7th grade writing and reading (403). 
We therefore expected websites to have a readability score at or below the level of 
American education 7th Grade (>70) to be deemed appropriate for a patient and public 
audience.  
Analysis 
The website characteristics and assessments were summarised in tabular form and 
presented with descriptive statistics within summary tables and diagrams.   
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6.4 RESULTS 
The search strategy identified 750 websites which were assessed for eligibility. We 
screened 211 websites following the exclusion of 539 duplicate websites.  Two authors 
independently applied an inclusion and exclusion criteria when screening the websites. 
We included 54 websites in our final assessment (figure 16, Table 13). 
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Figure 16 - Flow of included websites   
Websites retrieved n=750 
AOL  150 
Ask  150 
Bing  150 
Duplicates excluded n=539 
Potentially relevant n=211 
AOL  44 
Ask  37 
Bing  44 
Google  48 
Yahoo  38 
  
Included websites n=54 
AOL  15 
Ask  10 
Bing  12 
Google             9 
Yahoo   8 
 
Excluded Websites     n=155 
Institution   54 
Other search website             29 
Advertising:   26 
Insufficient information  16 
Not specific   10 
Individual experience             9 
Scientific    8 
Requires login              2 
Inaccessible   2 
Other    1 
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Table 13 - Web site characteristics and a summary of quality, accuracy, credibility, and 
readability assessment 
 
 
 Co
un
try
 
Li
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ut
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rs
 
Pr
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y  
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 Q
ua
lit
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Cr
ed
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ty
 
 Re
ad
ab
ili
ty
 I.D. Web Domain 
1. endocenter.org USA No Yes 46 6 7 26.8 
2. endometriosis.org Global No Yes 62 10 8 30.7 
3. endometriosis.org Global No Yes 50 12 6 39 
4. endometriosis.org Global No Yes 50 10 8 38.3 
5. endometriosis.org Global Yes Yes 37 1 4 47.6 
6. endometriosis.org Global No Yes 42 7 5 38.5 
7. home.bt.com UK Yes Yes 46 5 5 38.2 
8. lifestyle.one UK Yes No 48 4 5 52.3 
9. medical-dictionary.thefreedictionary.com USA No Yes 62 10 8 24.3 
10. metro.co.uk UK Yes No 37 2 3 61 
11. pain.about.com USA Yes Yes 61 13 6 45.9 
12. patient.info UK Yes No 69 10 9 48.1 
13. shetrust.org.uk UK No No 35 2 4 23 
14. sogc.org Canada No Yes 42 9 4 33.7 
15. womenshealth.about.com USA Yes Yes 42 2 6 32.6 
16. activebeat.com Canada No Yes 28 1 3 34.8 
17. babycentre.co.uk Global No Yes 40 10 8 55.4 
18. channel4embarrassingillnesses.com UK No Yes 32 2 5 49.8 
19. cwhn.ca/node/40781 Canada No No 43 4 3 38.5 
20. endo-resolved.com UK No No 35 3 4 38.3 
21. endo-resolved.com UK No No 37 2 4 32.2 
22. endo-resolved.com UK No No 54 5 4 47.3 
23. endometriosis.ie Ireland No Yes 39 10 4 23.5 
24. endometriosisaustralia.org Australia No No 58 10 5 49.1 
25. endometriosisinstitute.com USA No No 50 8 4 23 
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26. endometriosisinstitute.com USA No No 51 8 4 21.3 
27. evidentlycochrane.net UK Yes No 45 4 7 29.6 
28. evidentlycochrane.net UK Yes No 56 2 7 40.4 
29. healthline.com USA Yes Yes 62 7 8 40.6 
30. hellomagazine.com UK No Yes 38 3 4 51.7 
31. independent.co.uk UK Yes Yes 32 4 5 46.3 
32. livescience.com Global Yes Yes 47 6 3 34.9 
33. medicalnewstoday.com UK Yes Yes 45 2 8 24.8 
34. netmums.com UK No No 45 5 4 28.1 
35. nytimes.com USA Yes Yes 51 5 8 57 
36. nzendo.org.nz New 
Zealand 
No No 40 6 4 34.2 
37. pelvicpain.org.uk UK No Yes 57 11 8 21.5 
38. pelvicpain.org.uk UK No Yes 38 6 5 33.6 
39. prevention.com USA Yes Yes 35 3 4 32.8 
40. students4bestevidence.net UK Yes Yes 47 28 7 5 
41. theguardian.com UK Yes Yes 40 6 3 56.8 
42. theguardian.com UK Yes Yes 31 5 4 53.4 
43. uptodate.com UK Yes Yes 64 13 9 33.8 
44. womens-health.co.uk New 
Zealand 
No Yes 22 3 3    38.1 
45. womens-health.co.uk New 
Zealand 
No Yes 35 5 2 49.3 
46. youngwomenshealth.org USA Yes No 61 4 4 55.1 
47. en.wikipedia.org Global No Yes 50 11 8 23.9 
48. health.facty.com Canada Yes Yes 32 1 5 44.9 
49. betterhealth.vic.gov.au Australia No Yes 61 8 7 30.8 
50. endometriosis-uk.org UK No Yes 42 2 5 31 
51. endometriosis-uk.org UK No Yes 40 1 5 24.8 
52. endometriosis-uk.org UK No Yes 41 2 5 32 
53. endometriosis-uk.org UK No Yes 53 0 5 51.6 
54. endometriosis-uk.org UK No Yes 33 2 5 48.3 
 
Median 
 
IQR 
 
44 
 
(37–51) 
 
5 
 
(4-7) 
 
5 
 
(2–9) 
 
38.2 
 
(30–48) 
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aDISCERN tool to assess quality of information (range 16 - 80) 
bAccuracy assessed using selected criteria from 2013 ESHRE guidelines (range 0 - 30) 
cCredibility based on ten criteria (range 0 - 10) 
dReadability assessed using the Flesch Reading Ease tool (range 0 - 100) 
 
Website characteristics  
Twenty-one (39%) websites did not report the authors and 25 (46%) of websites did not 
report sources of information or academic references. The majority of included websites 
were published in the United Kingdom (25 websites; 46%).  All websites presented 
structured content. Almost two thirds of the websites reported a privacy statement (38 
websites; 70%) (Table 13). 
Accuracy 
A single website provided accurate information, evidentlycochrane.net. The median 
accuracy of included websites was 5 (Interquartile range [IQR] 4 – 7). Included websites 
contained limited information (Table 13), skewed towards the diagnosis of endometriosis. 
Information pertaining to the medical or surgical management of pain or infertility 
associated with endometriosis were poorly represented. The most commonly reported 
recommendation, “Clinicians should consider the diagnosis of endometriosis in the 
presence of gynaecological symptoms such as: dysmenorrhea, non-cyclical pelvic pain, 
deep dyspareunia, infertility, fatigue in the presence of any of the above”, was described 
by four fifths of included websites (43 websites, 80%). The least frequently described 
recommendations, described by a small minority of included websites (3 websites; 6%) 
were: 1) “In infertile women with endometriosis, clinicians may offer treatment with 
assisted reproductive technologies after surgery, since cumulative endometriosis 
recurrence rates are not increased after controlled ovarian stimulation for IVF/ Intra-
cytoplasmic sperm injection (ICSI).”  2) “Clinicians [should] inform women with 
endometriosis requesting information on their risk of developing cancer that 1) there is 
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no evidence that endometriosis causes cancer, 2) there is no increase in overall 
incidence of cancer in women with endometriosis, and 3) some cancers (ovarian cancer 
and non-Hodgkin’s lymphoma) are slightly more common in women with endometriosis”. 
The delivery of inaccurate, outdated or dangerous information remains prevalent in 
websites. Inaccuracies include: 1) “Your specialist may also suggest flushing out your 
blocked fallopian tubes. This procedure is an alternative to surgery and is usually 
successful” website ID 1. Routine tubal flushing is used in diagnostic evaluation of tubal 
patency and it is not recommended therapeutic approach (404). 2) “The only reliable way 
to confirm the presence of the disease is by visually inspecting the abdominal organs by 
a procedure called a laparoscopy” Website ID 20. There are many difficulties associated 
with visually confirming endometriosis. The most reliable way to diagnose endometriosis 
is laparoscopy, biopsy and histopathological examination. Visual diagnosis is no longer 
recommended (107). 3) ”It is suspected that between 10-20% of reproductive aged 
women have the disease.” Website ID 20. The estimated prevalence within the general 
population is up to 10% (107). 
Credibility  
Credibility was defined as a score equal to or greater than seven. Sixteen websites 
(29%) were assessed as credible. The median credibility of included websites was 5 
(IQR 2 - 8.8). The highest scoring criteria included context relevant to the disease and 
originality with all websites fulfilling these criteria.  The least frequently described area of 
credibility was the discussion of content limitations which was reported by one website 
(Table 13). 
Quality assessment  
Thirteen websites (24%) were assessed to be high quality, 40 (74%) websites were 
assessed to be of moderate quality, and a single website (2%) was assessed as low 
quality. The highest scoring criteria included describing aims (median = 5; IQR 3-4) and 
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being unbiased (median 5; IQR 4-5). Websites typically did not describe the 
consequences of no treatment (median 1; IQR 1-1). 
Readability 
All included websites were assessed as fairly difficult to read (10th, 11th, and 12th 
grade), difficult to read (college), or very difficult to read (college graduate).  The median 
readability score was 38.2 (IQR 30.7 – 48.0), indicating an average educational status of 
a college student would be required to understand the written content (Table 13 and 
table 14). Forty-five websites (83%) presented written information at a level at or above 
college standard.  
There were no substantial discrepancies between authors in the data extraction of 
quantitative parameters and we observed very high interrater agreement.  
Table 14 - Readability 
Ease of reading USA educational level Webpages (n) 
Very easy to read (score 90-100) 5th Grade  0 
Easy to read (score 80-90) 6th Grade 0 
Fairly easy to read (score 70-80) 7th Grade 0 
Plain English (score 60-70) 8th-9th Grade 1 
Fairly difficult to read (score 50-60) 10th-12th Grade 8 
Difficult to read (score 30-50) College 32 
Very difficult to read (score 0-30) College Graduate 13 
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6.5 DISCUSSION 
Summary 
There are no websites which provide high quality, accurate, and credible health 
information pertaining to endometriosis.  Currently, websites contain limited amounts of 
information which are skewed towards the diagnosis of endometriosis. In the unlikely 
event that a website reports high quality, accurate, and credible health information, it is 
typically written in language that is challenging for a lay audience to comprehend. 
Strengths and Weaknesses 
To our knowledge, this is the first study to examine the quality, credibility, accuracy, and 
readability of patient focused online information pertaining to the diagnosis and 
management of endometriosis. We followed a robust, prospective systematic review 
method with validated instruments to assess the information presented. We evaluated 
individual websites using four validated instruments in a systematic process, 
independently performing all assessments in duplicate. We involved women with 
endometriosis, to inform the research question, design and delivery of the research 
study, and its dissemination.  All reviewers underwent recommended training prior to 
commencing the study. 
This study is not without limitations. Limiting the search to the first three pages may have 
resulted in the exclusion of potentially eligible websites, however only 2.6% of people 
search past Googles’ third page (www.protofuse.com). Included websites were only 
written in English language, limiting the generalisability of our findings.  The search was 
conducted while computer location services were disabled, however there may have 
been regional differences in search results, out of the authors control, which account for 
the predominance of British websites. We designed and registered this systematic 
review prospectively with a pre-defined inclusion criteria and analysis plan. There are 
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few scientific publications which evaluate online information for patients allowing limited 
precedent to guide our methods. We observed diminishing returns, however this was not 
quantified. All websites were designed and managed within high resource countries. This 
limits the applicability of this research to inform low resource settings. We did not 
calculate weighted kappa to explore agreement between authors as the statistical level 
of agreement required in health research is unclear (405). This evaluation is not currently 
recommended by the Cochrane Collaboration (395). We could have conducted in-depth 
qualitative interviews of women with endometriosis to explore their satisfaction with 
reading individual websites and evaluate the correlation with accuracy, credibility, quality 
and readability.  
Interpretation   
As clinicians we must be aware that patients are increasingly seeking unregulated health 
information online which shapes opinions and treatment choices. The essence of 
modern clinical consultations is changing from a reliance on face-to-face interaction to 
information gathering online prior to seeking professional opinion. In the United States of 
America, there are over 400,000 endometriosis searches per month in Google alone. We 
have demonstrated that individual websites are frequently incomplete, inaccurate, and 
poorly written. This is a barrier to patient education and results in those vulnerable 
patients who seek reliable information being misinformed. This is of greater importance 
to non-expert patients (majority) who may be less able to evaluate the reliability of online 
information and be susceptible to the bias and inaccuracies contained within. These 
forays into online information gathering can lead to a breakdown in doctor patient 
relationships.  Inaccurate online health information can lead to clinicians advocating 
guideline-supported recommendations different from those read on “reputable” online 
sources. This mismatch of information can lead to a breakdown in trust in the clinician-
patient relationship.  
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A review conducted by the United States Office of Disease Prevention and Health 
Promotion (ODPHP) concluded that the potential for harm from inaccurate online 
information is significant (406). Harm can be: 1) physical, from inappropriate treatments, 
adverse effects, or untreated disease; 2) emotional, from anxiety or false hope arising 
from inaccurate diagnostic, prognostic, or therapeutic information; 3) financial, costs 
incurred from unnecessary purchase of ineffective health services or products (406). The 
ODPHP concluded that the Internet is critical to disease prevention, health promotion, 
and health care because of the increasing amount of information and services available 
via the internet. This included a key objective to increase the quality of online health 
information (407). 
The readability of a website is an essential facet of online information. Information 
presented at a standard above patients’ comprehension will limit its ability to inform the 
patient. Healthcare professionals should be aware that there is very limited information 
available to women with endometriosis with basic levels of literacy (indicates skills 
necessary to perform simple and everyday literacy activities), and therefore directing 
them to online information is of limited value in informing decision making.  
Many online information rating systems use proxy markers for quality that do not 
consider the needs and opinions of patients and the public. Meric and colleagues (408), 
determined website popularity did not correlate well with traditional standards of website 
quality. Quality of online information is crucial as patients want to know about the risks, 
benefits, and uncertainty associated with diagnostic and therapeutic options. This 
information must be accurate to ensure that patients seeking information are gaining 
correct and complete information about the disease from up to date scientific evidence. 
Without access to good quality information, patients are unable to make informed 
choices about their treatment. 
Recommendation(s) 
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Healthcare professionals and the wider medical community are increasingly quizzed by 
patients regarding health information found online. It is essential that healthcare 
professionals acknowledge their position of responsibility and proactively inform women 
with endometriosis about the risk of outdated, inaccurate, or even dangerous information 
online. Interactive consultations using online clinical practice guidelines such as those 
produced by the American College of Obstetrics and Gynecology (409) or the Society of 
Obstetricians and Gynaecologists of Canada (SOGC) (410) can provide the basis for 
clear, concise, evidence based management discussions. Following consultations, 
patients should be sign posted towards higher quality and more reliable sources of online 
information to answer questions they may have forgotten to ask during their limited 
consultation time.  
While it may sound unrealistic to regulate health information on the internet, codes of 
conduct have been developed and implemented. The Health on the Net Foundation, 
based in the United States, provides accreditation to websites, which meet pre-defined 
standards related to readability, accessibility, and accuracy (398). The Information 
Standard, based in the United Kingdom, assesses online health information to ensure 
the information is clear, accurate, balanced, evidence-based, and up-to-date. Information 
produced by the Royal College of Obstetricians and Gynaecologists is accredited by this 
information standard (https://www.england.nhs.uk/tis/). 
We acknowledge that regulating health information on the internet has inherent 
difficulties as online authors are not bound by the same codes of practice as licensed 
healthcare professionals. The implementation of a robust Information Standard 
internationally will incentivise providers of online information to establish and adhere to 
codes of conduct ensuring an improvement in the quality of online information. 
Healthcare professionals and professional bodies should direct women with 
endometriosis towards higher quality, more reliable sources of online information.  In 
general, websites who comply with an Information Standard, should be prioritised.  
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The internet will continue to increase its role as a provider of online health information. 
The media by which health information is transferred from source to patient should not 
compromise the fundamental features of accuracy, credibility, quality and readability. It 
would not be tolerated if a healthcare professional were delivering sub-standard 
information in a face-to-face consultation. A strategy is required to improve the standard 
of online information for women with endometriosis with evident need for the 
development of patient focused online information with a robust evidence base. The 
translation of research from trials or systematic reviews into online sources has a direct 
pathway currently being delivered by Cochrane in the form of Evidently Cochrane 
summaries. These webpages summarise Cochrane systematic reviews into patient 
focused bite size pieces of information (411).   
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6.6 CONCLUSION 
In the unlikely event that a website reports high quality, accurate, and credible health 
information it is typically challenging for a lay audience to comprehend. Healthcare 
professionals, and the wider community, should inform women with endometriosis of the 
risk of outdated, inaccurate, or even dangerous information online. Providers of online 
information should engage with established codes of conduct, such as the Information 
Standard. 
 
This chapter is based on the following peer reviewed publication: 
Hirsch M, Aggarwal S, Barker C, Davis CJ, Duffy JM. Googling endometriosis: a 
systematic review of information available on the Internet. Am J Obstet Gynecol. 2016 
Nov 11. pii: S0002-9378(16)31987-1. 
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CHAPTER 6: 
DIAGNOSIS AND MANAGEMENT 
OF ENDOMETRIOSIS: A 
SYSTEMATIC REVIEW OF 
INTERNATIONAL AND 
NATIONAL GUIDELINES. 
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7.1 ABSTRACT 
Objective 
We evaluated the methodological quality of endometriosis guidelines, mapped their 
recommendations, and explored the relationships between recommendations and 
research evidence.  
Data Sources 
We searched: [1] EMBASE; [2] Medline; and [3] Pubmed from inception to February 
2016. 
Methods of guideline selection  
We included guidelines related to the diagnosis and management of endometriosis. Four 
independent authors assessed the methodological quality of included guidelines using 
the Appraisal of Guidelines for REsearch & Evaluation (AGREE-II) instrument and 
systematically extracted the guideline recommendations and supporting research 
evidence. 
Tabulation, Integration, and Results 
The search strategy identified 1879 titles and abstracts. We include two international and 
five national guidelines.  No guideline followed the standardised guideline development 
methods (AGREE-II). Guidelines performed poorly in the domains of stakeholder 
involvement and rigor of development and very poorly in the domains of applicability and 
editorial independence. The ESHRE guideline was objectively evaluated as the highest 
quality guideline (methodological quality score: 88/100).  One hundred and fifty-two 
different recommendations were made, 10 (7%) recommendations were comparable 
across guidelines. There was substantial variation between the supporting evidence 
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presented by individual guidelines for comparable recommendations. Forty-two (27%) 
recommendations were not supported by research evidence or cited expert opinion.   
Conclusion 
There is substantial variation in the methodological quality of endometriosis guidelines. 
Future guidelines should be developed with reference to high quality methods, in 
consultation with key stakeholders, including women with endometriosis, ensuring their 
scope can truly inform clinical practice and eliminate unwarranted and unjustified 
variation in clinical practice.   
  
 173. 
7.2 INTRODUCTION 
Endometriosis is a common benign gynaecological disease characterised by pain and 
subfertility with substantial reductions in quality of life (106). The disease has three 
common manifestations: [1] peritoneal endometriosis; [2] ovarian endometriosis; and [3] 
DIE. The disease was first described in 1860 yet the etiology and pathogenesis remain 
poorly understood (91).Treatment strategies vary significantly between disease severity 
and presenting symptoms of pain and / or subfertility (412). These challenges have 
resulted in difficulties producing accurate diagnostic tests or effective therapeutic 
interventions.  
Guidelines are systematically developed statements based upon research evidence 
(413).Their purpose is to improve patient care by informing clinical practice, reducing 
unwarranted variations in care, expediting the implementation of effective interventions, 
and eliminating ineffective interventions (414,415). The generation of robust guideline 
recommendations requires standardised guideline development methodology informed 
by evidence synthesis, including: [1] consensus method; [2] stakeholder engagement; 
and [3] quality assessment of research evidence. The methodological quality of 
guidelines has been reported to be inconsistent (416–418). Appropriate methodologies 
and rigorous strategies in the guideline development process are important for the 
successful implementation of the guideline recommendations (419,420). Previous 
comparisons of national endometriosis guidelines were limited by scope, setting, and did 
not map recommendations and supporting evidence across individual guidelines (421). 
We evaluated the methodological quality of endometriosis guidelines, mapped their 
recommendations, and explored the relationships between recommendations and 
research evidence.   
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7.3 SOURCES 
A protocol with explicitly defined objectives, criteria for guideline selection, and 
approaches assessing outcome selection was developed and registered with the 
International PROSPERO (CRD42016036145). This review is reported in accordance 
with the PRISMA statement (328). Search terms were generated in consultation with 
healthcare professionals, researchers, and women with endometriosis. We searched the 
following sources: [1] EMBASE; [2] Google; [3] Medline; and [4] PubMed from inception 
to February 2016 (figure 17). We used the following search terms: [1] endometriosis; [2] 
endometrio*; [3] guideline; [4] guidance; and [5] consensus. 
 
Figure 17 - Medline search strategy 
Search terms 
endometriosis.ti,ab 
Number of citations 
17872 
endometrio*.ti,ab 23895 
guideline.ti,ab 33770 
guidance.ti,ab 74046 
consensus.ti,ab 116903 
1 OR 2 23895 
3 OR 4 OR 5 219169 
6 AND 7 217 
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7.3 GUIDELINE SELECTION 
Selection Criteria 
We organised the extracted guidelines and removed duplicates.  Two reviewers (M.B. 
and M.H.) independently screened the full content of guidelines to assess eligibility, 
using a piloted data extraction tool. Any discrepancies between the reviewers were 
resolved by discussion. We included guidelines reporting recommendations for practice 
related to the diagnosis or management of endometriosis. Full text documents were 
selected for inclusion if they met the following criteria; [1] document type: guideline, 
consensus statement, healthcare technology assessment, produced by an international 
or national professional organisation; [2] subject: diagnosis and / or management of 
endometriosis published in English. We excluded guidelines for the following reasons: [1] 
local or regional guideline; [2] non-English language; and [3] more recent guideline 
available from the same authority. 
Guideline Characteristics  
Two reviewers (M.B, and M.H.) extracted guideline characteristics independently using a 
pilot tested data extraction sheet. During the piloting stage, authors were asked to 
provide feedback with regards to the form layout and instructions. No significant changes 
were needed following the pilot testing (395). 
Information extracted included country of origin, year of publication, consensus method, 
stakeholders involved, disease area examined, description of database search, search 
terms used, language restriction, dates of searches, inclusion / exclusion criteria use, 
and quality assessment instrument use.  
Assessment of Methodological Quality 
Four reviewers (M.B, J.D, M.H, and E.P.) underwent training in the use of the quality 
assessment instrument, Appraisal of Guidelines for REsearch & Evaluation II (AGREE-II) 
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(422).  Each reviewer independently assessed the quality of all included guidelines using 
the AGREE-II instrument. This validated assessment instrument contains 23 items 
grouped into six quality domains with a 7-point Likert scale score anchored between 1 
(strongly disagree) and 7 (strongly agree) for each item. The AGREE-II instrument is 
divided in to six domains: [1] Scope and purpose (items 1–3); [2] Stakeholder 
involvement (items 4–7); [3] Rigor of development (items 8–14); [4] Clarity and 
presentation (items 15–18); [5] Applicability (items 19–21); and [6] Editorial 
independence (items 22–23) (422). Each appraiser allocated a score between 1 and 7 
for each item, and a total domain score was calculated (422). 
In addition, we assessed each guideline against six features of systematic review 
methodology (395); [1] named database search; [2] clearly defined search terms; [3] 
language restrictions; [4] dates of search; [5] detailed search strategy; and [6] description 
of an inclusion / exclusion criteria. Discrepancies were resolved by discussion (422). 
Recommendations for Clinical Practice and Supporting Research Evidence  
Two authors (M.B. and M.H) extracted guideline recommendations and their supporting 
references independently. We mapped the recommendation to five pre-specified 
domains: [1] diagnosis; [2] medical management for pain; [3] surgical management for 
pain; [4] medical management for infertility; and [5] surgical management of infertility. 
References supporting clinical recommendations were retrieved and categorised 
according to hierarchy of medical evidence: [1] Cochrane review; [2] systematic review; 
[3] randomised control trial; [4] non-randomised control trial; [5] expert opinion; and [6] no 
reference. Discrepancies were resolved by discussion.  
Analysis 
A total domain score for the AGREE-II instrument was calculated by summation of its 
items and standardised using the prescribed equation: [(obtained score – minimum 
possible score)/ (maximum possible score – minimum possible score)] x 100, where 
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maximum possible score was 7 (strongly agree) x number of items x 4 (number of 
appraisers), and minimum possible score was 1 (strongly disagree) x number of items x 
4 (number of appraisers). This provides a quality score anchored between 0 and 100% 
for each of the six domains. We categorised guidelines in to poor quality (0-33%), 
moderate quality (34-66%), high quality (67- 100%). This was chosen as the most 
appropriate categorisation following discussion amongst the authors. 
Tabulation and data 
Descriptive statistics were calculated for all domains (median, range, IQR). We mapped 
the data for clinical recommendations, their supporting research evidence, and variation 
in clinical recommendations. There were no substantial discrepancies between authors 
in the data extraction of quantitative parameters and we observed high interrater 
agreement.   
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7.4 RESULTS 
Guideline search and selection 
The search strategy identified 1879 titles and abstracts. We screened 1583 titles and 
abstracts following the exclusion of 296 duplicate records (figure 18). We included the 
following two international (107,423) and five national (410,424–427) guidelines: [1] 
ACOG (424); [2] Australasian Certificate of Reproductive Endocrinology and Infertility 
Consensus Expert Panel on Trial Evidence (ACCEPT) (425); [3] Collége National des 
Gynécologues et Obstétriciens Français (CNGOF) Guidelines for the Management of 
Endometriosis (410); [4] (ESHRE) Management of women with endometriosis (107); [5] 
National German Guideline (S2k) Guideline for the Diagnosis and Treatment of 
Endometriosis (NGG) (426); [6] SOGC (427); and [7] WES Consensus on current 
management of endometriosis (423).    
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Figure 18 - Flow of included guidelines. 
  
Records identified through database search  n = 
1879 
EMBASE   n = 432 
Google            n = 1000 
MEDLINE  n = 217  
Pubmed  n = 230 
    
Records screened (titles and abstract)   n = 1583 
Duplicates removed  n = 296 
Records excluded n = 1565 
Full text assessed for eligibility    n = 18 
Guidelines included     n = 7 
Excluded   n = 11 
Review article  n = 2 
Outdated   n = 6 
Non-English  n = 3 
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Guideline characteristics  
The selected guidelines were published between 2006 (410) and 2014 (107,426). Five of 
the guidelines were applicable to the diagnosis and management of pain and subfertility 
associated with endometriosis (107,410,426,427). Two guidelines had narrower scopes: 
the Australasian Certificate of Reproductive Endocrinology and Infertility Consensus 
Expert Panel on Trial Evidence (ACCEPT) guideline addresses the management of 
subfertility associated with endometriosis (425); and the WES guideline addresses the 
management of pain and subfertility associated with endometriosis (423). 
Between 15 (107) to 56 (423) individuals were involved in guideline development. 
Between one and four different stakeholder groups assisted in developing the included 
guidelines. Three guidelines were developed in collaboration with women with 
endometriosis (107,423,426). Two guidelines did not report the geographical location of 
their developers (410,424) and one guideline was developed by individuals living in a 
single country (427). All guidelines made recommendations relevant to high-resource 
settings only (311). Two guidelines explicitly defined a consensus development method, 
including the nominal group technique and modified Delphi method (107,425).  No 
guideline described a detailed search strategy to identify evidence for use in 
recommendation formation. Five guidelines described methods to quality assess the 
evidence retrieved from their search strategy (107,423–425,427). We summarised 
guideline characteristics in table 15.
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Table 15 - Guideline Characteristics 
 
Guideline  
(year) 
Scope Stakeholders (n; location) 
Consensus 
method 
Identification of 
evidence Quality assessment of evidence 
ACCEPT 
(2012)  
(425) 
 
[1] Infertility 
management  
[2] Pain 
management 
[1] Healthcare professionals 
(36; unclear) 
[2] Women with 
endometriosis (unclear) 
[3] Pharmaceutical 
employees (unclear) 
[4] Researchers (unclear) 
[1] Nominal group 
technique 
Database: [1] Embase [2] 
Pubmed 
Search terms: reported 
Language: English 
Dates: not reported 
Detailed search strategy: 
not reported 
Inclusion / exclusion 
criteria: not reported 
National Health and Medical Research 
Council 
ACOG 
(2010) 
(424) 
[1] Infertility 
management  
[2] Pain 
management  
 
Not reported Not reported 
Database: [1] ACOG [2] 
CENTRAL [3] Medline 
Search terms: not reported 
Language: English  
Dates: 1985 - 2010 
Detailed search strategy: 
not reported 
United States Preventative Services Task 
Force 
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Inclusion / exclusion 
criteria: unclear  
CNGOF 
(2006)  
(410) 
[1] Diagnosis 
[2] Infertility 
management  
[3] Pain 
management 
Not reported Not reported 
Database: not reported 
Search terms: not reported 
Language: not reported 
Dates: not reported 
Detailed search strategy: 
not reported 
Inclusion / exclusion 
criteria: not reported  
Not reported 
EHSRE 
(2014)  
(107) 
[1] Diagnosis 
[2] Infertility 
management 
[3] Pain 
management 
[1] Healthcare professionals 
(unclear) 
[2] Women with 
endometriosis (1; one 
country) 
[3] Pharmaceutical 
employees (unclear) 
[4] Researchers (n=14; 
Europe; nine countries) 
[1] Nominal group 
technique 
[2] Modified Delphi 
method 
Database: [1] CENTRAL [2] 
Pubmed 
Search terms: not reported 
Language: not reported 
Dates: Inception –January 
2012 
Detailed search strategy: 
not reported 
Inclusion / exclusion 
criteria: not reported  
Grading of Recommendations 
Assessment, Development, and 
Evaluation (GRADE) 
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NGG (2014)  
(426) 
[1] Diagnosis 
[2] Infertility 
management 
[3] Pain 
management 
[1] Healthcare professionals 
(11; unclear) 
[2] Women with 
endometriosis (unclear) 
[3] Pharmaceutical 
employees (unclear) 
[4] Researchers (21; Europe; 
five countries) 
 
Not reported 
Database: 1] CENTRAL [2] 
Medline [3] Pubmed 
Search terms: not reported 
Language: not reported 
Dates: not reported 
Detailed search strategy: 
not reported 
Inclusion / exclusion 
criteria: not reported 
Not reported 
SOGC 
(2010) 
(427)  
[1] Infertility 
management  
[2] Pain 
management 
[1] Healthcare professionals 
(unclear) 
[2] Women with 
endometriosis (unclear) 
[3] Pharmaceutical 
employees (unclear) 
[4] Researchers (20; 
Canada) 
Not reported 
Database: [1] CENTRAL [2] 
Medline 
Search terms: not reported 
Language: English 
Dates: 1985 - 2010 
Detailed search strategy: 
not reported 
Inclusion /exclusion criteria: 
not reported  
Canadian Task Force on Preventative 
Health Care 
WES (2013)  
(423) 
[1] Diagnosis 
[2] Infertility 
management 
[1] Healthcare professionals 
(unclear) 
[2] Women with 
endometriosis (unclear) 
Unclear 
Database: not reported 
Search terms: not reported 
Language: English 
Dates: 1985 - 2010 
Grading of Recommendations 
Assessment, Development, and 
Evaluation (GRADE) 
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[3] Pain 
management 
[3] Pharmaceutical 
employees (unclear) 
[4] Researchers (n=56; 
International; 17 countries) 
Detailed search strategy: 
not reported 
Inclusion / exclusion 
criteria: not reported 
 
Abbreviations: ACCEPT: Australasian CREI Consensus Expert Panel on Trial Evidence (2012); ACOG: The American Congress of Obstetricians and 
Gynecologists (2010); CENTRAL; CNGOF: Collège National des Gynécologues et Obstétriciens Français (2006); ESHRE: ESHRE (2014);  NGG: 
National German Guideline: Guideline for the Diagnosis and Treatment of Endometriosis (2014); SD: Standard deviation; SOGC: The Society of 
Obstetricians and Gynaecologists of Canada (2010); WES: World Endometriosis Society (2013). 
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Assessment of methodological quality 
A systematic review was described by the majority of guidelines (107,423–427), 
however, no guideline explicitly described the all six methodological features (table 15). 
The most commonly reported feature, naming of the database(s) searched, was 
described by five (73%) guidelines (107,424–427).The most detailed guidelines reported 
three features (50%) (424,425,427), while the CNGOF (410) guideline reported no 
features. There was no guideline which reported a detailed search strategy or described 
an inclusion or exclusion criteria for the evidence they sought.  
Four guidelines did not report a consensus method (410,424,426,427). The majority of 
guidelines (107,423,425–427) reported the inclusion of multiple stakeholder groups, 
however only three guidelines (107,423,426) clearly report the inclusion of women with 
endometriosis in its development. Quality assessment of retrieved references was 
described by five guidelines (107,423–425,427). Assessment methods included: [1] 
Grading of Recommendations Assessment, Development, and Evaluation (107,423); [2] 
Canadian Task Force on Preventative Health Care (427); [3] National Health and 
Medical Research Council (425); and [4] United States Preventative Services Task Force 
(424). 
Two guidelines were assessed as high quality (107,423), four guidelines were assessed 
as moderate quality (424–427) and one guideline was assessed as low quality (Table 
16) (410). Guidelines were typically of high quality in the domains of clarity and 
presentation and scope and purpose. Guidelines were of moderate quality in the 
domains of stakeholder involvement and rigor of development. Guidelines were of low 
quality in the domains of applicability and editorial independence (Table 16).   
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Table 16 - Methodological quality of endometriosis guidelines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 • - Low quality 
 • - Moderate quality 
 • - High quality 
 
 
 
 
 
Recommendations for clinical practice 
We extracted all statements recommending clinical practice in the domains of [1] 
diagnosis (36 recommendations); [2] medical management for pain (30 
recommendations); [3] surgical management for pain (39 recommendations); [4] Artificial 
reproductive techniques for infertility (12 recommendations); [5] surgical management of 
infertility (22 recommendations); and [6] alternative treatments for pain and infertility (13 
recommendations). A total 152 separate recommendations were included for analysis. 
Only ten (7%) of 152 recommendations were comparable and cited by all guidelines 
(Table 17 and Table 18) (Appendices 3-5). The comparable recommendations are 
underlined in appendices 3-5. We summarised the variation in recommendations of all 
medical treatments for pain associated with endometriosis described across all included 
guidelines (Table 19).   
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ACCEPT (2012)(425) • • • • • • • 
ACOG (2010)(424) • • • • • • • 
CNGOF (2006)(410) • • • • • • • 
ESHRE (2014)(107) • • • • • • • 
NGG (2014)(426) • • • • • • • 
SOGC (2010)(427) • • • • • • • 
WES (2013)(423) • • • • • • • 
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Table 17 - Guideline recommendations for the diagnosis of endometriosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• Recommendations 
 
 
 
 
 
 
 
World Endometriosis Society (2013) (423) and Australasian CREI Consensus Expert Panel on 
Trial Evidence (2012) (425) provide no recommendations for the diagnosis of endometriosis. 
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Guideline 
                
ACOG (2010)(424) • 
  
• • 
 
• 
 
• 
     
• 
  
CNGOF (2006)(410) 
 
• • • • 
  
• • 
    
• • 
  
ESHRE (2014)(107) • • 
 
• • 
  
• • 
 
• 
  
• • 
 
• 
NGG (2014)(426) 
  
• • • 
  
• • 
    
• • • • 
SOCG (2010)(427) • • • • • 
 
• • • • 
   
• • • • 
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Table 18 - Level of evidence supporting recommendations. 
Example 1: Biomarkers should not be used to diagnose endometriosis. 
 
 
 
 
 
 
 
 
 
 
 
• Recommendation stated 
 
 
 
 
 
 
 
 
Example 2: Diagnostic laparoscopy and histopathology should be used to diagnose 
endometriosis. 
 
 
 
 
 
 
 
 
 
 
 
• Recommendation stated 
 
 
 
 
 
 
 
 
* World Endometriosis Society (2013)(423) and Australasian CREI Consensus Expert Panel on Trial 
Evidence (2012)(425) provide no recommendations for the diagnosis of endometriosis.  
          Level of    
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ESHRE (2014)(107)     •  
NGG (2014)(426)  • • •   
SOCG (2010)(427)      • 
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Table 19 - Medical intervention for pain associated with endometriosis. 
 
                                
Recommendation 
                 (number of guidelines) 
 
 
 
 
 
 
Intervention U
se
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Hormonal      
Aromatase Inhibitors  2  4 1 
Combined oral contraceptive pill 6   1  
Gonadotropin releasing hormone analogue 3 3  1  
Levonorgestrel-releasing IUS 4   2 1 
Progestagens 6   1  
Selective progesterone receptor modulator 1 4  2  
      
Non-hormonal      
Anti-tumour necrosis factor alpha   1 6  
Chinese medicine    6 1 
Fish oil  1  6  
Lactic ferments    6  
Magnesium 1   6  
Minerals  1  6  
Pentoxifylline   1 6  
Rosiglitizone    6 1 
Salts  1  6  
Valproic acid    6 1 
Vitamin B1 & B6 1   6  
      
Other      
Acupuncture 1   6  
Physiotherapy   1 6  
Psychological 1   5 1 
Transcutaneous electrical nerve stimulator 1   6  
 
Five guidelines report recommendations for the diagnosis of endometriosis. 
Recommendations for diagnosis of endometriosis totalled 36 (Table 17) (Appendix 3).  
Seventeen recommendations (47%) citied no research evidence or expert opinion. Four 
recommendations were described by all five guidelines (107,410,424,426,427). These 
recommendations were: [1] histological confirmation is recommended for the diagnosis 
of mild to moderate endometriosis (Table 18); [2] biomarkers are not recommended for 
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the diagnosis of endometriosis (Table 18); [3] histology is recommended to confirm 
diagnosis; and [4] transvaginal ultrasound imaging is recommended for the diagnosis of 
endometrioma (Appendix 3).  
Recommendations for the medical management of endometriosis associated pain 
totalled 30.  Three recommendations (10%) citied no research evidence or expert 
opinion. Three recommendations were described by all guidelines 
(107,410,423,424,426,427). These recommendations were: [1] the COCP is 
recommended for endometriosis associated pain; [2] progestogens are recommended 
for endometriosis associated pain; and [3] gonadotropin releasing hormone analogues 
are recommended for endometriosis associated pain (Appendix 4). We summarised the 
variation in strength of recommendations highlighting the variation in clinical advice 
between international and national guidelines (Table 19).  
Recommendations for the surgical management of endometriosis associated infertility 
totalled 21, four (19%) of these cited no research evidence or expert opinion (Appendix 
5). A single recommendation, surgery improves fertility with endometriosis associated 
subfertility, was described by all guidelines (107,410,423–427).   Alternative interventions 
to manage endometriosis associated pain was infrequently discussed and the benefits of 
psychological therapy was seldom reviewed (Appendix 5).  
Additional comparable recommendations across all guidelines include: laparoscopic 
uterosacral nerve ablation (LUNA) does not improve endometriosis associated pain; and 
Gonadotrophin releasing hormone analogues (GnRHa) can be used as an adjunct prior 
to IVF (Appendix 4-5). 
Research evidence supporting recommendations 
The number of references cited in each guideline ranges from 0 (410) to 211(426) with 
publication years between 1925 through 2014 (Appendix 3-5). The total number of 
Cochrane systematic reviews used within each guideline ranged from 0 (410) – 25 (423) 
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and the number of RCTs used ranged from 0 (410) – 28 (427). Where available we 
sought the original references used to generate recommendations. We summarised the 
references and study design type used to form each individual guideline (Appendix 3-5).   
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7.5 DISCUSSION 
Main Findings 
There is significant variation in endometriosis guidelines. No guideline followed the 
standardised approach to guideline development advocated by AGREE-II guidelines. 
The involvement of women with endometriosis varied significantly. The consensus 
method for recommendation development was clearly described in only two guidelines. 
No guideline addressed endometriosis care in a low-resource setting. The funding-
sources and conflicts of interest were poorly described with competing interests 
frequently not reported. These findings justify the critical appraisal of these guidelines, 
especially in an area such as endometriosis management, where diagnosis and 
treatment strategies are deemed suboptimal (428). A total of 152 separate 
recommendations exist across seven guidelines, only ten recommendations (7%) are 
comparable across guidelines. With differences in guideline development methods it is 
not surprising to find there was a paucity of comparable recommendations with wide 
intra-guideline variation in the supporting evidence.  
Strengths and Limitations 
The strengths of this systematic review includes its originality, robust search strategy, 
and methodological design. To our knowledge, this is the first study to systematically 
appraise the methodological quality and map the recommendations of endometriosis 
guidelines. There was good agreement between all four reviewers with discrepancies 
resolved quickly through discussion. We involved a patient representative (C.B.) in the 
design and conduct of our research.  
Systematic reviews are not without limitations. Several studies have highlighted 
limitations of the AGREE-II instrument (422). The subjectivity of scoring the domain 
items, and the overall score has not been definitively associated with implementation. 
However, it is important to note the association between domain score for applicability 
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and the guidelines’ use in clinical practice (429). We did not calculate weighted kappa to 
explore agreement between authors as the statistical level of agreement required in 
health research is unclear and it is not currently recommended by the Cochrane 
Collaboration (395,405). We could have considered systematically reviewing the RCTs 
and systematic reviews to form a judgement on the appropriateness of guideline 
recommendations. However, this would be unlikely to yield substantial benefit in the 
context of the considerable resource allocation required. 
Interpretation 
Guidelines are developed by searching, collecting, and collating evidence to make value 
judgements through consensus. The methods to achieve this in an unbiased manner are 
described clearly in the Appraisal of Guidelines for Research and Evaluation in Europe 
(AGREE-II) criteria. A recent Institute of Medicine report on guideline development and 
their worth in modern clinical practice highlights widespread methodological limitations in 
formation (430). This review highlights the shortcomings in methodological areas of 
stakeholder involvement, rigor of development, applicability and editorial independence 
of guidelines for the diagnosis and management of endometriosis.  
Guideline developers can be prohibited by the availability of research evidence to 
answer the questions raised. It is well known that research in the area of obstetrics and 
gynaecology, as in other fields, is lacking RCT evidence (431). There is wide outcome 
reporting variation within those few RCTs making synthesis into systematic review or 
guideline recommendations difficult (384). The selection of predefined appropriate 
outcomes within endometriosis research is essential to reduce bias and enhance 
guideline formation. The development and use of a collection of well-defined, 
discriminatory, and feasible outcomes termed a core outcome set would help to address 
the concerns of data deficiency which prohibit guideline formation. Core outcome sets 
represent a minimum number of outcomes chosen by the key stakeholders and do not 
confine a particular trial or systematic review to the core outcome set.  
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A poor search strategy will exacerbate the difficulties of highlighting research to answer 
clinical questions. This can result in difficulties making clear recommendations in the 
absence of high quality evidence. In this systematic review, the description of specific 
search terms was only reported in a single guideline (425). No guideline published a 
detailed search strategy.  
A total of 42 (28%) of the 152 recommendations had little or no scientific background. 
These were either unreferenced or supported by expert opinion (Appendices 3-5), which 
are particularly susceptible to bias (431). It is important to consider the number of 
guidelines, which considered a particular modality of diagnosis or treatment in the 
interpretation of the reliability and strength of agreement. There was considerable 
variation in the references used to inform identical recommendations between 
guidelines. This represents significant methodological variation in study selection, study 
assessment, or data interpretation between individual guidelines development groups.  
These findings remain consistent with a previous study (421) reporting the low quality of 
guidelines for pain associated with endometriosis. Limited progress has been 
demonstrated in the development of guidelines for the diagnosis and management of 
endometriosis in over a decade. The development of guidelines without a standardised 
methodological process will lead to the omission of beneficial therapies, preventable 
harm, and suboptimal patient outcomes or experiences. This review has demonstrated 
that even highly trusted guidelines suffer from limitations in their development process. 
Most guidelines were of low quality for the domain ‘applicability’. This domain obtained 
remarkably low scores, as most guidelines did even not discuss the topics of practical 
implementation, barriers to application, costs and monitoring/auditing criteria. These 
findings are of concern given the intensity and cost of efforts to generate an ever-
increasing body of guidelines that are not used (432). In future guidelines, more attention 
has to be paid to providing advice on how the recommendations should be put into 
practice.  
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As a whole, guidelines were of moderate quality for the domain of stakeholder 
involvement. Three (107,423,426) of the seven guidelines involved patients in the 
development of their guideline. This finding illustrates the minimal patient participation in 
the guidelines creation and the little importance placed on their involvement. 
Endometriosis is a chronic disease which can result in long term symptoms for sufferers. 
Chronic diseases require greater patient representation in guideline development as 
there may be a perceived mismatch between clinician and patient priorities. The 
multidisciplinary contribution serves to broaden the approach to health care problems, 
increase completeness of evidence finding strategies and help to identify hurdles to 
implementation.  
The development of guidelines is an expensive and time consuming process. Currently 
there are seven international and national organisations who develop guidelines. Despite 
an electronically connected academic society with a single pool of research evidence to 
guide, there remains multiple suboptimal guidelines for the diagnosis and management 
of endometriosis.  There are no universally agreed recommendations for the diagnosis 
and management of endometriosis associated pain and subfertility. A coordinated 
approach toward developing updated, evidence-based, international, expert consensus 
recommendations for the diagnosis and management of endometriosis is needed. A 
single guideline which follows the AGREE-II guidelines for development will reduce 
variation in clinical care and prevent patient harm. 
There is a strong coordinated move toward higher-quality published research, initiated by 
CoRe Outcomes in Womens’s and Newborn health (CROWN) Initiative, and supported 
by journal editors including the Journal of Obstetrics and Gynecology (433). These highly 
influential journals editors will, where present, encourage the publication of studies using 
outcomes from a core outcome set.  The implementation of core outcome sets will 
augment the production of comparable data for improved evidence-synthesis within 
clinical guidelines (382,434). This will improve the delivery of evidence based patient 
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care. International and national stakeholders including the World Health Organisation, 
the National Institutes of Health, and the Cochrane Collaboration are committed to 
supporting, developing, and implementing core outcome sets across women’s health.   
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7.6 CONCLUSION 
Despite highlighted methodological deficiencies over a decade ago, there remains 
substantial variation in quality and content within international and national guidelines for 
the diagnosis and management of endometriosis. This could lead to unjustified and 
unwarranted variations in patient care. This variation in care could lead to some patients 
benefiting from improved outcomes however, many patients will suffer harm as a result. 
There is evident need for more consistent synthesis of evidence for guideline formation. 
This would be facilitated by the implementation of a core outcome set within future 
endometriosis trials, systematic reviews and clinical guidelines. 
 
This chapter is based on the following peer reviewed publication: 
Hirsch, M., Begum, M. R., Paniz, É., Barker, C., Davis, C. J. and Duffy, J. M. N. 
Diagnosis and management of endometriosis: a systematic review of international and 
national guidelines. BJOG: Int J Obstet Gy. doi:10.1111/1471-0528.14838 
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CHAPTER 7: 
INVESTIGATING THE ROLE OF 
SURGERY IN THE TREATMENT 
OF OVARIAN ENDOMETRIOSIS 
IN WOMEN WITH SUBFERTILITY  
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In this chapter I explore the role of surgical therapies for the management of ovarian 
endometrioma in the context of subfertility. 
8.1 BACKGROUND 
Background: The optimal surgical management technique of ovarian endometrioma 
amongst women with endometriosis associated subfertility is not known. Recent studies 
demonstrate an adverse effect of some techniques on surrogate markers of ovarian 
reserve amongst women with ovarian endometriosis. Convincing evidence of a benefit of 
surgery on fertility outcomes is lacking. 
Objective: To review the current surgical management of ovarian endometriosis 
amongst women with subfertility and summarise the results.  
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8.2 BACKGROUND 
Endometriosis affects up to 10% of women of reproductive age yet its aetiology is poorly 
understood. The disease has three common manifestations; ovarian endometriosis, 
peritoneal endometriosis and DIE (90). Ovarian endometriosis can manifest as deposits 
on outside of the ovarian cortex or as Ovarian endometriomata (OE). The theories 
behind formation of OE include Sampson et al (59) who hypothesised that refluxed 
endometrial deposits on the ovarian cortex cause adhesions to the uterus causing a 
cavity which expands forming an OE. To contrast this, Brosens et al (435) speculate that 
OE are formed from the invagination of superficial ectopic endometrial deposits on the 
ovarian cortex. A further and more recent theory from Vercellini et al (436) suggests that 
refluxed endometrial deposits lead to ovarian adhesions with the pelvic peritoneum. This 
area of adhesion progresses on to the invagination of the external ovarian cortex leading 
to the formation of a pseudocyst. Regardless of aetiology, OE are common, found in 17-
44% of women with endometriosis, (437) of which between 2-50% can be asymptomatic 
(98). 
The clinical manifestation of OE is often pelvic pain and or subfertility (438). The 
mechanisms responsible for increased rates of subfertility are unclear yet theories of 
endometriosis-mediated subfertility include: 1) impaired tubal function as a result of 
adhesions from pelvic endometriosis 2) adverse effect on ovulation; 3) reduced oocyte 
quality; 4) reduced ovarian reserve mediated through pressure atrophy; 5) reduced 
vascularisation of normal ovarian cortex from expanding OE, and/or through an 
inflammatory reaction to OE (439). Theories of clinical symptoms are discussed in 
section 1.4. 
Treatments for OE or symptoms secondary to OE include expectant management, 
medical management, and surgical management. Medical treatments are commonly 
successful at reducing the size of the OE but only during treatment, after which they 
  
 201. 
return to their original size. Surgical treatments aim to destroy or remove the OE 
(171(240).  
Surgical treatment of OE can also have an adverse effect on ovarian reserve (440,441). 
This has led to debate over the optimal surgical technique for the treatment of OEs. 
There has been a shift of opinion over the past decade with clinicians favouring a more 
conservative approach in the management of OE. This is particularly amongst women 
with subfertility. In this review, we will examine the recent data on the different surgical 
techniques for managing endometrioma in a fertility clinic setting. 
8.2.1 THE SHIFT OF OPINION 
 
A 2010 survey of European Gynaecologists suggested that surgery was the most 
common management strategy for OE (442). This was based on international guidelines 
(ESHRE 2005) suggesting that endometriomas >4cm in diameter should be treated 
surgically. This was believed to improve fertility in the following domains: 1) increased 
spontaneous pregnancy rates; 2) facilitate access to the ovaries during transvaginal 
oocyte retrieval (TVOR); 3) reduce the risk of infection at TVOR; 4) provide a histological 
diagnosis; and 5) improve response to controlled ovarian hyperstimulation (COH) (104). 
Laparoscopic ovarian cystectomy with stripping the cyst wall from the ovarian cortex was 
the preferred route and surgical technique. This has favourable improvements in fertility 
and pain symptoms together with lower recurrence rates when compared to drainage 
and electrocoagulation (238).  
The potential adverse effects of surgical interventions for OE prior to ART include 
reduced ovarian reserve (443).  A recent Cochrane review (240), showed no evidence of 
benefit on clinical pregnancy rates from surgery for OE compared to expectant 
management. This review highlighted concerns that cystectomy appeared to reduce 
ovarian response during COH with no effect on the number of oocytes retrieved. The 
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review was unable to report live birth as this outcome was not reported by a single trial. 
Since this robust review, several further trials have expressed concerns of the potential 
adverse effect of surgery for OE, highlighting the lack of convincing evidence for 
improved pregnancy outcomes in women with OE surgery followed by ART (76,444–
446).  
The concerns of harm without convincing evidence of benefit has led to a recent change 
of clinical recommendations from both the American Society for Reproductive Medicine  
and ESHRE supporting conservative management of OE prior to ART treatment 
(107,447). The 2013 ESHRE guidelines clearly describe the indications for surgery: 1) 
OE >3cm in diameter; 2) pain symptoms; and 3) improve access to ovarian follicles 
during ART. Importantly, women undergoing surgery should be counselled about the risk 
of reduced ovarian reserve and the potential loss of the ovary (107). 
8.3 ENDOMETRIOMA AND OVARIAN RESERVE: INHERENT OR IATROGENIC 
INJURY? 
 
The effect of OE on ovarian reserve has been the subject of much controversy in recent 
years. Ovarian reserve is measured using markers including: 1) ultrasonic markers such 
as antral follicle count (AFC); 2) biochemical markers including anti-Müllerian hormone 
(AMH) and follicle stimulating hormone (FSH) levels; 3) histological markers such as 
follicular density and perhaps most importantly; and 4) clinical markers including 
response to COH and pregnancy rates. There is no single marker to determine function 
or capacity of the ovary at any given stage, therefore, these are referred to as surrogate 
markers of ovarian reserve. 
 
The mere presence of OE has been associated with a reduced ovarian reserve as 
evidenced by a 31% reduction in ovulation rate in ovaries containing OEs compared to 
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healthy ovaries (75) and lower baseline AMH levels in the presence of OEs (448,449). 
Clinical surrogate markers of ovarian reserve have also suggested an adverse effect of 
the presence of OE on COH (450). Histological studies have also suggested that OEs 
have an adverse effect on ovarian reserve as evidenced by reduced follicular density in 
ovarian cortex surrounding OEs compared to cortex around other benign cysts (451–
453), especially in younger patients (<35 years old) (454). However, there has been no 
reduction in ovarian response to COH when comparing ovaries containing small (<3cm) 
endometriomas to unaffected ovaries (455–457) suggesting that the size of OE is 
important in determining the effect on ovarian response. It has been shown that small 
(mean diameter 23mm) bilateral OEs have a combined effect on ovarian response as 
evidenced by a reduced number of developing follicles during COH. However, there is no 
demonstrable effect on oocyte quality or clinical pregnancy rates (458). 
 
Mechanisms of surgical damage include accidental removal of healthy tissue during 
endometrioma cystectomy and direct damage to ovarian cortex following surgical 
haemostasis and scar tissue formation.  
Earlier reports had shown a reduced ovulation rate following endometrioma surgery 
(75,459) but more recent research has focused on the effect of surgery on surrogate 
serum markers of which AMH has been shown to be the most reliable (460,461). Two 
recent meta-analyses (440,441) showed strong evidence of sustained reduction in post-
operative AMH levels of up to 40% after ovarian surgery, with the decline being more 
pronounced in bilateral surgery and in women over 38 years old (462). Further studies 
have shown a sustained reduction in AMH levels for at least 6 months after surgery 
(462–465). This  correlates with the bilaterality and severity of endometriosis (466) and 
with cyst size (467). Interestingly, two groups have demonstrated a partial recovery in 
AMH levels up to 65% of pre-operative levels three months after surgery (468,469). 
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Mechanisms implicated in this recovery of ovarian function include re-vascularisation 
after surgery, compensation from remaining follicles or an unaffected ovary (439) and 
rearrangement of follicle cohorts (470). 
Histological studies offer an explanation for this partial recovery with healthy ovarian 
tissue removed in 85-97% of excised endometrioma specimens (454,471,472). The size 
of the endometrioma is an important determinant of the amount of healthy tissue 
removed, with 200µm of tissue lost per cm increase in cyst diameter (471).  Healthy 
ovarian tissue is found in the majority of endometrioma cyst wall specimens, even in the 
hands of experienced surgeons (473). There is little evidence to suggest that the degree 
of surgical experience, among appropriately trained laparoscopic surgeons, has a 
significant detrimental effect on post-operative ovarian reserve (474–476). 
8.4 TREATMENT OPTIONS FOR OE 
 8.4.1 SURGICAL THERAPIES 
The intended advantages of surgery for OEs include: obtaining a histological diagnosis 
of the cyst (0.8% risk of occult malignancy (477)); improving clinical symptoms; 
improving monitoring of follicular growth; access to the follicles during ART; and reducing 
the small risk of spontaneous endometrioma rupture (478–480). 
Disadvantages of surgery include; adverse effect on ovarian reserve, delay in 
commencing ART, the cost of surgery (481) and the risk of surgical complications (482). 
Successful surgery is a balance of removing the maximum amount of endometriotic 
tissue, reducing the risk of recurrence, whilst keeping bleeding at a minimum, and 
minimising the need for haemostatic measures that can damage the ovarian reserve.  
Surgical techniques that have been described in the literature include laparoscopic 
drainage and ablation (with various different energy sources), laparoscopic cystectomy 
(using the stripping technique), combination techniques, the vasopressin technique 
  
 205. 
(aiming for relatively bloodless hydrodissection with diluted vasopressin) and aggressive 
treatment in the form of oophorectomy. In centres in which minimal access surgical 
expertise is not available, open surgery still has a role (483).  
Comparing the two commonest techniques of ovarian cystectomy vs drainage and 
ablation through a recent systematic review showed that laparoscopic cystectomy has 
lower recurrence and higher spontaneous pregnancy rates (484).  
Plasma energy coagulation is an alternative energy modality which offers a low depth of 
tissue penetration (<1.5 mm), limiting damage to the healthy ovarian tissue (485). 
Preliminary studies demonstrate small beneficial effect on markers of ovarian reserve 
compared with ovarian cystectomy (486) with comparable recurrence and pregnancy 
rates (487). The clinical relevance of these results remains to be confirmed in a large 
RCT.  
Recent evidence has suggested that using alternative methods to achieve ovarian 
haemostasis rather than bipolar diathermy has a beneficial effect on markers of ovarian 
reserve. Methods include haemostatic sealants along with ovarian suturing to achieve 
haemostasis following cystectomy (488,489). Despite risks of suturing induced ischaemic 
changes and postoperative adhesions that can adversely affect ovarian function suturing 
is believed to be favourable in the context of subfertility.  
Combined techniques have also shown promising results. Partial cystectomy of 80 – 
90% of the endometrioma wall combined with CO2 laser vaporisation to the ovarian 
hilum (in which the plane of cleavage is not easily identified) maintained postoperative 
ovarian volume and AFC, and resulted in a low recurrence rate (2%) and a 41% 
spontaneous pregnancy rate at a mean follow-up of 8.3 months (490). A three-step 
technique of laparoscopic cyst drainage, treatment with GnRHa for three months before 
a repeat laparoscopic laser ablation of the cyst wall, resulted in improved AFC and AMH 
at follow up when compared with routine ovarian cystectomy in a small RCT (491).  
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Finally, two recent studies (492,493) have shown promising results using the 
vasopressin technique, in which a solution of diluted vasopressin was injected in the 
endometrioma cyst wall prior to cystectomy. Employing this technique, the hydro- 
dissection can help identify the plane of cleavage, whilst the vasoconstrictive effect of 
vasopressin reduces the need to use other haemostasis control methods and thus helps 
preserve ovarian function.
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Surgery with combined Medical therapy 
A single study assessing 125 patients evaluated the impact of surgery with a combined 
medical therapy for the treatment of OE. The medical therapies assessed were GnRH-a, 
3.6mg every month for 3 months.  
This study performed a prospective comparative analysis of a cohort of participants with 
stage II-IV endometriosis and OE noted on ultrasound. The cohort all underwent 
conservative laparoscopic ovarian cystectomies with half the group being subsequently 
allocated to hormonal therapy and half to no post-operative medical therapy. There was 
a significant increase in spontaneous pregnancy rate (57.1% vs 36.8%) amongst those 
taking GnRH-a within the 18 month follow up period along with a significant reduction in 
cyst recurrence seen in the experimental group (12.7% vs 27.4%). 
There was a significant rise in post-operative FSH at 3 months compared to pre-
operative levels amongst the control group. This was not seen in the experimental group 
and may be due to pituitary suppression induced by the GnRH-a. 
 
Ultrasound guided drainage & Sclerotherapy 
The concerns regarding the effect of surgery on ovarian function together with the 
surgical risks associated with a surgical approach to treating OE have led researchers to 
seek less invasive treatments such as ultrasound scan (USS) guided drainage, usually 
combined, with irrigation with a sclerosing agent. Sclerosing agents tried in the past 
include ethanol (497)], tetracycline (498), synthetic IL-2 (499) and methotrexate (500). 
Results have demonstrated conflicting evidence with recurrence rates varying between 
5.4% - 83.3% at follow up of less than a year (501). Concerns surround the risk of 
abscess formation and missing occult malignancy, and lack of improvement in 
reproductive outcomes after ART (502–505). No major complications have been 
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reported in patients, but a recent study on an animal model of albino rats, endometrioma 
aspiration and ethanol sclerotherapy raised the concern of a reduction in the ovarian 
reserve following the treatment (506).  
 
Overall, USS-guided endometrioma drainage does not seem to have a role in the current 
management of the disease as it has a poor efficacy in relieving the symptoms and a 
high risk of introducing infection and cyst recurrence (507). It may, however, have a role 
in facilitating oocyte retrieval in patients who decline or are not fit for surgery to improve 
access to follicles.  
 
8.8 CONCLUSIONS 
 
Ovarian endometriosis remains a challenging disease. There is growing evidence that 
both the physical presence of OEs and the surgery to remove them can further adversely 
affect ovarian function and thus the consensus has now shifted towards a more 
conservative approach in treatment (107,423,447).  
 
The positive effect of ovarian cystectomy on spontaneous pregnancy rates has wrongly 
been extrapolated as a positive effect on assisted reproduction technology (ART) 
outcomes leading to the widely accepted practice of surgical treatment for OE prior to 
embarking on ART treatment such as in-vitro fertilisation (IVF) or intra-cytoplasmic 
sperm injection (ICSI). A meta-analysis in 2009 found no adverse effect of surgical 
treatment of endometriomas on the outcomes of ART treatment when compared to 
conservative management (239). Surgery can severely compromise ovarian reserve with  
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premature ovarian failure reported in up to 16.3% (508) and a 13% rate of failure to 
respond to gonadotrophin stimulation (445) have been reported. 
 
There is marked heterogeneity in disease and surgical technique among the reported 
studies with a relative paucity of evidence from high quality RCTs(240). Determining the 
optimal surgical technique requires a greater volume of comparable high quality 
evidence. This was conformed in a recent Cochrane systematic review of interventions 
for the management of endometrioma prior to ART found no studies reporting live birth 
as a primary outcome. This highlights the difficulties of outcome reporting variation that 
was discussed in chapter 4. These significant methodological difficulties are likely to 
result in delays establishing the optimal surgical technique.  
 
A more rounded view on the clinical scenario including: severity of symptoms; concern 
regarding malignancy; access to follicles; and desire to preserve fertility should be taken 
into consideration prior to performing surgery for OEs. The decisions need to be on a 
case-by-case basis after fully informed consent, including a 2.4% risk of immediate 
ovarian failure following bilateral ovarian cystectomy (509).  We recommend that surgery 
should be reserved for symptomatic patients after their family is complete. Repeat 
surgery is best reserved until fertility is no longer desired however, with delayed 
conception, this is becoming a more frequent challenge. 
 
For patients with subfertility and OEs the ovarian reserve and other fertility parameters 
should be assessed pre-operatively with subsequent triage for ART treatment or surgery 
depending on age and ovarian reserve. ART should be considered as the first option 
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where there is evidence of reduced ovarian reserve. This should also be the case for 
patients with small (<3cm) OEs as these do not appear to affect the outcome of ART.  
 
The focus of research has been heavily targeting the easily collected and easily reported 
surrogate markers of fertility such as AFC, AMH, and FSH without reporting live birth, 
arguably the primary reason that a patient attends the fertility clinic.  
 
The key to successful surgery may be to avoid the need for diathermy induced 
haemostasis, as this has been shown to compromise ovarian function(510). Surgical skill 
is required to perform the optimal balance minimising ovarian damage against complete 
cyst excision. Whatever the skill level, it is essential that the patient be aware of the 
benefits and risks involved, reaching an individualised treatment plan avoiding 
permanent irreversible ovarian damage. Overall, there is growing consensus that OEs 
should not be routinely removed prior to ART. Research should be focused on improving 
the surgical techniques which best preserve post-operative ovarian function, for those 
individual patients where an operation is deemed necessary. A harmonised approach to 
reporting key outcomes important to patients, clinicians and researchers needs to be 
developed to maximise the usefulness of future research to improve patient care. 
 
This chapter has been adapted and updated from the following peer reviewed 
publication: 
Psaroudakis D, Hirsch M, Davis C. Review of the management of ovarian endometriosis: 
paradigm shift towards conservative approaches. Curr Opin Obstet Gynecol. 2014 
Aug;26(4):266-74. 
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CHAPTER 8: 
THE LONG TERM RISKS OF 
HYSTERECTOMY AND 
BILATERAL OOPHORECTOMY 
FOR WOMEN WITH 
ENDOMETRIOSIS – A 
SYSTEMATIC REVIEW AND 
META-ANALYSIS 
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9.1 ABSTRACT  
Background: 
There are over 2,000 hysterectomies performed each day in the United States of 
America, frequently with bilateral oophorectomy. We performed a systematic review and 
meta-analysis, investigating if health outcomes are altered by adding bilateral 
oophorectomy to hysterectomy for benign indications. 
 
Methods:  
We searched CENTRAL, Embase, and MEDLINE from their inception to August, 2015. 
We included observational studies that followed up women undergoing hysterectomy, 
with or without bilateral oophorectomy, for a range of health outcomes. We used the 
Newcastle-Ottawa Scale to assess the methodological quality. We computed, using 
random effects meta-analysis, risk ratios (RR) for various outcomes comparing women 
with vs without bilateral oophorectomy.   
 
Findings:  
Of 13,470 citations, there were 48 relevant studies (1,272,071 women). Hysterectomy 
with bilateral oophorectomy (498,603 women) vs without (773,468 women) was 
associated with increase in stroke (RR 1.09, 95% CI 1.03 – 1.16; baseline risk = 35%; 
number needed to harm [NNH] = 32) and anxiety (RR 1.26, 95% CI 1.06 – 1.51; baseline 
risk =5.9%; NNH = 65); and decrease in ovarian cancer (RR 0.09, 95% CI 0.04 – 0.19; 
baseline risk = 2.5%; number needed to treat [NNT] = 44); and breast cancer (hazard 
ratio 0.85, 95% CI 0.73 – 0.99; baseline risk = 12%; NNT = 55).  
 
Interpretation:  
The balance of adverse and beneficial health outcomes associated with bilateral 
oophorectomy should be employed when counselling women concerning benign 
hysterectomy.  
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9.2 INTRODUCTION 
Hysterectomy for benign disease such as leiomyoma, abnormal uterine bleeding, 
endometriosis, and pelvic pain is the most common gynaecological operation with over 
2,000 procedures performed daily in The United States of America (511). Women face a 
choice at operation as to whether their ovaries are conserved or removed. Ovarian 
hormone production provides health benefits both before the menopause and extending 
into later life (512,513). An oophorectomy leads to a fall in circulating oestrogen and 
androgen levels which may have clinically significant consequences on mortality, bone 
health, malignancy, cardiac risk, and mental health (514).  
There are no national or internationals recommendations for the pre-menopausal 
conservation or removal of ovaries in women with benign gynaecological disease (424). 
The routine inclusion of bilateral oophorectomy is common clinical practice occurring in 
up to 30% of all hysterectomies under age fifty (515) and increasing in frequency (516). 
The commonest indication cited is the reduction in the lifetime risk of developing ovarian 
cancer (424) which remains low at 1.4% (517). Reviews of comparisons for long term 
health outcomes between women having undergone hysterectomy with and without 
bilateral oophorectomy are limited. We lack evidence syntheses to guide future clinical 
practice and individual decision making in decisions surrounding ovarian conservation at 
the time of hysterectomy (518). 
We conducted a systematic review and meta-analysis to investigate the association 
between hysterectomy with or without bilateral oophorectomy, and various health 
outcomes.  
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9.3 METHODS 
A protocol with explicitly defined objectives, criteria for study selection, approaches to 
assessing study quality, and statistical methods was developed and prospectively 
registered with the International PROSPERO (registration number CRD42015026411). 
We reported the systematic review and meta-analysis in accordance with PRISMA (328). 
  
SEARCH STRATEGY AND SELECTION CRITERIA 
We performed a comprehensive and systematic search of the following databases from 
their inception to August, 2015:  CENTRAL, January 1, 1898 – August 21, 2015), 
Cochrane Database of Systematic Reviews (CDSR), Cochrane Groups, Cochrane 
Library, Cochrane Methodology Register (CMR), Database of Abstracts of Reviews of 
Effects (DARE), Economic evaluations, Embase (January 1, 1947 – August 21, 2015), 
Health technology Assessment Database (HTA),  Medline (January 1, 1946 – August 21, 
2015). We performed keyword and MeSH searches for “hysterectomy” and checked 
reference lists of relevant papers and reviews for additional studies. The search was 
limited to studies on humans but was not limited by language.  
Two independent reviewers (MH & JOK) worked in duplicate to screen the titles and 
abstracts in Covidence systematic review software (Veritas Health Innovation, 
Melbourne, Australia) (519) for eligibility. We retrieved all relevant citations and reviewed 
the full texts. Any disagreements were resolved through discussion with a senior 
investigator (JD & KK). We excluded conference abstracts, case reports, and case 
series.  
The predefined inclusion criteria were, observational studies, including cohort and case-
control designs, in any language with adult female patients undergoing hysterectomy 
were included. We compared hysterectomy with bilateral oophorectomy to hysterectomy 
with ovarian conservation. We excluded studies where hysterectomy was undertaken for 
malignant disease.  
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Outcomes studied were: [1] all-cause mortality; [2] cardiovascular disease; [3] coronary 
heart disease; [4] stroke; [5] malignancy; [6] osteoporosis; [7] neurological disease; [8] 
depression; and [9] anxiety. We measured outcomes from 5 years postoperatively for 
cardiovascular disease, coronary heart disease, and stroke. We measured outcomes 
from 1 year for malignancy, osteoporosis, neurological disease, depression and anxiety. 
We investigated whether study participants were users of hormone replacement therapy 
(HRT). Any factors statistically corrected for in the data we extracted and recorded. 
DATA EXTRACTION AND QUALITY ASSESSMENT 
Two independent investigators (MH & JOK) extracted data using a standardised, pre-
designed data extraction in Microsoft Excel 2013. If data were presented following 
multivariable adjustment they were selected over non-adjusted data. Disagreements 
were resolved by discussion with a senior author (JD & KK). We contacted authors 
where data was not presented within the manuscript (520–525).  
We assessed methodological quality and risk of bias of the included studies with criteria 
set by the Newcastle-Ottawa Scale (526). Two reviewers (MH & JOK) undertook quality 
assessment independently and in duplicated according to the pre-defined criteria. A low 
risk of bias was attributed to studies that scored four stars for selection, two stars for 
comparability, and three stars for ascertainment of the outcome. Medium risk of bias 
allocated to studies with two or three stars for selection, one for comparability, and two 
for outcome ascertainment. All studies with a score of one for selection or outcome 
ascertainment, or zero for any of the three domains, was regarded as having a high risk 
of bias (527).  
DATA SYNTHESIS 
We tabulated characteristics and results of all included studies. We compared health 
outcomes in women undergoing hysterectomy with oophorectomy to women undergoing 
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hysterectomy alone. After pooling data we reported the random and fixed effects meta-
analysis as RR with 95% CIs. Heterogeneity was assessed as I2 statistic. We calculated 
number need to treat (NNT) and number need to harm (NNH) for all statistically 
significant outcomes. We used the following formula: NNT/NNH = 1/baseline risk x (1-
RR). The baseline risk was calculated from the control group of the highest quality study 
which reported the specified outcome. We attempted to perform subgroup analysis by 
age, HRT use, and menopausal status however this data was not available from the 
included studies.  
ROLE OF THE FUNDING SOURCE 
There was no funding source for this study. The corresponding author had full access to 
all the data in the study and had final responsibility for the decision to submit for 
publication.  
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9.4 RESULTS 
Searches of electronic databases and reference lists generated 13,470 references. On 
evaluation of their titles and abstracts, 338 articles (2.5%) were potentially relevant for 
detailed assessment (figure 19), and of these 48 studies (517,520–522,524,525,528–
569), comprising 1,272,071 women, met our inclusion criteria for quantitative synthesis 
(Table 20). We included 24 studies (517,520,528–535,537,541–543,554,556,559–
561,563–565,567,569), comprising 760,186 women for meta-analysis (Table 20). Of the 
48 studies, 24 were cohort, 11 case-control and 13 cross-sectional. There were 41 
different population-based cohorts (517,520–522,524,525,528–569). These included 
data from the following study populations: Black Women’s Health Study (535); Breast 
Cancer Detection Demonstration Project (536); Cancer prevention study II (543); DOM 
Project (534); Early postmenopausal Interventional Cohort study (520);  Eindhoven 
Perimenopausal Osteoporosis Study (525); Framingham Study (567); Kuopio 
Osteoporosis Risk Factor and Prevention Study (522); Maryland Women’s Health Study 
(564); Mini-Finland Health Survey (529,546); National Climacteric Survey of the Mexican 
Association for the Study of the Climacteric (563); Nurses’ Health Study (531–533,566); 
Rancho Bernardo Heart and Chronic Disease Study (554,562); Study of Women’s Health 
Across the Nation (521); and Women’s Health Initiative Observational Study (528,568). 
We included five studies using registry data (529,540,541,546,550,569). The size of the 
studies varied from 335,216 participants (540) to 28 (557) participants with a median 
study size of 847 (563). The follow up ranged from 12 months (558,564) to 28 years 
(532).  
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Figure 19 - Flow of included studies 
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Table 20 - Study Characteristics  
Study Population  Expos
ure 
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Author 
Year 
(Country) 
Study 
Design 
Data Source 
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MORTALITY AND CARDIOVASCULAR DISEASE 
Colditz 
1987 
(USA) 
Cohort The Nurses’ Health Study. 
Biennial questionnaire of self-reported exposure 
and outcome. 
Follow up 6 years (1976-1982). 
16,563 Married 
registered 
nurses living 
in 11 
American 
States. Aged 
30-55 in 
1976. 
Menopausal.  
Diagnosis of 
coronary 
heart disease 
at entry. 
Unknown 
exposure. 
Unadjust
ed data. 
Not specified. Hysterecto
my 
n=8,061 
 
Hysterecto
my & BSO 
n=8,502 
       
Gordon 
1978 
(USA) 
Cohort The Framingham Study. 
Biennial examination of women assessing 
exposure and outcome. 
Follow up 24 years. 
544 Women in 
the 
Framingham 
Study.  Aged 
29 to 62 in 
1948. 
Not 
described. 
Unadjust
ed data. 
Not specified. Hysterecto
my n=146 
 
Hysterecto
my & BSO 
n=398 
       
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Howard 
2005 
(USA) 
Cohort Women's Health Initiative Observational Study. 
Annual self-reported exposure and outcome. 
Mean follow up 5.1 years. 
36,924 Postmenopa
usal women, 
40 clinical 
centres in 
the USA. 
Aged 50-79 
years in 
1994-1998.  
Migration 
within 3 
years. 
Terminal 
illness. 
Inability to 
provide 
informed 
consent. 
Unadjust
ed data. 
Age, ethnicity, 
family history, 
income, 
education ,  
body mass 
index, white 
blood cell count, 
physical activity, 
dietary saturated 
fat.  
Hypertension, 
diabetes, high 
cholesterol, 
smoking, 
peripheral 
arterial disease, 
and deep 
venous 
thrombosis 
histories. 
Baseline 
cardiovascular 
disease, angina, 
or congestive 
heart failure. 
Hysterecto
my 
n=18,688 
 
Hysterecto
my & BSO 
n=18,236 
       
Ingelsson 
2010 
(Sweden) 
Cohort The Swedish Classification of Operations and 
Major Procedures & Swedish Inpatient Register: 
Medical record linkage for recruitment, exposure 
and outcome assessment. 
Median follow up 10.4 years (1973-2003). 
184,441 Hysterectom
y for benign 
disease 
between 
1973 and 
2003. 
Outcome 
present at 
study entry. 
Exposure for 
malignant 
disease. 
Exposure 
less than 18 
years of age. 
Death before 
follow up. 
Migration 
during follow 
up.   
Unadjust
ed data. 
Age, calendar 
time, county, 
socio-economic 
status. 
Hysterecto
my 
n=156,305 
 
Hysterecto
my & BSO 
n=24,910 
       
Jacoby 
2011 
(USA) 
Cohort Women's Health Initiative Observational Study. 
Annual self-reported outcome and exposure.  
Mean follow up 5.1 years.  
25,448 
 
Postmenopa
usal women, 
40 clinical 
centres in 
the USA. 
Aged 50-79 
Migration 
within 3 
years. 
Terminal 
illness. 
Inability to 
provide 
informed 
Adjusted 
data. 
Age, ethnicity, 
education, 
medical 
insurance, 
current health 
care provider, 
parity, body 
mass index, 
Hysterecto
my 
n=11,194 
 
       
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years in 
1994-1998. 
consent. 
Unknown 
exposure. 
Previous 
malignancy. 
Family 
history of 
ovarian 
malignancy. 
HRT use, 
smoking, alcohol 
, exercise, 
hypertension, 
diabetes 
mellitus, high 
cholesterol 
levels requiring 
medication, 
personal history 
of myocardial 
infarction, 
coronary artery 
bypass graft, 
percutaneous 
transluminal 
coronary 
angioplasty, 
stroke or family 
history of 
myocardial 
infarction or 
stroke. 
Hysterecto
my & BSO 
n=14,254 
Luoto 
1995 
(Finland) 
Cross-
sectional 
Mini-Finland Health Survey. 
Self-reported exposure. 
Medical record linkage for outcome. 
Surveyed in 1977-1980. 
226 
 
Women 
aged 30-95 
years old 
having a 
hysterectom
y (between 
1944 and 
1979). 
Unconfirmed 
hysterectomi
es and 
missing 
information 
on 
cardiovascul
ar risk 
factors. 
Adjusted 
data. 
Age, body mass 
index, interaction 
between age 
and body mass 
index, HRT, 
cholesterol,  
triglycerides, 
glucose, 
smoking, 
alcohol, 
education. 
Hysterecto
my n=163 
 
Hysterecto
my & BSO 
n=55 
       
Palmer 
1992 
(USA) 
Case-control Multi-centre state wide recruitment, 
Massachusetts, USA. 
Medical record linkage of outcome. 
Self-reported exposure. 
480 Cases: Aged 
45-69. 
Hospitalisati
on for a first 
nonfatal 
myocardial 
infarction.  
 
Control: Age 
and 
geographical
Unable to 
contact by 
telephone. 
Adjusted 
data. 
Smoking, 
hypertension, 
high cholesterol, 
diabetes 
mellitus, family 
history of 
myocardial 
infarction, body 
mass index, 
coffee and 
alcohol 
consumption, 
patient and 
Case: 
Hysterecto
my n=87 
Case: 
Hysterecto
my & BSO 
n=157 
 
       
  
 222. 
ly matched. 
No history of 
myocardial 
infarction.  
spouse 
education, HRT 
use, occupation, 
age at 
menarche, 
parity, age at 
first birth, 
menopausal 
status. 
Control 
Hysterecto
my n=96 
Control 
Hysterecto
my & BSO 
n=140 
Parker 
2009 
(USA) 
Cohort The Nurses’ Health Study. 
Self-reported biennial postal questionnaire of 
exposure and outcome.   
Follow up 24 years. 
29,380 
 
Married 
registered 
nurses living 
in 11 
American 
States. Aged 
30-55 in 
1976. No 
diagnosis of 
gynaecologi
cal cancer. 
USO or 
partial 
oophorectom
y. Unknown 
ovarian 
status at time 
of 
hysterectomy
. Prior history 
of an 
outcome of 
interest. 
Oophorectom
y before 
hysterectomy
. Missing 
information 
on past oral 
contraceptive 
use. 
Adjusted 
data. 
Age, age at 
hysterectomy, 
diabetes, high 
blood pressure, 
hypercholesterol
emia, family 
history of 
myocardial 
infarction before 
age 60 years, 
body mass index 
in 1976, smoking 
status, use of 
HRT, duration of 
oral 
contraceptive 
use, parity, 
alcohol intake, 
physical activity, 
aspirin use. 
Hysterecto
my 
n=13,035 
 
Hysterecto
my & BSO 
n=16,345 
       
Parker 
2013 
(USA) 
Cohort The Nurses’ Health Study. 
Self-reported biennial postal questionnaire of 
exposure and outcome.   
Follow up 28 years. 
30,117 
 
 
Married 
registered 
nurses living 
in 11 
American 
States. Aged 
30-55 in 
1976. 
Hysterectom
y for benign 
disease. 
History of 
other 
cancers, 
coronary 
heart 
disease, 
stroke or 
pulmonary 
embolus.  
USO or 
partial 
oophorectom
y. Unknown 
age or 
ovarian 
status at time 
of 
hysterectomy
Adjusted 
data. 
Age, age at 
hysterectomy, 
body mass index 
in 1976, smoking 
status, use of 
HRT, past 
duration of oral 
contraceptive 
use, parity, 
physical activity, 
alcohol intake, 
aspirin use.  
Hysterecto
my 
n=13,203 
 
Hysterecto
my & BSO 
n=16,914        
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.  
Oophorectom
y not at time 
of 
hysterectomy
. 
Rosenburg 
1981 
(USA) 
Case-control The Nurses’ Health Study. 
Medical record linkage for outcome. 
Self-reported exposure. 
1,264 Married 
registered 
nurses living 
in 11 
American 
States. Born 
from 1921-
1946.  
 
Case: 
Hospitalised 
for 
myocardial 
infarction in 
1965-1977. 
 
Control: Age 
matched. No 
history of 
myocardial 
infarction. 
Known 
menopause 
status. 
Case:  
Unknown 
type of 
menopause. 
Hospitalised 
in year that 
menopause 
occurred. 
Adjusted 
for length 
of use. 
Age at 
hospitalisation, 
area of 
residence, year 
of 
hospitalisation, 
length of use of 
post-
menopausal 
HRT, use of oral 
contraceptive in 
month prior to 
hospitalisation, 
obesity, 
smoking, history 
of hypertension, 
diabetes, high 
cholesterol, 
angina and 
parental 
myocardial 
infarction before 
age 50. 
Case: 
Hysterecto
my n=50 
Case: 
Hysterecto
my & BSO 
n=48 
 
Control 
Hysterecto
my n=769 
Control 
Hysterecto
my & BSO 
n=397 
       
Van der 
Schouw 
1996 
(Netherlan
ds) 
Cohort DOM Project for breast cancer screening. 
Self-reported exposure. 
Medical record linkage for outcome. 
Median follow up 10 years.  
1,678 
 
Aged 50-65 
at 
enrolment. 
Residents of 
Utrecht, 
Netherlands.  
 
Use of HRT. Women 
using 
HRT 
excluded 
from 
study. 
Age at 
menopause. 
Hysterecto
my n=791 
 
Hysterecto
my & BSO 
n=887 
       
MALIGNANCY 
  
 224. 
Boggs 
2014 
(USA) 
Cohort Black Women’s Health Study.  
Biennial patient questionnaire for exposure.  
Medical record linkage for outcome. 
Follow up 1995-2011. 
9,132 At least 40 
years old 
during follow 
up period. 
No previous 
malignancy 
before 
enrolment.  
History of 
cancer at 
baseline, 
family history 
of ovarian 
cancer, 
oophorectom
y without 
hysterectomy
. 
Adjusted 
data. 
Age, body mass 
index, 
menopausal 
hormone use, 
smoking history, 
education, 
geographic 
region, family 
history of breast 
cancer. 
Hysterecto
my 
n=4,576 
 
Hysterecto
my & BSO 
n=4,556 
       
Brinton 
1981 
(USA) 
Case-Control Breast Cancer Detection Demonstration Project. 
Self-reported exposure. 
Medical record linkage for outcome. 
Follow up 4 years (1973-1977). 
624 Asymptomat
ic women 
aged 35-74 
from 29 
centres in 
the USA. 
Not 
described. 
Stratified 
by HRT 
use and 
regime. 
Age, type of 
menopause, 
HRT use. 
Case: 
Hysterecto
my n=156 
Case: 
Hysterecto
my & BSO 
n=158 
 
Control 
Hysterecto
my n=133 
Control 
Hysterecto
my & BSO 
n=177 
       
Cape 
1999 
(Canada) 
Cohort Inpatient and outpatient recruitment. 
Medical record linkage of exposure.   
Medical record linkage of outcome assessment. 
Mean follow up 7-8 years.   
266,514 Women 
aged 15-64 
who had 
gynaecologi
cal surgery 
from 1979-
1993. 
Operation 
within 6 
months of 
malignancy 
diagnosis. 
Not 
specified. 
Not specified. Hysterecto
my 
n=187,838 
(479) 
 
Hysterecto
my & BSO 
n=77,676 
(328) 
       
Chan 
2014 
Cohort Inpatient recruitment. 
Medical record linkage of exposure. 
52,716 Women 
aged 18-84 
undergoing 
benign 
gynaecologi
Previous 
malignancy, 
pre-
malignancy 
abnormal 
Not 
specified. 
Age at 
intervention, 
ethnicity. 
Hysterecto
my 
n=22,051 
(31) 
       
  
 225. 
(USA) Medical record linkage of outcome assessment. 
Follow up 18 years (1988-2006). 
cal surgery.  
Median age 
45.   
cervical 
smear or 
malignancy 
diagnosis 
within 90 
days of 
surgery. 
 
Hysterecto
my & BSO 
n=30,665 
(13) 
Cui 
2014 
(USA) 
Case-control Inpatient recruitment (case), community 
recruitment (control). 
Medical record linkage of outcome. 
Self-reported exposure. 
Recruitment 2001-2011. 
1,097 Case: 
Women 
aged 25-75, 
primary 
breast 
cancer, 
Nashville 
Tennessee. 
 
Control:  
Random 
geographical 
community 
matched 
controls. 
Case: 
Previous 
malignancy. 
 
Control:  Not 
described. 
Stratified 
by never 
used 
HRT and 
ever 
used 
HRT. 
Age, education. Case: 
Hysterecto
my n=213 
Case: 
Hysterecto
my & BSO 
n=336 
 
Control: 
Hysterecto
my n=177 
Control: 
Hysterecto
my & BSO 
n=371 
       
Duell 
2004 
(USA) 
Case-control Inpatient recruitment (case), community 
recruitment (control). 
Structured interviews assessment of exposure. 
Medical record linkage of outcome. 
Recruitment 1995-1999. 
 
599 Case: 
Women with 
primary 
adenocarcin
oma of the 
exocrine 
pancreas. 
Aged 21-85. 
 
Control: 
Community 
based. Age, 
race and 
geographical
ly matched 
to cases. 
Case:  Not 
described. 
 
Control:  Not 
described. 
Unadjust
ed data. 
Age, education, 
smoking. 
Case 
hysterecto
my n=83 
Case 
hysterecto
my & BSO 
n=47 
 
Control 
hysterecto
my n=313 
Control 
hysterecto
my & BSO 
n=156 
       
  
 226. 
Duell 
2010 
(10 
European 
countries) 
Cohort Community recruitment.  
Self-reported questionnaires for exposure. 
Outcome assessment via national cancer 
registry.  
Mean follow up 8.7 years. 
335,216 Women 
aged 35-70 
between 
1992-1998. 
Widespread 
malignancy 
at the time of 
recruitment. 
Unadjust
ed data. 
Age, location, 
smoking, 
education, body 
mass index, 
calorie-adjusted 
food intakes. 
Hysterecto
my = 
159,380 
person-
years 
 
Hysterecto
my & BSO 
= 86,508 
person 
years 
       
Falconer 
2015 
(Sweden) 
Cohort National database recruitment; Swedish cancer 
register.   
Surgical medical record linkage for exposure 
and outcome. 
Mean follow up 23.1 years. 
135,374 Women 
aged 16-74 
undergoing 
operation 
between 
1973-1996. 
Previous 
primary 
ovarian 
malignancy 
at 
recruitment. 
Not 
specified. 
Age, education, 
parity. 
Hysterecto
my 
n=98,026 
(278) 
 
Hysterecto
my & BSO 
n=37,348 
(7) 
       
Gallagher 
2013 
(China) 
Cohort Community recruitment. 
Self-reported exposure. 
Medical record linkage for outcome. 
Mean follow up 9.3 person-years (1989-2000). 
248 Women born 
1925-1958 
working in 
textile 
factories in 
Shanghai. 
Not 
described 
Not 
specified. 
Age, smoking. Hysterecto
my n=160 
(38) 
 
Hysterecto
my & BSO 
n=88 (24) 
       
Gaudet 
2014 
(USA) 
Cohort Cancer Prevention Study-II Nutrition Cohort. 
Biennial self-reported questionnaires to 
establish exposure and outcome.  
Median follow up 13.9 years (1992-2009). 
25,405 Women 
aged 50-74 
from 21 
American 
States. 
Previous 
malignancy 
at enrolment. 
Previous 
smoker.  
Adjusted 
data. 
Age, ethnicity, 
parity, 
education, 
alcohol, 
smoking, HRT 
use, 
menopause, 
physical activity, 
body mass 
index. 
Hysterecto
my n= 
9,655 
(1143) 
 
Hysterecto
my & BSO 
n=15,750 
(1892) 
       
  
 227. 
Helmrich 
1983 
(USA, 
Canada, 
Israel) 
Case-control Inpatient recruitment of cases and controls. 
Self-reported questionnaire assessing exposure 
and outcome. 
1,187 Case: 
Women 
ages less 
than 70 
years with a 
diagnosis of 
breast 
cancer 
within 1 
year.  
 
Control: 
Hospital 
inpatients 
less than 70 
years with 
non-breast 
and non-
gynaecologi
cal disease. 
Previous 
history of 
cancer. 
Admission for 
gynaecologic
al disease.  
Not 
specified. 
Age at cancer, 
age at 
menopause. 
Case: 
Hysterecto
my n=123 
Case: 
Hysterecto
my & BSO: 
99 
 
Control: 
Hysterecto
my n=436 
Control: 
Hysterecto
my & BSO 
n=529 
       
Holly 
1994 
(USA) 
Case-control Surveillance, Epidemiology, and End Results 
program.  
Structured interviews for exposure.  
Hospital record linkage for outcome. 
 
269 
 
 
Case: Aged 
25-59. 
Diagnosis of 
cutaneous 
melanoma 
between 
1981-1987. 
 
Control:  
Aged 25-59. 
Identified via 
random-digit 
dialling. 
Aged and 
geographic 
matching to 
cases. 
Not 
described 
Stratified 
by HRT 
use. 
Age, education. Case: 
Hysterecto
my n=85 
Case: 
Hysterecto
my & BSO 
n=58 
 
Control: 
Hysterecto
my n=80 
Control: 
Hysterecto
my & BSO 
n=46 
       
  
 228. 
Luoto 
2003 
(Finland) 
Cohort The Mini-Finland Health Survey. 
Medical record linkage for exposure and 
outcome using national database: Finnish 
Cancer Registry. 
Mean follow up 6 years (1986-1995). 
85,200 Total or 
subtotal 
hysterectom
y with and 
without BSO 
between 
1986–1995.  
 
Not 
described. 
Not 
specified. 
Not specified. Hysterecto
my 
n=58,721 
(80) 
 
Hysterecto
my & BSO 
n=26,479 
(31) 
       
Mack 
1999 
(USA) 
Case-control Consecutive community recruitment (1980-
1983) of cases and controls. 
Self-reported exposure at interview. 
Medical record linkage for outcome. 
 
 
50 Case: 
Age15-54 
with 
histological 
diagnosis of 
thyroid 
cancer. 
 
Control: 
Community 
matched by 
age and 
race. 
Non-English-
speaking, 
non-white 
women. 
Adjusted 
data. 
Hormone use, 
thyroid disease. 
Case: 
Hysterecto
my n=18 
Case: 
Hysterecto
my & BSO 
n=14 
 
Control: 
Hysterecto
my n=15 
Control: 
Hysterecto
my & BSO 
n=3  
       
Nichols 
2010 
(USA) 
Case-control Inpatient recruitment (cases) and community 
recruitment (controls) from 1992–1995. 
Structured interview assessment of exposure.  
Medical record linkage of outcome. 
 
2,796 Case: 50-79 
years old 
with invasive 
breast 
cancer. 
 
Control: age 
and location 
matched 
community 
controls. 
Case: 
Previous 
cancer. 
 
Control: 
Previous 
cancer. 
Adjusted 
data. 
Age, 
geographical 
location, age at 
menarche, 
duration of oral 
contraceptive 
use, parity, age 
at first delivery, 
HRT use, body 
mass index, 
mammography, 
family history of 
breast cancer. 
Case 
hysterecto
my n=476 
Case 
hysterecto
my + BSO 
n= 885 
 
Control 
hysterecto
my n=474 
       
  
 229. 
Control 
hysterecto
my & BSO 
n=961 
Parazzini 
1997 
(Italy) 
Case-control Inpatient recruitment of cases and controls. 
Self-reported exposure. 
Medical record linkage for outcome. 
 
1,103 Case: 22-74 
years old, 
median age 
54, and 
cancer of 
the breast 
histologically 
confirmed 
within 1 
year. 
 
Control: 
Inpatients 
admitted 
with acute 
illness. 20-
74 years old 
(median age 
55).  Age 
and 
geographical
ly matched. 
Case: Not 
described. 
 
Control: 
Hospital 
admission for 
gynaecologic
al or 
neoplastic 
disease.  
Not 
specified. 
Age, calendar 
year of follow up, 
education, 
parity, age at 
delivery, family 
history. 
Case 
hysterecto
my n=235 
Case 
hysterecto
my & BSO 
n=268 
 
Control 
hysterecto
my n=299 
Control 
hysterecto
my & BSO 
n=301 
       
Schairer 
1997 
(Sweden) 
Cohort Swedish National Cancer Registry. 
Medical record linkage of exposure and 
outcomes. 
Mean follow up 12.2 years (1965-1987). 
15,844 All women 
undergoing 
hysterectom
y and/or 
oophorecto
my for 
benign 
disease in 
Uppsala 
region of 
Sweden 
1965-1983. 
No previous 
malignancy 
at time of 
operation. 
Not 
specified. 
Not specified. Hysterecto
my n=data 
unavailabl
e 
 
Hysterecto
my & BSO 
n=data 
unavailabl
e 
       
  
 230. 
MUSCULOSKELETAL DISORDERS 
Fletcher 
2013 
(Jamaica) 
Cross- 
sectional 
 
University Hospital of the West Indies. 
Medical record linkage of exposure. 
Self-reported outcomes at interview. 
403 Afro-
Jamaican 
women. 
 
Case: 
Community 
based 
premenopau
sal women 
aged over 
40 years. 
Hysterectom
y from 1980-
2000. 
 
Control: 
Community 
based, age 
matched 
controls.  No 
hysterectom
y or 
hysterectom
y with BSO. 
Not 
described. 
Not 
specified. 
Not specified. Case: 
Hysterecto
my n=252 
Case: 
Hysterecto
my & BSO 
n=151 
      
 
 
Forsmo 
2001 
(Norway) 
Cross-
sectional 
 
Community-based recruitment. 
Exposure by self-reported postal health 
questionnaire.  
Outcome by health examination and bone 
densitometry. 
112 Perimenopa
usal and  
postmenopa
usal women 
aged  
50-59 years 
old.  
 
No data on 
menopause 
Unadjust
ed data. 
Not specified. Hysterecto
my n=91 
 
Hysterecto
my & BSO 
n=21 
       
Grainge 
2001 
Cross-
sectional 
Early Postmenopausal Interventional Cohort 
study at the UK centre and 20 community based 
women. 
130 Postmenopa
usal aged 
45-61 years. 
In good 
Hormone 
replacement 
within the last 
3 months. 
Unadjust
ed data. 
Not specified. Hysterecto
my n=95        
  
 231. 
(UK) Interviewer administered questionnaire for 
exposure. 
Medical record linkage for outcomes. 
 
health. 
Lumbar 
spine 
anatomy 
suitable for 
bone 
densitometry
. 
Disease 
likely to have 
affected bone 
turnover. 
Current use 
of medication 
which may 
affect bone 
metabolism. 
Allergy to 
bisphosphon
ates. 
Gastrointesti
nal 
symptoms 
within the 
previous 
year.  
Excessive 
body weight. 
No more than 
10% of 
women were 
permitted to 
have a spinal 
bone mineral 
density below 
0.8g/cm2. 
 
Hysterecto
my & BSO 
n=35 
Hreshchys
hyn 
1988 
(USA) 
Cross-
sectional 
Self-reported exposure. 
Medical record linkage for outcomes. 
82 Ambulatory 
white 
women aged 
35-65. 
Ambulatory. 
Normal 
lumbar 
spines. 
Traumatic 
fractures of 
any kind. 
Cessation of 
menses 
before age 
37. 
Data 
represent
ing no 
HRT use 
selected. 
Not specified. Hysterecto
my n=37 
 
Hysterecto
my & BSO 
n=45 
       
Johansson 
1993 
(Sweden) 
Cross-
sectional 
Intervention Trial, part of the gerontological 
study. 
Self-reported exposure at interview. 
Medical record linkage for outcomes. 
40 
 
Aged 70. Hormone 
replacement. 
Users of 
cortisone, 
heparin, 
phenytoin, 
vitamin D, L-
thyroxine. 
Women with 
Women 
using 
HRT 
excluded 
from 
study. 
Socio-economic 
factors, body 
mass index, 
smoking. 
Hysterecto
my n=22 
 
Hysterecto
my & BSO 
n=18 
       
  
 232. 
hyperthyroidi
sm. 
Kritz-
Silverstein 
2004 
(USA) 
Cohort Rancho Bernardo Heart and Chronic Disease 
Study. 
Self-reported exposure at interview. 
Medical record linkage for outcomes. 
Initial (1988-1991) and follow up visit (1992-
1995).  
447 
 
Aged 60-89 
years 
(average 71 
years) at 
initial 
interview. 
Ambulatory. 
Change of 
HT use 
status 
between 
follow up 
visits. Never 
menstruated. 
Adjusted 
data. 
Age, body mass 
index, age at 
menopause, 
HRT use. 
Hysterecto
my n=122 
 
Hysterecto
my & BSO 
n=91 
       
Loizzi 
1989 
(Italy) 
Cohort Gynaecological clinic outpatient recruitment. 
Medical record linkage of exposure. 
Self-reported outcome. 
1-6 years postoperatively. 
965 
 
Hysterectom
y for benign 
indications 
between 
1982-1987.  
Mean age at 
hysterectom
y 48.2 years.   
Malignant 
disease. 
Unadjust
ed data. 
Not specified. Hysterecto
my n=234 
 
Hysterecto
my & BSO 
n=609 
       
Nakamura 
1991 
(Japan) 
Cross-
sectional 
Outpatient recruitment. 
Self-reported questionnaires for exposure. 
Medical record linkage for outcomes. 
161 
 
Women 
within 4 
years post-
surgery.  
Not 
described. 
Not 
specified. 
Not specified. Hysterecto
my n=75 
 
Hysterecto
my & BSO 
n=86 
       
Shilbayeh 
2003 
(Jordan) 
Cross-
sectional 
Recruitment via outpatient primary health clinics 
in and random telephone survey. 
Self-reposted exposure by interviewer-
administered questionnaire. 
Medical record linkage for outcomes. 
 
28 
 
Attending 
outpatient 
clinics or 
randomly 
selected via 
telephone 
from 2000-
2002.  Mean 
age 53 
years. 
Pregnancy 
and lactation. 
Unadjust
ed data. 
Not specified. Hysterecto
my n=21 
 
Hysterecto
my & BSO 
n=7 
       
Smeets-
Goevaers 
1998 
 
Cross-
sectional 
The Eindhoven Perimenopausal Osteoporosis 
Study. 
Self-reported questionnaire for exposure. 
 
1,117 
White Dutch 
women aged 
46-54 years 
Failure to 
provide 
relevant 
information. 
Unable to 
Data 
represent
ing all 
women 
Not specified. Hysterecto
my n=777 
 
       
  
 233. 
(The 
Netherland
s) 
Medical record linkage for outcomes.  (average 50 
years). 
measure 
bone mineral 
density.  
using 
HRT. 
Hysterecto
my & BSO 
n=340 
Tuppurain
en 
1995 
(Finland) 
 
Cross-
sectional 
Kuopio Osteoporosis Risk Factor and 
Prevention Study. 
Postal questionnaire for exposure. 
Medical record linkage for outcomes. 
 
265 
 
Perimenopa
usal women 
aged 47-57 
years (in 
1989). 
Past or 
current use 
of hormone 
replacement. 
Hip 
deformities; 
marked spine 
osteophytes 
or deformities 
Unadjust
ed data. 
Not specified. Hysterecto
my n=195 
 
Hysterecto
my & BSO 
n=70 
       
ANXIETY AND DEPRESSION 
Aziz 
2005 
(Sweden) 
 
Cohort 
Multi-centre study, inpatient recruitment. 
Medical record linkage for exposure. 
Self-reported outcome.  
Preoperative and one year follow up. 
 
362 
Last 
menstruatio
n less than 
12 months 
ago, 
sexually 
active 
women of a 
partner 
relationship.  
Aged 45-55 
at entry. 
Hysterectom
y for benign 
indication, 
operated on 
between 
1996 and 
1999. 
A mental or 
physical 
disease that 
would 
interfere with 
the studied 
parameters.  
Previous 
medical help 
for sexual 
problems. 
Unadjust
ed data. 
Not specified. Hysterecto
my n=217 
 
Hysterecto
my & BSO 
n=106 
       
Chen 
2013 
(China) 
 
Cross-
sectional 
Community recruitment. 
Medical record linkage for exposure. 
Self-reported outcome at interview. 
 
593 
Aged 45-60 
years. At 
menopausal 
transition or 
less than 5 
years post 
menopause. 
Capable of 
verbal 
communicati
on.  
Persistent 
smoking or 
alcohol habit, 
long term use 
of oral 
contraceptive
s or NSAID 
drugs. Heavy 
manual job. 
History of 
HRT use. 
Women 
with 
history of 
HRT use 
excluded 
from 
study. 
Not specified. Hysterecto
my n=337 
 
Hysterecto
my & BSO 
n=256 
       
  
 234. 
Hysterectom
y for benign 
indication 
with no 
malignancy 
revealed by 
post-
operative 
pathology, 
between 
2003 and 
2008. 
Pre-existing 
pelvic floor 
dysfunction 
or psychiatric 
disorder.  
Farquhar 
2005 
(New 
Zealand) 
 
Cohort 
Inpatient recruitment. 
Self-reported questionnaires for exposure. 
Self-reported outcomes. 
Assessed one week before surgery, then post-
surgery at 6 weeks, 6 months, and annually for 
3 years.  
 
314 
Younger 
than 46 
years. 
Malignancy 
of the cervix, 
endometrium 
or ovary. 
Not 
specified. 
Not specified. Hysterecto
my n=257 
 
Hysterecto
my & BSO 
n=57 
       
Gibson 
2012 
(USA) 
 
Cohort 
Study of Women’s Health Across the Nation.  
Self-reported exposure. 
Outcome by questionnaire, Centre for 
Epidemiologic Studies Depression Score), blood 
samples and physical examination. 
Baseline interview (1996-1997) followed 
annually for up to 10 years. 
 
177 
Aged 42-52 
years. Not 
pregnant, 
not using 
HRT. One or 
more 
menstrual 
cycles in the 
3 months 
prior to the 
interview.  
Not 
described. 
Adjusted 
data. 
Hysterectomy 
status, time 
since final 
menstrual period 
or surgery, 
geographical 
location, 
ethnicity, 
education, 
menopausal 
status, age, 
body mass 
index, self-rated 
health, 
antidepressant 
use, HRT use. 
Hysterecto
my n=76 
 
Hysterecto
my & BSO 
n=101        
Haines 
1993 
(Hong 
Kong) 
 
Cohort 
Inpatient recruitment. 
Medical record linkage for exposure. 
Self-reported outcome. 
 
66 
Aged over 
35, 
undergoing 
laparotomy 
for any 
indication. 
Not 
described. 
Not 
specified. 
Not specified. Hysterecto
my n=33 
        
  
 235. 
Follow up postoperatively on day of discharge 
and outpatient visits at least 6 weeks 
postoperatively.  
Hysterecto
my & BSO 
n=33 
Kritz-
Silverstein 
1994 
(USA) 
 
Cross-
sectional 
Rancho Bernardo Heart and Chronic Disease 
Study (enrolment and interviews in 1972-1974).  
Self-reported exposure at interview. 
Self-reported outcome. 
 
463 
Postmenopa
usal aged 
50-89 
(average 
age 70.1). 
Women 
uncertain if 
their ovaries 
had been 
removed. 
Reported 
uterine or 
ovarian 
cancer. 
Adjusted 
data. 
Age, HRT use, 
age at 
menopause. 
Hysterecto
my n=240 
 
Hysterecto
my & BSO 
n=223 
       
Legorreta 
2013 
(Mexico) 
 
 
Cross-
sectional 
National Climateric Survey of the Mexican 
Association for the Study of the Climacteric. 
Exposure by interviewer-administered 
questionnaire. 
Self-reported outcome at interview 
 
 
 
847 
Aged 40-59 
years (mean 
49.5 years). 
Attending 
gynaecologi
cal clinics 
across 
Mexico for 
any 
indication. 
Significant 
mental or 
physical 
impairment. 
Unadjust
ed data. 
Not specified. Hysterecto
my n=762 
 
Hysterecto
my & BSO 
n=85 
       
Rohl 
2008 
(Australia) 
 
Cohort 
Maryland Women’s Health Study. Depressive 
symptoms. 
Exposure and outcome by interviewer-
administered questionnaire for outcome (Profile 
of Mood States Survey). 
Baseline and 12 month follow up. 
 
1,047 
Premenopau
sal women 
in Australia 
having 
surgery in 
1992-1993. 
Benign 
indications 
and findings 
at time of 
surgery.  
Malignancy 
diagnosed at 
the time of 
surgery. 
Unadjust
ed data. 
Age, parity, 
ethnicity, 
income, 
endometriosis, 
smoking. 
Hysterecto
my n=614 
 
Hysterecto
my & BSO 
n=433 
       
NEUROLOGICAL 
Imtiaz 
2014 
(Finland) 
Case-control Residing in Finland on 31st December 2005. 
Finish National Registry 
Exposure from coded registry linkage 
4013 
 
Aged 42–
101 years. 
Case: 
Women with 
Alzheimer’s 
disease 
Case: 
Surgeries 
after   
Alzheimer’s 
disease   
diagnosis. 
Adjusted 
data. 
Adjusted for use 
and duration of 
HRT and 
modified 
Charlson 
Case 
Hysterecto
my 
n=1274 
       
  
 236. 
Outcome from coded registry linkage  
Community controls  
decline in 
cognition 
supported 
by 
neuroimagin
g or 
cerebrospin
al fluid 
findings. 
Confirmed 
by a 
geriatrician 
or a 
neurologist. 
 
Control:  
Matched 
with a 
control by 
age, gender 
and region 
of residence. 
 
Control: Not 
described. 
comorbidity 
index. 
Hysterecto
my & BSO 
n=611 
 
Control 
Hysterecto
my 
n=1426 
Hysterecto
my & BSO 
n=702 
Total 
 
 
1,272,0
71 
 
 
       
 
+ Hormone replacement therapy 
* Cardiovascular outcomes include: coronary heart disease incidence and deaths, myocardial infarction incidence and deaths, angina incidence, cardiovascular 
disease incidence and deaths, stroke incidence and deaths. 
** Musculoskeletal outcomes include: osteoporosis, osteopenia, bone mineral density, fracture. 
 
BSO; bilateral salpingo-oophorectomy 
USO; unilateral salpingo-oophorectomy 
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Table 21 - Quality Assessment  
 
 Newcastle Ottawa Score (risk of bias) 
Author, Year (Country) Selection Comparability Outcome 
Mortality and cardiovascular disease 
Colditz, 1987 (USA) Medium Medium Medium 
Gordon, 1978 (USA) High Medium High 
Howard, 2005 (USA) Medium Medium Low 
Ingelsson, 2010 (Sweden) Low Medium Low 
Jacoby, 2011 (USA) Medium Low Low 
Luoto, 1995 (Finland) Medium Low Medium 
Palmer, 1992 (USA) Low Low Medium 
Parker, 2009 (USA) High Low Medium 
Parker, 2013 (USA) Medium Low Medium 
Rosenburg, 1981 (USA) Medium Medium Medium 
Van der Schouw, 1996 (The Netherlands) Medium Medium Low 
Malignancy 
Boggs, 2014 (USA) Medium Medium Medium 
Brinton, 1981 (USA) High Low Medium 
Cape, 1999 (Canada) Low Medium Low 
Chan, 2014 (USA) Low Medium Low 
Cui, 2014 (USA) Low Medium Medium 
Duell, 2004 (USA) Medium Medium Medium 
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Duell, 2010 (Europe) Medium Medium Low 
Falconer, 2015 (Sweden) Low Medium Low 
Gallagher, 2013 (China) High Medium Low 
Gaudet 2014 (USA) Medium Low Medium 
Helmrich, 1983 (USA) High High High 
Holly, 1999 (USA) Medium Medium Medium 
Luoto, 2003 (Finland) Medium Medium Low 
Mack, 1999 (USA) High Medium High 
Nichols, 2010 (USA) Low Low Medium 
Parazzini, 1997 (Italy) Medium Medium Medium 
Schairer, 1997 (Sweden) Medium Medium Low 
Musculoskeletal 
Fletcher, 2013 (Jamaica) Low Medium Low 
Forsmo, 2001 (Norway) Medium High Medium 
Grainge, 2001 (UK) Low Medium Medium 
Hreshchyshyn, 1988 (USA) Medium Medium Medium 
Johansson, 1993 (Sweden) Low Low Medium 
Kritz-Silverstein, 2004 (USA) Medium Medium Medium 
Loizzi, 1989 (Italy) Medium High Medium 
Nakamura, 1991 (Japan) Medium High Medium 
Shilbayeh, 2003 (Jordan) Medium High Medium 
Smeets-Goevaers, 1988 (The Netherlands) Medium High High 
Tuppurainen, 1995 (Finland) Medium Medium High 
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Comparator descriptions were restricted to hysterectomy with ovarian conservation. 
Studies measured various outcomes (Table 20) including mortality (528,531,532,568), 
cardiovascular disease (528–534,566–569), coronary heart disease 
(528,529,532,567,569), stroke (528,532,569), osteoporosis (520,556,565), sexual 
dysfunction (558,559), depression (521,560,562–564), anxiety (559,561,563), and 
malignancy (517,535–550).  
Outcomes were routinely assessed by hospital records (including death certificate) 
(517,520,522,525,530,533–542,545,546,548–553,555–557,562,564,565,567,569), and 
self-reported questionnaires or interview (521,524,528,531,532,543,544,547,554,558–
561,563,566,568). Some outcomes were measured shortly after the procedure; others 
Depression and anxiety 
Aziz, 2005 (Sweden) Medium High Low 
Chen, 2013 (China) Low Medium Low 
Farquhar, 2005 (New Zealand) Medium High Low 
Gibson, 2012 (USA) Medium Low Low 
Haines, 1993 (Hong Kong) Medium High Medium 
Kritz-Silverstein, 1994 (USA) Medium Medium Low 
Legorreta, 2013 (Mexico) Medium High High 
Rohl, 2008 (Australia) Medium Medium Low 
Neurological  
Imtiaz 2014 (Finland) Low Low Low 
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were measured at several times over the course of follow up period. The studies 
included assessed the following disease domains, cardiovascular disease, 
musculoskeletal disorders, malignancy, mortality, anxiety, depression and neurological 
disease.  
Cardiovascular outcomes were assessed in 11 studies (528–534,566–569) with five 
outcomes reported: cardiovascular disease; cardiovascular death; coronary heart 
disease; myocardial infarction; and stroke. Six studies were included for meta-analysis 
(528,532,534,567,569). 
Musculoskeletal disease outcomes were assessed by ten studies 
(520,522,524,525,552–557,562,565)  with four outcomes reported: bone mineral density; 
fracture; osteopenia; and osteoporosis. The methodology used for reporting outcomes 
varied greatly: five studies (525,553,554,556,565) used bone mineral density across four 
sites; three studies (524,525,555) reported the number of women with osteoporosis; and 
three studies (528,531,556) reported fracture occurrence. Five studies were included for 
meta-analysis (520,528,531,556,565). 
Twenty-one studies (517,528,531,532,535–550,568) examined the relationship with 
malignancy. These studies reported five outcomes; all cancer; breast cancer; colorectal 
cancer; lung cancer, and ovarian cancer. Meta-analysis was performed by study type 
stratifying by type of malignancy. Eight studies (517,528,531,535,537,541–543) were 
included for meta-analysis. 
All-cause Mortality was assessed in four studies (528,531,532,568) with all-cause 
mortality as the only outcome reported. Two studies were included for meta-analysis 
(528,532). 
Eight studies (521,558–564) reported anxiety and depression with one comparable 
outcome; diagnosis of anxiety and depression (yes/no), reported by two studies 
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(559,563). The reporting of depression and anxiety varied, with some studies reporting 
patient event rate (560–562), and others using a change in validated depression rating 
scale (521,558,559,563,564). Four studies were included for meta-analysis (559,562–
564).  
We identified only one study examining neurological disorders, Alzheimer’s disease 
(551); we therefore did not perform a meta-analysis of this outcome.  
Studies confounded for the following variable during analysis: age 
(528,529,531,532,535,536,538–543,545,548,549,551,554,562,564,568,569); age at first 
birth (530,548,549); age at intervention (517,531,532,562); age at menarche (530,548); 
age at outcome (533,544); alcohol (528–532,543); antidepressant use (521); BMI 
(521,528–533,535,540,543,548,553,554,568),; cardiovascular medications (568); deep 
vein thrombosis (568); diabetes (528,531,533); dietary saturated fat (568); duration of 
contraceptive use (531–533,547,548); education (521,528,529,535,538–
541,543,545,549); endometriosis (564); ethnicity (517,521,528,543,568); family history of 
outcome (528,530,531,535,548,549,568); food intake (540); geographical location 
(521,533,535,540,548,551,569); HRT use (521,528,529,531–
533,536,543,547,548,551,554,564); hypercholesterolaemia (528,530–533,568); 
hypertension (528–531,533,535); Income (564,568); mammography (548); medical 
insurance (528); menopausal status (521,530,543,562); parity (528,530–
532,541,543,548,549,564); peripheral arterial disease (568); physical activity 
(528,531,532,543,568); self-rated health (521); smoking (528–
533,535,540,542,543,553,564,568); socioeconomic status (553,569); and White Blood 
Cell count (568). 
Quality of included studies varied (Table 21): 30 (64%) of studies had low or medium risk 
of bias across all domains (517,521,524,528–530,532–535,537–
539,541,543,545,546,548–554,559,560,564,566,568,569). Twelve (24%) of the studies 
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(517,520,524,530,537,538,541,548,551,553,559,569) had low risk of bias for study 
selection; 30 (63%) studies (521,522,525,528,529,533–
535,539,540,543,545,546,549,550,552,554–558,560–566,568) had medium risk; and six 
studies (13%)(531,536,542,544,547,567) had high risk of bias. For comparability, 11 
(22%) studies (521,528–531,536,543,548,551,553) had low risk, 28 (69%) studies 
(517,520,522,524,533–535,537–539,541,542,545–
547,549,550,552,559,560,562,564,566–569) had medium risk, and nine (19%) studies 
(525,544,555–558,561,563,565) had high risk of bias. The risk of bias for outcome 
assessment was low in 19 (39%) studies (517,521,524,528,534,537,540–
542,546,550,551,558–560,562,564,568,569), medium in 24 (48%) studies (520,529–
533,535,536,538,539,543,545,548,549,552–557,561,565,566), and high in 6 (13%) 
studies (522,525,544,547,563,567). 
Hysterectomy and bilateral oophorectomy compared to hysterectomy alone significantly 
increases the risk of stroke (figure 20), RR 1.09 (95% CI 1.03 – 1.16), and anxiety, RR 
1.26 (95% CI 1.06 – 1.51). There are significant reductions in risk of ovarian cancer, RR 
0.09 (95% CI 0.04 – 0.19), and breast cancer, hazard ratio 0.85 (95% CI 0.73 – 0.99) 
(figure 20). There were non-significant increases in risk for the following outcomes: 
coronary heart disease 1.10 (95% CI 0.95 – 1.28); cardiovascular disease 1.04 (95% CI 
1.00 – 1.09); mortality 1.06 (95% CI 0.92 – 1.22); all cause malignancy 1.02 (95% CI 
0.98 – 1.06); lung cancer 1.13 (95% CI 0.97 – 1.31); colorectal cancer 1.07 (95% CI 0.97 
– 1.19); and cardiovascular disease deaths 1.04 HR (95% CI 0.82 – 1.33).  There were 
non-significant reductions in risk for the following outcomes: hip fracture 0.89 RR (95% 
CI 0.77 – 1.05); and bone mass density -0.25 SMD (95% CI -1.02 – 0.52). There were no 
differences noted for risk of developing depression 1.03 RR (95% CI 0.34 – 3.19) (20). 
Event rates for hysterectomy and hysterectomy with bilateral oophorectomy are reported 
in Table 22. Heterogeneity was high across all outcome domains: mortality 76.7%; 
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cardiovascular outcomes 0-86.3%; malignancy 0-77.9%; musculoskeletal system 48.5-
91.2%; and psychological outcomes 62.3-91.5%.  
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Figure 20 - Summary forest plot 
 
 
 
 
 
 
 
 
 
 
BMD: bone mass density, BSO: bilateral salpingo-oophorectomy , CHD: coronary heart disease, CVD: 
cardiovascular disease, CI: confidence Interval, RR: relative Risk, HR: hazard ratio
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Table 22 - Event Rate  
Author, 
Year 
(Country) 
Pa
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an
ts
 (n
)  
Intervention 
hysterectomy  
(n) 
Event rate 
hysterectomy 
(n) 
Event rate per 
1000 for 
hysterectomy 
Intervention 
hysterectomy 
and bilateral 
salpino-
oophorectomy 
(n) 
Event rate 
hysterectomy 
and bilateral 
salpingo-
oophorectom
y (n) 
Event rate per 
1000 for 
hysterectomy  
and bilateral 
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Forest plot A: Coronary heart disease incidence 
Gordon 
1978 
(USA) 
544 146 7 47.9 398 14 35.1        
Ingelsson 
2010 
(Sweden) 
184,441 156,305 3,774 24.1 24,910 610 24.5        
Jacoby 
2011 
(USA) 
25,448 11,194 298 26.6 14,254 405 28.4        
Parker 
2013 
(USA) 
30,117 13,203 169 12.8 16,914 289 17.6        
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Luoto 
1995 
(Finland) 
226 163 19 116.6 55 10 181.8        
Forest plot B: Cardiovascular disease incidence 
Ingelsson 
2010 
(Sweden) 
184,441 156,305 8,871 56.8 24,910 1,492 59.9        
Jacoby 
2011 
(USA) 
25,448 11,194 1,171 104.6 14,254 1,513 106.1        
Forest plot C: Stroke incidence 
Ingelsson 
2010 
(Sweden) 
184,441 
156,305 
 
5,098 32.6 24,910 882 35.4        
Jacoby 
2011 
(USA) 
25,448 11,194 263 23.4 14,254 341 23.9        
Parker 
2013 
(USA) 
30,117 13,203 112 8.5 16,914 192 11.4        
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Forest plot D:  Cardiovascular disease deaths 
Parker 
2013 
(USA) 
30,117 13,203 281 21.2 16,914 481 28.4  
 
 
     
Van der Schouw 
1996 
(Netherlands) 
1,678 791 Not specified - 887 Not specified -        
Forest plot D:  Myocardial infarction incidence 
Rosenburg 
1981 
(USA) 
1,264 - 
Case 50 
Control 769 
- - 
Case 48 
Control 397 
-        
Palmer 
1992 
(USA) 
480 - 
Case 87 
Control 96 
- - 
Case 157 
Control 140 
-        
Forest plot D:  All-cause mortality 
Jacoby 
2011 
(USA) 
25,448 11,194 673 60.1 14,254 857 60.1        
Parker 30,117 13,203 1,749 132.5 16,914 2,850 168.5        
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2013 
(USA) 
Forest plot D:  All malignancy 
Jacoby 
2011 
(USA) 
25,448 11,194 951 85.0 14,254 1,205 84.5        
Parker 
2009 
(USA) 
30,117 13,035 1,716 131.6 16,345 2,183 133.6        
Boggs 
2014 
(USA) 
9,132 4,576 411 89.8 4,556 469 102.9        
Gaudet 
2014 
(USA) 
25,405 9,655 1,143 118.4 15,750 1,892 120.1        
Forest plot D:  Ovarian cancer 
Jacoby 
2011 
(USA) 
25,448 11,194 951 85.0 14,254 1,205 84.5        
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Parker 
2009 
(USA) 
30,117 13,035 99 7.6 16,345 5 0.3        
Chan 
2014 
(USA) 
52,716 22,051 31 1.4 30,665 13 0.4        
Falconer 
2015 
(Sweden) 
135,374 98,026 278 2.8 37,348 7 0.2        
Gaudet 
2014 
(USA) 
25,405 9,655 1,143 118.4 15,750 1,892 120.1        
Forest plot D: Breast cancer 
Jacoby 
2011 
(USA) 
25,448 11,194 309 27.6 14,254 430 30.2        
Parker 
2009 
(USA) 
30,117 13,035 775 59.5 16,345 895 54.8        
Boggs 
2014 
9,132 4,576 180 39.3 4,556 183 40.2        
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(USA) 
Gaudet 
2014 
(USA) 
25,405 9,655 419 43.4 15,750 715 45.4        
Forest plot D: Lung cancer 
Jacoby 
2011 
(USA) 
25,448 11,194 99 8.8 14,254 129 9.1        
Parker 
2009 
(USA) 
30,117 13,035 170 13.0 16,345 284 17.4        
Boggs 
2014 
(USA) 
9,132 4,576 43 9.4 4,556 76 16.7        
Gallagher 
2013 
(China) 
248 160 38 237.5 88 24 272.7        
Gaudet 
2014 
(USA) 
25,405 9,655 58 6.0 15,750 111 7.0        
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Forest plot D: Colorectal cancer 
Jacoby 
2011 
(USA) 
25,448 11,194 89 8.0 14,254 126 8.8        
Parker 
2009 
(USA) 
30,117 13,035 154 11.8 16,345 234 14.3        
Boggs 
2014 
(USA) 
9,132 4,576 44 9.6 4,556 62 13.6        
Cape 
1999 
(Canada) 
266,514 187,838 497 2.6 77,676 328 4.2        
Gaudet 
2014 
(USA) 
25,405 9,655 116 12.0 15,750 219 13.9        
Forest plot D: Osteoporosis 
Forsmo 
2001 
(Norway) 
112 91 Not applicable - 21 Not applicable -        
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Grainge 
2001 
(UK) 
130 95 Not applicable - 35 Not applicable -        
Nakamura 
1991 
(Japan) 
 
161 
 
75 Not applicable - 86 Not applicable -        
Forest plot D: Anxiety 
Chen 
2013 
(China) 
593 337 49 145.4 256 57 222.7        
Haines 
1993 
(Hong Kong) 
66 33 3 90.9 33 5 151.5        
Legorreta 
2013 
(Mexico) 
847 762 392 514.4 85 33 388.2        
Forest plot D: Depression 
Chen 
2013 
(China) 
593 337 61 181.0 256 92 359.4        
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Farquhar 
2005 
(New Zealand) 
314 257 53 206.2 57 23 403.5        
Kritz-Silverstein 
1994 
(USA) 
463 240 19 79.2 223 28 125.6        
Legorreta 
2013 
(Mexico) 
847 762 499 654.9 85 31 364        
Rohl 
2008 
(Australia) 
1,047 614 93 151.5 433 39 90.1        
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The range in NNH varied according to the prior baseline risk for the population (Table 
23). Amongst high risk populations for stroke (baseline risk = 35%) the NNH was 32 
hysterectomies and BSO for one additional stroke. This increased to 222 hysterectomies 
with bilateral oophorectomy for one stroke in a low risk (baseline risk = 5%) population. 
The NNH for an additional case of anxiety (baseline risk = 5.9%) was 65 hysterectomies 
with bilateral oophorectomy. The NNT to prevent one case of ovarian cancer (baseline 
risk = 2.5%) was 44. The NNT to prevent one case of breast cancer (baseline risk = 
12%) was 56 hysterectomies with bilateral oophorectomy. To prevent one case of 
ovarian cancer it is estimated that there will be an additional 1.4 episodes of stroke 
amongst high risk women and 0.7 episodes of anxiety.  To prevent one case of breast 
cancer there will be an estimated 1.8 additional stroke episodes and 0.9 episodes of 
anxiety.  
Table 23 - Number need to treat and harm. 
Outcome Scenario Lifetime risk Relative risk NNH 
Anxiety All 5.92% 1.26 65 
     
Stroke Low risk 5% 1.09 222 
 Moderate risk 20%  56 
 High risk 35%  32 
     
    NNT 
Breast cancer All 12% 0.85 56 
     
Ovarian cancer All 2.5% 0.09 44 
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9.5 DISCUSSION 
Main findings 
Our meta-analysis generated quantitative estimation of the health risks following 
hysterectomy, with and without oophorectomy.  In women undergoing hysterectomy with 
bilateral oophorectomy for benign gynaecological disease there was a significant 
increase in stroke and anxiety with concurrent reductions in breast and ovarian cancers. 
There were increases associated with cardiovascular disease, coronary heart disease, 
all cause malignancy, bowel malignancy, and lung malignancy associated with bilateral 
oophorectomy at the time of hysterectomy which did not reach statistical significance. 
Our review, with the essential quantitative information about long term health risks 
associated with hysterectomy and oophorectomy, will help in counselling to ensure that 
the 2,000 women each day who undergo hysterectomy are fully informed of the risks and 
benefits of a concurrent bilateral oophorectomy. 
Strengths  
To our knowledge this is the first prospectively registered systematic review to address 
health outcomes associated with bilateral oophorectomy at the time of benign 
hysterectomy. We conducted a comprehensive search strategy, employed a robust 
methodology, and used advanced statistical syntheses. Using the Newcastle-Ottawa 
scale, we assessed study quality and risk of bias. We believe that this study is the most 
comprehensive systematic review and meta-analysis evaluating the health risks of 
bilateral oophorectomy at the time of hysterectomy, including 1,665,063 women.  
 
Limitations 
There are no RCTs which address this question despite the large population which 
undergo this procedure each year with a lack of robust evidence to guide practice has 
limited previous Cochrane reviews of this topic (518). Observational studies including 
cohort and case-control were included in this systematic review. Expanding our search 
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of the literature to include observational studies has been essential to our review. It can 
be argued that there are disadvantages to meta-analysing observational data. However, 
we used a thorough search strategy, without language restrictions, and a comprehensive 
selection process to ensure all relevant studies were captured. Individual studies were 
assessed and carefully considered prior to inclusion. 
Demographic variants including location, ethnicity, and age, varied across studies. We 
aimed to control for the effect of HRT in our analysis. Due to inconsistency of outcome 
reporting, we were limited in our meta-analysis. We were unable to explore the effects 
on blood pressure or BMI due to poor outcome reporting quality (529,570–572). Due to 
variation in outcome measures used to evaluate bone mineral density(522,525,552–554) 
we were unable to compare data. The presentation of data within studies prohibited sub-
group analysis by indication for hysterectomy or age at hysterectomy. The possible 
protective effects of post-menopausal ovaries were not analysable due to heterogeneous 
outcome reporting. We were unable to make an assessment on whether age, HT use, or 
menopause status has an influence on the outcomes evaluated. This could be 
addressed in future research through an individual patient data meta-analysis. The 
unwarranted variation in outcome and outcome measure reporting within studies has 
been highlighted as a major limitation within women’s health research (384). This is 
being addressed by the CoRe Outcomes in Women’s and Newborn health (CROWN) 
initiative which advocates for the development of a core outcome set for every women’s 
health disease and procedure (382).  
There was a large amount of statistical heterogeneity, so we used random effects meta-
analyses, which produces more conservative CIs. This is acknowledged to only partly 
remove effects of heterogeneity (573). We believe that to combine this data would 
provide a more clinically useful result than to include a smaller number of homogeneous 
studies.  
 
  
 257. 
Interpretation 
Hysterectomy with bilateral oophorectomy significantly increases a patients’ risk of future 
stroke and anxiety compared to hysterectomy alone. There is concomitant reduction in 
risk of hormonal dependent cancers of the breast and ovary. This offers clinicians and 
patients a greater insight into health risks associated with bilateral oophorectomy at the 
time of hysterectomy. This can aid shared decision making for patients and clinicians 
prior to surgery together with the iatrogenic health sequelae of prophylactic bilateral 
oophorectomy.  
There have been significant trends towards rising BMI in females that may result in the 
development of cardiac disease. The results of this study indicate both significant and 
multiple non-significant increases in cardiac diseases with bilateral oophorectomy at the 
time of hysterectomy. This important, and growing, risk factor should play a role in 
clinician-patient decision making prior to hysterectomy. Patients at higher risk of future 
stroke should have appropriate counselling of the detrimental and contributory effects 
that bilateral oophorectomy may have on their health in later life. Following natural 
menopause, the ovaries continue to produce testosterone and androstenedione which 
are converted to oestrogen in peripheral tissues (574). The surgical removal of healthy 
ovaries without clinical indication prohibits the protective effects that post-menopausal 
ovaries provide. The non-significant trend towards a reduction in hip fractures and higher 
BMD is difficult to explain. This may be explained via greater clinician vigilance and use 
of medical therapies to prevent osteoporotic morbidity in later life.  
To address the need for bilateral oophorectomy at the time of hysterectomy, more 
effective screening tools for ovarian cancer need to be developed. The prompt initiation 
of treatment for early stage ovarian cancer leads to cure rates as high as 90% to 95% 
while vague and non-specific symptoms lead to presentation with a late stage diagnosis 
in 75% of patients. At this advanced stage, ovarian cancer has a low cure rate. An 
effective and affordable screening test that allows early diagnosis, when ovarian cancer 
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is most treatable, could eliminate the justification for bilateral oophorectomy at the time 
of hysterectomy (575).  
We are not aware of any other systematic review that assesses long term outcomes 
specifically relating to ovarian removal or conservation at hysterectomy for benign 
disease. On the basis of our findings, women undergoing hysterectomy for benign 
disease, should be informed of the small but significant increase in cardiovascular and 
psychiatric risks associated with bilateral oophorectomy.   
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9.6 CONCLUSION 
Current recommendations surrounding the choice of ovarian removal or conservation at 
hysterectomy for benign indications are limited. Hysterectomy and bilateral 
oophorectomy compared with hysterectomy alone significantly increase a range of risks 
for patients, which need to be balanced against possible benefits. Gynaecologists need 
to provide women with advice on the choices they face at the time of hysterectomy with 
both acute and chronic risks. An individual patient data meta-analysis in the future will 
produce more robust evidence synthesis regarding the risks and benefits of bilateral 
oophorectomy at the time of benign hysterectomy. 
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CHAPTER 9: 
TO EVALUATE THE ROLE OF 
MUSIC TO AID POST-
OPERATIVE RECOVERY 
FOLLOWING ENDOMETRIOSIS 
SURGERY  
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10.1 ABSTRACT 
 
Background 
Music is a non-invasive, safe and inexpensive intervention that can be easily delivered to 
patients. This systematic review aimed to evaluate music to as aid to postoperative 
recovery following endometriosis surgery. 
Methods 
RCTs in any language of adult patients undergoing surgery for endometriosis were 
included. Any form of music initiated before, during or after surgery was compared to 
standard care or other non-drug interventions. Medline (1946-Dec 2015), Embase (1947-
Dec 2015), CINAHL (1960-Dec 2015), and Cochrane Central (1898-Dec 2015) were 
searched, using MESH and keyword search terms: endometriosis, endometrio*, 
gynaecolog*, gynecolog*, music, music therapy, surg*, operat*, recovery, recuperation, 
rehabilitation, convalescence, post-op*. Inclusions, data extraction and quality 
assessment were in duplicate. Meta-analysis with RevMan (5.2), with standardised 
mean differences (SMD) and random effects models, and STATA for meta-regression 
were used. (Prospero-CRD42013005220). 
Results 
No studies assessed endometriosis surgery and the criteria was expanded to include all 
gynaecological surgery. 10 studies were included assessing 1056 participants with size 
varying between 26 - 372 participants.  Choice of music, timing and duration varied. 
Comparators included routine care, headphones with no music, and recording of 
operating room noise. Postoperatively music reduced anxiety (SMD -0.56 (95% CIs 
(95%CI) -1.02 to -0.02 ). There were non-significant improvements in pain SMD -0.37 
(95%CI -0.80 to 0.06), and analgesia use SMD -0.32 (95%CI -0.96 to 0.33) and 
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increased patient satisfaction SMD 0.52 (95%CI -0.98 to 2.03), and length of stay SMD -
0.19 (95%CI –0.71 to 0.32)).  
Conclusions 
This systematic review demonstrates that music improves anxiety following 
gynaecological surgery. We are unable to make meaning conclusions regarding the 
efficacy of music within benign gynaecological surgery to improve pain, satisfaction, and 
length of stay. Due its low cost and low risk profile music should be encouraged to all 
patients undergoing operative benign gynaecological procedures.  
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10.2 INTRODUCTION 
Surgical procedures are common and represent the gold standard for diagnosing 
endometriosis. Endometriosis affects one in ten women worldwide and is characterised 
by pain and subfertility. Following initial surgical diagnosis and treatment an estimated 
40-50% will have symptom recurrence within five years (576). Many women with 
endometriosis require multiple surgical procedures to control and manage this enigmatic 
disease. Current surgical recovery strategies, such as Enhanced Recovery (577–579) 
recommend numerous successful perioperative interventions within this package. Some 
preoperative strategies, such as patient education and nutritional additives, have been 
seen to reduce postoperative pain requirements and improve satisfaction levels (577–
579) but many non-pharmacological interventions are yet to be evaluated or 
incorporated. 
Music has an historic foundation within medical care and was first described as an 
adjunct to patient recovery during operations in the early twentieth century by Kane et al. 
(580) this was later advocated by Florence Nightingale (581). Music has a demonstrable 
impact on the emotions and neurophysiology (582–584).  
The delivery of pre-recorded music through headphones, musical pillows or background 
sound systems is an alternative inexpensive, non-invasive, and safe intervention in the 
post-operative setting (585). Music has been investigated in the context of recovery from 
invasive and minimally invasive operative procedures with numerous RCTs affirming 
positive effects on patients’ postoperative recovery (586,587). 
Previous systematic reviews have investigated music and its role as an aid to specific 
surgical procedures (12,13) and all surgical procedures combined (590) without 
analysing gynaecological procedures individually.  
Endometriosis is a chronic disease characterised by pain. Music is not currently being 
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used during the surgical pathway for managing the disease. Barriers to implementation 
include a lack of: budget, research dissemination and integration of the intervention in 
daily practice (591).  
We aim to review the effectiveness of music to improve postoperative recovery following 
surgery for endometriosis.  
  
 265. 
10.3 METHODS 
We developed and registered a protocol for this systematic review 
(CRD42016017631). The pre-defined inclusion criteria were RCTs in any language 
with adult female patients undergoing endometriosis surgery which was later expanded 
to include all gynaecological operations. Any form of music initiated before, during or 
after surgery was compared to standard care or any other non-drug interventions such 
as massage, undisturbed rest or relaxation. Outcomes of interest were: postoperative 
pain, analgesia requirement, anxiety, infection rates, wound healing, costs, length of 
stay, and satisfaction with care. Analgesia use included any opioids or NSAIDs. If both 
were reported, opioid use was used in the meta-analyses. The outcomes were 
measured up to six weeks postoperatively.  
The following databases were searched: Medline (1946-December 2015), Embase 
(1947-Decmber 2015), Cumulative Index to Nursing and Allied Health Literature 
(CINAHL) (1960-December 2015), and Cochrane Central (1898-Dec 2015). The 
following search terms were used; music, music therapy, surg*, operat*, recovery, 
recuperation, rehabilitation, convalescence, post-op*. Both MESH terms and keywords 
were used. Reference lists of relevant reviews were checked for additional studies. All 
relevant titles and abstracts were transferred to Endnote Web for assessment. Where no 
includable trials were available for the laparoscopic treatment of endometriosis, we 
chose to expand the search to all gynaecological procedures. 
Two reviewers (JH and MH) checked study eligibility. Both independently extracted data 
from studies using a standardised, pre-designed extraction form in Microsoft Excel 2007. 
Disagreements were resolved through discussion or referral to a senior reviewer (JMD). 
Quality of included studies was assessed using criteria set by The York Centre for 
Reviews and Dissemination (592); focusing on randomisation, allocation concealment, 
presence of blinding, explanation of withdrawals and presence or absence of intention-
to-treat analysis. 
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We tabulated the characteristics and results of all the included studies; analysis was 
quantitative. Where standard errors or ranges were provided, SDs were calculated using 
standard formulae. Review Manager (version 5.2, The Cochrane Library) was used for 
meta-analyses. We used random effects models because of heterogeneity of 
participants and interventions. All outcomes were continuous measures and we used 
standardised mean differences (SMD) where the outcomes had differing measurement 
scales.  
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10.4 RESULTS 
Searches retrieved 1,261 titles and abstracts. No trials evaluated the use of music to aid 
post-operative recovery following surgery for endometriosis. We included 10 RCTs 
including 966 women evaluating music as an aid to post-operative recovery from benign 
gynaecological surgery. (figure 21).  
Figure 21 – Flow of included studies  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
1,261 citations identified: 
 145 CINHAHL 
 151 Cochrane Central 
 472 Embase 
 493 Medline    
 
 
 
  
1,197 articles excluded: 
217 duplicates 
980 exclusion criteria 
10 studies included in quantitative synthesis  
 54 articles excluded: 
16 inappropriate interventions    
12 inappropriate outcome 
12 inappropriate population 
 6 reviews 
 4 data cannot be extracted 
 3 conference abstracts 
 1 unable to access 
 
 
 
 
 
  
64 full text articles assessed 
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Characteristics of included studies are found in table 24. The size of the studies varied 
between 26 - 372 participants, and they underwent a variety of different surgical 
procedures ranging from minor endoscopic interventions to open hysterectomy. Most 
studies only included elective procedures. Choice of music could be by patient or 
researcher. Patients chose a wide variety of styles. Researchers determined single types 
of music such as Chinese classical music,or gave patients’ choice from a list of six or 
more styles. Most were of a soothing quality. Delivery could be by headphones or music 
pillows for patients only to hear, or loudspeakers which could also be heard by the 
medical team. When music was delivered by headphones, it was often at a sufficiently 
low level that patients could still communicate easily. Timing could be pre, intra or 
postoperative, or a combination. The music could be played when patients were awake 
or anesthetised. Duration of music varied between a few minutes to repeated episodes 
over several days. Comparator descriptions varied, and included routine care, 
headphones with no music, white noise, and undisturbed bed rest. Duration and timing 
was normally similar to the interventions. Outcomes included postoperative pain, 
analgesia requirement, anxiety, length of stay, and satisfaction with care. None of the 
RCTs measured infection rates, wound healing or costs. Some outcomes were 
measured during or just after the procedure, others were measured at multiple times 
during the hospital stay.
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Table 24 - Characteristics of included trials  
Author 
(year) 
Number of Participants 
(n) 
Control Group Procedure General 
Anaesthesia 
Music type Patient 
Choice 
Timing of delivery Duration of 
Music 
 Intervention Control        
Agwu & 
Okoye 
(2006) 
50 50 Routine Care HSG 
 
No Patient’s own Yes Intraoperative Duration of 
procedure 
Angioli 
(2015) 
185 187 Routine Care Hysteroscopy No Pop, Jazz, 
Classical, or 
Rock 
Yes Intraoperative Duration of 
procedure 
Guerrero 
(2011) 
54 47 Routine Care Surgical 
management of 
miscarriage 
No Patient choice Yes Intraoperative Duration of 
Procedure 
Ikonomidu 
(2004) 
29 26 Blank CD Laparoscopic 
Sterilisation 
Yes Pan flutes No Pre and post operative 
periods 
30 minutes 
Johnson 
(2012) 
43 43 Headphones 
only 
Gynaecological 
surgery 
Yes / No Country Jazz 
or New Age 
Yes Pre operative Until 
Anaesthetised 
Migneault 
(2004) 
15 15 Routine Care Open 
Gynaecological 
Surgery 
Yes Classical, 
jazz, new age, 
or Piano 
Yes Intraoperative Intraoperative 
only 
Mullooly 
(1988) 
14 14 Routine Care Hysterectomy Yes Instrumental No Day 2 post operative 10 minutes 
Nilsson 
(2001) 
30 28 CD of Operating 
room noise 
Hysterectomy Yes Soothing 
sounds of the 
sea 
No Intraoperative Intraoperative 
only 
Wu 
(2012) 
13 13 Routine Care Termination of 
pregnancy 
No Patients 
choice 
Yes Intraoperative Intraoperative 
only 
Zhang 
(2005) 
55 55 Headphones 
only 
Hysterectomy Yes Calming and 
comforting 
Yes Intraoperative Intraoperative 
only 
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A variety of outcomes were measured (table 25). Pain was usually measured with visual 
analogue scales (VAS) or numerical rating scales (NRS). An indirect measure of pain 
was the consumption of analgesia, which varied considerably between the studies 
including opioid-based drugs such as pethidine, fentanyl, and morphine, and non-
steroidal anti-inflammatories such as diclofenac, ibuprofen, and paracetamol.
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Table 25 - Outcomes measured  
Author 
(year) 
Pain score 
reported 
Analgesia use 
reported Anxiety score reported Length of stay reported  Other outcomes reported 
Agwu & 
Okoye 
(2006) 
No No Yes, STAI No Physiological parameters, HR and BP 
Angioli 
(2015) Yes, VAS No Yes, STAI No No 
Guerrero 
(2011) Yes, VAS No Yes, STAI No 
Physiological parameters, HR and 
BP 
Ikonomidu 
(2004) Yes, VAS Yes, mg per drug No No Patient wellbeing, VAS 
Johnson 
(2012) No No Yes, STAI Yes, time spent in PACU* No 
Migneault 
(2004) No Yes, mg per drug No No No 
Mullooly 
(1988) Yes, VAS No Yes, Likert No No 
Nilsson 
(2001) Yes, VAS Yes, mg per drug No Yes, mobilisation time 
Patient wellbeing and nausea, five-
grade scale 
Wu 
(2012) Yes, NRS* No Yes, NRS* No No 
Zhang 
(2005) No No No No Patient satisfaction, VAS 
 
*Not included in numerical meta-analysis result because SD as not reported. 
NRS – numerical rating scale. STAI – Stait Trait Anxiety Inventory, HR – heart rate, BP – Blood pressure, VAS – Visual analogue scale, mg – milligram, PACU – Post 
anaesthetic care unit, 
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Quality of included studies varied (Table 26) but a number of the studies gave 
insufficient details to assess all aspects of quality. An intervention such as this cannot be 
blinded to the patient unless they are under general anaesthesia, but blinding of 
investigators and outcome assessment would be possible but was not stated in many of 
the studies. Where music was delivered when the patient was under anaesthesia it was 
unclear whether the patient knew beforehand to which group they were allocated.  
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Table 26 - Risk of Bias (JADAD criteria)  
 
 
 
Author 
(year) 
Was the trial described as 
randomised? 
Did the trial use an 
appropriate method of 
randomisation? 
Was the trial blinded? 
Did the trial use an 
appropriate method of 
blinding? 
Did the trial account for 
all patients 
randomised? 
Agwu & Okoye 
(2006) Yes Yes No No Yes 
Angioli  
(2015) Yes Yes No No Yes 
Guerrero  
(2011) Yes Yes No No Yes 
Ikonomidu  
(2004) Yes No Yes Yes Yes 
Johnson  
(2012) Yes No No No Yes 
Migneault  
(2004) Yes No Yes Yes Yes 
Mullooly  
(1988) Yes No No No Yes 
Nilsson  
(2001) Yes Yes Yes Yes No 
Wu  
(2012) Yes Yes No No Yes 
Zhang  
(2005) Yes Yes Yes Yes Yes 
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The results showed that postoperatively music reduced pain (6 RCTS, SMD –0.37 
(95%CI-0.80 – 0.06)) (figure 22), anxiety (6 RCTS, SMD -0.52 (95%CI –1.02 - -0.02)) 
(figure 23), and analgesia use (3 RCTS, SMD -0.32 (95%CI-0.96 – 0.33)) (figure 23) but 
there was no difference in length of stay (2 RCTs, SMD -0.19 (95%CI-0.71 – 0.32)) 
(figure 24). Pain and anxiety SMD outcomes were back-calculated into specific 
measurements most used in the RCTs.  
Figure 22 - Forest plot of music intervention for pain  
 
Figure 23 - Forest plot of music for Anxiety  
 
 
Figure 24 - Forest plot of music for postoperative analgesia use  
 
 
Heterogeneity was high for pain, anxiety and analgesia use, with I2 varying between 72 -
87%. No RCTs reported wound healing rates, costs, wound infections or serious adverse 
events. A subgroup analysis by type of control (routine care vs control with attention) 
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made little difference to the effectiveness of music.  
None of the included studies reported side effects. However, some reported that they 
ensured that the low volume delivered permitted communication with medical teams.  
Figure 25 - Forest plot of music for length of stay  
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10.5 DISCUSSION 
Statement of principal findings 
In this study we demonstrate that playing music in the perioperative setting reduces 
postoperative anxiety following benign gynaecological surgery. There were similar non-
significant trends towards improvement in postoperative pain, length of stay and 
analgesia requirements. None of the studies investigated the effects of music on 
infections, wound healing rates, or costs. 
Strengths and weaknesses 
The strengths of this systematic review and meta-analysis include its originality, robust 
search strategy, and methodological design. To our knowledge, this is the first 
systematic review and meta-analysis to examine the effectiveness of music for the 
postoperative recovery following benign gynaecological surgery. The search strategy 
was guided by the Cochrane handbook of systematic reviews and there was good 
agreement between reviewers for the selection of trials with quick resolution of 
discrepancies. 
We were unable to answer the principle study question due to a lack of studies 
evaluating the effectiveness of music on postoperative recovery following endometriosis 
surgery. We broadened or inclusion criteria to evaluate all studies performing surgical 
interventions for benign gynaecological disease.  This makes the results more 
generalisable to a wider gynaecological clinical practice. We combined all studies 
reporting analgesia use despite studies reporting different analgesics and types of 
interventions. This introduces clinical heterogeneity. The statistical measures of 
heterogeneity within this meta-analyses indicated that there was a large amount of 
statistical heterogeneity in the main analyses for analgesia use, anxiety, and pain. We 
used a random effects model for meta-analyses which is acknowledged to partially 
account for the impact of heterogeneity (573). Combining data provides a more clinically 
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meaningful result than including a narrower range of homogenous studies. The 
implication of combining clinically heterogeneous studies is that we cannot be sure 
whether music applies equally to all clinical scenarios however this study was limited by 
small number of includable studies. Further limitations include the small size of the 
studies ranging from 26 to 372 participants. 
Many of these small RCTs were hard to find in lesser-known journals, which illustrates 
the benefits of systemic reviews and meta-analysis.  
Strengths and weaknesses in relation to other systematic 
One strength of this systematic review is the robust methodology. This systematic review 
includes data and studies used with a previously published systematic review assessing 
all interventions(590). Prior to this, the most comprehensive systematic review used a 
vote-counting approach to summarise results only (593). Some of the previous 
systematic reviews only investigated one outcome, such as anxiety or pain, whereas we 
report all relevant clinical outcomes. We believe this is the most comprehensive 
systematic review to date on the use of music to aid recovery following gynaecological 
surgery, including 626 patients. Our results are similar to Cepeda (2013) in magnitude of 
effect size (589). We found no side effects reported, as did a recent Cochrane review 
(587). 
Interpretation 
The general findings on the beneficial effects of music on the wellbeing of patients 
undergoing gynaecological surgery are consistent with expectations and the public’s 
perception of music. There are a number of potential mechanisms that could help to 
explain the effects of music, from the patient’s and the medical team’s perspective. 
Modern theories of pain suggest that pain experience is affected by physical and 
psychological factors. Cognitive activities such as listening to music can influence 
perceived intensity and unpleasantness of pain, allowing for a reduced pain sensation by 
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the patient (594). Another potential mechanism could be a reduction in autonomic 
nervous system activity such as reduced pulse and respiration rate and lower blood 
pressure (595). For those undergoing general anaesthesia there is some RCT evidence 
that parts of the brain involved in hearing may sometimes remain perceptive during 
general anaesthetic (596). For approximately one in a thousand people undergoing 
general anaesthesia, unwanted intraoperative awareness during the anaesthetic is a risk 
factor for post-traumatic stress (597). It is unclear at the moment whether intraoperative 
music might have prevented this by reducing anxiety levels. 
Other primary studies and systematic reviews have found that, for medical teams, carers 
may be more relaxed and attentive (598) where there is music playing that they enjoy, 
but its use may be inappropriate in certain settings. The medical team may be distracted 
if music is audible from the patient’s headphones. Music may impede communication 
with patients, particularly during an awake procedure. If patients need to be able to 
communicate with healthcare workers, bilateral headphone use may be an obstacle. 
Music and noise have the potential to obstruct other interventions through negatively 
affecting the surgeon’s performance. Because of this, music should not be imposed on 
the medical team, particularly during the procedure. If medical teams intend to introduce 
music into the perioperative setting care needs to be taken that music does not interfere 
with the communication between the medical team (599,600).  
Conclusions 
Music is a non-invasive, safe and inexpensive intervention that can be delivered easily 
and successfully in a hospital setting. We recommend that a large RCT would 
additionally address the issues around heterogeneity. This systematic review and meta-
analysis is unable to determine whether music is an effective intervention for 
endometriosis or all benign gynaecological surgery across all domains of postoperative 
recovery. Recovery from gynaecological surgery has no particular individually mitigating 
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features to suspect that the findings of Hole et al are not applicable.  
Patients should be able to choose the type of music they would like to hear. The timing 
of music does not make much difference to outcomes so may be adapted to the 
individual clinical setting and medical team(590). 
This chapter set out to evaluate the role of music in the recovery from endometriosis 
surgery. There were no studies which answered that question directly and we therefore 
used gynaecological surgery as a surrogate marker. Endometriosis is different from 
many other forms of gynaecological disease causing pain in a multitude of different 
hypothesised mechanisms (601). It is unclear whether all these different pathways would 
be improved by the listening of music. Further research is required to assess whether 
the addition of music to the perioperative setting will aid postoperative recovery for 
patients having endometriosis surgery.  
 
 
 
 
 
 
This chapter was based on and adapted from the following peer reviewed publication: 
Hole J, Hirsch M, Ball E, Meads C. Music as an aid for postoperative recovery in adults: a 
systematic review and meta-analysis. Lancet. 2015 Oct 24;386(10004):1659-71. 
 
.  
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CHAPTER 10: 
DISCUSSION AND 
PERSPECTIVES 
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10.1 SUMMARY OF FINDINGS 
10.1.1 NON-INVASIVE DIAGNOSTIC ACCURACY TESTS FOR 
ENDOMETRIOSIS 
We evaluated recent studies assessing the accuracy of non-invasive tests for the 
diagnosis of endometriosis. The commonest marker evaluated was a glycoprotein CA 
125. This biomarker had extensive diagnostic accuracy assessment including a meta-
analysis with a historic reference standard (visual diagnosis) compared to the current 
gold standard (biopsy and histopathological analysis). There was limited diagnostic 
evaluation of the current gold standard. We decided to perform a diagnostic meta-
analysis, chapter 2.  
10.1.2 THE DIAGNOSITC ACCURACY OF CA-125 FOR ENDOMETRIOSIS IN 
SYMPTOMATIC WOMEN – A SYSTEMATIC REVIEW AND META-ANALYSIS  
Nineteen studies (15 cohort, four case-control), 3163 participants, were included. 
Bivariate hierarchical models were used to pool accuracy data of 13 studies (2611 
participants) using CA 125 ≥30 iu/ml. Pooled specificity was 91% (95% CI 89% - 94%) 
and sensitivity 51% (95% CI 35% - 66%).  CA 125 was significantly more sensitive for 
the diagnosis of moderate or severe endometriosis compared to minimal disease (62.6% 
95% CI 44.6 - 77.6 vs. 24.8% 95%CI 18.8 - 32.1, p value=0.003). CA 125 performs well 
as a rule in test facilitating expedited diagnosis and ensuring investigation and treatment 
can be confidently tailored towards the management of endometriosis.  Unfortunately, a 
negative test, CA 125 < 30 iu/ml, is unable to rule out endometriosis. 
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10.1.3 THE DIAGNOSTIC ACCURACY OF CA-125 FOR ENDOMETRIOSIS IN 
WOMEN WITH PAIN OR SUBFERTILITY – A PRIMARY STUDY  
Fifty-eight consecutive women recruited between October 2013 to March 2015. Women 
with endometriosis had a higher CA 125 level than those without endometriosis (mean 
54.7 +/-71.6 vs 16.2 +/- 8.0). The specificity of CA 125 ³ 30 iu/ml was 96% (95% CI 81.7 
– 99.9%) and sensitivity was 57% (95% CI 37.4 – 74.5%). The positive likelihood ratio 
for the histological presence of endometriosis with a CA 125 ³ 30 iu/ml was 15.8 (95% 
CI 2.3-112) providing a post-test probability of 94% (95% CI 71% - 99%) in women with 
pelvic pain or subfertility. The area under the curve, 0.85 (95% CI 0.74 – 0.96) indicates 
high test accuracy. CA 125 ³ 30 iu/ml is highly predictive of endometriosis in women with 
symptoms of pain and / or subfertility. CA 125 should be considered as a rule-in test for 
expediting the diagnosis and management of endometriosis, CA 125 <30 iu/ml is, 
however, unable to rule out endometriosis.   
 
10.1.4 ASSESSING THE QUALITY OF OUTCOME REPORTING IN 
ENDOMETRIOSIS TRIALS  
A total of 54 RCTS evaluating interventions on 5427 patients were analysed. A total of 
164 outcomes were reported using 113 outcome measures. The most commonly 
reported pain outcome, dysmenorrhoea, was reported by 23 RCTS using 10 outcome 
measures. The most commonly reported fertility outcome, pregnancy, was reported by 
26 RCTS using 3 outcome measures. The quality of outcome reporting was measured 
using a previously validated tool anchored between 0 (poor outcome reporting) and 6 
(excellent outcome reporting). Median outcome reporting quality score was 3 (IQR 2). 
There was an association between outcome reporting score and methodological quality 
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and year of publication on multivariate analysis. There was no association between 
outcome reporting quality and journal impact factor in the year of publication.  
Variation in outcome reporting prohibits comparison, combination, and synthesis of data 
to improve patient care. 
10.1.5 ASSESSING THE QUALITY OF INFORMATION AVAILABLE ONLINE 
FOR ENDOMETRIOSIS  
We identified 750 websites, of which 54 were included. Over a third of websites did not 
attribute authorship and almost half the included websites did not report the sources of 
information or academic references.  No websites provided information assessed as 
being written in plain English. A minority of websites were assessed as high quality. A 
single website provided accurate information, evidentlycochrane.net. Available 
information was, in general, skewed towards the diagnosis of endometriosis.  There 
were 16 credible websites, however the content limitations were infrequently discussed. 
No website scored highly across all four domains. In the unlikely event that a website 
reports high quality, accurate, and credible health information it is typically challenging 
for a lay audience to comprehend. Healthcare professionals, and the wider community, 
should inform women with endometriosis of the risk of outdated, inaccurate, or even 
dangerous information online. The implementation of an Information Standard will 
incentivise providers of online information to establish and adhere to codes of conduct.  
 
 
10.1.6 ASSESSING THE QUALITY OF GUIDELINES FOR THE DIAGNOSIS 
AND MANAGEMENT OF ENDOMETRIOSIS  
  
 284. 
A total of 7 national and international guidelines on the diagnosis and management of 
endometriosis were retrieved following a systematic search. The quality of guidelines 
was assessed using a validated assessment tool AGREE-II anchored between 0 (poor 
quality) 100 (excellent quality). The median quality of guidelines ranged from 4 (French) 
to 88 (ESHRE). The guideline recommendations were consistent in their clinical 
guidance but varied significantly in the methodological processes used to develop these 
statements.  
Greater clarity and harmonisation is required in the development of guidelines. It is an 
unnecessary use of expertise and research funds to develop multiple clinical guidelines 
for a single condition.   
 
10.1.7 ASSESSING THE MANAGEMENT OF OVARIAN ENDOMETRIOMA IN 
WOMEN WITH SUBFERTILITY  
For patients with subfertility and OEs the ovarian reserve and other fertility parameters 
should be assessed pre-operatively with subsequent triage for ART treatment or surgery 
depending on age and ovarian reserve. ART should be considered as the first option 
where there is evidence of reduced ovarian reserve. This should also be the case for 
patients with small (<3cm) OEs as these do not appear to affect the outcome of ART. 
10.1.8 ASSESSING THE RISKS OF HYSTERECTOMY AND BILATERAL 
OOPHORECTOMY FOR THE MANAGEMENT OF ENDOMETRIOSIS  
We highlighted 48 relevant studies (1,272,071 women). Hysterectomy with bilateral 
oophorectomy (498,603 women) vs without (773,468 women) was associated with 
increase in stroke (RR 1.09, 95% CI 1.03 – 1.16; baseline risk = 35%; number needed to 
harm [NNH] = 32) and anxiety (RR 1.26, 95% CI 1.06 – 1.51; baseline risk =5.9%; NNH 
= 65); and decrease in ovarian cancer (RR 0.09, 95% CI 0.04 – 0.19; baseline risk = 
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2.5%; number needed to treat [NNT] = 44); and breast cancer (hazard ratio 0.85, 95% CI 
0.73 – 0.99; baseline risk = 12%; NNT = 55). The balance of adverse and beneficial 
health outcomes associated with bilateral oophorectomy should be employed when 
counselling women concerning benign hysterectomy. 
 
10.1.9 ASSESSING THE ROLE OF MUSIC IN THE RECOVERY OF PATIENTS 
FOLLOWING ENDOMETRIOSIS SURGERY  
No studies assessed endometriosis surgery and the criteria was expanded to include all 
gynaecological surgery. 10 studies were included assessing 1056 participants with size 
varying between 26 - 372 participants. Postoperatively music reduced anxiety (SMD -
0.56 (95% CIs (95%CI) -1.02 to -0.02 ) however, there were non-significant 
improvements in pain SMD -0.37 (95%CI -0.80 to 0.06), and analgesia use SMD -0.32 
(95%CI -0.96 to 0.33) and increased patient satisfaction SMD 0.52 (95%CI -0.98 to 
2.03), and length of stay SMD -0.19 (95%CI –0.71 to 0.32)). Due its low cost and low risk 
profile music should be encouraged to all patients undergoing operative benign 
gynaecological procedures.  
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10.2 STRENTHS AND LIMITATIONS  
This three-part thesis attempted to explore and answer: [1] diagnostic, [2] 
methodological and [3] therapeutic difficulties within endometriosis research. A series of 
systematic reviews (chapters 2,4-8), literature review (chapters 1,8) and primary study 
(chapter 3) had robust methodology with prospective registration adhering to 
standardised reporting methods. Many of these chapters have undergone thorough 
scrutiny during the peer review process of publication (appendix 6). 
The primary study described in chapter 3 was limited by the number of participants 
recruited despite being powered this study would have benefitted from greater 
participant numbers. This study had a two-stage prospective recruitment of participants 
requiring pre-operative evaluation and further assessment at laparoscopy where they 
could be excluded. This limited the number of participants included. 
The extensive methodological review of information sources available to the three key 
stakeholders (patients, researchers, and clinicians) in the diagnosis and management of 
endometriosis could be considered the gold standard for the development of a core 
outcome set.  
We chose not to evaluate publication bias in the two chapters meta-analysing 
interventions (chapter 9 & 8) due to the low numbers of studies / trials evaluating each 
outcome.  
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10.3 IMPLICATIONS FOR CLINICAL PRACTICE  
10.3.1 THESIS SECTION 1 (CHAPTERS 1-3).. 
 
The non-invasive diagnosis of endometriosis has been highlighted as research priority 
since 2009 (111). Despite this, there has been little progress towards the development 
and use of a sensitive and specific non-invasive diagnostic test to aid speed of 
diagnosis, confidence with empirical medical treatment, reduce invasive surgical 
diagnosis, and improve psychological wellbeing of sufferers. Chapters 2 and 3 
demonstrate with good replicability that CA-125 has a role within the non-invasive 
diagnosis of endometriosis. We developed a cut-off level of 30iu/ml from chapter 2 and 
for methodological consistency we used this to perform test accuracy in chapter 3. A CA-
125 blood test result ³ 30iu/ml provides high positive predictive value of 93-94% 
amongst women with symptoms of the disease. A negative test result does not exclude 
endometriosis and around 50% of those with histologically confirmed disease will have a 
negative test. In the absence of other non-invasive diagnostic tests we recommend that 
CA-125 be used as a rule in adjunct amongst symptomatic women without ultrasonic 
evidence of endometriosis. 
 
10.3.2 THESIS SECTION 2 (CHAPTERS 4-6) 
 
The methodological evaluation performed suggests that multidirectional research has led 
to variation in clinical guidance. The findings indicate that all three consumers 
(researchers, clinicians and patients) of researcher productivity would benefit from the 
development and implementation of a core outcome set with endometriosis. The 
implementation of a minimum set of outcomes that are reported in trails, systematic 
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reviews and guidelines would facilitate the production of high quality and quantity data 
that can be compared and contrasted to inform future clinical practice and patient care. 
 
10.3.3 THESIS SECTION 3 (CHAPTERS 7-9) 
 
The surgical management of endometrioma in the context of subfertility remains a 
difficult and individualised scenario. The risks and benefits of ovarian surgery must be 
clearly explained to patients as the surgical removal of endometrioma prior to ART is no 
longer mandatory. Definitive surgery for endometriosis associated pain has 
considereable long term health risks that need to be considered alongside the beneficial 
reduction in risk of hormonal mediated malignancies of the ovary and breast. 
The use of music in the peri-operative setting reduces anxiety and carries a low risk 
profile. The provision of patient preferred music during recovery could aid recovery and 
reduce exposure to analgesics. 
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10.4 RECOMMENDATIONS FOR FUTURE RESEARCH  
10.4.1 CHALLENGES  
 
The biggest challenge facing the future care of women with endometriosis is the 
unwarranted, unhelpful and often confusing variation in outcome collection and reporting. 
The development and use of a core outcome set would help to address this challenge as 
core outcome sets are well-defined, discriminatory, and feasible outcomes routinely 
collected and reported in randomised trials and systematic reviews. This represents a 
minimum data set of outcomes selected and prioritised by key stakeholders including 
healthcare professionals, researchers, and patients. The development and use of a core 
outcome set does not enforce harmony at the expense of innovation.  The existence or 
use of a core outcome set does not imply that outcomes in an endometriosis trial should 
be restricted (434).  Rather, there is an expectation that the core outcomes will be 
collected and reported, making it easier for the results of trials to be compared, 
contrasted and combined as appropriate; while researchers continue to explore other 
outcomes as well (327,382).  
Recognising that the current inconsistency in outcome reporting is a serious hindrance to 
progress in our specialty, seventy-eight editors of Women’s Health journals have formed 
a consortium to support the development, dissemination, and implementation of core 
outcome sets (382). CROWN initiative [www.crown-initiative.org] will support the 
implementation of a core outcome set for endometriosis to increase the value of an initial 
research effort and ensure all future endometriosis trials report core outcomes, and 
therefore, routinely contribute data to important research questions. 
 
10.4.2 OBJECTIVES 
We aim to produce, disseminate, and implement a core outcome set for endometriosis. 
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10.4.3 METHODS  
 
PROSPECTIVE REGISTRATION  
This study has been prospectively registered with the COMET initiative, the registration 
number is 691 and is available online [www.comet-initiative.org/studies/details/691]. 
 
ETHICAL REVIEW  
We asked the advice of the National Research Ethics Service (NRES) about whether 
this study required ethical review by an NHS Research Ethics Committee, and they 
advised that this should be considered as service evaluation and development. All 
participants involved will be asked for their consent before participation in the Delphi 
study, and all procedures will be conducted according to the Declaration of Helsinki. 
 
STEERING GROUP  
An international steering group, including healthcare professionals, researchers, and 
patients, has been formed to guide the development of this core outcome set. 
 
SCOPE OF THIS CORE OUTCOME SET  
The steering group has recommended the core outcome set should apply to clinical 
studies evaluating therapeutic interventions for women with endometriosis. All 
therapeutic interventions for endometriosis will be considered regardless of type, setting, 
or mode of administration. We are not seeking to reach consensus regarding the 
standardisation of study design including clinical, covariate, and surgical phenotype 
recording nor specimen collection, processing, and storage. We acknowledge the work 
of colleagues in these areas (3-6). 
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STEP ONE: IDENTIFYING POTENTIAL OUTCOMES  
We performed a systematic review of randomised trials evaluating therapeutic 
interventions for treatment of endometriosis (384). We have extracted all outcomes and 
outcome measures reported within the trial reports. Working with patient and public 
representatives we have developed lay definitions for these outcomes. The outcomes 
will be arranged into four domains: harm, pain, quality of life, and subfertility which, 
following the steering group’s agreement, will be entered into a modified Delphi method.  
 
STEP TWO: DETERMINING CORE OUTCOMES 
The core outcomes will be determined using a modified Delphi method. The method 
consists of a series of controlled rounds, where repeated surveys are administered 
(602). The modified Delphi method facilitates repeated reflection and rescoring. This 
promotes whole and individual stakeholder group convergence upon a consensus of 
“core” outcomes and has advantages over less structured consensus methods. An 
online modified Delphi method allows for scoring without the influence of dominant 
individuals or junior participants feeling obliged to agree with more senior members. Web 
based Delphi surveys facilitate international participation and are considered feasible, 
efficient and acceptable to the user (602,603). The modified Delphi method will be 
delivered within a web based software hosted, designed and delivered by the University 
of Liverpool. 
 
All key stakeholders will be invited to participate including gynaecologists managing pain 
or subfertility associated with endometriosis, family physicians, researchers, and 
patients. There are no clear recommendations for calculating the required sample size, 
but based upon previous studies we will aim to include 30 participants from each 
  
 292. 
stakeholder group. We will recruit at least 36 participants for each stakeholder group 
anticipating an attrition rate of 20% (9).  
 
10.4.4 ROUND ONE  
 
Participants will be asked to register online, provide demographic details, and commit to 
all three rounds. They will be allocated a unique identifier which will anonymise their 
responses. Outcomes will be listed in four domains. Outcomes within each domain will 
be listed randomly to avoid survey fatigue from perceived repetition. Participants will be 
asked to score individual outcomes using a seven point Likert Scale anchored between 
one [not important] to seven [critical]. This scale was created by the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) working group 
and it has been widely adopted by core outcome set developers (604). During the first 
round, participants will be invited to suggest additional outcomes. The round will close 
following a four-week window. 
 
For each outcome, the median and interquartile range of scores will be calculated and 
summarised graphically for the whole and individual stakeholder group responses using 
GraphPad Prism (GraphPad, USA). Additional outcomes listed by participants will be 
reviewed by the outcome committee and, if novel, listed in round two. 
 
10.4.5 ROUND TWO  
 
Participants will be presented with whole group and individual stakeholder group 
response and asked to reflect on the similarities and differences observed before 
  
 293. 
proceeding to score each outcome again. The round will close following a four-week 
window. 
 
For each outcome the median and interquartile range of scores will be summarised 
graphically by whole and individual stakeholder group response. A standardised 
definition of this round’s results will enable individual outcomes to be classified: 
[1] Consensus in (classify as a core outcome): Over 70% of participants in each 
stakeholder group score this outcome domain 'critical' AND less than 15% of participants 
in each stakeholder group score outcome domain 'not important'.  
[2] Consensus out (do not classify as a core outcome): Over 70% of participants in each 
stakeholder group score outcome domain 'not important' AND less than 15% of 
participants in each stakeholder group score outcome domain 'critical'.  
[3] No consensus (do not classify as a core outcome): Anything else (602).  
 
If ten or more outcomes have been classified as consensus ‘core’ outcomes the process 
will conclude. If less than ten outcomes have been classified as consensus ‘core’ 
outcomes a further round will be considered by the steering group. 
 
10.4.6 STEP THREE – STAKEHOLDER CONSULTATION  
This final phase will involve a face-to-face meeting with key stakeholders. The meeting 
will include a range of views from participants that will be purposively sampled from 
those who have completed all rounds of the Delphi study. The objective of the 
consensus meeting is to discuss outcomes where there was disagreement in the Delphi 
study and validate a list of final “core” outcomes. A half-day meeting is planned where 
the results from each round of the Delphi survey will be presented. To ensure unbiased 
consensus formation amongst a group of varied participants, the steering committee will 
ensure that the meeting is informal, inclusive, participatory and values all opinions (603). 
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To promote wide dissemination, we will invite editors from key journals, for 
example American Journal of Obstetrics and Gynecology, and funders of endometriosis 
research. 
 
 
10.4.7 STEP FOUR – MEASURING CORE-OUTCOMES  
Once core outcomes are agreed upon it will be important to determine how the 
outcomes should be measured. A framework comprising of truth, discrimination, and 
feasibility exists to assess the quality of potential instruments (605). High quality 
outcome measures will be associated with each core outcome. The study will not 
advocate the use of a single outcome measure if several high quality outcome measures 
are identified for a single outcome. If no high quality outcome instruments exist for a core 
outcome this will be acknowledged. 
 
10.4.8 IMPACT  
Implementing and disseminating a core outcome set for endometriosis in future clinical 
studies, systematic reviews, and clinical guidelines could make a profound contribution 
to advancing the reach and relevance of research to inform clinical practice, enhance 
patient care, and improve patient outcomes. 
 
The selection of appropriate outcomes and outcome measures in future clinical trials is 
critical. The development of a core outcome set ensures consensus outcomes important 
to all stakeholders, including patients, are routinely collected and reported. The Standard 
Protocol Items Recommendations for Interventional Trials (SPIRIT) statement 
recommends the use of core outcome sets where they exist (606). An endorsement by 
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national and international funders, including National Institutes of Health, will facilitate 
[and fund] the collection and reporting of core outcomes. 
 
The Core Outcomes in Women’s Health (CROWN) initiative, supported by 78 specialty 
journals has resolved to implement core outcome sets. Participating journals will require 
authors to report the results for core outcomes and offer conclusions based on these 
outcomes rather than non-core or surrogate outcomes (382). 
 
The production of high quantity and quality comparable data to be summarised within 
systematic reviews to inform clinical practice guidelines would be an important step 
forward for guideline developers. The National Institute of Clinical Excellence 
encourages the use of core outcomes sets where available when selecting outcomes 
during evidence scoping and synthesis. A core outcome set for endometriosis could 
directly influence national and international clinical practice.  
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10.5 CONCLUSION 
The development of a core outcome set in endometriosis will enable the collection and 
reporting of a minimum data set important to all stakeholders, including patients.  
Harmonising outcome collection and reporting for future clinical trials, systematic 
reviews, and clinical guidelines will make a profound and important contribution to 
patient care. 
 
This chapter was based on the following peer reviewed publication: 
Hirsch M, Duffy JM, Barker C, Hummelshoj L, Johnson NP, Mol B, Khan KS, Farquhar 
C. Protocol for developing, disseminating and implementing a core outcome set for 
endometriosis. BMJ Open. 2016 Dec 21;6(12):e013998 
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Appendix 1.  Contribution to each chapter 
 
• Chapter 1 – I wrote this chapter entirely 
• Chapter 2 – I conceived the idea for the study, performed searches, selected 
studies, extracted data, performed quality assessment of studies, created tables, 
created figures, and drafted the manuscript. 
• Chapter 3 – I conceived the idea for the study, recruited patients, analysed data, 
created tables, created figures, and drafted the manuscript. 
• Chapter 4 - I conceived the idea for the study, performed searches, selected 
studies, extracted data, performed quality assessment of studies, created tables, 
created figures, and drafted the manuscript. 
• Chapter 5 - I conceived the idea for the study, performed searches, selected 
websites, extracted data, performed quality assessment of websites, created 
tables, created figures, and drafted the manuscript. 
• Chapter 6 - I conceived the idea for the study, performed searches, selected 
guidelines, extracted data, performed quality assessment of guidelines, created 
tables, created figures, and drafted the manuscript. 
• Chapter 7 – I contributed to the study design, performed searches, selected 
studies, created tables, contributed to drafting original manuscript and this 
updated version. 
• Chapter 8 - I refined the study, performed searches, selected studies, extracted 
data, performed quality assessment of studies, created tables, created figures, 
and drafted the manuscript. 
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• Chapter 9 – I conceived the idea for the study, performed searches, selected 
studies, extracted data, analysed data, performed quality assessment of studies, 
created tables, created figures, and drafted the manuscript. 
• Chapter 10 - I conceived the idea for the protocol and drafted the manuscript.
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Appendix 2: Summary of ESHRE Guidelines for Accuracy Assessment 
1. The GDG recommends that clinicians should consider the diagnosis of endometriosis 
in the presence of gynecological symptoms such as: dysmenorrhea, non-cyclical 
pelvic pain, deep dyspareunia, infertility, fatigue in the presence of any of the above.  
 
2. The GDG recommends that clinicians confirm a positive laparoscopy by histology, 
since positive histology confirms the diagnosis of endometriosis, even though negative 
histology does not exclude it. 
 
3. Clinicians are recommended to perform transvaginal sonography to diagnose or to 
exclude an ovarian endometrioma. 
 
4. Clinicians are recommended not to use immunological biomarkers, including CA-125, 
in plasma, urine or serum to diagnose endometriosis. 
 
5. The GDG recommends clinicians to counsel women with symptoms presumed to be 
due to endometriosis thoroughly, and to empirically treat them with adequate 
analgesia, combined hormonal contraceptives or progestagens. 
 
6. Clinicians are recommended to prescribe hormonal treatment [hormonal 
contraceptives (level B), progestagens (level A), anti-progestagens (level A), or GnRH 
agonists (level A)] as one of the options, as it reduces endometriosis-associated pain. 
 
7. When endometriosis is identified at laparoscopy, clinicians are recommended to 
surgically treat endometriosis, as this is effective for reducing endometriosis-
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associated pain i.e. ‘see and treat’. 
 
8. When performing surgery in women with ovarian endometrioma, clinicians should 
perform cystectomy instead of drainage and coagulation, as cystectomy reduces 
endometriosis-associated pain. 
 
9. The GDG recommends that clinicians refer women with suspected or diagnosed deep 
endometriosis to a centre of expertise that offers all available treatments in a 
multidisciplinary context. 
 
10. In infertile women with AFS/ASRM stage I/II endometriosis, clinicians should perform 
operative laparoscopy (excision or ablation of the endometriosis lesions) including 
adhesiolysis, rather than performing diagnostic laparoscopy only, to increase ongoing 
pregnancy rates. 
 
11. In infertile women with ovarian endometrioma undergoing surgery, clinicians should 
perform excision of the endometrioma capsule, instead of drainage and 
electrocoagulation of the endometrioma wall, to increase spontaneous pregnancy 
rates. 
 
12. The GDG recommends that clinicians counsel women with endometrioma regarding 
the risks of reduced ovarian function after surgery and the possible loss of the ovary. 
The decision to proceed with surgery should be considered carefully if the woman has 
had previous ovarian surgery. 
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13. Clinicians can prescribe GnRH agonists for a period of 3 to 6 months prior to treatment 
with assisted reproductive technologies to improve clinical pregnancy rates in infertile 
women with endometriosis. 
 
14. In infertile women with endometriosis, clinicians may offer treatment with assisted 
reproductive technologies after surgery, since cumulative endometriosis recurrence 
rates are not increased after controlled ovarian stimulation for IVF/ICSI. 
 
15. The GDG recommends that clinicians inform women with endometriosis requesting 
information on their risk of developing cancer that 1) there is no evidence that 
endometriosis causes cancer, 2) there is no increase in overall incidence of cancer in 
women with endometriosis, and 3) some cancers (ovarian cancer and non-Hodgkin’s 
lymphoma) are slightly more common in women with endometriosis. 
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Appendix 3. Summarised guideline recommendations for the diagnosis of endometriosis. 
 
 
ACOG (2010) ACCEPT (2012) CNGOF (2006) ESHRE (2014) NGG (2014) SOGC (2010) WES (2013) 
       
Mild to moderate endometriosis 
Symptoms 
No validated instrument 
1 non-RCT 
 
Symptoms 
No recommendations 
 
Symptoms 
No recommendations 
Symptoms 
No validated instrument 
1 non-RCT 
Symptoms 
No recommendations 
 
Symptoms 
No validated instrument 
No reference  
Symptoms 
No recommendations 
 
Examination 
No recommendations 
 
Examination 
No recommendations 
 
 
Examination 
Pelvic examination 
No reference 
 
Rectal examination 
No reference 
 
Examination 
Pelvic examination 
Expert opinion  
 
Rectal examination 
Expert opinion 
Examination 
No recommendations 
 
Examination 
Pelvic examination 
No reference 
 
Rectal examination 
No reference 
Examination 
No recommendations 
 
 
Imaging 
No recommendations 
 
Imaging 
No recommendations 
 
Imaging 
Urinary tract imaging recommended 
No reference 
Imaging 
No recommendations 
 
Imaging 
Transvaginal ultrasound 
Not recommended 
Imaging 
Transvaginal ultrasound 
recommended 
Imaging 
No recommendations 
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MRI 
not recommended 
No reference 
 
 
 
 
 
 
 
 
1 systematic review (17 non-RCTs) 
 
MRI 
Not recommended 
No reference 
 
No reference 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biomarkers 
Not recommended 
3 non-RCTs  
 
Biomarkers 
No recommendations 
 
 
 
Biomarkers 
Not recommended  
No reference 
 
 
Biomarkers 
Not recommended 
3 systematic reviews 
(266 non-RCTs) 
 
Biomarkers 
Not recommended 
1 systematic review  
(23 non-RCTs)  
 
Biomarkers 
Not recommended 
1 systematic review  
(23 non-RCTs) 
 
Biomarkers 
No recommendations 
 
 
 
Diagnostic laparoscopy 
Histopathology 
No reference 
Diagnostic laparoscopy 
No recommendations 
 
Diagnostic laparoscopy 
Histopathology  
No reference 
Diagnostic laparoscopy 
Histopathology 
Expert opinion 
Diagnostic laparoscopy 
Histopathology  
2 systematic reviews  
(10 RCTs) 
1 RCT 
1 case series 
Diagnostic laparoscopy 
Histopathology 
No reference 
 
Diagnostic laparoscopy 
No recommendations 
       
Severe endometriosis 
Symptoms Symptoms Symptoms Symptoms Symptoms Symptoms Symptoms 
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No validated diagnostic instrument 
4 non-RCTs  
1 literature review 
 
No recommendations 
 
 
 
No recommendations 
 
 
No recommendations 
 
 
No recommendations 
 
 
No validated instrument 
No reference  
 
No recommendations 
 
 
Examination 
No recommendations 
 
Examination 
No recommendations 
 
Examination 
Pelvic  
No reference 
 
Examination 
Clinical examination 
1 non-RCT   
 
Examination 
Pelvic  
No reference 
 
Proctosigmoidoscopy  
No reference 
 
Examination 
Pelvic 
No reference  
 
Rectal 
No reference  
 
Examination 
No recommendations 
 
 
Imaging 
Transvaginal ultrasound  
4 non-RCTs  
 
MRI 
2 non-RCTs  
 
Cystoscopy with biopsy  
No reference 
 
Imaging 
No recommendations 
 
 
 
 
 
 
 
 
Imaging 
MRI 
No reference 
 
 
 
 
 
 
 
Imaging 
Transvaginal ultrasound  
1 systematic review  
10 non-RCTs 
 
Transrectal sonography 
Expert opinion 
 
MRI 
Expert opinion 
Imaging 
Transvaginal ultrasound 
1 Systematic Review (10 non-RCTs) 
2 non-RCTs 
 
Transrectal sonography 
1 non-RCT 
 
MRI 
1non-RCT 
Imaging 
Transrectal sonography 
No reference 
 
MRI 
No reference 
 
Cystoscopy  
No reference 
 
Imaging 
No recommendations 
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Barium Enema 
1 non-RCT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Barium enema 
Expert opinion 
 
Three dimensial ultrasound  
not recommended 
1 non-RCT 
 
 
Barium enema 
No reference 
 
Cystoscopy 
No reference 
 
Colonoscopy 
No reference 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biomarkers 
No recommendations 
 
Biomarkers 
No recommendations 
 
Biomarkers 
No recommendations 
 
Biomarkers 
No recommendations 
 
Biomarkers 
No recommendations 
 
Biomarkers 
Not recommended 
1 systematic review  
(23 non-RCTs) 
 
Biomarkers 
No recommendations 
 
Diagnostic laparoscopy 
No recommendations 
 
Diagnostic laparoscopy 
No recommendations 
Diagnostic laparoscopy 
No recommendations 
Diagnostic laparoscopy 
Histopathology  
No reference 
Diagnostic laparoscopy 
No recommendations 
 
Diagnostic laparoscopy 
No recommendations 
 
Diagnostic laparoscopy 
No recommendations 
 
       
Endometrioma 
Symptoms 
No recommendations 
 
Symptoms 
No recommendations 
 
Symptoms 
No recommendations 
 
Symptoms 
No recommendations 
 
Symptoms 
No recommendations 
 
Symptoms 
No recommendations 
 
Symptoms 
No recommendations 
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Examination 
No recommendations 
Examination 
No recommendations 
 
Examination 
Pelvic 
No reference 
Examination 
Pelvic 
5 non-RCTs   
Examination 
Pelvic 
No reference  
Examination 
Pelvic 
No reference 
Examination 
No recommendations 
 
 
Imaging 
Transvaginal ultrasound 
1 non-RCT 
 
MRI 
1 non-RCT 
 
Computed Tomography 
1 non-RCT 
 
Imaging 
No recommendations 
 
 
 
 
 
 
 
 
Imaging 
Transvaginal ultrasound 
No reference 
 
MRI 
Not recommended 
No reference 
Imaging 
Transvaginal ultrasound 
1 systematic review  
7 non-RCTs 
 
 
Imaging 
Transvaginal ultrasound 
1 non-RCT 
 
 
Imaging 
Transvaginal ultrasound 
No reference 
 
 
Imaging 
No recommendations 
 
Biomarkers 
No recommendations 
 
 
Biomarkers 
No recommendations 
 
 
Biomarkers 
No recommendations 
 
 
Biomarkers 
No recommendations 
 
 
Biomarkers 
Cancer anitgen-125  
2 non-RCTs 
 
Biomarkers 
Cancer anitgen-125  
1 guideline 
1 systematic review  
 
Biomarkers 
No recommendations 
 
 
Diagnostic laparoscopy 
No recommendations 
Diagnostic laparoscopy 
No recommendations 
Diagnostic laparoscopy 
No recommendations 
Diagnostic laparoscopy 
Histopathology 
Diagnostic laparoscopy 
Histopathology  
Diagnostic laparoscopy 
Histopathology 
Diagnostic laparoscopy 
No recommendations 
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   Expert opinion No reference No reference  
       
Malignancy 
Symptoms 
No recommendations 
 
Symptoms 
No recommendations 
 
Symptoms 
No recommendations 
 
Symptoms 
No recommendations 
 
Symptoms 
No recommendations 
 
Symptoms 
No recommendations 
 
Symptoms 
No recommendations 
 
Examination 
No recommendations 
 
Examination 
No recommendations 
 
Examination 
No recommendations 
 
Examination 
No recommendations 
 
Examination 
No recommendations 
 
Examination 
No recommendations 
 
Examination 
No recommendations 
 
Imaging 
No recommendations 
 
Imaging 
No recommendations 
 
Imaging 
No recommendations 
 
Imaging 
No recommendations 
 
Imaging 
No recommendations 
 
Imaging 
No recommendations 
 
Imaging 
No recommendations 
 
Biomarkers 
No recommendations 
 
Biomarkers 
No recommendations 
 
Biomarkers 
No recommendations 
 
Biomarkers 
No recommendations 
 
Biomarkers 
No recommendations 
 
Biomarkers 
Cancer Antigen-125  
1 guideline 
 
Biomarkers 
No recommendations 
 
Diagnostic laparoscopy 
No recommendations 
 
Diagnostic laparoscopy 
No recommendations 
 
Diagnostic laparoscopy 
No recommendations 
 
Diagnostic laparoscopy 
Histopathology  
Expert opinion 
Diagnostic laparoscopy 
No recommendations 
 
Diagnostic laparoscopy 
Histopathology  
No reference 
Diagnostic laparoscopy 
No recommendations 
 
       
Extra-pelvic endometriosis 
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Symptoms 
No recommendations 
 
Symptoms 
No recommendations 
 
Symptoms 
No recommendations 
 
Symptoms 
No recommendations 
 
Symptoms 
No recommendations 
 
Symptoms 
No recommendations 
 
Symptoms  
No recommendations 
 
Examination 
No recommendations 
 
Examination 
No recommendations 
 
Examination 
No recommendations 
 
Examination 
No recommendations 
 
Examination 
No recommendations 
 
Examination 
No recommendations 
 
Examination 
No recommendations 
 
Imaging 
No recommendations 
 
 
 
 
 
 
 
 
 
 
 
 
 
Imaging 
No recommendations 
 
 
 
 
 
 
 
 
 
 
 
 
 
Imaging 
Adenomyosis 
Ultrasound 
MRI 
No reference 
 
Pulmonary endometriosis 
Computed tomography 
No reference 
 
MRI 
No reference 
 
Bronchoscopy 
No reference 
Imaging 
No recommendations 
 
 
 
 
 
 
 
 
 
 
 
 
 
Imaging 
Adenomyosis 
Transvaginal ultrasound  
2 systematic reviews  
(2 RCTs) 
2 non-RCTs 
 
 
 
 
 
 
 
 
 
Imaging 
No recommendations 
 
 
 
 
 
 
 
 
 
 
 
 
 
Imaging 
No recommendations 
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Pleural endometriosis Thoracoscopy  
Not recommended  
No reference 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biomarkers 
No recommendations 
 
Biomarkers 
No recommendations 
 
Biomarkers 
No recommendations 
 
Biomarkers 
No recommendations 
 
Biomarkers 
Not recommended 
 
Biomarkers 
No recommendations 
 
Biomarkers 
No recommendations 
 
Diagnostic laparoscopy 
No recommendations 
 
Diagnostic laparoscopy 
No recommendations 
 
Diagnostic laparoscopy 
Adenomyosis  
Histopathology at hysterectomy 
No reference 
Diagnostic laparoscopy 
No recommendations 
 
Diagnostic laparoscopy 
Adenomyosis  
Histopathology at hysterectomy 
No reference 
Diagnostic laparoscopy 
No recommendations 
Diagnostic laparoscopy 
No recommendations 
 
 
 
 
 
Abbreviations: RCT: Randomised controlled trial. 
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Appendix 4. Summarised guideline recommendations for the medical and surgical treatment of endometriosis associated 
pain. 
 
ACOG (2010) ACCEPT (2012) CNGOF (2006) ESHRE (2014) NGG (2014) SOGC (2010) WES (2013)  
       
Medical management of pain associated with mild to moderate endometriosis                                                                                                                                                        
Empirical 
No recommendations 
Empirical 
No 
recommendations 
Empirical 
No recommendations 
Empirical 
No recommendations 
Empirical 
No recommendations 
Empirical 
No recommendations 
Empirical 
No recommendations 
 
Analgesics 
No recommendations 
 
Analgesics 
No 
recommendations 
 
Analgesics 
No recommendations 
Analgesics 
No recommendations 
Analgesics 
No recommendations 
Analgesics 
No recommendations 
Analgesics 
No recommendations 
Hormonal Treatments 
No recommendations 
Hormonal 
Treatments 
No 
recommendations 
Hormonal 
Treatments 
No recommendations 
Hormonal Treatments 
No recommendations 
Hormonal Treatments 
No recommendations 
Hormonal Treatments 
No recommendations 
Hormonal Treatments 
No recommendations 
       
Medical management of pain associated with severe endometriosis 
Empirical 
No recommendations 
 
Empirical 
No 
recommendations 
Empirical 
No recommendations 
Empirical 
No recommendations 
Empirical 
No recommendations 
Empirical 
No recommendations 
Empirical 
No recommendations 
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Analgesics 
No recommendations 
 
Analgesics 
No 
recommendations 
 
Analgesics 
No recommendations 
 
Analgesics 
No recommendations 
 
Analgesics 
No recommendations 
 
Analgesics 
No recommendations 
 
Analgesics 
No recommendations 
 
Hormonal treatments 
No recommendations 
 
Hormonal 
treatments 
No 
recommendations 
 
Hormonal 
treatments 
No recommendations 
 
Hormonal treatments 
Aromatase inhibitors  
2 systematic reviews (5 RCTs, 6 
non-RCTs, 7 case 
reports/series) 
 
Hormonal treatments 
Progestagens 
No reference 
 
monophasic continuous 
combined oral contraceptive  
No reference 
 
Gonadotropin releasing 
hormone analogue with add-
back HT 
No reference 
 
Levonorgestrel-releasing IUS 
1 non-RCT 
Hormonal treatments 
No recommendations 
 
Hormonal treatments 
No recommendations 
 
       
Medical management of endometriosis associated pain 
Empirical treatment 
1st line 
Empirical 
treatment 
No 
recommendations 
Empirical treatment 
No recommendations 
Empirical treatment 
Nonsteroidal anti-inflammatory 
drugs 
Empirical treatment 
No recommendations 
 
Empirical treatment 
No recommendations 
 
Empirical treatment 
1st line:  
Nonsteroidal anti-
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Nonsteroidal anti-inflammatory 
drugs 
1 Cochrane review (1 RCT) 
 
Combined oral contraceptive 
pill 
1 Cochrane review (1 RCT) 
 
2nd line 
Extended-cycle pills  
1 non-RCT  
 
3rd line 
Gonadotropin releasing 
hormone analogues  
1 RCT 
 
 
 
Expert opinion  
 
Combined oral contraceptive pill 
Expert opinion  
 
Progestagens 
Expert opinion  
 
 
  
 
inflammatory drugs 
1 Cochrane review (1 RCT) 
 
Paracetamol 
Expert opnion 
 
Opioids  
Expert opinion 
 
Combined oral contraceptive 
pill 
1 Cochrane review (1 RCT) 
1 RCT 
2 non-RCT 
 
Medroxyprogesterone 
acetate 
2 RCT 
 
Progestagens  
anti-progestagens  
1 Cochrane review 
(13 RCTs) 
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Dienogest  
6 RCTs 
2 non-RCTs 
 
2nd line:  
Gonadotropin releasing 
hormone analogues with add-
back HT  
1 Cochrane review (41 
RCTs) 
 
Levonorgestrel-releasing IUS 
1 Cochrane review (1 RCT) 
 
Analgesics 
No recommendations 
 
 
Analgesics 
No 
recommendations 
 
Analgesics 
Not reported 
 
Analgesics 
Nonsteroidal anti-inflammatory 
drugs or other analgesics 
Expert opinion 
 
Analgesics 
Nonsteroidal anti-inflammatory 
drugs 
No evidence for use 
No reference 
 
Analgesics 
Nonsteroidal anti-
inflammatory drugs or 
opioids  
No reference 
 
Analgesics 
Nonsteroidal anti-
inflammatory drugs 
1 Cochrane review (1 RCT) 
 
Hormonal treatments 
Combined oral contraceptive 
pill 
Hormonal 
treatments 
No 
recommendations 
Hormonal 
treatments 
Contraceptives 
Hormonal treatments 
Combined oral contraceptive pill 
1 RCT  
Hormonal treatments 
Combined oral contraceptive 
pill 
Hormonal treatments 
1st line:  
Hormonal treatments 
1st & 2nd line as above 
 
  
 315. 
2 Cochrane reviews (2 RCTs) 
1 RCT 
 
Gonadotropin releasing 
hormone analogue with add-
back HT  
1 Cochrane review (41 RCTs) 
3 RCTs  
 
Oral progestins 
No reference 
 
Subcutaneous  
Depot medroxyprogesterone 
Acetate 
2 RCTs 
 
Levonorgestrel-releasing IUS 
3 RCTs  
1 non-RCT  
 
Danazol 
No reference 
 No reference 
 
Combined oral 
contraceptive pill 
No reference 
 
Progestins 
No reference 
 
Gonadotropin releasing 
hormone analogue with 
add-back HT 
No reference 
 
Danazol 
No reference 
 
 
Continuous combined oral 
contraceptive pill 
1 non-RCT 
 
Vaginal contraceptive ring or 
transdermal 
(oestrogen/progestin) patch 
1non-RCT  
 
Progestagens and anti-
progestagens 
1 Cochrane review (13 RCTs) 
 
Levonorgestrel-releasing IUS 
3 RCTs  
 
Gonadotropin releasing 
hormone analogue with add-
back HT 
1 Cochrane review (41 RCTs) 
4 RCTs 
1 RCT 
 
Dienogest 
2 RCTs 
 
Gonadotropin releasing 
hormone analogue with add-
back HT 
1 Cochrane review (41 RCTs)  
1 RCT 
 
 
Combined oral contraceptive 
pill 
2 RCTs  
2 non-RCTs  
  
Oral, intramuscular or 
subcutaneous progestin 
 
Oral:  
Norethindrone Acetate  
1 non-RCT 
 
Dienogest 
4 RCTs  
 
Intramuscular: 
Depot medroxyprogesterone 
acetate 
No reference 
 
Subcutaneous: 
Depot medroxyprogesterone 
acetate 
2 RCTs  
3rd line: danazol  
1 Cochrane review (5 RCTs) 
 
  
 316. 
 
Aromatase inhibitors with 
progestin or Combined oral 
contraceptive pill  
Not recommended 
1 systematic review (1 RCT) 
1 non-RCT  
7 case reports/series 
 
 
 
2nd line: 
Gonadotropin releasing 
hormone analogue with add-
back HT 
5 non-RCTs 
 
Levonorgestrel-releasing IUS 
1 RCT  
2 non-RCTs  
 
3rd line: 
Danazol 
1 Cochrane review (5 RCTs) 
1 non-RCT 
 
Aromatase inhibitors  
Not recommended 
2 non-RCTs  
 
Extrapelvic 
endometriosis 
1st line: Gonadotropin releasing 
hormone analogue 
Extrapelvic 
endometriosis 
No 
recommendations 
Extrapelvic 
endometriosis 
Adenomyoisis – 
Extrapelvic endometriosis 
Consider medical treatment 
1 case series  
Extrapelvic 
endometriosis 
Adenomyosis - 
Extrapelvic 
endometriosis 
No recommendations 
Extrapelvic 
endometriosis 
No recommendations 
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3 case reports  
 
 Antigonadotopic 
progestins  
No reference 
 
Gonadotropin releasing 
hormone analogue  
No reference 
 
Levonorgestrel-releasing 
IUS 
No reference 
 
2 literature reviews 
 
 
 
Combined oral contraceptive 
pill 
1 non-RCT 
 
Progestogens 
1 RCT 
 
Levonorgestrel-releasing IUS 
1 non-RCT 
 
  
Post-menopausal 
women 
No recommendations 
 
Post-
menopausal 
women 
No 
recommendations 
 
Post-menopausal 
women 
No recommendations 
 
Post-menopausal women: 
After hysterectomy, avoid 
unopposed oestrogen treatment. 
Expert opinion 
 
After surgical menopause, treat 
with add-back HT to the age of 
natural menopause. 
Expert opinion 
Post-menopausal 
women 
No recommendations 
 
Post-menopausal 
women 
No recommendations 
 
Post-menopausal 
women 
No recommendations 
 
       
Surgical Management of pain associated with mild to moderate endometriosis 
General 
Conservative surgery 
General General 
No recommendations 
General 
No recommendations 
General 
No recommendations 
General 
No recommendations 
General 
No recommendations 
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1 RCT  
 
 
No 
recommendations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Approach 
No recommendations 
Approach 
No 
recommendations 
 
Approach 
No recommendations 
Approach 
No recommendations 
Approach 
No recommendations 
Approach 
No recommendations 
Approach 
No recommendations 
 
Technique 
No recommendations 
 
Technique 
No 
recommendations 
 
Technique 
No recommendations 
 
Technique 
Ablation or excision  
2 RCTs 
Technique 
No recommendations 
 
Technique 
Ablation or excision   
1 RCT 
Technique 
No recommendations 
 
       
Surgical management of pain associated with endometrioma                                                                                                                                                                                                                                          
 
General 
Cyst >3cm 
1 Guideline 
 
 
 
 
General 
No 
recommendations 
 
General 
No recommendations 
 
 
General 
No recommendations 
 
General 
No recommendations 
 
 
General 
Size >3cm: excision  
Size <3 cm: drainage and 
coagulation 
No reference 
 
General 
No recommendations 
 
Approach Approach Approach Approach Approach Approach Approach 
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Laparoscopic excision  
1 RCT  
 
 
No 
recommendations 
 
 
 
Laparotomy  
No reference 
 
No recommendations 
 
 
Laparoscopy  
1 Case series 
 
No recommendations 
 
 
 
No recommendations 
 
 
 
Technique 
Cystectomy  
1 Cochrane review (2 RCTs) 
 
 
 
 
 
Extrapelvic 
endometriosis 
 
Technique 
Not reported 
 
 
 
 
 
 
Extrapelvic 
endometriosis 
 
Technique 
No recommendations 
 
 
 
 
 
 
Extrapelvic 
endometriosis 
 
Technique 
Cystectomy 
1 Cochrane review (3 RCTs) 
 
Cystectomy > CO2 laser 
vaporisation 
1 RCT  
 
Extrapelvic endometriosis 
 
Technique 
Cystectomy  
1 RCT 
1 non RCT 
 
 
 
 
Extrapelvic 
endometriosis 
Appendix: 
Appendectomy 
No reference 
 
Bladder: 
Excision and closure 
No reference 
 
Technique 
Cystectomy  
1 Cochrane review (2 RCTs) 
 
 
 
 
 
Extrapelvic 
endometriosis 
 
Technique 
Cystectomy 
1 Cochrane review (4 RCTs) 
 
 
 
 
 
Extrapelvic 
endometriosis 
 
  
 320. 
Abdominal wall / perineal: 
Excision 
5 non-RCT 
 
       
Surgical management of pain associated with severe endometriosis 
General 
Conservative surgery 
1 RCT  
 
 
 
 
 
 
 
 
 
 
 
General 
No 
recommendations 
 
 
 
 
 
 
 
 
 
 
 
 
General 
No recommendations 
 
 
 
 
 
 
 
 
 
 
 
 
General 
Surgical removal 
2 systematic reviews (83 non-
RCTs) 
 
 
 
 
 
 
 
 
 
 
 
 
General 
Pre-menopausal age 
Hysterectomy with combined 
HT 
No reference 
 
Post-menopausal age 
Hysterectomy with combined 
HT or tibolone 
1 literature review 
1 consensus statement  
 
General 
Surgical removal 
1 non-RCT  
1 case series 
 
Bowel resection  
1 non-RCT  
 
Multidisciplinary approach at 
expert center 
No reference 
General 
No recommendations 
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Approach 
No recommendations 
 
 
 
 
 
 
Approach 
No 
recommendations 
 
 
 
 
 
 
Approach 
Laparoscopy 
No reference 
 
 
 
Approach 
Expert centers 
Expert opinion 
 
 
 
 
 
Approach 
Vaginal 
No reference 
 
Laparoscopic 
No reference 
 
Laparotomy  
No reference 
 
Approach 
Laparoscopy 
National guideline 
 
 
 
 
Approach 
No recommendations 
 
 
 
 
 
 
Technique 
No recommendations 
 
Technique 
No 
recommendations 
 
Technique 
Laparoscopic excision  
No reference 
 
Bladder: 
Partial cystectomy 
No reference 
 
Transurethral resection 
Not recommended  
No reference 
Technique 
Excisional surgery 
1 systematic review (34 non-
RCTs) 
 
Technique 
Resection, leaving a free margin 
on all sides 
1 systematic review (5 non-
RCTs) 
 
Technique 
No recommendations 
 
Technique 
Excisional surgery  
Expert opinion 
 
Hysterectomy  
1 non-RCT  
 
  
 322. 
       
Surgical management of endometriosis associated pain 
General 
No recommendations 
 
 
 
 
 
 
General 
No 
recommendations 
 
 
 
 
 
 
 
 
General 
No recommendations 
 
 
 
 
 
 
General 
Surgery 
1 Cochrane review (5 RCTs) 
 
 
General 
No recommendations 
 
 
 
 
 
 
General 
Surgery  
2 RCTs 
1 Cohort study  
 
Surgery to follow failed 
medical treatment 
No reference  
 
General 
Laparoscopic surgery  
1 Cochrane review (5 RCTs) 
 
 
 
 
Approach 
No recommendations 
 
 
 
 
 
 
Approach 
No 
recommendations 
 
 
 
 
 
 
Approach 
No recommendations 
 
 
 
 
 
Approach 
Laparotomy and laparoscopy  
No reference 
  
 
Approach 
Laparoscopy  
1 Cochrane review (5 RCTs) 
 
Approach 
Laparoscopy  
1 non-RCT 
 
Approach 
Laparoscopy 
No reference 
 
Expert centers 
Expert opinion  
 
Technique Technique Technique  Technique Technique Technique Technique 
  
 323. 
Hysterectomy with ovarian 
conservation  
1 non-RCT  
 
 
Hysterectomy with bilateral 
salpingo-oophorectomy  
No reference 
 
 
LUNA  
Not recommended 
1 Cochrane review (6 RCTs) 
1 RCT  
 
 
PSN  
1 RCT  
 
No 
recommendations 
 
Hysterectomy with 
ovarian conservation 
Not recommended  
No reference 
 
Hysterectomy with 
bilateral salpingo-
oopherectomy  
No reference 
 
 
LUNA 
Not recommended  
No reference 
 
 
 
PSN 
Insufficient data  
No reference 
 
Adhesiolysis 
Insufficient data  
Ablation or excision 
2 RCTs 
 
 
 
Hysterectomy and bilateral 
salpingo-oophorectomy 
Expert opinion 
 
 
LUNA  
Not recommended 
1 Cochrane review (6 RCTs) 
 
 
 
PSN 
1 Cochrane review (3 RCTs) 
 
Methods available (coagulation, 
vaporisation, excision) are 
unclear in equivalence 
1 RCT 
 
 
 
 
 
 
LUNA 
Not recommended 
1 RCT 
 
Hysterectomy with ovarian 
conservation 
1 non-RCT  
 
 
Conservative surgery  
No reference 
 
 
 
LUNA  
Not recommended 
1 RCT  
 
 
 
PSN  
3 RCTs 
Excision 
Expert opinion  
 
 
 
 
 
 
 
 
LUNA  
Not recommended 
1 Cochrane review (5 RCTs) 
 
 
PSN  
Not recommended 
1 Cochrane review (4 RCTs) 
 
  
 324. 
No reference 
       
Adjuvant therapy for the surgical management of endometriosis associated pain 
Preoperative 
Not recommended 
1 non-RCT  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Preoperative 
No 
recommendations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Preoperative 
Not recommended 
No reference 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Preoperative 
Not recommended 
1 Cochrane review (16 RCTs) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Preoperative 
(Endometrioma) 
Gonadotropin releasing 
hormone analogue  
1 non-RCT 
1 case series 
 
Preoperative 
Severe endometriosis  
Gonadotropin releasing 
hormone analogue  
Not recommended 
1 Cochrane review (16 RCTs)  
1 RCT 
 
Preoperative 
Extrapelvic 
Endometriosis: 
Adenomyosis - 
Gonadotropin releasing 
hormone analogue  
Preoperative 
No recommendations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Preoperative 
No recommendations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 325. 
 
 
 
 
 
 
  
 
 
 
2 case reports 
1 literature review 
 
 
 
 
 
 
Perioperative 
Not recommended 
1 Cochrane review (11 RCTs) 
 
Perioperative 
No 
recommendations 
 
 
 
Perioperative 
No recommendations 
 
 
 
Perioperative 
No recommendations 
 
 
 
Perioperative 
No recommendations 
 
 
 
Perioperative 
No recommendations 
 
 
 
Perioperative 
No recommendations 
 
 
 
Postoperative 
Combined oral contraceptive 
pill reduces endometrioma 
recurrence 
1 RCT  
1 Systematic review (4 RCTs, 3 
non-RCTs) 
 
Gonadotropin releasing 
hormone analogue  
1 systematic review (35 RCTs) 
1 RCT  
 
Levonorgestrel-releasing IUS 
1 Cochrane review (3 RCTs) 
Postoperative 
No 
recommendations 
 
Postoperative 
Not recommended 
No reference 
Postoperative 
Not routinely recommended 
1 Cochrane review (16 RCTs) 
 
Combined oral contraceptive pill  
1 systematic review (1 RCT, 1 
non-RCT) 
 
Levonorgestrel-releasing IUS 
1 Cochrane review (3 RCTs) 
1 systematic review (4 RCTs, 3 
non-RCTs) 
 
Postoperative 
Gonadotropin releasing 
hormone analogue  
Not recommended 
1 RCT 
 
Postoperative (Minimal 
to mild endometriosis)  
Levonorgestrel-releasing IUS 
1 Cochrane review (3 RCTs) 
 
Postoperative 
Severe endometriosis  
Gonadotropin releasing 
hormone analogue  
Postoperative 
Combined oral contraceptive 
pill  
1 RCT 
1 Systematic review (4 RCTs, 
3 non-RCTs) 
Postoperative 
Combined oral contraceptive 
pill 
reduces recurrence  
1 RCT 
 
  
 326. 
1 RCT 
 
 
Not recommended 
1 Cochrane review (16 RCTs)  
1 RCT 
       
Alternative management of pain associated with endometriosis 
Acupuncture 
No recommendations 
 
 
 
 
Acupuncture 
No 
recommendations 
 
 
 
 
Acupuncture 
No recommendations 
 
 
 
 
Accupuncture 
Not recommended 
Expert opinion 
 
 
 
Acupuncture 
No recommendations 
 
 
 
 
Acupuncture 
No recommendations 
 
 
 
 
Acupuncture 
1 Cochrane review (1 RCT) 
 
TENS 
No recommendations 
 
 
 
 
 
TENS 
No 
recommendations 
 
 
 
 
 
TENS 
No recommendations 
 
 
 
 
 
TENS 
Not recommended 
Expert opinion 
  
 
 
 
TENS 
No recommendations 
 
 
 
 
 
TENS 
No recommendations 
 
 
 
 
 
TENS 
1 Cochrane review (9 RCTs) 
 
Dietary 
No recommendations 
 
Dietary 
No 
recommendations 
Dietary 
No recommendations 
 
Dietary 
Not recommended 
Expert opinion 
Dietary 
No recommendations 
 
Dietary 
No recommendations 
 
Dietary 
Vitamins 
2 RCTs 
  
 327. 
  
Minerals  
2 RCTs 
 
Salts 
2 RCTs 
 
Lactic Ferments 
2 RCTs 
 
Fish Oil 
2 RCTS 
1 Non-RCT 
 
 
Abbreviations: CO2: Carbon Dioxide, FDA: Food and Drug Association; HRT: Hormone Replacement Therapy; IUS: IUS; LUNA: Laparoscopic Uterosacral Nerve Ablation; PSN: PSN; RCT: Randomised Controlled Trial. 
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Appendix 5. Summarised guideline recommendations for the medical and surgical treatment of subfertility associated with 
endometriosis. 
 
ACOG (2010) ACCEPT (2012) CNGOF (2006) ESHRE (2014) NGG (2014) SOGC (2010) WES (2013) 
       
Arti f ic ia l  reproduct ive  techniques(ART)  
Adjuvant therapy 
(prior to IVF) 
No recommendations 
 
 
 
 
 
 
 
 
Adjuvant therapy 
(prior to IVF) 
Gonadotropin releasing 
hormone analogue 
1 Cochrane review (3 RCTs) 
 
Combined oral contraceptive 
pill  
not recommended 
1 non-RCT 
Adjuvant therapy 
(prior to IVF) 
Gonadotropin releasing 
hormone analogue 
No reference 
 
Between cycles: 
Progestogens 
No reference 
 
Danazol 
No reference 
 
Adjuvant therapy 
(prior to IVF) 
Gonadotropin releasing 
hormone analogue 
1 Cochrane review (3 
RCTs) 
 
Endometrioma: 
Antibiotic prophylaxis at 
transvaginal oocyte retrival 
1 non-RCT 
 
Adjuvant therapy 
(prior to IVF) 
Gonadotropin releasing 
hormone analogue 
1 Cochrane review (3 
RCTs) 
 
 
 
Adjuvant therapy 
(prior to IVF) 
Gonadotropin releasing 
hormone analogue 
1 Cochrane review (3 
RCTs) 
 
 
 
 
 
 
Adjuvant therapy 
(prior to IVF) 
Gonadotropin releasing 
hormone analogue 
1 Cochrane review (3 RCTs) 
 
Combined oral contraceptive 
pill not recommended 
1 non-RCT 
 
Adjuvant therapy 
(prior to IUI) 
Adjuvant therapy 
(prior to IUI) 
Adjuvant therapy 
(prior to IUI) 
Adjuvant therapy 
(prior to IUI) 
Adjuvant therapy 
(prior to IUI) 
Adjuvant therapy 
(prior to IUI) 
Adjuvant therapy 
(prior to IUI) 
  
 329. 
No recommendations 
 
No recommendations 
 
No recommendations 
 
No recommendations 
 
No recommendations 
 
No recommendations 
 
Hormonal treatment 
not recommended 
1 RCT 
 
 
ART Technique 
No recommendations 
 
ART Technique 
Controlled ovarian 
stimulation 
and intrauterine insemination 
2 RCTs 
 
ART Technique 
First line: 
Controlled ovarian 
stimulation 
and intrauterine 
insemination 
No reference 
 
Intrauterine fertilisation 
Indication: distorted 
anatomy 
No reference 
ART Technique 
Controlled ovarian 
stimulation 
and intrauterine 
insemination 
1 RCT  
 
Intrauterine fertilisation 
Indication: distorted 
anatomy 
Expert opinion 
 
ART Technique 
Intrauterine insemination 
2 RCTs 
 
Controlled ovarian 
stimulation 
and oocyte 
Cryopreservation 
1 case report 
 
ART Technique 
Controlled ovarian 
stimulation 
and intrauterine 
insemination 
1 RCT  
 
ART Technique 
Controlled ovarian 
stimulation 
and intrauterine Insemination 
1 systematic review (6 RCTs)  
1 RCT 
 
Double insemination at 
intrauterine insemination 
1 non-RCT 
 
Intrauterine fertilisation 
1 RCT 
 
Ovulation induction  
not recommended 
  
 330. 
No reference available 
       
Surgical management of infertility associated with mild to moderate endometriosis 
General 
Surgery increases 
spontaneous pregnancy 
rates. 
2 RCTs 
 
General 
Surgery increases 
spontaneous pregnancy rates 
1 Cochrane review (2 RCTs) 
 
 
General 
Surgery increases 
spontaneous pregnancy 
rates 
No reference 
 
 
Avoid repeat surgery 
No reference 
 
General 
Surgery increases 
spontaneous pregnancy 
rates 
1 Cochrane review (2 
RCTs) 
1 RCT  
 
Surgery prior to ART 
1 non-RCT 
 
General 
Surgery increases 
spontaneous pregnancy 
rates 
1 Cochrane review (2 
RCTs) 
 
 
 
 
General 
Surgery increases 
spontaneous pregnancy 
rates  
1 RCT  
 
 
 
General 
Surgery increases 
spontaneous pregnancy rates 
1 Cochrane review (2 RCTs) 
 
 
Approach 
No recommendations 
 
Approach 
No recommendations 
 
Approach 
No recommendations 
 
Approach 
No recommendations 
 
Approach 
No recommendations 
 
Approach 
No recommendations 
 
Approach 
No recommendations 
 
Technique 
No recommendations 
Technique 
No recommendations 
Technique 
Laparoscopy excision  
No reference 
Technique 
Carbon dioxide laser  
1 RCT 
Technique 
No recommendations 
 
Technique 
Excision and ablation 
equally effective 
1 RCT 
Technique 
Not reported 
 
       
  
 331. 
Surgical management of infertility associated with endometrioma 
General 
Surgery increases 
spontaneous pregnancy 
rates. 
No reference 
 
Surgery may damage the 
ovary and reduce ovarian 
reserve. 
No reference 
 
 
General 
Surgery before IVF  
Not recommended 
Cochrane review (3 RCTs) 
 
 
 
General 
No recommendations 
 
 
 
 
 
 
General 
The decision to proceed 
with surgery should be 
considered carefully the 
woman has had previous 
ovarian surgery 
Expert opinion 
 
Surgery before IVF  
Not recommended 
2 Cochrane reviews (7 
RCTs) 
1 non-RCT 
General 
No recommendations 
 
 
 
 
General 
Cystectomy >3 cm  
1 Cochrane review (2 
RCTs)  
 
 
 
General  
Surgery before IVF 
Not recommended  
No reference 
 
 
 
 
Approach 
Laparoscopy  
1 RCT 
Approach 
No recommendations 
 
Approach 
No recommendations 
 
Approach 
No recommendations 
Approach 
Laparoscopy 
1 non-RCT 
 
Approach 
No recommendations 
 
Approach 
No recommendations 
 
Technique 
Cystectomy  
1 Cochrane Review (2 
RCTs)  
 
Technique 
Cystectomy 
1 Cochrane review (1 RCT) 
Technique 
No recommendations 
 
Technique 
Cystectomy  
1 Cochrane review (3 
RCTs) 
Technique 
Cystectomy 
1 Cochrane review (3 
RCTs)  
1 RCT 
 
Technique 
Cystectomy 
1 Cochrane review (2 
RCTs)  
 
Technique 
Cystectomy  
1 Cochrane review (1 RCTs) 
  
 332. 
       
Surgical management of infertility associated with severe endometriosis 
General 
Benefit unclear 
1 non-RCT 
 
 
 
General 
Benefit unclear 
2 non RCTs  
 
 
General 
No recommendations 
 
 
 
General 
Benefit prior to ART is 
unclear 
2 non-RCTs 
 
General 
No recommendations 
 
 
 
 
 
 
General 
Benefits unclear 
1 case series 
 
 
 
General 
IVF before surgery 
Expert opinion 
 
 
 
 
 
 
 
Approach 
No recommendations 
 
Approach 
No recommendations 
 
Approach 
No recommendations 
 
Approach 
Operative laparoscopy  
2 non-RCTs 
 
Approach 
No recommendations 
 
Approach 
No recommendations 
 
Approach 
No recommendations 
 
Technique 
No recommendations 
 
Technique 
No recommendations 
 
Technique 
No recommendations 
 
Technique 
No recommendations 
 
Technique 
No recommendations 
 
Technique 
No recommendations 
 
Technique 
Unclear 
6 non-RCTs 
       
  
 333. 
Surgical management of infertility associated with endometriosis 
General 
IVF > repeat operation, 
after surgery 
1 non-RCT  
 
Repetitive ovarian surgery 
has negative impact on IVF 
outcomes 
1 systematic review (22 
non-RCTs) 
 
General 
Primary surgery > repeat 
surgery 
1 systematic review (3 non-
RCTs) 
 
 
 
 
 
General 
No recommendations 
 
 
 
 
 
 
General 
No recommendations 
 
 
 
 
 
 
General 
No recommendations 
 
 
 
 
 
 
General 
No recommendations 
 
 
 
 
 
 
General 
No recommendations 
 
 
 
Approach 
No recommendations 
 
 
 
Approach 
Laparoscopy  
United Kingdom National 
Guideline  
 
Approach 
No recommendations 
 
 
 
Approach 
No recommendations 
 
 
 
Approach 
No recommendations 
 
 
 
Approach 
Laparoscopy 
1 case series (1399 cases) 
 
 
Approach 
No recommendations 
 
 
Technique 
No recommendations 
 
Technique 
No recommendations 
 
Technique 
No recommendations 
 
Technique 
No recommendations 
 
Technique 
No recommendations 
 
Technique 
No recommendations 
Technique 
Excision  
Expert opinion 
       
Adjuvant therapy for the surgical management of infertility associated with endometriosis (spontaneous conception / Not ART) 
  
 334. 
Not Specified 
No recommendations 
 
 
 
 
 
 
 
 
 
 
 
Not Specified 
Hormonal treatment  
Not recommended 
1 Cochrane review (23 
RCTs) 
 
Pentoxifyllline  
Not recommended 
1 Cochrane review (4 RCTs)  
 
Hysterosalpingogram with 
lipidol  
1 RCT 
 
Not Specified 
No recommendations 
 
 
 
 
 
 
 
 
 
 
 
 
Not Specified 
Hormonal treatment  
Not recommended 
1 Cochrane review (25 
RCTs) 
 
 
 
 
 
 
 
Not Specified 
No recommendations 
 
 
 
 
 
 
 
 
 
 
Not Specified 
No recommendations 
 
 
 
 
 
 
 
 
 
Not Specified 
Hormonal treatment  
Not recommended  
1 Cochrane review (23 
RCTs) 
 
Lipidol hysterosalpingogram  
1 RCT  
 
 
Preoperative  
No recommendations 
 
 
Preoperative 
No recommendations 
 
 
Preoperative 
No recommendations 
 
 
Preoperative 
Hormonal treatment  
Not recommended 
Expert opinion 
 
Preoperative 
Hormonal treatment 
Not recommended 
1 Cochrane review (3 
RCTs), 
1 case series 
 
Preoperative 
Hormonal treatment 
Not recommended 
1 Cochrane review (25 
RCTs) 
Preoperative 
No recommendations 
 
 
 
  
 335. 
Postoperative 
No recommendations 
 
Postoperative 
Hormonal treatment  
Not recommended  
1 Cochrane review (8 RCTs) 
 
Anti-adhesion treatment  
Not recommended 
1 Cochrane review (3 RCTs) 
Postoperative 
Hormonal treatment  
Not recommended 
No reference 
 
Direct referral to IVF  
No reference 
 
Postoperative 
Hormonal treatment  
Not recommended 
1 Cochrane review (11 
RCTs) 
Postoperative 
Gonadotropin releasing 
hormone analogue 
Not recommended  
1 Cochrane review (24 
RCTs)  
1 RCT 
 
Postoperative 
Hormonal treatment 
Not recommended 
1 Cochrane review (25 
RCTs) 
 
Postoperative 
No recommendations 
       
Alternative management of infertility associated with endometriosis 
Acupuncture 
No recommendations 
 
Acupuncture 
No recommendations 
 
Acupuncture 
No recommendations 
 
Accupuncture 
Not recommended 
Expert opinion 
 
Acupuncture 
Not recommended 
1 Cochrane review (39 
RCTs) 
 
Acupuncture 
No recommendations 
 
 
 
Acupuncture 
No recommendations 
 
 
 
Dietary 
No recommendations 
 
 
Dietary 
No recommendations 
 
 
Dietary 
No recommendations 
 
 
Dietary 
Not recommended 
Expert opinion 
 
Dietary 
No recommendations 
 
 
Dietary 
No recommendations 
 
 
Dietary 
No recommendations 
 
 
TENS TENS TENS TENS TENS TENS TENS 
  
 336. 
No recommendations 
 
No recommendations 
 
No recommendations 
 
Not recommended 
Expert opinion 
No recommendations No recommendations No recommendations 
 
 
 
Abbreviations: ART: Artificial Reproductive Techniques, IVF: In Vitro Fertilisation, IUI: Intrauterine Insemination, RCT: Randomised Control Trial, TENS: Transcutaneous Electrical Nerve Stimulation.  
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Appendix 6. – Peer reviewed publications arising from this thesis with permission to reproduce. 
 
 
  
 338. 
 
 
  
 339. 
 
 
  
  
 340. 
 
 
 
 
 
  
 341. 
 
 
  
 342. 
 
  
 343. 
 
 
  
 344. 
 
 
 
  
 345. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 346. 
 
 
 
  
 347. 
 
 
  
 348. 
 
  
 349. 
 
  
 350. 
 
 
  
 351. 
 
  
 352. 
 
 
 
 
  
 353. 
 
  
 354. 
 
  
 355. 
 
  
 356. 
 
  
 357. 
 
 
  
 358. 
 
  
 359. 
 
 
  
 360. 
 
  
 361. 
 
  
 362. 
 
  
 363. 
 
  
 364. 
 
 
  
 365. 
 
 
  
 366. 
  
 367. 
 
  
 368. 
 
  
 369. 
 
  
 370. 
 
  
 371. 
 
  
 372. 
 
  
 373. 
 
  
 374. 
 
  
 375. 
 
  
 376. 
 
  
 377. 
 
  
 378. 
 
  
 379. 
 
  
 380. 
 
  
 381. 
  
 382. 
  
 383. 
  
 384. 
  
 385. 
  
 386. 
  
 387. 
  
 388. 
  
 389. 
  
 390. 
  
 391. 
  
 392. 
  
 393. 
  
 394. 
  
 395. 
  
 396. 
  
 397. 
  
 398. 
  
 399. 
 
 
  
 400. 
  
 401. 
  
 402. 
  
 403. 
  
 404. 
 
  
 405. 
  
 406. 
  
 407. 
  
 408. 
  
 409. 
  
 410. 
  
 411. 
  
 412. 
  
 413. 
  
 414. 
  
 415. 
  
 416. 
 
 
  
 417. 
REFERENCES 
1.  Müller JP. Bildungsgeschichte der Genitalien aus anatomischen Untersuchungen 
an Embryonem des Menschen and der Thiere, nebst einem Anhang uber die 
chirurgische Behandlung der hypoplasia. Dusseldorf; 1830.  
2.  R C. Uber Uterusdrusen-Neubildung in Uterus- und Ovarial- Sarcomen. Zeitschr 
gesellschaft der Aerzte in Wien. 16th ed. 1860. 577-581 p.  
3.  F VR. Die Adenomyomata und Cystadenomata der Uterus und Tubenwandung: 
Ihre Abkunft von Resten des Wolffischen Koerpers. August Hirschwald Verlag. 
Berlin; 1896.  
4.  SAMPSON JA, Novak E, Smith RR, Savage S, Wolf EH, Hedley JP, et al. 
Perforating haemorrhagic (chocolate) cysts of Ovary: their importance and 
especially their relation to pelvic adenomas of endometriotic type (“adenomyoma” 
of the Uterus, rectovaginal septum,sigmoid,etc...). Arch Surg. American Medical 
Association; 1921 Sep 1;3(2):245.  
5.  Sampson JA. Metastatic or Embolic Endometriosis, due to the Menstrual 
Dissemination of Endometrial Tissue into the Venous Circulation. Am J Pathol. 
American Society for Investigative Pathology; 1927 Mar;3(2):93–110.43.  
6.  Cullen TS. Archives of surgery. 1st ed. 1920. 215-283 p.  
7.  Halme J, Hammond MG, Hulka JF, Raj SG, Talbert LM. Retrograde menstruation 
in healthy women and in patients with endometriosis. Obstet Gynecol. 1984 
Aug;64(2):151–4.  
8.  Classification of endometriosis. The American Fertility Society. Fertil Steril. 1979 
Dec;32(6):633–4.  
  
 418. 
9.  Troiano RN, McCarthy SM. Müllerian Duct Anomalies: Imaging and Clinical 
Issues. Radiology. 2004;233(1):19–34.  
10.  Sanfilippo JS, Wakim NG, Schikler KN, Yussman MA. Endometriosis in 
association with uterine anomaly. Am J Obstet Gynecol. 1986 Jan;154(1):39–43.  
11.  D’Hooghe TM, Bambra CS, Suleman MA, Dunselman GA, Evers HL, Koninckx 
PR. Development of a model of retrograde menstruation in baboons (Papio 
anubis). Fertil Steril. 1994 Sep;62(3):635–8.  
12.  Barbieri RL. Stenosis of the external cervical os: an association with 
endometriosis in women with chronic pelvic pain. Fertil Steril. 1998 
Sep;70(3):571–3.  
13.  Nawroth F, Rahimi G, Nawroth C, Foth D, Ludwig M, Schmidt T. Is there an 
association between septate uterus and endometriosis? 2006 Feb;21(2).  
14.  Matsuura K, Ohtake H, Katabuchi H, Okamura H. Coelomic metaplasia theory of 
endometriosis: evidence from in vivo studies and an in vitro experimental model. 
Gynecol Obstet Invest. 1999;47 Suppl 1:18-20; discussion 20-2.  
15.  Mok-Lin EY, Wolfberg A, Hollinquist H, Laufer MR. Endometriosis in a patient with 
Mayer-Rokitansky-Küster-Hauser syndrome and complete uterine agenesis: 
evidence to support the theory of coelomic metaplasia. J Pediatr Adolesc 
Gynecol. 2010 Feb;23(1):e35-7.  
16.  Van Schil PE, Vercauteren SR, Vermeire PA, Nackaerts YH, Van Marck EA. 
Catamenial pneumothorax caused by thoracic endometriosis. Ann Thorac Surg. 
1996 Aug;62(2):585–6.  
17.  Mikroulis D, Didilis V, Konstantinou F, Vretzakis G, Bougioukas G. Catamenial 
Pneumothorax. Thorac Cardiovasc Surg. 2008 Sep;56(06):374–5.  
  
 419. 
18.  Thibodeau LL, Prioleau GR, Manuelidis EE, Merino MJ, Heafner MD. Cerebral 
endometriosis. Case report. J Neurosurg. 1987 Apr;66(4):609–10.  
19.  Dessy LA, Buccheri EM, Chiummariello S, Gagliardi DN, Onesti MG. Umbilical 
endometriosis, our experience. In Vivo. 2008;22(6):811–5.  
20.  Nezhat C, Kazerooni T, Berker B, Lashay N, Fernandez S, Marziali M. 
Laparoscopic management of hepatic endometriosis: Report of two cases and 
review of the literature. J Minim Invasive Gynecol. 2005 Jun;12(3):196–200.  
21.  Bulun SE. Endometriosis. N Engl J Med. Massachusetts Medical Society; 2009 
Jan 15;360(3):268–79.  
22.  Signorile PG, Baldi F, Bussani R, D’Armiento M, De Falco M, Baldi A. Ectopic 
endometrium in human foetuses is a common event and sustains the theory of 
müllerianosis in the pathogenesis of endometriosis, a disease that predisposes to 
cancer. J Exp Clin Cancer Res. BioMed Central; 2009 Apr 9;28(1):49.  
23.  Lebovic DI, Mueller MD, Taylor RN. Immunobiology of endometriosis. Fertil Steril. 
2001 Jan;75(1):1–10.  
24.  Kyama CM, Overbergh L, Debrock S, Valckx D, Vander Perre S, Meuleman C, et 
al. Increased peritoneal and endometrial gene expression of biologically relevant 
cytokines and growth factors during the menstrual phase in women with 
endometriosis. Fertil Steril. 2006 Jun;85(6):1667–75.  
25.  Houston DE. Evidence for the risk of pelvic endometriosis by age, race and 
socioeconomic status. Epidemiol Rev. 1984;6:167–91.  
26.  Weed JC. Endometriosis in the Negro. Ann Surg. 1955 May;141(5):615–20.  
27.  Venter P. Endometriosis. S Afr Med J. 1980;(57):895–9.  
28.  Missmer SA, Hankinson SE, Spiegelman D, Barbieri RL, Marshall LM, Hunter DJ. 
  
 420. 
Incidence of laparoscopically confirmed endometriosis by demographic, 
anthropometric, and lifestyle factors. Am J Epidemiol. 2004 Oct 15;160(8):784–96.  
29.  Jeffcoate N. Principles of gynaecology. 4th ed. London; 1975.  
30.  Eggert J, Li X, Sundquist K. Country of birth and hospitalization for pelvic 
inflammatory disease, ectopic pregnancy, endometriosis, and infertility: a 
nationwide study of 2 million women in Sweden. Fertil Steril. 2008 
Oct;90(4):1019–25.  
31.  Ranney B. Endometriosis. IV. Hereditary tendency. Obstet Gynecol. 1971 
May;37(5):734–7.  
32.  Stefansson H, Geirsson RT, Steinthorsdottir V, Jonsson H, Manolescu A, Kong A, 
et al. Genetic factors contribute to the risk of developing endometriosis. Hum 
Reprod. 2002 Mar;17(3):555–9.  
33.  Treloar SA, O’Connor DT, O’Connor VM, Martin NG. Genetic influences on 
endometriosis in an Australian twin sample. sueT@qimr.edu.au. Fertil Steril. 1999 
Apr;71(4):701–10.  
34.  Hansen KA, Eyster KM. Genetics and genomics of endometriosis. Clin Obstet 
Gynecol. NIH Public Access; 2010 Jun;53(2):403–12.  
35.  Hadfield RM, Mardon HJ, Barlow DH, Kennedy SH. Endometriosis in monozygotic 
twins. Fertil Steril. 1997 Nov;68(5):941–2.  
36.  Moen MH. Endometriosis in monozygotic twins. Acta Obstet Gynecol Scand. 1994 
Jan;73(1):59–62.  
37.  Franco HL, Dai D, Lee KY, Rubel CA, Roop D, Boerboom D, et al. WNT4 is a key 
regulator of normal postnatal uterine development and progesterone signaling 
during embryo implantation and decidualization in the mouse. FASEB J. 2011 Apr 
  
 421. 
1;25(4):1176–87.  
38.  Banu SK, Lee J, Speights VO, Starzinski-Powitz A, Arosh JA. Selective inhibition 
of prostaglandin E2 receptors EP2 and EP4 induces apoptosis of human 
endometriotic cells through suppression of ERK1/2, AKT, NFkappaB, and beta-
catenin pathways and activation of intrinsic apoptotic mechanisms. Mol 
Endocrinol. 2009 Aug;23(8):1291–305.  
39.  Braga de Paula L, Pereira Braga N, Mendonça M, Moro L, Geber S. Apoptosis of 
ectopic endometrial cells is impaired in women with endometriosis. J Endometr. 
2012;4(1):17–20.  
40.  Abrao MS, Podgaec S, Dias JA, Averbach M, Garry R, Ferraz Silva LF, et al. 
Deeply infiltrating endometriosis affecting the rectum and lymph nodes. Fertil 
Steril [Internet]. 2006 Sep [cited 2016 Dec 5];86(3):543–7. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/16876165 
41.  Beavis AL, Matsuo K, Grubbs BH, Srivastava SA, Truong CM, Moffitt MN, et al. 
Endometriosis in para-aortic lymph nodes during pregnancy: case report and 
review of literature. Fertil Steril [Internet]. 2011 Jun [cited 2016 Dec 
5];95(7):2429.e9-13. Available from: 
http://linkinghub.elsevier.com/retrieve/pii/S0015028211002366 
42.  Tempfer CB, Wenzl R, Horvat R, Grimm C, Polterauer S, Buerkle B, et al. 
Lymphatic spread of endometriosis to pelvic sentinel lymph nodes: a prospective 
clinical study. Fertil Steril [Internet]. 2011 Sep [cited 2016 Dec 5];96(3):692–6. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/21880280 
43.  Bobek V, Kolostova K, Kucera E. Circulating endometrial cells in peripheral blood. 
Eur J Obstet Gynecol Reprod Biol. 2014 Oct;181:267–74.  
44.  Santulli P, Chouzenoux S, Fiorese M, Marcellin L, Lemarechal H, Millischer A-E, 
  
 422. 
et al. Protein oxidative stress markers in peritoneal fluids of women with deep 
infiltrating endometriosis are increased. Hum Reprod. 2015 Jan 1;30(1):49–60.  
45.  Lambert S, Santulli P, Chouzenoux S, Marcellin L, Borghese B, de Ziegler D, et al. 
Endometriosis: increasing concentrations of serum interleukin-1β and interleukin-
1sRII is associated with the deep form of this pathology. J Gynecol Obstet Biol 
Reprod (Paris). 2014 Nov;43(9):735–43.  
46.  Wu Y, Kajdacsy-Balla A, Strawn E, Basir Z, Halverson G, Jailwala P, et al. 
Transcriptional characterizations of differences between eutopic and ectopic 
endometrium. Endocrinology. 2006 Jan;147(1):232–46.  
47.  Sharpe-Timms KL, Cox KE. Paracrine regulation of matrix metalloproteinase 
expression in endometriosis. Ann N Y Acad Sci. 2002 Mar;955:147-56; discussion 
157-8, 396–406.  
48.  Noble LS, Simpson ER, Johns A, Bulun SE. Aromatase expression in 
endometriosis. J Clin Endocrinol Metab. 1996 Jan;81(1):174–9.  
49.  Tseng JF, Ryan IP, Milam TD, Murai JT, Schriock ED, Landers D V, et al. 
Interleukin-6 secretion in vitro is up-regulated in ectopic and eutopic endometrial 
stromal cells from women with endometriosis. J Clin Endocrinol Metab. 1996 
Mar;81(3):1118–22.  
50.  Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, et al. Regulation of 
aromatase expression in estrogen-responsive breast and uterine disease: from 
bench to treatment. Pharmacol Rev. 2005 Sep;57(3):359–83.  
51.  Bruner KL, Matrisian LM, Rodgers WH, Gorstein F, Osteen KG. Suppression of 
matrix metalloproteinases inhibits establishment of ectopic lesions by human 
endometrium in nude mice. J Clin Invest. 1997 Jun 15;99(12):2851–7.  
  
 423. 
52.  Ryan IP, Taylor RN. Endometriosis and infertility: new concepts. Obstet Gynecol 
Surv. 1997 Jun;52(6):365–71.  
53.  Reis FM, Petraglia F, Taylor RN. Endometriosis: hormone regulation and clinical 
consequences of chemotaxis and apoptosis. Hum Reprod Update. 2013 Jul 
1;19(4):406–18.  
54.  Eisermann J, Gast MJ, Pineda J, Odem RR, Collins JL. Tumor necrosis factor in 
peritoneal fluid of women undergoing laparoscopic surgery. Fertil Steril. 1988 
Oct;50(4):573–9.  
55.  Scholl B, Bersinger NA, Kuhn A, Mueller MD. Correlation between symptoms of 
pain and peritoneal fluid inflammatory cytokine concentrations in endometriosis. 
Gynecol Endocrinol. 2009 Nov 23;25(11):701–6.  
56.  Agarwal A, Gupta S, Sharma RK. Role of oxidative stress in female reproduction. 
Reprod Biol Endocrinol. 2005 Jul 14;3:28.  
57.  Jackson LW, Schisterman EF, Dey-Rao R, Browne R, Armstrong D. Oxidative 
stress and endometriosis.  
58.  Carvalho LFP, Samadder AN, Agarwal A, Fernandes LFC, Abrão MS. Oxidative 
stress biomarkers in patients with endometriosis: systematic review. Arch Gynecol 
Obstet. 2012 Oct 12;286(4):1033–40.  
59.  JA S. Peritoneal endometriosis due to menstrual dissemination of endometrial 
tissue into the peritoneal cavity. Am J Obs. 1921;14:422–69.  
60.  Albrecht H. Die Endometriose. In: Seitz L, Amreich AI (eds). Biologie und 
Pathologie des Weibes: Ein Handbuch der Frauenheilkunde und der Geburtshilfe. 
[Biology and pathology of the woman: a manual of gynecology and obstetrics.]. 
2nd ed. Berlin; 1955. 190-288 p.  
  
 424. 
61.  Acosta AA, Buttram VC, Besch PK, Malinak LR, Franklin RR, Vanderheyden JD. 
A proposed classification of pelvic endometriosis. Obstet Gynecol. 1973 
Jul;42(1):19–25.  
62.  Revised American Fertility Society classification of endometriosis: 1985. Fertil 
Steril. 1985 Mar;43(3):351–2.  
63.  Revised American Society for Reproductive Medicine classification of 
endometriosis: 1996. Fertil Steril. 1997 May;67(5):817–21.  
64.  Wykes CB, Clark TJ, Khan KS. Accuracy of laparoscopy in the diagnosis of 
endometriosis: a systematic quantitative review. BJOG An Int J Obstet Gynaecol. 
Blackwell Science Ltd; 2004 Oct 19;111(11):1204–12.  
65.  Hornstein MD, Gleason RE, Orav J, Haas ST, Friedman AJ, Rein MS, et al. The 
reproducibility of the revised American Fertility Society classification of 
endometriosis. Fertil Steril. 1993 May;59(5):1015–21.  
66.  Adamson GD, Hurd SJ, Pasta DJ, Rodriguez BD. Laparoscopic endometriosis 
treatment: is it better? Fertil Steril. 1993 Jan;59(1):35–44.  
67.  Guzick DS, Silliman NP, Adamson GD, Buttram VC, Canis M, Malinak LR, et al. 
Prediction of pregnancy in infertile women based on the American Society for 
Reproductive Medicine’s revised classification of endometriosis. Fertil Steril. 1997 
May;67(5):822–9.  
68.  Vercellini P, Trespidi L, De Giorgi O, Cortesi I, Parazzini F, Crosignani PG. 
Endometriosis and pelvic pain: relation to disease stage and localization. Fertil 
Steril. 1996 Feb;65(2):299–304.  
69.  Adamson GD, Pasta DJ. Endometriosis fertility index: the new, validated 
endometriosis staging system. Fertil Steril. 2010 Oct;94(5):1609–15.  
  
 425. 
70.  Vercellini P, Fedele L, Aimi G, Pietropaolo G, Consonni D, Crosignani PG. 
Association between endometriosis stage, lesion type, patient characteristics and 
severity of pelvic pain symptoms: a multivariate analysis of over 1000 patients. 
Hum Reprod. Oxford University Press; 2007 Jan;22(1):266–71.  
71.  Ballard K, Seaman H, de Vries C, Wright J. Can symptomatology help in the 
diagnosis of endometriosis? Findings from a national case-control study-Part 1. 
BJOG An Int J Obstet Gynaecol. 2008 Oct;115(11):1382–91.  
72.  Howard FM. Endometriosis and mechanisms of pelvic pain. J Minim Invasive 
Gynecol. 16(5):540–50.  
73.  Schliep KC, Mumford SL, Peterson CM, Chen Z, Johnstone EB, Sharp HT, et al. 
Pain typology and incident endometriosis. Hum Reprod. 2015 Oct;30(10):2427–
38.  
74.  Bulletti C, Coccia ME, Battistoni S, Borini A. Endometriosis and infertility. J Assist 
Reprod Genet [Internet]. Springer; 2010 Aug [cited 2016 Dec 1];27(8):441–7. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/20574791 
75.  Benaglia L, Somigliana E, Vercellini P, Abbiati A, Ragni G, Fedele L. 
Endometriotic ovarian cysts negatively affect the rate of spontaneous ovulation. 
Hum Reprod. 2009 Sep 1;24(9):2183–6.  
76.  Somigliana E, Arnoldi M, Benaglia L, Iemmello R, Nicolosi AE, Ragni G. IVF-ICSI 
outcome in women operated on for bilateral endometriomas. Hum Reprod. 2008 
Apr 18;23(7):1526–30.  
77.  Meuleman C, Tomassetti C, D’Hoore A, Van Cleynenbreugel B, Penninckx F, 
Vergote I, et al. Surgical treatment of deeply infiltrating endometriosis with 
colorectal involvement. Hum Reprod Update. 2011 May 1;17(3):311–26.  
  
 426. 
78.  The Practice Committee of the American Society for Reproductive Medicine. 
Endometriosis and infertility. Vol. 81, Fertility and Sterility. 2004. p. 1441–6.  
79.  Omland AK, Abyholm T, Fedorcsák P, Ertzeid G, Oldereid NB, Bjercke S, et al. 
Pregnancy outcome after IVF and ICSI in unexplained, endometriosis-associated 
and tubal factor infertility. Hum Reprod. 2005 Mar;20(3):722–7.  
80.  Technology S for AR. Clinic summary report. 2010.  
81.  Benaglia L, Somigliana E, Santi G, Scarduelli C, Ragni G, Fedele L. IVF and 
endometriosis-related symptom progression: insights from a prospective study. 
Hum Reprod. 2011 Sep 1;26(9):2368–72.  
82.  WHO. Programme on mental health: WHOQOL, measuring quality of life 
[Internet]. 1997. Available from: http://www.who.int/mental_health/media/68.pdf 
83.  Chen L-C, Hsu J-W, Huang K-L, Bai Y-M, Su T-P, Li C-T, et al. Risk of developing 
major depression and anxiety disorders among women with endometriosis: A 
longitudinal follow-up study. J Affect Disord [Internet]. 2016 Jan 15 [cited 2016 
Dec 1];190:282–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26544610 
84.  Lorençatto C, Petta CA, Navarro MJ, Bahamondes L, Matos A. Depression in 
women with endometriosis with and without chronic pelvic pain. Acta Obstet 
Gynecol Scand [Internet]. 2006 [cited 2016 Dec 1];85(1):88–92. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/16521687 
85.  Petrelluzzi KFS, Garcia MC, Petta CA, Grassi-Kassisse DM, Spadari-Bratfisch 
RC. Salivary cortisol concentrations, stress and quality of life in women with 
endometriosis and chronic pelvic pain. Stress [Internet]. 2008 Jan 7 [cited 2016 
Dec 5];11(5):390–7. Available from: 
http://www.tandfonline.com/doi/full/10.1080/10253890701840610 
  
 427. 
86.  Marques A, Bahamondes L, Aldrighi JM, Petta CA. Quality of life in Brazilian 
women with endometriosis assessed through a medical outcome questionnaire. J 
Reprod Med [Internet]. 2004 Feb [cited 2016 Dec 5];49(2):115–20. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/15018440 
87.  Sepulcri R de P, do Amaral VF. Depressive symptoms, anxiety, and quality of life 
in women with pelvic endometriosis. Eur J Obstet Gynecol Reprod Biol [Internet]. 
2009 Jan [cited 2016 Dec 5];142(1):53–6. Available from: 
http://linkinghub.elsevier.com/retrieve/pii/S0301211508003357 
88.  Stull DE, Wasiak R, Kreif N, Raluy M, Colligs A, Seitz C, et al. Validation of the 
SF-36 in patients with endometriosis. Qual Life Res [Internet]. 2014 Feb 13 [cited 
2016 Dec 5];23(1):103–17. Available from: 
http://link.springer.com/10.1007/s11136-013-0442-5 
89.  Brandes I. Lebensqualität von Endometriose-Patientinnen. Geburtshilfe 
Frauenheilkd. © Georg Thieme Verlag KG Stuttgart · New York; 2007 
Nov;67(11):1227–31.  
90.  Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. 
Fertil Steril. 2012 Sep;98(3):511–9.  
91.  Giudice LC, Kao LC. Endometriosis. Lancet. 2004 Nov;364(9447):1789–99.  
92.  Sensky TE, Liu DT. Endometriosis: associations with menorrhagia, infertility and 
oral contraceptives. Int J Gynaecol Obstet. 17(6):573–6.  
93.  Phipps WR, Cramer DW, Schiff I, Belisle S, Stillman R, Albrecht B, et al. The 
association between smoking and female infertility as influenced by cause of the 
infertility. Fertil Steril. 1987 Sep;48(3):377–82.  
94.  Giudice LC. Clinical practice. Endometriosis. N Engl J Med. 2010 Jun 
  
 428. 
24;362(25):2389–98.  
95.  Hadfield R, Mardon H, Barlow D, Kennedy S. Delay in the diagnosis of 
endometriosis: a survey of women from the USA and the UK. Hum Reprod. 1996 
Apr;11(4):878–80.  
96.  Husby GK, Haugen RS, Moen MH. Diagnostic delay in women with pain and 
endometriosis. Acta Obstet Gynecol Scand. 2003 Jul;82(7):649–53.  
97.  Nnoaham KE, Hummelshoj L, Webster P, d’Hooghe T, de Cicco Nardone F, de 
Cicco Nardone C, et al. Impact of endometriosis on quality of life and work 
productivity: a multicenter study across ten countries. Fertil Steril. 2011 
Aug;96(2):366–373.e8.  
98.  Fauconnier A, Chapron C. Endometriosis and pelvic pain: epidemiological 
evidence of the relationship and implications. Hum Reprod Update. 11(6):595–
606.  
99.  Sinaii N, Plumb K, Cotton L, Lambert A, Kennedy S, Zondervan K, et al. 
Differences in characteristics among 1,000 women with endometriosis based on 
extent of disease. Fertil Steril. NIH Public Access; 2008 Mar;89(3):538–45.  
100.  Falcone T, Lebovic DI. Clinical management of endometriosis. Obstet Gynecol. 
2011 Sep;118(3):691–705.  
101.  Simoens S, Dunselman G, Dirksen C, Hummelshoj L, Bokor A, Brandes I, et al. 
The burden of endometriosis: costs and quality of life of women with 
endometriosis and treated in referral centres. Hum Reprod. 2012 May 
1;27(5):1292–9.  
102.  Nisolle M. Ovarian endometriosis and peritoneal endometriosis: are they different 
entities from a fertility perspective? Curr Opin Obstet Gynecol. 2002 
  
 429. 
Jun;14(3):283–8.  
103.  Chopin N, Vieira M, Borghese B, Foulot H, Dousset B, Coste J, et al. Operative 
management of deeply infiltrating endometriosis: Results on pelvic pain symptoms 
according to a surgical classification. J Minim Invasive Gynecol. 2005 
Apr;12(2):106–12.  
104.  Kennedy S, Bergqvist A, Chapron C, D’Hooghe T, Dunselman G, Greb R, et al. 
ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. 
2005 Oct;20(10):2698–704.  
105.  Roberts CP, Rock JA. The current staging system for endometriosis: does it help? 
Obstet Gynecol Clin North Am. 2003 Mar;30(1):115–32.  
106.  Rogers PAW, D’Hooghe TM, Fazleabas A, Gargett CE, Giudice LC, Montgomery 
GW, et al. Priorities for endometriosis research: recommendations from an 
international consensus workshop. Reprod Sci. 2009 Apr 1;16(4):335–46.  
107.  Dunselman GAJ, Vermeulen N, Becker C, Calhaz-Jorge C, D’Hooghe T, De Bie 
B, et al. ESHRE guideline: Management of women with endometriosis. Hum 
Reprod. 2014;29(3):400–12.  
108.  Spaczynski RZ, Duleba AJ. Diagnosis of endometriosis. Semin Reprod Med. 2003 
May;21(2):193–208.  
109.  Walter AJ, Hentz JG, Magtibay PM, Cornella JL, Magrina JF. Endometriosis: 
correlation between histologic and visual findings at laparoscopy. Am J Obstet 
Gynecol. 2001 Jun;184(7):1407-11; discussion 1411-3.  
110.  Marchino GL, Gennarelli G, Enria R, Bongioanni F, Lipari G, Massobrio M. 
Diagnosis of pelvic endometriosis with use of macroscopic versus histologic 
findings. Fertil Steril. 2005 Jul;84(1):12–5.  
  
 430. 
111.  Rogers PAW, D’Hooghe TM, Fazleabas A, Giudice LC, Montgomery GW, 
Petraglia F, et al. Defining future directions for endometriosis research: workshop 
report from the 2011 World Congress of Endometriosis In Montpellier, France. 
Reprod Sci. SAGE Publications; 2013 May;20(5):483–99.  
112.  Fassbender A, Dorien O, De Moor B. “Biomarkers of endmetriosis” in 
endometriosis: pathogenesis and treatment. 1st ed. Harada T, editor. Berlin: 
Springer; 2014. 321-339 p.  
113.  Luo N, Johnson JA, Shaw JW, Feeny D, Coons SJ. Self-reported health status of 
the general adult U.S. population as assessed by the EQ-5D and Health Utilities 
Index. Med Care. 2005 Nov;43(11):1078–86.  
114.  Bernert S, Fernández A, Haro JM, König H-H, Alonso J, Vilagut G, et al. 
Comparison of Different Valuation Methods for Population Health Status 
Measured by the EQ-5D in Three European Countries. Value Heal. 2009 
Jul;12(5):750–8.  
115.  Sturgeon CM, Duffy MJ, Stenman U-H, Lilja H, Brünner N, Chan DW, et al. 
National Academy of Clinical Biochemistry laboratory medicine practice guidelines 
for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian 
cancers. Clin Chem. 2008 Dec;54(12):e11-79.  
116.  Mol BW, Bayram N, Lijmer JG, Wiegerinck MA, Bongers MY, van der Veen F, et 
al. The performance of CA-125 measurement in the detection of endometriosis: a 
meta-analysis. Fertil Steril. 1998 Dec;70(6):1101–8.  
117.  Barbieri RL, Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, et al. CA-125 
in patients with endometriosis. Fertil Steril. Elsevier; 1986 Jun;45(6):767–9.  
118.  Santulli P, Streuli I, Melonio I, Marcellin L, M’Baye M, Bititi A, et al. Increased 
serum cancer antigen-125 is a marker for severity of deep endometriosis. J Minim 
  
 431. 
Invasive Gynecol. 2015 Feb;22(2):275–84.  
119.  Vodolazkaia A, El-Aalamat Y, Popovic D, Mihalyi A, Bossuyt X, Kyama CM, et al. 
Evaluation of a panel of 28 biomarkers for the non-invasive diagnosis of 
endometriosis. Hum Reprod. 2012 Sep 1;27(9):2698–711.  
120.  Kubatova A, Erdem A, Erdem M, FiratMutlu M, Korucuoglu U. Serum cytokine and 
growth factor levels in patients with endometriosis. Cent Eur J Immunol. 
2013;4:500–4.  
121.  Mohamed ML, El Behery MM, Mansour SAE-A. Comparative study between 
VEGF-A and CA-125 in diagnosis and follow-up of advanced endometriosis after 
conservative laparoscopic surgery. Arch Gynecol Obstet. Springer-Verlag; 2013 
Jan 29;287(1):77–82.  
122.  Thubert T, Santulli P, Marcellin L, Menard S, M’Baye M, Streuli I, et al. 
Measurement of hs-CRP is irrelevant to diagnose and stage endometriosis: 
prospective study of 834 patients. Am J Obstet Gynecol. 2014 Jun;210(6):533.e1-
533.e10.  
123.  Vodolazkaia A, Bossuyt X, Fassbender A, Kyama CM, Meuleman C, Peeraer K, et 
al. A high sensitivity assay is more accurate than a classical assay for the 
measurement of plasma CRP levels in endometriosis. Reprod Biol Endocrinol. 
BioMed Central; 2011 Aug 9;9:113.  
124.  Lermann J, Mueller A, Körber F, Oppelt P, Beckmann MW, Dittrich R, et al. 
Evaluation of high-sensitivity C-reactive protein in comparison with C-reactive 
protein as biochemical serum markers in women with endometriosis. Fertil Steril. 
2010 May;93(7):2125–9.  
125.  Mihalyi A, Gevaert O, Kyama CM, Simsa P, Pochet N, De Smet F, et al. Non-
invasive diagnosis of endometriosis based on a combined analysis of six plasma 
  
 432. 
biomarkers. Hum Reprod. Oxford University Press; 2010 Mar;25(3):654–64.  
126.  Xavier P, Belo L, Beires J, Rebelo I, Martinez-de-Oliveira J, Lunet N, et al. Serum 
levels of VEGF and TNF-α and their association with C-reactive protein in patients 
with endometriosis. Arch Gynecol Obstet. Springer-Verlag; 2006 Jan 
6;273(4):227–31.  
127.  Gupta S, Agarwal A, Krajcir N, Alvarez JG. Role of oxidative stress in 
endometriosis. Reprod Biomed Online. 2006 Jul;13(1):126–34.  
128.  Moran LK, Gutteridge JM, Quinlan GJ. Thiols in cellular redox signalling and 
control. Curr Med Chem. 2001 Jun;8(7):763–72.  
129.  Rosa e Silva JC, do Amara VF, Mendonça JL, Rosa e Silva ACJ de S, Nakao LS, 
Poli Neto OB, et al. Serum markers of oxidative stress and endometriosis. Clin 
Exp Obstet Gynecol. 2014;41(4):371–4.  
130.  Ho H-N, Wu M-Y, Chen S-U, Chao K-H, Chen C-D, Yang Y-S. Total antioxidant 
status and nitric oxide do not increase in peritoneal fluids from women with 
endometriosis. Hum Reprod. 1997;12(12):2810–5.  
131.  Polak G, Wertel I, Kozioł-Montewka M, Tarkowski R, Kotarski J. Investigation of 
glutathione concentrations in peritoneal fluid from women with and without 
endometriosis. Eur J Obstet Gynecol Reprod Biol. 2003 Aug 15;109(2):206–8.  
132.  Ambros V. The functions of animal microRNAs. Nature. Nature Publishing Group; 
2004 Sep 16;431(7006):350–5.  
133.  Ebert MS, Sharp PA. Roles for microRNAs in conferring robustness to biological 
processes. Cell. 2012 Apr 27;149(3):515–24.  
134.  Ramón LA, Braza-Boïls A, Gilabert J, Chirivella M, España F, Estellés A, et al. 
microRNAs related to angiogenesis are dysregulated in endometrioid endometrial 
  
 433. 
cancer. Hum Reprod. Oxford University Press; 2012 Oct;27(10):3036–45.  
135.  Toloubeydokhti T, Pan Q, Luo X, Bukulmez O, Chegini N. The expression and 
ovarian steroid regulation of endometrial micro-RNAs. Reprod Sci. 2008 
Dec;15(10):993–1001.  
136.  Burney RO, Hamilton AE, Aghajanova L, Vo KC, Nezhat CN, Lessey BA, et al. 
MicroRNA expression profiling of eutopic secretory endometrium in women with 
versus without endometriosis. Mol Hum Reprod. Oxford University Press; 2009 
Oct;15(10):625–31.  
137.  Ramon LA, Braza-Boils A, Gilabert-Estelles J, Gilabert J, Espana F, Chirivella M, 
et al. microRNAs expression in endometriosis and their relation to angiogenic 
factors. Hum Reprod. 2011 May 1;26(5):1082–90.  
138.  Dai L, Lou W, Zhu J, Zhou X, Di W. MiR-199a inhibits the angiogenic potential of 
endometrial stromal cells under hypoxia by targeting HIF-1α/VEGF pathway. Int J 
Clin Exp Pathol. e-Century Publishing Corporation; 2015;8(5):4735–44.  
139.  Jia S -z., Yang Y, Lang J, Sun P, Leng J. Plasma miR-17-5p, miR-20a and miR-
22 are down-regulated in women with endometriosis. Hum Reprod. 2013 Feb 
1;28(2):322–30.  
140.  Suryawanshi S, Vlad AM, Lin H-M, Mantia-Smaldone G, Laskey R, Lee M, et al. 
Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-
associated ovarian cancer. Clin Cancer Res. 2013 Mar 1;19(5):1213–24.  
141.  Wang W-T, Zhao Y-N, Han B-W, Hong S-J, Chen Y-Q. Circulating microRNAs 
identified in a genome-wide serum microRNA expression analysis as noninvasive 
biomarkers for endometriosis. J Clin Endocrinol Metab. 2013 Jan;98(1):281–9.  
142.  Aghajanova L, Giudice LC. Molecular evidence for differences in endometrium in 
  
 434. 
severe versus mild endometriosis. Reprod Sci. SAGE Publications; 2011 
Mar;18(3):229–51.  
143.  Tokushige N, Markham R, Russell P, Fraser IS. High density of small nerve fibres 
in the functional layer of the endometrium in women with endometriosis. Hum 
Reprod. 2006 Mar;21(3):782–7.  
144.  Tokushige N, Markham R, Russell P, Fraser IS. Nerve fibres in peritoneal 
endometriosis. Hum Reprod. Oxford University Press; 2006 Nov;21(11):3001–7.  
145.  Tokushige N, Markham R, Russell P, Fraser IS. Different types of small nerve 
fibers in eutopic endometrium and myometrium in women with endometriosis. 
Fertil Steril. 2007;88:795–803.  
146.  Al-Jefout M, Andreadis N, Tokushige N, Markham R, Fraser I, Tokushige N, et al. 
A pilot study to evaluate the relative efficacy of endometrial biopsy and full 
curettage in making a diagnosis of endometriosis by the detection of endometrial 
nerve fibers. Am J Obstet Gynecol. Elsevier; 2007 Dec;197(6):578.e1-578.e4.  
147.  Al-Jefout M, Dezarnaulds G, Cooper M, Tokushige N, Luscombe GM, Markham 
R, et al. Diagnosis of endometriosis by detection of nerve fibres in an endometrial 
biopsy: a double blind study. Hum Reprod. 2009 Dec 1;24(12):3019–24.  
148.  Elgafor el Sharkwy IA. Combination of non-invasive and semi-invasive tests for 
diagnosis of minimal to mild endometriosis. Arch Gynecol Obstet. Springer Berlin 
Heidelberg; 2013 Oct 3;288(4):793–7.  
149.  Boudreaux DA, Chaney J, Maiti TK, Das C. Contribution of active site glutamine to 
rate enhancement in ubiquitin C-terminal hydrolases. FEBS J. Blackwell 
Publishing Ltd; 2012 Mar;279(6):1106–18.  
150.  Zevallos HB-V, McKinnon B, Tokushige N, Mueller MD, Fraser IS, Bersinger NA. 
  
 435. 
Detection of the pan neuronal marker PGP9.5 by immuno-histochemistry and 
quantitative PCR in eutopic endometrium from women with and without 
endometriosis. Arch Gynecol Obstet. 2015 Jan 22;291(1):85–91.  
151.  Gupta D, Hull M, Fraser I, Miller L, Bossuyt P, Johnson N, et al. Endometrial 
biomarkers for the non-invasive diagnosis of endometriosis (Review). Cochrane 
Database Syst Rev. 2016;(4):1–231.  
152.  Tokushige N, Markham R, Crossett B, Ahn SB, Nelaturi VL, Khan A, et al. 
Discovery of a novel biomarker in the urine in women with endometriosis. Fertil 
Steril. 2011 Jan;95(1):46–9.  
153.  Lessey BA, Savaris RF, Ali S, Brophy S, Tomazic-Allen S, Chwalisz K. Diagnostic 
accuracy of urinary cytokeratin 19 fragment for endometriosis. Reprod Sci. SAGE 
Publications; 2015 May;22(5):551–5.  
154.  Matsumoto K, Kanmatsuse K. Elevated vascular endothelial growth factor levels 
in the urine of patients with minimal-change nephrotic syndrome. Clin Nephrol. 
2001 Apr;55(4):269–74.  
155.  Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a 
critical cytokine in tumor angiogenesis and a potential target for diagnosis and 
therapy. J Clin Oncol. 2002 Nov 1;20(21):4368–80.  
156.  Buhimschi CS, Norwitz ER, Funai E, Richman S, Guller S, Lockwood CJ, et al. 
Urinary angiogenic factors cluster hypertensive disorders and identify women with 
severe preeclampsia. Am J Obstet Gynecol. 2005 Mar;192(3):734–41.  
157.  Cho SH, Oh YJ, Nam A, Kim HY, Park JH, Kim JH, et al. Evaluation of serum and 
urinary angiogenic factors in patients with endometriosis. Am J Reprod Immunol. 
Blackwell Publishing Ltd; 2007 Dec;58(6):497–504.  
  
 436. 
158.  Rivera M, Taléns-Visconti R, Sirera R, Bertomeu V, Salvador A, Cortés R, et al. 
Soluble TNF-a and interleukin-6 receptors in the urine of heart failure patients. 
Their clinical value and relationship with plasma levels. Eur J Hear Fail. 
2004;6:877–82.  
159.  Cho S, Choi YS, Yim SY, Yang HI, Jeon YE, Lee KE, et al. Urinary vitamin D-
binding protein is elevated in patients with endometriosis. Hum Reprod. 2012 Feb 
1;27(2):515–22.  
160.  Liu E, Nisenblat V, Farquhar C, Fraser I, Bossuyt PM, Johnson N, et al. Urinary 
biomarkers for the non-invasive diagnosis of endometriosis. In: Nisenblat V, 
editor. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & 
Sons, Ltd; 2015.  
161.  Hudelist G, Ballard K, English J, Wright J, Banerjee S, Mastoroudes H, et al. 
Transvaginal sonography vs. clinical examination in the preoperative diagnosis of 
deep infiltrating endometriosis. Ultrasound Obstet Gynecol. John Wiley & Sons, 
Ltd.; 2011 Apr;37(4):480–7.  
162.  Bazot M, Lafont C, Rouzier R, Roseau G, Thomassin-Naggara I, Daraï E. 
Diagnostic accuracy of physical examination, transvaginal sonography, rectal 
endoscopic sonography, and magnetic resonance imaging to diagnose deep 
infiltrating endometriosis. Fertil Steril. 2009 Dec;92(6):1825–33.  
163.  Abrao MS, Goncalves MO d. C, Dias JA, Podgaec S, Chamie LP, Blasbalg R. 
Comparison between clinical examination, transvaginal sonography and magnetic 
resonance imaging for the diagnosis of deep endometriosis. Hum Reprod. 2007 
Oct 18;22(12):3092–7.  
164.  Carneiro MM, Filogônio ID de S, Costa LMP, de Ávila I, Ferreira MCF. Clinical 
prediction of deeply infiltrating endometriosis before surgery: is it feasible? A 
  
 437. 
review of the literature. Biomed Res Int. Hindawi Publishing Corporation; 
2013;2013:564153.  
165.  Hudelist G, Oberwinkler KH, Singer CF, Tuttlies F, Rauter G, Ritter O, et al. 
Combination of transvaginal sonography and clinical examination for preoperative 
diagnosis of pelvic endometriosis. Hum Reprod. 2009 Feb 27;24(5):1018–24.  
166.  Fratelli N, Scioscia M, Bassi E, Musola M, Minelli L, Trivella G. Transvaginal 
sonography for preoperative assessment of deep endometriosis. J Clin 
Ultrasound. Wiley Subscription Services, Inc., A Wiley Company; 2013 
Feb;41(2):69–75.  
167.  Testa AC, Timmerman D, Van Holsbeke C, Zannoni GF, Fransis S, Moerman P, 
et al. Ovarian cancer arising in endometrioid cysts: ultrasound findings. 
Ultrasound Obstet Gynecol. John Wiley & Sons, Ltd.; 2011 Jul;38(1):99–106.  
168.  Van Holsbeke C, Van Calster B, Guerriero S, Savelli L, Paladini D, Lissoni AA, et 
al. Endometriomas: their ultrasound characteristics. Ultrasound Obstet Gynecol. 
John Wiley & Sons, Ltd.; 2010 Apr 20;35(6):n/a-n/a.  
169.  Redwine DB. Laparoscopic en bloc resection for treatment of the obliterated cul-
de-sac in endometriosis. J Reprod Med. 1992 Aug;37(8):695–8.  
170.  Piketty M, Chopin N, Dousset B, Millischer-Bellaische A-E, Roseau G, Leconte M, 
et al. Preoperative work-up for patients with deeply infiltrating endometriosis: 
transvaginal ultrasonography must definitely be the first-line imaging examination. 
Hum Reprod. 2008 Dec 4;24(3):602–7.  
171.  Guerriero S, Ajossa S, Garau N, Alcazar JL, Mais V, Melis GB. Diagnosis of pelvic 
adhesions in patients with endometrioma: the role of transvaginal 
ultrasonography. Fertil Steril. 2010 Jul;94(2):742–6.  
  
 438. 
172.  Holland TK, Yazbek J, Cutner A, Saridogan E, Hoo WL, Jurkovic D. Value of 
transvaginal ultrasound in assessing severity of pelvic endometriosis. Ultrasound 
Obstet Gynecol. 2010 May 14;36(2):241–8.  
173.  Hudelist G, Fritzer N, Staettner S, Tammaa A, Tinelli A, Sparic R, et al. Uterine 
sliding sign: a simple sonographic predictor for presence of deep infiltrating 
endometriosis of the rectum. Ultrasound Obstet Gynecol. 2013 Jun;41(6):692–5.  
174.  Reid S, Lu C, Hardy N, Casikar I, Reid G, Cario G, et al. Office gel 
sonovaginography for the prediction of posterior deep infiltrating endometriosis: a 
multicenter prospective observational study. Ultrasound Obstet Gynecol. 2014 
Dec;44(6):710–8.  
175.  Coutinho A, Bittencourt LK, Pires CE, Junqueira F, de Oliveira Lima CMA, 
Coutinho E, et al. MR imaging in deep pelvic endometriosis: a pictorial essay. 
RadioGraphics. 2011 Mar;31(2):549–67.  
176.  Hottat N, Larrousse C, Anaf V, Noël J-C, Matos C, Absil J, et al. Endometriosis: 
contribution of 3.0-T pelvic MR imaging in preoperative assessment—initial results 
1.  
177.  Kondo W, Bourdel N, Tamburro S, Cavoli D, Jardon K, Rabischong B, et al. 
Complications after surgery for deeply infiltrating pelvic endometriosis. BJOG An 
Int J Obstet Gynaecol. 2011 Feb;118(3):292–8.  
178.  Gougoutas CA, Siegelman ES, Hunt J, Outwater EK. Pelvic endometriosis: 
various manifestations and MR imaging findings. AJR Am J Roentgenol. 2000 
Aug;175(2):353–8.  
179.  Chamié LP, Blasbalg R, Gonçalves MOC, Carvalho FM, Abrão MS, de Oliveira IS. 
Accuracy of magnetic resonance imaging for diagnosis and preoperative 
assessment of deeply infiltrating endometriosis. Int J Gynecol Obstet. 2009 
  
 439. 
Sep;106(3):198–201.  
180.  Bazot M, Darai E, Hourani R, Thomassin I, Cortez A, Uzan S, et al. Deep pelvic 
endometriosis: MR imaging for diagnosis and prediction of extension of disease. 
Radiology. 2004 Aug;232(2):379–89.  
181.  Roy C, Balzan C, Thoma V, Sauer B, Wattiez A, Leroy J. Efficiency of MR imaging 
to orientate surgical treatment of posterior deep pelvic endometriosis. Abdom 
Imaging. Springer-Verlag; 2009 Apr;34(2):251–9.  
182.  Saba L, Guerriero S, Sulcis R, Pilloni M, Ajossa S, Melis G, et al. MRI and 
“tenderness guided” transvaginal ultrasonography in the diagnosis of recto-
sigmoid endometriosis. J Magn Reson Imaging. 2012 Feb;35(2):352–60.  
183.  Sherif MF, Badawy ME, Elkholi DGEY. Accuracy of magnetic resonance imaging 
in diagnosis of deeply infiltrating endometriosis. Egypt J Radiol Nucl Med. 
2015;46(1):159–65.  
184.  Nisenblat V, Prentice L, Bossuyt PMM, Farquhar C, Hull ML, Johnson N. 
Combination of the non-invasive tests for the diagnosis of endometriosis. 
Cochrane Database of Systematic Reviews. 2016.  
185.  Hudelist G, English J, Thomas AE, Tinelli A, Singer CF, Keckstein J. Diagnostic 
accuracy of transvaginal ultrasound for non-invasive diagnosis of bowel 
endometriosis: Systematic review and meta-analysis. Ultrasound Obstet Gynecol. 
2011;  
186.  Guerriero S, Ajossa S, Minguez JA, Jurado M, Mais V, Melis GB, et al. Accuracy 
of transvaginal ultrasound for diagnosis of deep endometriosis in uterosacral 
ligaments, rectovaginal septum, vagina and bladder: Systematic review and meta-
analysis. Ultrasound Obstet Gynecol. 2015;  
  
 440. 
187.  Guerriero S, Ajossa S, Orozco R, Perniciano M, Jurado M, Melis GB, et al. 
Accuracy of transvaginal ultrasound for diagnosis of deep endometriosis in the 
rectosigmoid: Systematic review and meta-analysis. Ultrasound Obstet Gynecol. 
2016;  
188.  Guerriero S, Saba L, Pascual MA, Ajossa S, Rodriguez I, Mais V, et al. 
Transvaginal ultrasound vs magnetic resonance imaging for diagnosing deep 
infiltrating endometriosis: systematic review and meta-analysis. Ultrasound in 
Obstetrics and Gynecology. 2018.  
189.  Noventa M, Saccardi C, Litta P, Vitagliano A, D’Antona D, Abdulrahim B, et al. 
Ultrasound techniques in the diagnosis of deep pelvic endometriosis: Algorithm 
based on a systematic review and meta-analysis. Fertility and Sterility. 2015.  
190.  Medeiros LR, Rosa MI, Silva BR, Reis ME, Simon CS, Dondossola ER, et al. 
Accuracy of magnetic resonance in deeply infiltrating endometriosis: a systematic 
review and meta-analysis. Arch Gynecol Obstet. 2015;  
191. 
 https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriage
s/conceptionandfertilityrates/datasets/childbearingforwomenbornindifferentyearsre
ferencetable [Internet]. Office for National Statistics, United Kingdom. 2015 [cited 
2017 Aug 28]. Available from: 
https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriage
s/conceptionandfertilityrates/datasets/childbearingforwomenbornindifferentyearsre
ferencetable 
192.  Surinova S, Schiess R, Hüttenhain R, Cerciello F, Wollscheid B, Aebersold R. On 
the development of plasma protein biomarkers. J Proteome Res. 2011 Jan 
7;10(1):5–16.  
  
 441. 
193.  Brown J, Crawford TJ, Allen C, Hopewell S, Prentice A. Nonsteroidal anti-
inflammatory drugs for pain in women with endometriosis. Vol. 2017, Cochrane 
Database of Systematic Reviews. 2017.  
194.  Ferreira RA, Vieira CS, Rosa-e-Silva JC, Sá Rosa-e-Silva ACJ, Nogueira AA, 
Ferriani RA. Effects of the levonorgestrel-releasing intrauterine system on 
cardiovascular risk markers in patients with endometriosis: a comparative study 
with the GnRH analogue. Contraception. 2010 Feb;81(2):117–22.  
195.  Gomes MKO, Ferriani RA, Rosa e Silva JC, Japur de Sá Rosa e Silva AC, Vieira 
CS, Cândido dos Reis FJ. The levonorgestrel-releasing intrauterine system and 
endometriosis staging. Fertil Steril. 2007 May;87(5):1231–4.  
196.  Petta CA. Randomized clinical trial of a levonorgestrel-releasing intrauterine 
system and a depot GnRH analogue for the treatment of chronic pelvic pain in 
women with endometriosis. Hum Reprod. 2005 May 19;20(7):1993–8.  
197.  Jain S, Dalton ME. Chocolate cysts from ovarian follicles. Fertil Steril. 1999 
Nov;72(5):852–6.  
198.  Rodgers AK, Falcone T. Treatment strategies for endometriosis. Expert Opin 
Pharmacother. 2008 Feb 17;9(2):243–55.  
199.  Meresman GF, Augé L, Barañao RI, Lombardi E, Tesone M, Sueldo C. Oral 
contraceptives suppress cell proliferation and enhance apoptosis of eutopic 
endometrial tissue from patients with endometriosis. Fertil Steril. 2002 
Jun;77(6):1141–7.  
200.  Vercellini P, Somigliana E, Daguati R, Vigano P, Meroni F, Crosignani PG, et al. 
Postoperative oral contraceptive exposure and risk of endometrioma recurrence. 
Am J Obstet Gynecol. Elsevier; 2008 May;198(5):504.e1-504.e5.  
  
 442. 
201.  Seracchioli R, Mabrouk M, Frascà C, Manuzzi L, Montanari G, Keramyda A, et al. 
Long-term cyclic and continuous oral contraceptive therapy and endometrioma 
recurrence: a randomized controlled trial. Fertil Steril. 2010 Jan;93(1):52–6.  
202.  Vercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R, Crosignani PG. 
Continuous use of an oral contraceptive for endometriosis-associated recurrent 
dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril. 2003 
Sep;80(3):560–3.  
203.  Vercellini P, Trespidi L, Colombo A, Vendola N, Marchini M, Crosignani PG. A 
gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for 
pelvic pain associated with endometriosis. Fertil Steril. 1993 Jul;60(1):75–9.  
204.  Soysal S, Soysal ME, Ozer S, Gul N, Gezgin T. The effects of post-surgical 
administration of goserelin plus anastrozole compared to goserelin alone in 
patients with severe endometriosis: a prospective randomized trial. Hum Reprod. 
2004 Jan;19(1):160–7.  
205.  Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain 
associated with endometriosis. In: Brown J, editor. Cochrane Database of 
Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2010.  
206.  Vercellini P, Crosignani PG, Fadini R, Radici E, Belloni C, Sismondi P. A 
gonadotrophin-releasing hormone agonist compared with expectant management 
after conservative surgery for symptomatic endometriosis. Br J Obstet Gynaecol. 
1999 Jul;106(7):672–7.  
207.  Bergqvist A, Jacobson J, Harris S. A double-blind randomized study of the 
treatment of endometriosis with nafarelin or nafarelin plus norethisterone. Gynecol 
Endocrinol. 1997 Jun;11(3):187–94.  
208.  Mäkäräinen L, Rönnberg L, Kauppila A. Medroxyprogesterone acetate 
  
 443. 
supplementation diminishes the hypoestrogenic side effects of gonadotropin-
releasing hormone agonist without changing its efficacy in endometriosis. Fertil 
Steril. 1996 Jan;65(1):29–34.  
209.  Moghissi KS, Schlaff WD, Olive DL, Skinner MA, Yin H. Goserelin acetate 
(Zoladex) with or without hormone replacement therapy for the treatment of 
endometriosis. Fertil Steril. 1998 Jun;69(6):1056–62.  
210.  Taskin O, Yalcinoglu AI, Kucuk S, Uryan I, Buhur A, Burak F. Effectiveness of 
tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients 
with endometriosis. Fertil Steril. 1997 Jan;67(1):40–5.  
211.  Al Kadri H, Hassan S, Al-Fozan HM, Hajeer A. Hormone therapy for 
endometriosis and surgical menopause. In: Al Kadri H, editor. Cochrane Database 
of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2009.  
212.  Moghissi KS. Pseudopregnancy induced by estrogen-progestogen or 
progestogens alone in the treatment of endometriosis. Prog Clin Biol Res. 1990;  
213.  Kistner  robert W. The use of newer progestins in the treatment of endometriosis. 
Am J Obstet Gynecol. 1958;  
214.  Brown J, Kives S, Akhtar M. Progestagens and anti-progestagens for pain 
associated with endometriosis. In: Cochrane Database of Systematic Reviews. 
2012.  
215.  Carvalho N, Margatho D, Cursino K, Benetti-Pinto CL, Bahamondes L. Control of 
endometriosis-associated pain with etonogestrel-releasing contraceptive implant 
and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial. 
Fertil Steril. 2018;  
216.  Liao SJ. The origin of the five elements in the traditional theorem of acupuncture: 
  
 444. 
A preliminary brief historic enquiry. Acupunct Electro-Therapeutics Res. 
1992;17(1):7–14.  
217.  Zhu X, Hamilton KD, McNicol ED. Acupuncture for pain in endometriosis. In: Zhu 
X, editor. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley 
& Sons, Ltd; 2011.  
218.  Huang YH, Cao LX SY. Effect of huoxue huayu xiaozheng method on expression 
of MMP˙9 and TIMP˙3 in patients with endometriosis. ninth Natl Acad Semin 
Chinese Gynecol. 2009;321–5.  
219.  Xu X. Clinical observation of the treatment of endometriosis using Hua Yu Zhi 
Tong pills. J Cheng Du Univ TCM. 2004;2:1–3.  
220.  Flower A, Liu JP, Lewith G, Little P, Li Q. Chinese herbal medicine for 
endometriosis. In: Flower A, editor. Cochrane Database of Systematic Reviews 
[Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2012 [cited 2016 Dec 5]. p. 
CD006568. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22592712 
221.  Jacobson TZ, Duffy JM, Barlow DH, Koninckx PR, Garry R. Laparoscopic surgery 
for pelvic pain associated with endometriosis. In: Jacobson TZ, editor. Cochrane 
Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2009.  
222.  Crosignani PG, Vercellini P, Biffignandi F, Costantini W, Cortesi I, Imparato E. 
Laparoscopy versus laparotomy in conservative surgical treatment for severe 
endometriosis. Fertil Steril. 1996 Nov;66(5):706–11.  
223.  Healey M, Ang WC, Cheng C. Surgical treatment of endometriosis: a prospective 
randomized double-blinded trial comparing excision and ablation. Fertil Steril. 
2010 Dec;94(7):2536–40.  
224.  Wright J, Lotfallah H, Jones K, Lovell D. A randomized trial of excision versus 
  
 445. 
ablation for mild endometriosis. Fertil Steril. 2005 Jun;83(6):1830–6.  
225.  Proctor M, Latthe P, Farquhar C, Khan K, Johnson N. Surgical interruption of 
pelvic nerve pathways for primary and secondary dysmenorrhoea. In: Proctor M, 
editor. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & 
Sons, Ltd; 2005.  
226.  Koninckx PR, Martin D. Treatment of deeply infiltrating endometriosis. Curr Opin 
Obstet Gynecol. 1994 Jun;6(3):231–41.  
227.  Porpora MG, Koninckx PR, Piazze J, Natili M, Colagrande S, Cosmi E V. 
Correlation between endometriosis and pelvic pain. J Am Assoc Gynecol 
Laparosc. 1999 Nov;6(4):429–34.  
228.  Chapron C, Fauconnier A, Dubuisson J-B, Barakat H, Vieira M, Bréart G. Deep 
infiltrating endometriosis: relation between severity of dysmenorrhoea and extent 
of disease. Hum Reprod. 2003 Apr;18(4):760–6.  
229.  De Cicco C, Corona R, Schonman R, Mailova K, Ussia A, Koninckx P. Bowel 
resection for deep endometriosis: a systematic review. BJOG An Int J Obstet 
Gynaecol. 2011 Feb;118(3):285–91.  
230.  Redwine DB, Wright JT. Laparoscopic treatment of complete obliteration of the 
cul-de-sac associated with endometriosis: long-term follow-up of en bloc 
resection. Fertil Steril. 2001 Aug;76(2):358–65.  
231.  Vercellini P, Somigliana E, Consonni D, Frattaruolo MP, De Giorgi O, Fedele L. 
Surgical versus medical treatment for endometriosis-associated severe deep 
dyspareunia: I. Effect on pain during intercourse and patient satisfaction. Hum 
Reprod. 2012 Dec 1;27(12):3450–9.  
232.  Ferrero S, Alessandri F, Racca A, Leone Roberti Maggiore U. Treatment of pain 
  
 446. 
associated with deep endometriosis: alternatives and evidence. Fertil Steril. 2015 
Oct;104(4):771–92.  
233.  Donnez J, Squifflet J. Complications, pregnancy and recurrence in a prospective 
series of 500 patients operated on by the shaving technique for deep rectovaginal 
endometriotic nodules. Hum Reprod. 2010 Aug 1;25(8):1949–58.  
234.  Iversen ML, Seyer-Hansen M, Forman A. Does surgery for deep infiltrating bowel 
endometriosis improve fertility? A systematic review. Vol. 96, Acta Obstetricia et 
Gynecologica Scandinavica. 2017. p. 688–93.  
235.  Martin DC. Hysterectomy for treatment of pain associated with endometriosis. J 
Minim Invasive Gynecol. 2006 Nov;13(6):566–72.  
236.  Abbott JA, Hawe J, Clayton RD, Garry R. The effects and effectiveness of 
laparoscopic excision of endometriosis: a prospective study with 2-5 year follow-
up. Hum Reprod. 2003 Sep;18(9):1922–7.  
237.  Fuchs F, Raynal P, Salama S, Guillot E, Le Tohic A, Chis C, et al. Reproductive 
outcome after laparoscopic treatment of endometriosis in an infertile population. J 
Gynecol Obstet Biol Reprod (Paris). 2007 Jun;36(4):354–9.  
238.  Hart RJ, Hickey M, Maouris P, Buckett W. Excisional surgery versus ablative 
surgery for ovarian endometriomata. In: Hart RJ, editor. Cochrane Database of 
Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2008.  
239.  Tsoumpou I, Kyrgiou M, Gelbaya TA, Nardo LG. The effect of surgical treatment 
for endometrioma on in vitro fertilization outcomes: a systematic review and meta-
analysis. Fertil Steril. 2009 Jul;92(1):75–87.  
240.  Benschop L, Farquhar C, van der Poel N, Heineman MJ. Interventions for women 
with endometrioma prior to assisted reproductive technology. In: Benschop L, 
  
 447. 
editor. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & 
Sons, Ltd; 2010.  
241.  Yang C, Geng Y, Li Y, Chen C, Gao Y. Impact of ovarian endometrioma on 
ovarian responsiveness and IVF: a systematic review and meta-analysis. Reprod 
Biomed Online. 2015 Jul;31(1):9–19.  
242.  Hamdan M, Dunselman G, Li TC, Cheong Y. The impact of endometrioma on 
IVF/ICSI outcomes: a systematic review and meta-analysis. Hum Reprod Update. 
21(6):809–25.  
243.  Nezhat C, Crowgey S, Nezhat F. Videolaseroscopy for the treatment of 
endometriosis associated with infertility. Fertil Steril. 1989 Feb;51(2):237–40.  
244.  Vercellini P, Fedele L, Aimi G, De Giorgi O, Consonni D, Crosignani PG. 
Reproductive performance, pain recurrence and disease relapse after 
conservative surgical treatment for endometriosis: the predictive value of the 
current classification system. Hum Reprod. 2006 Oct 1;21(10):2679–85.  
245.  Vercellini P, Somigliana E, Vigano P, Abbiati A, Barbara G, Crosignani PG. 
Surgery for endometriosis-associated infertility: a pragmatic approach. Hum 
Reprod. 2009 Feb 1;24(2):254–69.  
246.  Zhu S, Liu D, Huang W, Wang Q, Wang Q, Zhou L, et al. Post-laparoscopic oral 
contraceptive combined with Chinese herbal mixture in treatment of infertility and 
pain associated with minimal or mild endometriosis: a randomized controlled trial. 
BMC Complement Altern Med. BioMed Central; 2014 Jul 5;14:222.  
247.  Alkatout I, Mettler L, Beteta C, Hedderich J, Jonat W, Schollmeyer T, et al. 
Combined Surgical and Hormone Therapy for Endometriosis is the Most Effective 
Treatment: Prospective, Randomized, Controlled Trial. J Minim Invasive Gynecol. 
2013 Jul;20(4):473–81.  
  
 448. 
248.  Hoo WL, Stavroulis A, Pateman K, Saridogan E, Cutner A, Pandis G, et al. Does 
ovarian suspension following laparoscopic surgery for endometriosis reduce 
postoperative adhesions? An RCT. Hum Reprod. 2014 Apr 1;29(4):670–6.  
249.  Koninckx PR, Corona R, Timmerman D, Verguts J, Adamyan L. Peritoneal full-
conditioning reduces postoperative adhesions and pain: a randomised controlled 
trial in deep endometriosis surgery. J Ovarian Res. 2013;6(1):90.  
250.  Zhao R, Liu Y, Tan Y, Hao Z, Meng Q, Wang R, et al. Chinese medicine improves 
postoperative quality of life in endometriosis patients: A randomized controlled 
trial. Chin J Integr Med. 2013 Jan 29;19(1):15–21.  
251.  Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The 
impact of outcome reporting bias in randomised controlled trials on a cohort of 
systematic reviews. BMJ. 2010 Feb 15;340(feb15 1):c365–c365.  
252.  May KE, Conduit-Hulbert SA, Villar J, Kirtley S, Kennedy SH, Becker CM. 
Peripheral biomarkers of endometriosis: a systematic review. Hum Reprod 
Update. 2010 Nov 1;16(6):651–74.  
253.  Culley L, Law C, Hudson N, Denny E, Mitchell H, Baumgarten M, et al. The social 
and psychological impact of endometriosis on women’s lives: a critical narrative 
review. Hum Reprod Update. 2013 Nov 1;19(6):625–39.  
254.  Barbieri RL, Niloff JM, Bast RC, Scaetzl E, Kistner RW, Knapp RC. Elevated 
serum concentrations of CA-125 in patients with advanced endometriosis. Fertil 
Steril. 1986 May;45(5):630–4.  
255.  Abrão MS, Podgaec S, Filho BM, Ramos LO, Pinotti JA, de Oliveira RM. The use 
of biochemical markers in the diagnosis of pelvic endometriosis. Hum Reprod. 
1997 Nov;12(11):2523–7.  
  
 449. 
256.  Fedele L, Arcaini L, Vercellini P, Marchini M, Baglioni A, Bianchi S. Serum Ca-125 
concentrations in endometriosis. Acta Eur Fertil. 20(3):137–9.  
257.  Gürgan T, Kişnişçi H, Yarali H, Aksu T, Zeyneloğlu H, Develioğlu O. Serum and 
peritoneal fluid CA-125 levels in early stage endometriosis. Gynecol Obstet Invest. 
1990;30(2):105–8.  
258.  Fisk NM, Tan CE. CA 125 in peritoneal fluid and serum of patients with 
endometriosis. Eur J Obstet Gynecol Reprod Biol. 1988 Oct;29(2):153–8.  
259.  Berral J, Puertas P, Avisbal M, Capote C, Casas J, Velsaco A, et al. Niveles 
sericos de CA-125 y CA 19.9 en el diagnostico de pacientes con sospecha clinica 
de endometriosis. Rev Esp Med Nucl. 1996;15:71–6.  
260.  Yang H, Zhu L, Wang S, Lang J, Xu T. Noninvasive diagnosis of moderate to 
severe endometriosis: the platelet-lymphocyte ratio cannot be a neoadjuvant 
biomarker for serum cancer antigen 125. J Minim Invasive Gynecol. 22(3):373–7.  
261.  Kitawaki J, Ishihara H, Koshiba H, Kiyomizu M, Teramoto M, Kitaoka Y, et al. 
Usefulness and limits of CA-125 in diagnosis of endometriosis without associated 
ovarian endometriomas. Hum Reprod. Oxford University Press; 2005 
Jul;20(7):1999–2003.  
262.  CHO S, CHO H, NAM A, KIM H, CHOI Y, PARK K, et al. Neutrophil-to-lymphocyte 
ratio as an adjunct to CA-125 for the diagnosis of endometriosis. Fertil Steril. 2008 
Dec;90(6):2073–9.  
263.  Gajbhiye R, Sonawani A, Khan S, Suryawanshi A, Kadam S, Warty N, et al. 
Identification and validation of novel serum markers for early diagnosis of 
endometriosis. Hum Reprod. 2012 Feb 1;27(2):408–17.  
264.  Kurdoglu Z, Gursoy R, Kurdoglu M, Erdem M, Erdem O, Erdem A. Comparison of 
  
 450. 
the clinical value of CA 19-9 versus CA 125 for the diagnosis of endometriosis. 
Fertil Steril. 2009 Nov;92(5):1761–3.  
265.  Bilibio JP, Cunha-Filho JSL. Serum Prolactin and CA-125 Levels as Biomarkers of 
Peritoneal Endometriosis. Gynecol Obstet Invest. Karger Publishers; 
2016;81(1):96.  
266.  Moretuzzo RW, DiLauro S, Jenison E, Chen SL, Reindollar RH, McDonough PG. 
Serum and peritoneal lavage fluid CA-125 levels in endometriosis. Fertil Steril. 
1988 Sep;50(3):430–3.  
267.  Lanzone A, Marana R, Muscatello R, Fulghesu AM, Dell’Acqua S, Caruso A, et al. 
Serum CA-125 levels in the diagnosis and management of endometriosis. J 
Reprod Med. 1991 Aug;36(8):603–7.  
268.  Ozakşit G, Cağlar T, Ciçek N, Kuşçu E, Batioğlu S, Gökmen O. Serum CA 125 
levels before, during and after treatment for endometriosis. Int J Gynaecol Obstet. 
1995 Sep;50(3):269–73.  
269.  Jing J, Qiao Y, Suginami H, Taniguchi F, Shi H, Wang X. Two novel serum 
biomarkers for endometriosis screened by surface-enhanced laser 
desorption/ionization time-of-flight mass spectrometry and their change after 
laparoscopic removal of endometriosis. Fertil Steril. 2009 Oct;92(4):1221–7.  
270.  Adamyan L V, Fanchenko ND, Alexeyeva ML, Andreyeva YeN, Novikov YeA, 
Jahan I. Hormonal and immunologic methods in the diagnosis and treatment of 
patients with benign ovarian tumors and endometriotic cysts. Int J Fertil. 38(2):92–
8.  
271.  Sayan CD, Özakşit MG, Sarikaya E, Eryilmaz ÖG, Mollamahmutoğlu L, Deveer R. 
Serum interleukin-8, CA-125 levels, neutrophil-to-lymphocyte ratios, and 
combined markers in the diagnosis of endometriosis. Turk J Med Sci. 
  
 451. 
2013;43:417–23.  
272.  Molo MW, Kelly M, Radwanska E, Binor Z. Preoperative serum CA-125 and CA-
72 in predicting endometriosis in infertility patients. J Reprod Med. 1994 
Dec;39(12):964–6.  
273.  Tokmak A, Ugur M, Tonguc E, Var T, Moraloğlu O, Ozaksit G. The value of 
urocortin and Ca-125 in the diagnosis of endometrioma. Arch Gynecol Obstet. 
2011 May 18;283(5):1075–9.  
274.  Amaral VF do, Ferriani RA, Sá MFS de, Nogueira AA, Rosa e Silva JC, Rosa e 
Silva ACJ de S, et al. Positive correlation between serum and peritoneal fluid CA-
125 levels in women with pelvic endometriosis. Sao Paulo Med J. 2006 Jul 
6;124(4):223–7.  
275.  Chen FP, Soong YK, Lee N, Lo SK. The use of serum CA-125 as a marker for 
endometriosis in patients with dysmenorrhea for monitoring therapy and for 
recurrence of endometriosis. Acta Obstet Gynecol Scand. 1998 Jul;77(6):665–70.  
276.  Salehpour S, Sene AA, Mehrjerdi EK, Akhoond MR. The Correlation between 
Serum and Peritoneal Fluid CA125 Level in Women with Pelvic Endometriosis. 
2009;3(1).  
277.  Moloney MD, Thornton JG, Cooper EH. Serum CA 125 antigen levels and disease 
severity in patients with endometriosis. Obstet Gynecol. 1989 May;73(5 Pt 1):767–
9.  
278.  O’Shaughnessy A, Check JH, Nowroozi K, Lurie D. CA 125 levels measured in 
different phases of the menstrual cycle in screening for endometriosis. Obstet 
Gynecol. 1993 Jan;81(1):99–103.  
279.  Koninckx PR, Riittinen L, Seppala M CF. CA-125 and Placental Protein 14 
  
 452. 
Concentrations in Plasma and Peritoneal Fluid of Women With Deeply Infiltrating 
Pelvic Endometriosis. Fertil Steril. 1992;57:523–30.  
280.  Colacurci N, Fortunato N, De Franciscis P, Cardone A. Relevance of CA-125 in 
the evaluation of endometriosis. Clin Exp Obstet Gynecol. 1996;23(3):150–4.  
281.  Muscatello R, Cucinelli F, Fulghesu A, Lanzone A, Caruso A, Mancuso S. Multiple 
serum marker assay in the diagnosis of endometriosis. Gynecol Endocrinol. 1992 
Dec;6(4):265–9.  
282.  Medl M, Ogris E, Peters-Engl C, Mierau M, Buxbaum P, Leodolter S. Serum levels 
of the tumour-associated trypsin inhibitor in patients with endometriosis. BJOG An 
Int J Obstet Gynaecol. Blackwell Publishing Ltd; 1997 Jan;104(1):78–81.  
283.  Takahashi K, Nagata H, Musa AA, Shibukawa T, Yamasaki H, Kitao M. Clinical 
usefulness of CA-125 levels in the menstrual discharge in patients with 
endometriosis. Fertil Steril. 1990 Aug;54(2):360–2.  
284.  Koninckx PR, Meuleman C, Oosterlynck D, Cornillie FJ. Diagnosis of deep 
endometriosis by clinical examination during menstruation and plasma CA-125 
concentration. Fertil Steril. 1996 Feb;65(2):280–7.  
285.  Kruitwagen RF, Thomas C, Poels LG, Koster AM, Willemsen WN, Rolland R. High 
CA-125 concentrations in peritoneal fluid of normal cyclic women with various 
infertility-related factors as demonstrated with two-step immunoradiometric assay. 
Fertil Steril. 1991 Nov;56(5):863–9.  
286.  Ismail MA, Rotmensch J, Mercer LJ, Block BS, Salti GI, Holt JA. CA-125 in 
peritoneal fluid from patients with nonmalignant gynecologic disorders. J Reprod 
Med. 1994 Jul;39(7):510–2.  
287.  Bianchi M, Macaya R, Durruty G, Manzur A. Correlation between CA-125 marker 
  
 453. 
with the presence and severity of pelvic endometriosis. Rev Med Chil. 2003 
Apr;131(4):367–72.  
288.  Harada T, Kubota T, Aso T. Usefulness of CA19-9 versus CA125 for the diagnosis 
of endometriosis. Fertil Steril. 2002 Oct;78(4):733–9.  
289.  Nabeta M, Abe Y, Haraguchi R, Kito K, Kusanagi Y, Ito M. Serum anti-PDIK1L 
autoantibody as a novel marker for endometriosis. Fertil Steril. 2010 
Dec;94(7):2552–2557.e1.  
290.  Nabeta M, Abe Y, Takaoka Y, Kusanagi Y, Ito M. Identification of anti-syntaxin 5 
autoantibody as a novel serum marker of endometriosis. J Reprod Immunol. 2011 
Sep;91(1–2):48–55.  
291.  Ozhan E, Kokcu A, Yanik K, Gunaydin M. Investigation of diagnostic potentials of 
nine different biomarkers in endometriosis. Eur J Obstet Gynecol Reprod Biol. 
2014 Jul;178:128–33.  
292.  Penninx J, Brandes M, de Bruin JP, Schneeberger PM, Hamilton CJCM. 
Prediction of pelvic pathology in subfertile women with combined Chlamydia 
antibody and CA-125 tests. Eur J Obstet Gynecol Reprod Biol. 2009 
Dec;147(2):178–82.  
293.  Rosa e Silva ACJS, Rosa e Silva JC, Ferriani RA. Serum CA-125 in the diagnosis 
of endometriosis. Int J Gynecol Obstet. 2007 Mar;96(3):206–7.  
294.  Seeber B, Sammel MD, Fan X, Gerton GL, Shaunik A, Chittams J, et al. 
Proteomic analysis of serum yields six candidate proteins that are differentially 
regulated in a subset of women with endometriosis. Fertil Steril. NIH Public 
Access; 2010 May 1;93(7):2137–44.  
295.  Socolov R, Butureanu S, Angioni S, Sindilar A, Boiculese L, Cozma L, et al. The 
  
 454. 
value of serological markers in the diagnosis and prognosis of endometriosis: a 
prospective case–control study. Eur J Obstet Gynecol Reprod Biol. 2011 
Feb;154(2):215–7.  
296.  Xavier P, Beires J, Belo L, Rebelo I, Martinez-de-Oliveira J, Lunet N, et al. Are we 
employing the most effective CA 125 and CA 19-9 cut-off values to detect 
endometriosis? Eur J Obstet Gynecol Reprod Biol. 2005 Dec 1;123(2):254–5.  
297.  Gagné D, Rivard M, Pagé M, Lépine M, Platon C, Shazand K, et al. Development 
of a nonsurgical diagnostic tool for endometriosis based on the detection of 
endometrial leukocyte subsets and serum CA-125 levels. Fertil Steril. 2003 
Oct;80(4):876–85.  
298.  Pittaway DE, Fayez JA. The use of CA-125 in the diagnosis and management of 
endometriosis. Fertil Steril. 1986 Nov;46(5):790–5.  
299.  Barbati A, Cosmi E V, Spaziani R, Ventura R, Montanino G. Serum and peritoneal 
fluid CA-125 levels in patients with endometriosis. Fertil Steril. 1994 
Mar;61(3):438–42.  
300.  Patton PE, Field CS, Harms RW, Coulam CB. CA-125 levels in endometriosis. 
Fertil Steril. 1986 Jun;45(6):770–3.  
301.  Hornstein MD, Harlow BL, Thomas PP, Check JH. Use of a new CA 125 assay in 
the diagnosis of endometriosis. Hum Reprod. 1995 Apr;10(4):932–4.  
302.  Shen A, Xu S, Ma Y, Guo H, Li C, Yang C, et al. Diagnostic value of serum 
CA125, CA19-9 and CA15-3 in endometriosis: A meta-analysis. J Int Med Res. 
2015 Oct 1;43(5):599–609.  
303.  Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting 
items for systematic reviews and meta-analyses: the PRISMA statement. PLoS 
  
 455. 
Med. 2009 Jul 21;6(7):e1000097.  
304.  Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. 
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy 
studies. Ann Intern Med. 2011 Oct 18;155(8):529–36.  
305.  Ramos IM de L, Podgaec S, Abrão MS, Oliveira R de, Baracat EC. Evaluation of 
CA-125 and soluble CD-23 in patients with pelvic endometriosis: a case-control 
study. Rev Assoc Med Bras. 58(1):26–32.  
306.  Kraśnicki D. Serum and peritoneal fluid CA-125 concentration in women with 
endometriosis. Ginekol Pol. 2001 Dec;72(12A):1365–9.  
307.  Bischof P. What do we know about the origin of CA 125? Eur J Obstet Gynecol 
Reprod Biol. 1993 Apr;49(1–2):93–8.  
308.  Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman 
AH. Bivariate analysis of sensitivity and specificity produces informative summary 
measures in diagnostic reviews. J Clin Epidemiol. 2005 Oct;58(10):982–90.  
309.  Wild RA, Hirisave V, Bianco A, Podczaski ES, Demers LM. Endometrial 
antibodies versus CA-125 for the detection of endometriosis. Fertil Steril. 1991 
Jan;55(1):90–4.  
310.  Florio P, Reis FM, Torres PB, Calonaci F, Abrao MS, Nascimento LL, et al. High 
serum follistatin levels in women with ovarian endometriosis. Hum Reprod. 2009 
Oct 1;24(10):2600–6.  
311.  WHO | Hinari Eligibility [Internet]. WHO. World Health Organization; 2016. 
Available from: http://www.who.int/hinari/eligibility/en/ 
312.  Janssen EB, Rijkers ACM, Hoppenbrouwers K, Meuleman C, D’Hooghe TM. 
Prevalence of endometriosis diagnosed by laparoscopy in adolescents with 
  
 456. 
dysmenorrhea or chronic pelvic pain: A systematic review. Hum Reprod Update. 
2013;19(5):570–82.  
313.  Leeflang MMG. Systematic reviews and meta-analyses of diagnostic test 
accuracy. Clinical Microbiology and Infection. 2014.  
314.  Hornstein MD, Thomas PP, Gleason RE, Barbieri RL. Menstrual cyclicity of CA-
125 in patients with endometriosis. Fertil Steril. 1992 Aug;58(2):279–83.  
315.  Hirsch M, Duffy J, Davis C, Nieves Plana M, Khan K. The diagnostic accuracy of 
cancer antigen 125 for endometriosis: a systematic review and meta-analysis. 
BJOG An Int J Obstet Gynaecol. 2016 Oct;123(11):1761–8.  
316.  Fassbender A, Vodolazkaia A, Saunders P, Lebovic D, Waelkens E, De Moor B, 
et al. Biomarkers of endometriosis. Fertil Steril. 2013 Mar;99(4):1135–45.  
317.  Fassbender A, Burney RO, F. O D, D’Hooghe T, Giudice L, Fassbender A, et al. 
Update on biomarkers for the detection of endometriosis. Biomed Res Int. Hindawi 
Publishing Corporation; 2015;2015:1–14.  
318.  Jacobs I. Screening for ovarian cancer by CA-125 measurement. Vol. 331, The 
Lancet. Elsevier; 1988. p. 889.  
319.  Zegers-Hochschild F, Adamson GD, de Mouzon J, Ishihara O, Mansour R, 
Nygren K, et al. International committee for monitoring assisted reproductive 
technology (ICMART) and the World Health Organization (WHO) revised glossary 
of ART terminology, 2009. Fertil Steril. 2009 Nov;92(5):1520–4.  
320.  Caraguel CGB, Vanderstichel R. The two-step Fagan’s nomogram: ad hoc 
interpretation of a diagnostic test result without calculation. Evid Based Med. 2013 
Aug;18(4):125–8.  
321.  Masahashi T, Matsuzawa K, Ohsawa M, Narita O, Asai T, Ishihara M. Serum CA 
  
 457. 
125 levels in patients with endometriosis: changes in CA 125 levels during 
menstruation. Obstet Gynecol. 1988 Sep;72(3 Pt 1):328–31.  
322.  Khan KN, Fujishita A, Kitajima M, Hiraki K, Nakashima M, Masuzaki H. Occult 
microscopic endometriosis: Undetectable by laparoscopy in normal peritoneum. 
Hum Reprod. 2014;29(3):462–72.  
323.  Hirsch M, Davis CJ. Preoperative assessment and diagnosis of endometriosis: are 
we any closer? Curr Opin Obs Gynecol. 2015 Aug;27(4):284–90.  
324.  Altman DG. The scandal of poor medical research. Bmj. 1994;308(6924):283–4.  
325.  Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical 
trials. A survey of three medical journals. N Engl J Med. 1987 Aug 13;317(7):426–
32.  
326.  Patient-Centered Outcomes Research Institute. Preliminary draft methodology 
report. Z Evid Fortbild Qual Gesundhwes. 2012;106(7):496–9.  
327.  Core Outcome Measures in Effectiveness Trials. COMET initiative [Internet]. [cited 
2013 Dec 30]. Available from: www.comet-initiative.org 
328.  Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. 
The PRISMA statement for reporting systematic reviews and meta-analyses of 
studies that evaluate health care interventions: explanation and elaboration. PLoS 
Med. Public Library of Science; 2009 Jul 21;6(7):e1000100.  
329.  Cochrane Community. Cochrane Central Register of Controlled Trials (CENTRAL) 
[Internet]. Available from: http://community.cochrane.org/editorial-and-publishing-
policy-resource 
330.  Handler A, Kennelly J, Peacock NR. Reducing racial/ethnic disparities in 
reproductive and perinatal outcomes : the evidence from population-based 
  
 458. 
interventions. Springer; 2011. 7-20 p.  
331.  Harman NL, Bruce IA, Callery P, Tierney S, Sharif MO, O’Brien K, et al. MOMENT 
– Management of Otitis Media with Effusion in Cleft Palate: protocol for a 
systematic review of the literature and identification of a core outcome set using a 
Delphi survey. Trials. 2013;14(1):70.  
332.  Abu Hashim H, El Rakhawy M, Abd Elaal I. Randomized comparison of 
superovulation with letrozole vs. clomiphene citrate in an IUI program for women 
with recently surgically treated minimal to mild endometriosis. Acta Obstet 
Gynecol Scand. 2012 Mar;91(3):338–45.  
333.  Acién P, Quereda F, Campos A, Gomez-Torres M-J, Velasco I, Gutierrez M. Use 
of intraperitoneal interferon alpha-2b therapy after conservative surgery for 
endometriosis and postoperative medical treatment with depot gonadotropin-
releasing hormone analog: a randomized clinical trial. Fertil Steril. 2002 
Oct;78(4):705–11.  
334.  Alborzi S, Momtahan M, Parsanezhad ME, Dehbashi S, Zolghadri J, Alborzi S. A 
prospective, randomized study comparing laparoscopic ovarian cystectomy 
versus fenestration and coagulation in patients with endometriomas. Fertil Steril. 
2004 Dec;82(6):1633–7.  
335.  Alborzi S, Ravanbakhsh R, Parsanezhad ME, Alborzi M, Alborzi S, Dehbashi S. A 
comparison of follicular response of ovaries to ovulation induction after 
laparoscopic ovarian cystectomy or fenestration and coagulation versus normal 
ovaries in patients with endometrioma. Fertil Steril. 2007 Aug;88(2):507–9.  
336.  Alborzi S, Hamedi B, Omidvar A, Dehbashi S, Alborzi S, Alborzi M. A comparison 
of the effect of short-term aromatase inhibitor (letrozole) and GnRH agonist 
(triptorelin) versus case control on pregnancy rate and symptom and sign 
  
 459. 
recurrence after laparoscopic treatment of endometriosis. Arch Gynecol Obstet. 
2011 Jul 27;284(1):105–10.  
337.  Audebert A, Descamps P, Marret H, Ory-Lavollee L, Bailleul F, Hamamah S. Pre 
or post-operative medical treatment with nafarelin in stage III-IV endometriosis: a 
French multicenter study. Eur J Obstet Gynecol Reprod Biol. 1998 
Aug;79(2):145–8.  
338.  Ballester M, Chereau E, Dubernard G, Coutant C, Bazot M, Daraï E. Urinary 
dysfunction after colorectal resection for endometriosis: results of a prospective 
randomized trial comparing laparoscopy to open surgery. Am J Obstet Gynecol. 
2011 Apr;204(4):303.e1-303.e6.  
339.  Beretta P, Franchi M, Ghezzi F, Busacca M, Zupi E, Bolis P. Randomized clinical 
trial of two laparoscopic treatments of endometriomas: cystectomy versus 
drainage and coagulation. Fertil Steril. 1998 Dec;70(6):1176–80.  
340.  Bianchi S, Busacca M, Agnoli B, Candiani M, Calia C, Vignali M. Effects of 3 
month therapy with danazol after laparoscopic surgery for stage III/IV 
endometriosis: a randomized study. Hum Reprod. 1999 May;14(5):1335–7.  
341.  Busacca M, Somigliana E, Bianchi S, De Marinis S, Calia C, Candiani M, et al. 
Post-operative GnRH analogue treatment after conservative surgery for 
symptomatic endometriosis stage III-IV: a randomized controlled trial. Hum 
Reprod. 2001 Nov;16(11):2399–402.  
342.  Candiani GB, Fedele L, Vercellini P, Bianchi S, Di Nola G. Presacral neurectomy 
for the treatment of pelvic pain associated with endometriosis: a controlled study. 
Am J Obstet Gynecol. 1992 Jul;167(1):100–3.  
343.  Cobellis L, Castaldi MA, Giordano V, Trabucco E, De Franciscis P, Torella M, et 
al. Effectiveness of the association micronized N-Palmitoylethanolamine (PEA)–
  
 460. 
transpolydatin in the treatment of chronic pelvic pain related to endometriosis after 
laparoscopic assessment: a pilot study. Eur J Obstet Gynecol Reprod Biol. 2011 
Sep;158(1):82–6.  
344.  Cosson M, Querleu D, Donnez J, Madelenat P, Konincks P, Audebert A, et al. 
Dienogest is as effective as triptorelin in the treatment of endometriosis after 
laparoscopic surgery: results of a prospective, multicenter, randomized study. 
Fertil Steril. 2002 Apr;77(4):684–92.  
345.  Costello MF, Abbott J, Katz S, Vancaillie T, Wilson S. A prospective, randomized, 
double-blind, placebo-controlled trial of multimodal intraoperative analgesia for 
laparoscopic excision of endometriosis. Fertil Steril. 2010 Jul;94(2):436–43.  
346.  Creus M, Fabregues F, Carmona F, del Pino M, Manau D, Balasch J. Combined 
laparoscopic surgery and pentoxifylline therapy for treatment of endometriosis-
associated infertility: a preliminary trial. Hum Reprod. 2008 May 15;23(8):1910–6.  
347.  Daraï E, Dubernard G, Coutant C, Frey C, Rouzier R, Ballester M. Randomized 
Trial of Laparoscopically Assisted Versus Open Colorectal Resection for 
Endometriosis: morbidity, symptoms, quality of life and fertility. Ann Surg. 2010 
Jun;251(6):1018–23.  
348.  Daraï E, Lesieur B, Dubernard G, Rouzier R, Bazot M, Ballester M. Fertility after 
colorectal resection for endometriosis: results of a prospective study comparing 
laparoscopy with open surgery. Fertil Steril. 2011 May;95(6):1903–8.  
349.  diZerega GS, Coad J, Donnez J. Clinical evaluation of endometriosis and 
differential response to surgical therapy with and without application of 
Oxiplex/AP* adhesion barrier gel. Fertil Steril. 2007 Mar;87(3):485–9.  
350.  Jarrell J, Mohindra R, Ross S, Taenzer P, Brant R. Laparoscopy and reported 
pain among patients with endometriosis. J Obstet Gynaecol Can. 2005 
  
 461. 
May;27(5):477–85.  
351.  Kamencic H, Thiel JA. Pentoxifylline After Conservative Surgery for 
Endometriosis: A Randomized, Controlled Trial. J Minim Invasive Gynecol. 2008 
Jan;15(1):62–6.  
352.  Lalchandani S, Baxter A, Phillips K. Is helium thermal coagulator therapy for the 
treatment of women with minimal to moderate endometriosis cost-effective? A 
prospective randomised controlled trial. Gynecol Surg. Springer-Verlag; 2005 Dec 
17;2(4):255–8.  
353.  Loverro G, Carriero C, Rossi AC, Putignano G, Nicolardi V, Selvaggi L. A 
randomized study comparing triptorelin or expectant management following 
conservative laparoscopic surgery for symptomatic stage III–IV endometriosis. Eur 
J Obstet Gynecol Reprod Biol. 2008 Feb;136(2):194–8.  
354.  Mais V, Ajossa S, Marongiu D, Peiretti RF, Guerriero S, Melis GB. Reduction of 
adhesion reformation after laparoscopic endometriosis surgery: a randomized trial 
with an oxidized regenerated cellulose absorbable barrier. Obstet Gynecol. 1995 
Oct;86(4 Pt 1):512–5.  
355.  Marcoux S, Maheux R, Bérubé S. Laparoscopic surgery in infertile women with 
minimal or mild endometriosis. Canadian Collaborative Group on Endometriosis. 
N Engl J Med. 1997 Jul 24;337(4):217–22.  
356.  Matorras R, Elorriaga MA, Pijoan JI, Ramón O, Rodríguez-Escudero FJ. 
Recurrence of endometriosis in women with bilateral adnexectomy (with or without 
total hysterectomy) who received hormone replacement therapy. Fertil Steril. 2002 
Feb;77(2):303–8.  
357.  Moini A, Bahar L, Ashrafinia M, Eslami B, Hosseini R, Ashrafinia N. Fertility 
outcome after operative laparoscopy versus no treatment in infertile women with 
  
 462. 
minimal or mild endometriosis. Int J Fertil Steril. Royan Institute; 2012 
Jan;5(4):235–40.  
358.  Morgante G, Ditto A, La Marca A, De Leo V. Low-dose danazol after combined 
surgical and medical therapy reduces the incidence of pelvic pain in women with 
moderate and severe endometriosis. Hum Reprod. 1999 Sep;14(9):2371–4.  
359.  Nowroozi K, Chase JS, Check JH, Wu CH. The importance of laparoscopic 
coagulation of mild endometriosis in infertile women. Int J Fertil. 32(6):442–4.  
360.  Parazzini F, Fedele L, Busacca M, Falsetti L, Pellegrini S, Venturini PL, et al. 
Postsurgical medical treatment of advanced endometriosis: results of a 
randomized clinical trial. Am J Obstet Gynecol. 1994 Nov;171(5):1205–7.  
361.  Parazzini F. Ablation of lesions or no treatment in minimal-mild endometriosis in 
infertile women: a randomized trial. Gruppo Italiano per lo Studio 
dell’Endometriosi. Hum Reprod. 1999 May;14(5):1332–4.  
362.  Seiler JC, Gidwani G, Ballard L. Laparoscopic cauterization of endometriosis for 
fertility: a controlled study. Fertil Steril. 1986 Dec;46(6):1098–100.  
363.  Surrey MW, Hill DL. Treatment of endometriosis by carbon dioxide laser during 
gamete intrafallopian transfer. J Am Coll Surg. 1994 Oct;179(4):440–2.  
364.  Sutton CJ, Ewen SP, Whitelaw N, Haines P. Prospective, randomized, double-
blind, controlled trial of laser laparoscopy in the treatment of pelvic pain 
associated with minimal, mild, and moderate endometriosis. Fertil Steril. 1994 
Oct;62(4):696–700.  
365.  Sutton CJ, Pooley AS, Ewen SP, Haines P. Follow-up report on a randomized 
controlled trial of laser laparoscopy in the treatment of pelvic pain associated with 
minimal to moderate endometriosis. Fertil Steril. 1997 Dec;68(6):1070–4.  
  
 463. 
366.  Sutton C J, Pooley AS, Jones KD, Dover RW HP. A prospective, randomized, 
double-blind controlled trial of laparoscopic uterine nerve ablation in the treatment 
of pelvic pain associated with endometriosis. Gynaecol Endosc. 2001;10((4)):217–
222.  
367.  Tanmahasamut P, Rattanachaiyanont M, Angsuwathana S, Techatraisak K, 
Indhavivadhana S, Leerasiri P. Postoperative levonorgestrel-releasing intrauterine 
system for pelvic endometriosis-related pain: a randomized controlled trial. Obstet 
Gynecol. 2012 Mar;119(3):519–26.  
368.  Telimaa S. Danazol and medroxyprogesterone acetate inefficacious in the 
treatment of infertility in endometriosis. Fertil Steril. 1988 Dec;50(6):872–5.  
369.  Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, Chuang J, Seow K-M. Short-term 
postoperative GnRH analogue or danazol treatment after conservative surgery for 
stage III or IV endometriosis before ovarian stimulation: a prospective, 
randomized study. J Reprod Med. 2004 Dec;49(12):955–9.  
370.  Vercellini P, De Giorgi O, Mosconi P, Stellato G, Vicentini S, Crosignani PG. 
Cyproterone acetate versus a continuous monophasic oral contraceptive in the 
treatment of recurrent pelvic pain after conservative surgery for symptomatic 
endometriosis. Fertil Steril. 2002 Jan;77(1):52–61.  
371.  Vercellini P, Aimi G, Busacca M, Apolone G, Uglietti A, Crosignani PG. 
Laparoscopic uterosacral ligament resection for dysmenorrhea associated with 
endometriosis: results of a randomized, controlled trial. Fertil Steril. 2003 
Aug;80(2):310–9.  
372.  Vercellini P, Frontino G, De Giorgi O, Aimi G, Zaina B, Crosignani PG. 
Comparison of a levonorgestrel-releasing intrauterine device versus expectant 
management after conservative surgery for symptomatic endometriosis: a pilot 
  
 464. 
study. Fertil Steril. 2003 Aug;80(2):305–9.  
373.  Wickstrom K, Bruse C, Sjosten A, Spira J, Edelstam G. Pertubation with 
lignocaine as a new treatment of dysmenorrhea due to endometriosis: a 
randomized controlled trial. Hum Reprod. 2012 Mar 1;27(3):695–701.  
374.  Zhao R, Hao Z, Zhang Y, Lian F, Sun W, Liu Y, et al. Controlling the recurrence of 
pelvic endometriosis after a conservative operation: Comparison between 
Chinese herbal medicine and western medicine. Chin J Integr Med. 2013 Nov 
22;19(11):820–5.  
375.  Zullo F, Palomba S, Zupi E, Russo T, Morelli M, Cappiello F, et al. Effectiveness 
of presacral neurectomy in women with severe dysmenorrhea caused by 
endometriosis who were treated with laparoscopic conservative surgery: a 1-year 
prospective randomized double-blind controlled trial. Am J Obstet Gynecol. 2003 
Jul;189(1):5–10.  
376.  Abbott J, Hawe J, Hunter D, Holmes M, Finn P, Garry R. Laparoscopic excision of 
endometriosis: A randomized, placebo-controlled trial. Fertil Steril. 2004 
Oct;82(4):878–84.  
377.  Tirlapur SA, Riordain RN, Khan KS. Variations in the reporting of outcomes used 
in systematic reviews of treatment effectiveness research in bladder pain 
syndrome. Eur J Obstet Gynecol Reprod Biol. 2014 Sep;180:61–7.  
378.  Simpson RC, Thomas KS, Murphy R. Outcome measures for vulval skin 
conditions: a systematic review of randomized controlled trials. Br J Dermatol. 
2013 Sep;169(3):494–501.  
379.  Chalmers I, Glasziou P, Liberati A, Scherer R, Langenberg P, Elm E von, et al. 
Avoidable waste in the production and reporting of research evidence. Lancet 
(London, England). Elsevier; 2009 Jul 4;374(9683):86–9.  
  
 465. 
380.  Song F, Parekh S, Hooper L, Loke Y, Ryder J, Sutton A, et al. Dissemination and 
publication of research findings: an updated review of related biases. Health 
Technol Assess (Rockv). 2010 Feb;14(8).  
381.  Kirkham JJ, Gargon E, Clarke M, Williamson PR. Can a core outcome set improve 
the quality of systematic reviews? – a survey of the Co-ordinating Editors of 
Cochrane review groups. Trials. 2013;14(1):21.  
382.  Khan K, O’Donovan P, Williamson P, Altman D, Blazeby J, Clarke M, et al. The 
CROWN initiative: journal editors invite researchers to develop core outcomes in 
women’s health. BMC Pregnancy Childbirth. BioMed Central; 2014 Dec 
23;14(1):199.  
383.  Duffy JM, Arambage K, Correa FJ, Olive D, Farquhar C, Garry R, et al. 
Laparoscopic surgery for endometriosis. In: Duffy JM, editor. Cochrane Database 
of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2014.  
384.  Hirsch M, Duffy JMN, Kusznir JO, Davis CJ, Plana MN, Khan KS. Variation in 
outcome reporting in endometriosis trials: a systematic review. Am J Obstet 
Gynecol. 2016 Apr;214(4):452–64.  
385.  Eysenbach G, Kohler C. What is the prevalence of health-related searches on the 
World Wide Web? Qualitative and quantitative analysis of search engine queries 
on the internet. AMIA . Annu Symp proceedings AMIA Symp. American Medical 
Informatics Association; 2003;2003:225–9.  
386.  Mackey TK, Liang BA, Kohler JC, Attaran A. Health domains for sale: the need for 
global health Internet governance. J Med Internet Res. JMIR Publications Inc.; 
2014 Mar 5;16(3):e62.  
387.  HANDFIELD B, TURNBULL S, BELL RJ. What do obstetricians think about media 
influences on their patients? Aust New Zeal J Obstet Gynaecol. 2006 
  
 466. 
Oct;46(5):379–83.  
388.  Kaicker J, Debono VB, Dang W, Buckley N, Thabane L. Assessment of the quality 
and variability of health information on chronic pain websites using the DISCERN 
instrument. BMC Med. 2010 Dec 12;8(1):59.  
389.  Hesse BW, Nelson DE, Kreps GL, Croyle RT, Arora NK, Rimer BK, et al. Trust 
and sources of health information: the impact of the Internet and its implications 
for health care providers: findings from the first Health Information National Trends 
Survey. Arch Intern Med. 165(22):2618–24.  
390.  Cline RJ, Haynes KM. Consumer health information seeking on the Internet: the 
state of the art. Health Educ Res. 2001 Dec;16(6):671–92.  
391.  Berkman ND, Sheridan SL, Donahue KE, Halpern DJ, Crotty K. Low health 
literacy and health outcomes: an updated systematic review. Ann Intern Med. 
2011 Jul 19;155(2):97–107.  
392.  Sacchetti P, Zvara P, Plante MK. The Internet and patient education--resources 
and their reliability: focus on a select urologic topic. Urology. 1999 
Jun;53(6):1117–20.  
393.  McMullan M. Patients using the Internet to obtain health information: how this 
affects the patient-health professional relationship. Patient Educ Couns. 2006 
Oct;63(1–2):24–8.  
394.  Benigeri M, Pluye P. Shortcomings of health information on the Internet. Health 
Promot Int. 2003 Dec;18(4):381–6.  
395.  Higgins J, Green S. Cochrane handbook for systematic reviews of interventions 
version 5.1.0 [updated March 2011] [Internet]. The Cochrane database of 
systematic reviews. 2011. Available from: www.cochrane-handbook.org 
  
 467. 
396.  J A, R G, FM P, J R, H R. White paper: criteria for assessing the quality of health 
information on the internet. 1997;  
397.  Charnock D, Shepperd S, Needham G, Gann R. DISCERN: an instrument for 
judging the quality of written consumer health information on treatment choices. J 
Epidemiol Community Health. BMJ Group; 1999 Feb;53(2):105–11.  
398.  JP K, RP Jr F, RL R, BS C. Derivation of new readability formulas (Automated 
Readability Index, Fog Count and Flesch Reading Ease Formula) for Navy 
enlisted personnel. Memphis, TN. Nav Air Stn. 1975;  
399.  Hirsch M, MR B, E P, C B, CJ D, JMN D. Diagnosis and management of 
endometriosis: a systematic review of international and national guidelines. 
Submitt Publ to Obstet Gynacology, Oct 2016.  
400.  Fisher JH, O’Connor D, Flexman AM, Shapera S, Ryerson CJ. Accuracy and 
Reliability of Internet Resources for Information on Idiopathic Pulmonary Fibrosis. 
Am J Respir Crit Care Med. 2016 Jul 15;194(2):218–25.  
401.  Tirlapur SA, Leiu C, Khan KS. Quality of information on the internet related to 
bladder pain syndrome: a systematic review of the evidence. Int Urogynecol J. 
2013 Aug 20;24(8):1257–62.  
402.  Education SNC for. National Assessment of Adult Literacy (NAAL). National 
Center for Education Statistics; [cited 2008 Aug 6]; Available from: 
http://nces.ed.gov/naal 
403.  Bernstam E V., Shelton DM, Walji M, Meric-Bernstam F. Instruments to assess 
the quality of health information on the World Wide Web: what can our patients 
actually use? Int J Med Inform. 2005 Jan;74(1):13–9.  
404.  Duffy JMN, Johnson N, Ahmad G, Watson A. Postoperative procedures for 
  
 468. 
improving fertility following pelvic reproductive surgery. In: Watson A, editor. 
Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, 
Ltd; 2009.  
405.  McHugh ML. Interrater reliability: the kappa statistic. Biochem medica. 
2012;22(3):276–82.  
406.  Department of Health and Human Services US. Healthy People 2010: 
Understanding and Improving Health. 2nd ed. U.S. Government Printing office; 
2010.  
407.  Crocco AG, Villasis-Keever M, Jadad AR. Analysis of cases of harm associated 
with use of health information on the internet. JAMA. 2002 Jun 5;287(21):2869–
71.  
408.  Meric F, Bernstam E V, Mirza NQ, Hunt KK, Ames FC, Ross MI, et al. Breast 
cancer on the world wide web: cross sectional survey of quality of information and 
popularity of websites. BMJ. 2002 Mar 9;324(7337):577–81.  
409.  Management C, For G. P R AC T I C E BUL L E T I N Management of 
Endometriosis. 2010;116(1):223–36.  
410.  English HTM, Endometriosis D. CNGOF Guidelines for the Management of 
Endometriosis Anatomoclinical forms of endometriosis Clinical and biological 
assessment of endometriosis. 2007;1–9.  
411.  Hirsch M. Hormone therapy for teh menopause after endometriosis surgery - 
friend or foe? [Internet]. Evidently Cochrane. 2015. Available from: 
http://www.evidentlycochrane.net/hormone-therapy-menopause-endometriosis-
surgery-friend-foe/ 
412.  de Ziegler D, Borghese B, Chapron C. Endometriosis and infertility: 
  
 469. 
pathophysiology and management. Lancet. 2010 Aug;376(9742):730–8.  
413.  Grol R, Dalhuijsen J, Thomas S, Veld C, Rutten G, Mokkink H. Attributes of 
clinical guidelines that influence use of guidelines in general practice: 
observational study. BMJ. 1998 Sep 26;317(7162):858–61.  
414.  Neumann I, Brignardello-Petersen R, Wiercioch W, Carrasco-Labra A, Cuello C, 
Akl E, et al. The GRADE evidence-to-decision framework: a report of its testing 
and application in 15 international guideline panels. Implement Sci. 2015 Dec 
15;11(1):93.  
415.  Patient Safety – Making it Happen! Luxembourg Declaration on Patient Safety. 
2005;  
416.  Shaneyfelt TM, Mayo-Smith MF, Rothwangl J. Are guidelines following 
guidelines? The methodological quality of clinical practice guidelines in the peer-
reviewed medical literature. JAMA. 1999 May 26;281(20):1900–5.  
417.  Grilli R, Magrini N, Penna A, Mura G, Liberati A. Practice guidelines developed by 
specialty societies: the need for a critical appraisal. Lancet. 2000 
Jan;355(9198):103–6.  
418.  Burgers JS, Fervers B, Haugh M, Brouwers M, Browman G, Philip T, et al. 
International assessment of the quality of clinical practice guidelines in oncology 
using the Appraisal of Guidelines and Research and Evaluation Instrument. J Clin 
Oncol. 2004 May 15;22(10):2000–7.  
419.  Grol R. Successes and failures in the implementation of evidence-based 
guidelines for clinical practice. Med Care. 2001 Aug;39(8 Suppl 2):II46-54.  
420.  Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a 
systematic review of rigorous evaluations. Lancet (London, England). 1993 Nov 
  
 470. 
27;342(8883):1317–22.  
421.  Appleyard TL, Mann CH, Khan KS. Guidelines for the management of pelvic pain 
associated with endometriosis: A systematic appraisal of their quality. BJOG An 
Int J Obstet Gynaecol. 2006;113(7):749–57.  
422.  AGREE Collaboration. Development and validation of an international appraisal 
instrument for assessing the quality of clinical practice guidelines: the AGREE 
project. Qual Saf Health Care. 2003 Feb;12(1):18–23.  
423.  Johnson NP, Hummelshoj L. Consensus on current management of 
endometriosis. Hum Reprod. 2013;28(6):1552–68.  
424.  Practice bulletin no. 114: management of endometriosis. Obstet Gynecol. 2010 
Jul;116(1):223–36.  
425.  Koch J, Rowan K, Rombauts L, Yazdani A, Chapman M, Johnson N. 
Endometriosis and Infertility - A consensus statement from ACCEPT (Australasian 
CREI Consensus Expert Panel on Trial evidence). Aust New Zeal J Obstet 
Gynaecol. 2012;52(6):513–22.  
426.  Ulrich U, Buchweitz O, Greb R, Keckstein J, von Leffern I, Oppelt P, et al. National 
German Guideline (S2k): Guideline for the Diagnosis and Treatment of 
Endometriosis: Long Version - AWMF Registry No. 015-045. Geburtshilfe 
Frauenheilkd. 2014;74(12):1104–18.  
427.  Leyland N, Casper R, Laberge P, Singh SS, SOGC. Endometriosis: diagnosis and 
management. J Obstet Gynaecol Can. 2010 Jul;32(7 Suppl 2):S1-32.  
428.  Vercellini P, Giudice LC, Evers JLH, Abrao MS. Reducing low-value care in 
endometriosis between limited evidence and unresolved issues: a proposal. Hum 
Reprod. 2015 Sep;30(9):1996–2004.  
  
 471. 
429.  Murthy L, Shepperd S, Clarke MJ, Garner SE, Lavis JN, Perrier L, et al. 
Interventions to improve the use of systematic reviews in decision-making by 
health system managers, policy makers and clinicians. In: Shepperd S, editor. 
Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, 
Ltd; 2012.  
430.  Guidelines I of M (US) C on S for DTCP, Graham R, Mancher M, Wolman DM, 
Greenfield S, Steinberg E. Clinical Practice Guidelines We Can Trust. Clinical 
Practice Guidelines We Can Trust. National Academies Press (US); 2011.  
431.  Prusova K, Churcher L, Tyler A, Lokugamage AU. Royal College of Obstetricians 
and Gynaecologists guidelines: how evidence-based are they? J Obstet 
Gynaecol. Informa Healthcare; 2014 Nov;34(8):706–11.  
432.  Gagliardi AR, Brouwers MC. Do guidelines offer implementation advice to target 
users? A systematic review of guideline applicability. BMJ Open. British Medical 
Journal Publishing Group; 2015 Feb 18;5(2):e007047.  
433.  Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. 
Development of AMSTAR: a measurement tool to assess the methodological 
quality of systematic reviews. BMC Med Res Methodol. BioMed Central; 2007 Dec 
15;7(1):10.  
434.  Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, et al. 
Developing core outcome sets for clinical trials: issues to consider. Trials. BioMed 
Central; 2012 Aug 6;13:132.  
435.  Brosens I a, Puttemans PJ, Deprest J. The endoscopic localization of endometrial 
implants in the ovarian chocolate cyst. Fertil Steril [Internet]. 1994;61(6):1034–8. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/8194613 
436.  Vercellini P, Chapron C, De Giorgi O, Consonni D, Frontino G, Crosignani PG. 
  
 472. 
Coagulation or excision of ovarian endometriomas? Vol. 188, American Journal of 
Obstetrics and Gynecology. 2003. p. 606–10.  
437.  Busacca M, Vignali M. Ovarian endometriosis: from pathogenesis to surgical 
treatment. Curr Opin Obstet Gynecol. 2003 Aug;15(4):321–6.  
438.  Ferrero S, Arena E, Morando A, Remorgida V. Prevalence of newly diagnosed 
endometriosis in women attending the general practitioner. Int J Gynecol Obstet. 
2010 Sep;110(3):203–7.  
439.  Shah D. Diminished Ovarian Reserve and Endometriosis: Insult upon Injury. 
Semin Reprod Med. 2013 Feb 27;31(02):144–9.  
440.  Somigliana E, Berlanda N, Benaglia L, Viganò P, Vercellini P, Fedele L. Surgical 
excision of endometriomas and ovarian reserve: a systematic review on serum 
antimüllerian hormone level modifications. Fertil Steril. 2012 Dec;98(6):1531–8.  
441.  Raffi F, Metwally M, Amer S. The impact of excision of ovarian endometrioma on 
ovarian reserve: a systematic review and meta-analysis. J Clin Endocrinol Metab. 
2012 Sep;97(9):3146–54.  
442.  Gelbaya TA, Gordts S, D’Hooghe TM, Gergolet M, Nardo LG. Management of 
endometrioma prior to IVF: compliance with ESHRE guidelines. Reprod Biomed 
Online. 2010 Sep;21(3):325–30.  
443.  Streuli I, de Ziegler D, Gayet V, Santulli P, Bijaoui G, de Mouzon J, et al. In 
women with endometriosis anti-Müllerian hormone levels are decreased only in 
those with previous endometrioma surgery. Hum Reprod. 2012 Nov;27(11):3294–
303.  
444.  Esinler I, Bozdag G, Aybar F, Bayar U, Yarali H. Outcome of in vitro 
fertilization/intracytoplasmic sperm injection after laparoscopic cystectomy for 
  
 473. 
endometriomas. Fertil Steril. 2006 Jun;85(6):1730–5.  
445.  Benaglia L, Somigliana E, Vighi V, Ragni G, Vercellini P, Fedele L. Rate of severe 
ovarian damage following surgery for endometriomas. Hum Reprod. 2010 Mar 
1;25(3):678–82.  
446.  Almog B, Sheizaf B, Shalom-Paz E, Shehata F, Al-Talib A, Tulandi T, et al. Effects 
of excision of ovarian endometrioma on the antral follicle count and collected 
oocytes for in vitro fertilization. Fertil Steril. Elsevier; 2010 Nov;94(6):2340–2.  
447.  The Practice Committee of the American Society for Reproductive Medicine. 
Endometriosis and infertility: a committee opinion.  
448.  Kim JY, Jee BC, Suh CS, Kim SH. Preoperative serum anti-mullerian hormone 
level in women with ovarian endometrioma and mature cystic teratoma. Yonsei 
Med J. 2013 Jul;54(4):921–6.  
449.  Uncu G, Kasapoglu I, Ozerkan K, Seyhan A, Oral Yilmaztepe A, Ata B. 
Prospective assessment of the impact of endometriomas and their removal on 
ovarian reserve and determinants of the rate of decline in ovarian reserve. Hum 
Reprod. 2013 Aug 1;28(8):2140–5.  
450.  Somigliana E, Infantino M, Benedetti F, Arnoldi M, Calanna G, Ragni G. The 
presence of ovarian endometriomas is associated with a reduced responsiveness 
to gonadotropins. Fertil Steril. 2006 Jul;86(1):192–6.  
451.  Maneschi F, Marasá L, Incandela S, Mazzarese M, Zupi E. Ovarian cortex 
surrounding benign neoplasms: a histologic study. Am J Obstet Gynecol. 1993 
Aug;169(2 Pt 1):388–93.  
452.  Schubert B, Canis M, Darcha C, Artonne C, Pouly J-L, Déchelotte P, et al. Human 
ovarian tissue from cortex surrounding benign cysts: a model to study ovarian 
  
 474. 
tissue cryopreservation.  
453.  Kitajima M, Defrère S, Dolmans M-M, Colette S, Squifflet J, Van Langendonckt A, 
et al. Endometriomas as a possible cause of reduced ovarian reserve in women 
with endometriosis. Fertil Steril. 2011 Sep;96(3):685–91.  
454.  Kuroda M, Kuroda K, Arakawa A, Fukumura Y, Kitade M, Kikuchi I, et al. 
Histological assessment of impact of ovarian endometrioma and laparoscopic 
cystectomy on ovarian reserve. J Obstet Gynaecol Res. 2012 Sep;38(9):1187–93.  
455.  Esinler I, Bozdag G, Arikan I, Demir B, Yarali H. Endometrioma ≤3 cm in diameter 
per se does not affect ovarian reserve in intracytoplasmic sperm injection cycles. 
Gynecol Obstet Invest. 2012;74(4):261–4.  
456.  Almog B, Shehata F, Sheizaf B, Tan SL, Tulandi T. Effects of ovarian 
endometrioma on the number of oocytes retrieved for in vitro fertilization. Fertil 
Steril. 2011 Feb;95(2):525–7.  
457.  Benaglia L, Pasin R, Somigliana E, Vercellini P, Ragni G, Fedele L. Unoperated 
ovarian endometriomas and responsiveness to hyperstimulation. Hum Reprod. 
2011 Jun 1;26(6):1356–61.  
458.  Benaglia L, Bermejo A, Somigliana E, Faulisi S, Ragni G, Fedele L, et al. In vitro 
fertilization outcome in women with unoperated bilateral endometriomas. Fertil 
Steril. 2013 May;99(6):1714–9.  
459.  Horikawa T, Nakagawa K, Ohgi S, Kojima R, Nakashima A, Ito M, et al. The 
frequency of ovulation from the affected ovary decreases following laparoscopic 
cystectomy in infertile women with unilateral endometrioma during a natural cycle. 
J Assist Reprod Genet. Springer; 2008 Jun;25(6):239–44.  
460.  Nelson SM, Anderson RA, Broekmans FJ, Raine-Fenning N, Fleming R, La Marca 
  
 475. 
A. Anti-Müllerian hormone: clairvoyance or crystal clear? Hum Reprod. 2012 
Mar;27(3):631–6.  
461.  Nelson SM. Biomarkers of ovarian response: current and future applications. Fertil 
Steril. 2013 Mar;99(4):963–9.  
462.  Alborzi S, Keramati P, Younesi M, Samsami A, Dadras N. The impact of 
laparoscopic cystectomy on ovarian reserve in patients with unilateral and bilateral 
endometriomas. Fertil Steril. 2014 Feb;101(2):427–34.  
463.  Celik HG, Dogan E, Okyay E, Ulukus C, Saatli B, Uysal S, et al. Effect of 
laparoscopic excision of endometriomas on ovarian reserve: serial changes in the 
serum antimüllerian hormone levels. Fertil Steril. 2012 Jun;97(6):1472–8.  
464.  Urman B, Alper E, Yakin K, Oktem O, Aksoy S, Alatas C, et al. Removal of 
unilateral endometriomas is associated with immediate and sustained reduction in 
ovarian reserve. Reprod Biomed Online. 2013 Aug;27(2):212–6.  
465.  Kwon SK, Kim SH, Yun S-C, Kim DY, Chae HD, Kim C-H, et al. Decline of serum 
antimüllerian hormone levels after laparoscopic ovarian cystectomy in 
endometrioma and other benign cysts: a prospective cohort study. Fertil Steril. 
2014 Feb;101(2):435–41.  
466.  Hirokawa W, Iwase A, Goto M, Takikawa S, Nagatomo Y, Nakahara T, et al. The 
post-operative decline in serum anti-Mullerian hormone correlates with the 
bilaterality and severity of endometriosis. Hum Reprod. 2011 Apr 1;26(4):904–10.  
467.  Tang Y, Chen S-L, Chen X, He Y-X, Ye D-S, Guo W, et al. Ovarian damage after 
laparoscopic endometrioma excision might be related to the size of cyst. Fertil 
Steril. 2013 Aug;100(2):464–9.  
468.  Chang HJ, Han SH, Lee JR, Jee BC, Lee BI, Suh CS, et al. Impact of 
  
 476. 
laparoscopic cystectomy on ovarian reserve: serial changes of serum anti-
Müllerian hormone levels. Fertil Steril. 2010 Jun;94(1):343–9.  
469.  Suksompong S, Dejarkom S, Petyim S, Dangrat C, Orachon D, Choavaratana R. 
Ovarian reserve evaluation by anti-mullerian hormone in women undergoing 
laparoscopic cystectomy of endometrioma. J Med Assoc Thai. 2012 
Nov;95(11):1389–95.  
470.  Sugita A, Iwase A, Goto M, Nakahara T, Nakamura T, Kondo M, et al. One-year 
follow-up of serum antimüllerian hormone levels in patients with cystectomy: are 
different sequential changes due to different mechanisms causing damage to the 
ovarian reserve? Fertil Steril. Elsevier; 2013 Aug;100(2):516–522.e3.  
471.  Roman H, Tarta O, Pura I, Opris I, Bourdel N, Marpeau L, et al. Direct proportional 
relationship between endometrioma size and ovarian parenchyma inadvertently 
removed during cystectomy, and its implication on the management of enlarged 
endometriomas. Hum Reprod. 2010 Jun 1;25(6):1428–32.  
472.  Dogan E, Ulukus EC, Okyay E, Ertugrul C, Saygili U, Koyuncuoglu M. 
Retrospective analysis of follicle loss after laparoscopic excision of endometrioma 
compared with benign nonendometriotic ovarian cysts. Int J Gynecol Obstet. 2011 
Aug;114(2):124–7.  
473.  Matsuzaki S, Houlle C, Darcha C, Pouly J-L, Mage G, Canis M. Analysis of risk 
factors for the removal of normal ovarian tissue during laparoscopic cystectomy 
for ovarian endometriosis. Hum Reprod. 2009 Jun 1;24(6):1402–6.  
474.  Muzii L, Marana R, Angioli R, Bianchi A, Cucinella G, Vignali M, et al. Histologic 
analysis of specimens from laparoscopic endometrioma excision performed by 
different surgeons: does the surgeon matter? Fertil Steril. 2011 May;95(6):2116–
9.  
  
 477. 
475.  Biacchiardi CP, Piane LD, Camanni M, Deltetto F, Delpiano EM, Marchino GL, et 
al. Laparoscopic stripping of endometriomas negatively affects ovarian follicular 
reserve even if performed by experienced surgeons. Reprod Biomed Online. 2011 
Dec;23(6):740–6.  
476.  Yu H-T, Huang H-Y, Soong Y-K, Lee C-L, Chao A, Wang C-J. Laparoscopic 
ovarian cystectomy of endometriomas: surgeons’ experience may affect ovarian 
reserve and live-born rate in infertile patients with in vitro fertilization-
intracytoplasmic sperm injection. Eur J Obstet Gynecol Reprod Biol. 2010 
Oct;152(2):172–5.  
477.  Kobayashi H, Kajihara H, Yamada Y, Tanase Y, Kanayama S, Furukawa N, et al. 
Risk of carcinoma in women with ovarian endometrioma. Front Biosci (Elite Ed). 
2011 Jan 1;3:529–39.  
478.  Ueda Y, Enomoto T, Miyatake T, Fujita M, Yamamoto R, Kanagawa T, et al. A 
retrospective analysis of ovarian endometriosis during pregnancy. Fertil Steril. 
2010 Jun;94(1):78–84.  
479.  Reif P, Schöll W, Klaritsch P, Lang U. Rupture of endometriotic ovarian cyst 
causes acute hemoperitoneum in twin pregnancy. Fertil Steril. 2011 
May;95(6):2125.e1-2125.e3.  
480.  Brosens I, Brosens JJ, Fusi L, Al-Sabbagh M, Kuroda K, Benagiano G. Risks of 
adverse pregnancy outcome in endometriosis. Fertil Steril. 2012 Jul;98(1):30–5.  
481.  Philips Z, Barraza-Llorens M, Posnett J. Evaluation of the relative cost-
effectiveness of treatments for infertility in the UK. Hum Reprod. 2000 
Jan;15(1):95–106.  
482.  Chapron C, Fauconnier A, Goffinet F, Bréart G, Dubuisson JB. Laparoscopic 
surgery is not inherently dangerous for patients presenting with benign 
  
 478. 
gynaecologic pathology. Results of a meta-analysis. Hum Reprod. 2002 
May;17(5):1334–42.  
483.  Zaitoun MM, Zaitoun MM, El Behery MM. Comparing long term impact on ovarian 
reserve between laparoscopic ovarian cystectomy and open laprotomy for ovarian 
endometrioma. J Ovarian Res. BioMed Central; 2013 Nov 2;6(1):76.  
484.  Dan H, Limin F. Laparoscopic ovarian cystectomy versus fenestration/coagulation 
or laser vaporization for the treatment of endometriomas: a meta-analysis of 
randomized controlled trials. Gynecol Obstet Invest. 2013;76(2):75–82.  
485.  Roman H, Pura I, Tarta O, Mokdad C, Auber M, Bourdel N, et al. Vaporization of 
ovarian endometrioma using plasma energy: histologic findings of a pilot study. 
Fertil Steril. 2010;  
486.  Roman H, Auber M, Mokdad C, Martin C, Diguet A, Marpeau L, et al. Ovarian 
endometrioma ablation using plasma energy versus cystectomy: a step toward 
better preservation of the ovarian parenchyma in women wishing to conceive. 
Fertil Steril. 2011 Dec;96(6):1396–400.  
487.  Roman H, Auber M, Bourdel N, Martin C, Marpeau L, Puscasiu L. Postoperative 
recurrence and fertility after endometrioma ablation using plasma energy: 
retrospective assessment of a 3-year experience. J Minim Invasive Gynecol. 2013 
Sep;20(5):573–82.  
488.  Asgari Z, Rouholamin S, Hosseini R, Sepidarkish M, Hafizi L, Javaheri A. 
Comparing ovarian reserve after laparoscopic excision of endometriotic cysts and 
hemostasis achieved either by bipolar coagulation or suturing: a randomized 
clinical trial. Arch Gynecol Obstet. 2016;293(5):1015–22.  
489.  Ata B, Turkgeldi E, Seyhan A, Urman B. Effect of Hemostatic Method on Ovarian 
Reserve Following Laparoscopic Endometrioma Excision; Comparison of Suture, 
  
 479. 
Hemostatic Sealant, and Bipolar Dessication. A Systematic Review and Meta-
Analysis. Vol. 22, Journal of Minimally Invasive Gynecology. 2015. p. 363–75.  
490.  Donnez J, Lousse J-C, Jadoul P, Donnez O, Squifflet J. Laparoscopic 
management of endometriomas using a combined technique of excisional 
(cystectomy) and ablative surgery. Fertil Steril. 2010 Jun;94(1):28–32.  
491.  Tsolakidis D, Pados G, Vavilis D, Athanatos D, Tsalikis T, Giannakou A, et al. The 
impact on ovarian reserve after laparoscopic ovarian cystectomy versus three-
stage management in patients with endometriomas: a prospective randomized 
study. Fertil Steril. 2010 Jun;94(1):71–7.  
492.  Saeki A, Matsumoto T, Ikuma K, Tanase Y, Inaba F, Oku H, et al. The 
vasopressin injection technique for laparoscopic excision of ovarian 
endometrioma: a technique to reduce the use of coagulation. J Minim Invasive 
Gynecol. 17(2):176–9.  
493.  Qiong-Zhen R, Ge Y, Deng Y, Qian Z-H, Zhu W-P. Effect of vasopressin injection 
technique in laparoscopic excision of bilateral ovarian endometriomas on ovarian 
reserve: prospective randomized study. J Minim Invasive Gynecol. 
2014;21(2):266–71.  
494.  Vercellini P, DE Matteis S, Somigliana E, Buggio L, Frattaruolo MP, Fedele L. 
Long-term adjuvant therapy for the prevention of postoperative endometrioma 
recurrence: a systematic review and meta-analysis. Acta Obs Gynecol Scand. 
2013 Jan;92(1):8–16.  
495.  Muzii L, Di Tucci C, Achilli C, Di Donato V, Musella A, Palaia I, et al. Continuous 
versus cyclic oral contraceptives after laparoscopic excision of ovarian 
endometriomas: A systematic review and metaanalysis. American Journal of 
Obstetrics and Gynecology. 2016.  
  
 480. 
496.  Seracchioli R, Mabrouk M, Frasca C, Manuzzi L, Savelli L, Venturoli S. Long-term 
oral contraceptive pills and postoperative pain management after laparoscopic 
excision of ovarian endometrioma: a randomized controlled trial. Fertil Steril. 
(Seracchioli, Mabrouk, Frasca, Manuzzi, Savelli, Venturoli) Minimally Invasive 
Gynaecological Surgery Unit, Reproductive Medicine Unit, S.Orsola-Malpighi 
Hospital, Bologna, Italy; 2010;94(2):464–71.  
497.  Noma J, Yoshida N. Efficacy of ethanol sclerotherapy for ovarian endometriomas. 
Int J Gynaecol Obstet. 2001 Jan;72(1):35–9.  
498.  Aboulghar MA, Mansour RT, Serour GI, Sattar M, Ramzy AM, Amin YM. 
Treatment of recurrent chocolate cysts by transvaginal aspiration and tetracycline 
sclerotherapy. J Assist Reprod Genet. Kluwer Academic Publishers-Plenum 
Publishers; 1993 Nov;10(8):531–3.  
499.  Acién P, Quereda FJ, Gómez-Torres M-J, Bermejo R, Gutierrez M. GnRH 
analogues, transvaginal ultrasound-guided drainage and intracystic injection of 
recombinant interleukin-2 in the treatment of endometriosis. Gynecol Obstet 
Invest. Karger Publishers; 2003;55(2):96–104.  
500.  Mesogitis S, Antsaklis A, Daskalakis G, Papantoniou N, Michalas S. Combined 
ultrasonographically guided drainage and methotrexate administration for 
treatment of endometriotic cysts. Lancet. 355.  
501.  Chan LY, So WW, Lao TT. Rapid recurrence of endometrioma after transvaginal 
ultrasound-guided aspiration. Eur J Obstet Gynecol Reprod Biol. 2003 Aug 
15;109(2):196–8.  
502.  Pabuccu R, Onalan G, Goktolga U, Kucuk T, Orhon E, Ceyhan T. Aspiration of 
ovarian endometriomas before intracytoplasmic sperm injection. Fertil Steril. 2004 
Sep;82(3):705–11.  
  
 481. 
503.  Fisch JD, Sher G. Sclerotherapy with 5% tetracycline is a simple alternative to 
potentially complex surgical treatment of ovarian endometriomas before in vitro 
fertilization. Fertil Steril. 2004 Aug;82(2):437–41.  
504.  Koike T, Minakami H, Motoyama M, Ogawa S, Fujiwara H, Sato I. Reproductive 
performance after ultrasound-guided transvaginal ethanol sclerotherapy for 
ovarian endometriotic cysts. Eur J Obstet Gynecol Reprod Biol. 2002;105(1):39–
43.  
505.  Yazbeck C, Madelenat P, Ayel JP, Jacquesson L, Bontoux LM, Solal P, et al. 
Ethanol sclerotherapy: a treatment option for ovarian endometriomas before 
ovarian stimulation. Reprod Biomed Online. 2009 Jul;19(1):121–5.  
506.  Atilgan R, Ozkan ZS, Kuloglu T, Kocaman N, Baspinar M, Can B, et al. Impact of 
intracystic ethanol instillation on ovarian cyst diameter and adjacent ovarian 
tissue. Eur J Obstet Gynecol Reprod Biol. 2014 Mar;174:133–6.  
507.  Zhu W, Tan Z, Fu Z, Li X, Chen X, Zhou Y. Repeat transvaginal ultrasound-guided 
aspiration of ovarian endometrioma in infertile women with endometriosis. Am J 
Obstet Gynecol. 2011 Jan;204(1):61.e1-61.e6.  
508.  Coccia ME, Rizzello F, Mariani G, Bulletti C, Palagiano A, Scarselli G. Ovarian 
surgery for bilateral endometriomas influences age at menopause. Hum Reprod. 
2011 Nov 1;26(11):3000–7.  
509.  Busacca M, Riparini J, Somigliana E, Oggioni G, Izzo S, Vignali M, et al. 
Postsurgical ovarian failure after laparoscopic excision of bilateral endometriomas. 
Am J Obstet Gynecol. 2006 Aug;195(2):421–5.  
510.  Zhang CH, Wu L, Li PQ. Clinical study of the impact on ovarian reserve by 
different hemostasis methods in laparoscopic cystectomy for ovarian 
endometrioma. Taiwan J Obstet Gynecol. 2016;55(4):507–11.  
  
 482. 
511.  Whiteman MK, Hillis SD, Jamieson DJ, Morrow B, Podgornik MN, Brett KM, et al. 
Inpatient hysterectomy surveillance in the United States, 2000-2004. Am J Obstet 
Gynecol. 2008 Jan;198(1):34.e1-7.  
512.  Fogle RH, Stanczyk FZ, Zhang X, Paulson RJ. Ovarian androgen production in 
postmenopausal women. J Clin Endocrinol Metab. 2007 Aug;92(8):3040–3.  
513.  Sluijmer A V, Heineman MJ, De Jong FH, Evers JL. Endocrine activity of the 
postmenopausal ovary: the effects of pituitary down-regulation and oophorectomy. 
J Clin Endocrinol Metab. 1995 Jul;80(7):2163–7.  
514.  Parker WH, Broder MS, Liu Z, Shoupe D, Farquhar C, Berek JS. Ovarian 
conservation at the time of hysterectomy for benign disease. Obstet Gynecol. 
2005 Aug;106(2):219–26.  
515.  Asante A, Whiteman MK, Kulkarni A, Cox S, Marchbanks PA, Jamieson DJ. 
Elective oophorectomy in the United States: trends and in-hospital complications, 
1998-2006. Obstet Gynecol. 2010 Nov;116(5):1088–95.  
516.  Keshavarz H, Kieke B, Marchbanks P. Hysterectomy Surveillance - United States, 
1994-1999. Morbidity and mortality weekly report surveillance summaries. 
2002;51:1–8.  
517.  Chan JK, Urban R, Capra AM, Jacoby V, Osann K, Whittemore A, et al. Ovarian 
cancer rates after hysterectomy with and without salpingo-oophorectomy. Obstet 
Gynecol. 2014 Jan;123(1):65–72.  
518.  Orozco LJ, Tristan M, Vreugdenhil MMT, Salazar A. Hysterectomy versus 
hysterectomy plus oophorectomy for premenopausal women. Cochrane database 
Syst Rev. 2014 Jul 28;(7):CD005638.  
519.  Veritas Health Innovation. Covidence - Accelerate your systematic review 
  
 483. 
[Internet]. Melbourne, Australia. Available from: https://www.covidence.org/ 
520.  Grainge MJ, Coupland CA, Cliffe SJ, Chilvers CE, Hosking DJ. Reproductive, 
menstrual and menopausal factors: which are associated with bone mineral 
density in early postmenopausal women? Osteoporos Int. 2001;12(9):777–87.  
521.  Gibson CJ, Joffe H, Bromberger JT, Thurston RC, Lewis TT, Khalil N, et al. Mood 
symptoms after natural menopause and hysterectomy with and without bilateral 
oophorectomy among women in midlife. Obstet Gynecol. 2012 May;119(5):935–
41.  
522.  Tuppurainen M, Kröger H, Saarikoski S, Honkanen R, Alhava E. The effect of 
gynecological risk factors on lumbar and femoral bone mineral density in peri- and 
postmenopausal women. Maturitas. 1995 Feb;21(2):137–45.  
523.  Michelsen TM, Dørum A, Cvancarova M, Liavaag AH, Dahl AA. Association 
between hysterectomy with ovarian preservation and cardiovascular disease in a 
Norwegian population-based sample. Gynecol Obstet Invest. 2013;75(1):61–7.  
524.  Fletcher HM, Bennett F, Simms-Stewart D, Reid M, Williams NP, Wharfe GH. 
Bone mineral density in Jamaican black women after hysterectomy and bilateral 
oophorectomy: an observational study. West Indian Med J. 2013 Sep;62(7):593–
8.  
525.  Smeets-Goevaers CG, Lesusink GL, Papapoulos SE, Maartens LW, Keyzer JJ, 
Weerdenburg JP, et al. The prevalence of low bone mineral density in Dutch 
perimenopausal women: the Eindhoven perimenopausal osteoporosis study. 
Osteoporos Int. 1998;8(5):404–9.  
526.  Wells G, Shea B, O ’connell D, Peterson J, Welch V, Losos M, et al. The 
Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised 
studies in meta- analyses. Oxford. 2000;  
  
 484. 
527.  Viale L, Allotey J, Cheong-See F, Arroyo-Manzano D, Mccorry D, Bagary M, et al. 
Epilepsy in pregnancy and reproductive outcomes: a systematic review and meta-
analysis. Lancet. Elsevier; 2015 Nov;386(10006):1845–52.  
528.  Jacoby VL, Grady D, Wactawski-Wende J, Manson JE, Allison MA, Kuppermann 
M, et al. Oophorectomy vs ovarian conservation with hysterectomy: 
cardiovascular disease, hip fracture, and cancer in the Women’s Health Initiative 
Observational Study. Arch Intern Med. 2011 Apr 25;171(8):760–8.  
529.  Luoto R, Kaprio J, Reunanen A, Rutanen EM. Cardiovascular morbidity in relation 
to ovarian function after hysterectomy. Obstet Gynecol. 1995 Apr;85(4):515–22.  
530.  Palmer JR, Rosenberg L, Shapiro S. Reproductive factors and risk of myocardial 
infarction. Am J Epidemiol. 1992 Aug 15;136(4):408–16.  
531.  Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, et al. Ovarian 
conservation at the time of hysterectomy and long-term health outcomes in the 
nurses’ health study. Obstet Gynecol. 2009 May;113(5):1027–37.  
532.  Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, et al. 
Long-term mortality associated with oophorectomy compared with ovarian 
conservation in the nurses’ health study. Obstet Gynecol. 2013 Apr;121(4):709–
16.  
533.  Rosenberg L, Hennekens CH, Rosner B, Belanger C, Rothman KJ, Speizer FE. 
Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol. 
1981 Jan;139(1):47–51.  
534.  van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD. 
Age at menopause as a risk factor for cardiovascular mortality. Lancet (London, 
England). 1996 Mar 16;347(9003):714–8.  
  
 485. 
535.  Boggs DA, Palmer JR, Rosenberg L. Bilateral oophorectomy and risk of cancer in 
African American women. Cancer Causes Control. 2014 Apr;25(4):507–13.  
536.  Brinton LA, Hoover RN, Szklo M, Fraumeni JF. Menopausal estrogen use and risk 
of breast cancer. Cancer. 1981 May 15;47(10):2517–22.  
537.  Cape DB, Kreiger N. Gynaecological surgical procedures and risk of colorectal 
cancer in women. Eur J Cancer Prev. 1999 Dec;8(6):495–500.  
538.  Cui Y, Deming-Halverson SL, Beeghly-Fadiel A, Lipworth L, Shrubsole MJ, Fair 
AM, et al. Interactions of hormone replacement therapy, body weight, and bilateral 
oophorectomy in breast cancer risk. Clin Cancer Res. 2014 Mar 1;20(5):1169–78.  
539.  Duell EJ, Holly EA. Reproductive and menstrual risk factors for pancreatic cancer: 
a population-based study of San Francisco Bay Area women. Am J Epidemiol. 
2005 Apr 15;161(8):741–7.  
540.  Duell EJ, Travier N, Lujan-Barroso L, Boutron-Ruault MC, Clavel-Chapelon F, 
Palli D, et al. Menstrual and reproductive factors, exogenous hormone use, and 
gastric cancer risk in a cohort of women from the European Prospective 
Investigation Into Cancer and Nutrition. Am J Epidemiol. Oxford University Press; 
2010 Dec 15;172(12):1384–93.  
541.  Falconer H, Yin L, Grönberg H, Altman D. Ovarian cancer risk after 
salpingectomy: a nationwide population-based study. J Natl Cancer Inst. 2015 
Feb;107(2).  
542.  Gallagher LG, Rosenblatt KA, Ray RM, Checkoway H, Thomas DB. Reproductive 
factors and risk of lung cancer in female textile workers in Shanghai , China. 
2013;1305–14.  
543.  Gaudet MM, Gapstur SM, Sun J, Campbell PT, Patel A V, Teras LR. 
  
 486. 
Oophorectomy and Hysterectomy and Cancer Incidence in the Cancer Prevention 
Study-II Nutrition Cohort. 2014;123(6):1247–55.  
544.  Helmrich SP, Shapiro S, Rosenberg L, Kaufman DW, Slone D, Bain C, et al. Risk 
factors for breast cancer. Am J Epidemiol. 1983 Jan;117(1):35–45.  
545.  Holly EA, Cress RD, Ahn DK. Cutaneous melanoma in women: ovulatory life, 
menopause, and use of exogenous estrogens. Cancer Epidemiol Prev 
Biomarkers. 1994;3(8):661–8.  
546.  Luoto R, Raitanen J, Pukkala E, Anttila A. Effect of hysterectomy on incidence 
trends of endometrial and cervical cancer in Finland 1953-2010. Br J Cancer. 
Nature Publishing Group; 2004 May 4;90(9):1756–9.  
547.  Mack WJ, Preston-Martin S, Bernstein L, Qian D, Xiang M. Reproductive and 
hormonal risk factors for thyroid cancer in Los Angeles County females. Cancer 
Epidemiol Biomarkers Prev. 1999 Nov;8(11):991–7.  
548.  Nichols HB, Visvanathan K, Newcomb PA, Hampton JM, Egan KM, Titus-Ernstoff 
L, et al. Bilateral oophorectomy in relation to risk of postmenopausal breast 
cancer: confounding by nonmalignant indications for surgery? Am J Epidemiol. 
2011 May 15;173(10):1111–20.  
549.  Parazzini F, Braga C, La Vecchia C, Negri E, Acerboni S, Franceschi S. 
Hysterectomy, oophorectomy in premenopause, and risk of breast cancer. Obstet 
Gynecol. 1997 Sep;90(3):453–6.  
550.  Schairer C, Persson I, Falkeborn M, Naessen T, Troisi R, Brinton LA. Breast 
cancer risk associated with gynecologic surgery and indications for such surgery. 
Int J cancer. 1997 Jan 17;70(2):150–4.  
551.  Imtiaz B, Tuppurainen M, Tiihonen M, Kivipelto M, Soininen H, Hartikainen S, et 
  
 487. 
al. Oophorectomy, hysterectomy, and risk of Alzheimer’s disease: a nationwide 
case-control study. J Alzheimers Dis. 2014;42(2):575–81.  
552.  Hreshchyshyn MM, Hopkins A, Zylstra S, Anbar M. Effects of natural menopause, 
hysterectomy, and oophorectomy on lumbar spine and femoral neck bone 
densities. Obstet Gynecol. 1988 Oct;72(4):631–8.  
553.  Johansson C, Mellström D, Milsom I. Reproductive factors as predictors of bone 
density and fractures in women at the age of 70. Maturitas. 1993 Jul;17(1):39–50.  
554.  Kritz-Silverstein D, von Mühlen DG, Barrett-Connor E. Hysterectomy and 
oophorectomy are unrelated to bone loss in older women. Maturitas. 2004 Jan 
20;47(1):61–9.  
555.  Loizzi P, Carriero C, Di Gesù A, Greco P, Nappi R. Removal or preservation of 
ovaries during hysterectomy: a six year review. Int J Gynaecol Obstet. 1990 
Mar;31(3):257–61.  
556.  Nakamura T, Orimo H. Physiological and pathological aging in bone--contribution 
of risk factors to bone loss with aging. Nihon Ronen Igakkai Zasshi. 1991 
May;28(3):318–24.  
557.  Shilbayeh S. Prevalence of osteoporosis and its reproductive risk factors among 
Jordanian women: a cross-sectional study. Osteoporos int. 2003 Nov;14(11):929–
40.  
558.  Aziz A, Bergquist C, Nordholm L, Möller A, Silfverstolpe G, Avis NE, et al. 
Prophylactic oophorectomy at elective hysterectomy. Effects on psychological 
well-being at 1-year follow-up and its correlations to sexuality. Maturitas. Elsevier; 
2005 Aug 16;51(4):349–57.  
559.  Chen X, Guo T, Li B. Influence of prophylactic oophorectomy on mood and sexual 
  
 488. 
function in women of menopausal transition or postmenopausal period. Arch 
Gynecol Obstet. 2013 Nov;288(5):1101–6.  
560.  Farquhar CM, Sadler L, Harvey SA, Stewart AW. The association of hysterectomy 
and menopause: a prospective cohort study. BJOG. 2005 Jul;112(7):956–62.  
561.  Haines CJ, Chung TK, Leung DH, McKinley S, Jeffrys M, Hagstad A, et al. A 
prospective study of the frequency of acute menopausal symptoms in Hong Kong 
Chinese women. Maturitas. Elsevier; 1994 Mar;18(3):175–81.  
562.  Kritz-silverstein D, Wpngard DL, Barrett-Connor E, Morton DJ. Hysterectomy, 
oophorectomy, and depression in older Women. J Women’s Heal. 1994 
Aug;3(4):255–63.  
563.  Legorreta D, Montaño JA, Hernández I, Salinas C, Hernández-Bueno JA, AMEC 
Research Committee. Age at menopause, motives for consultation and symptoms 
reported by 40-59-year-old Mexican women. Climacteric. 2013 Aug;16(4):417–25.  
564.  Rohl J, Kjerulff K, Langenberg P, Steege J. Bilateral oophorectomy and 
depressive symptoms 12 months after hysterectomy. Am J Obstet Gynecol. 2008 
Jul;199(1):22.e1-5.  
565.  Forsmo S, Schei B, Langhammer A, Forsén L. How do reproductive and lifestyle 
factors influence bone density in distal and ultradistal radius of early 
postmenopausal women? The Nord-Trøndelag Health Survey, Norway. 
Osteoporos int. 2001;12(3):222–9.  
566.  Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. 
Menopause and the risk of coronary heart disease in women. N Engl J Med. 1987 
Apr 30;316(18):1105–10.  
567.  Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary 
  
 489. 
heart disease. The Framingham Study. Ann Intern Med. 1978 Aug;89(2):157–61.  
568.  Howard B V, Kuller L, Langer R, Manson JE, Allen C, Assaf A, et al. Risk of 
cardiovascular disease by hysterectomy status, with and without oophorectomy: 
the Women’s Health Initiative Observational Study. Circulation. 2005 Mar 
29;111(12):1462–70.  
569.  Ingelsson E, Lundholm C, Johansson AL V, Altman D. Hysterectomy and risk of 
cardiovascular disease: a population-based cohort study. Eur Heart J. 2011 
Mar;32(6):745–50.  
570.  Dørum A, Tonstad S, Liavaag AH, Michelsen TM, Hildrum B, Dahl AA. Bilateral 
oophorectomy before 50 years of age is significantly associated with the metabolic 
syndrome and Framingham risk score: a controlled, population-based study 
(HUNT-2). Gynecol Oncol. 2008 Jun;109(3):377–83.  
571.  Fletcher HM, Bennett F, Simms-Stewart D, Reid M, Williams NP, Wharfe GH, et 
al. Cardiovascular disease risk factors in menopausal Jamaican black women 
after hysterectomy and bilateral oophorectomy: an observational study. West 
Indian Med J. 2010 Dec;59(6):625–32.  
572.  Cooper R, Kuh D, Hardy R, Power C. Is there an association between 
hysterectomy and subsequent adiposity? Maturitas. Elsevier; 2007 Nov 
20;58(3):296–307.  
573.  Khan K, Kunz R, Kleijnen J, Antes G. Systematic reviews to support evidence-
based medicine. 2nd ed. London: Hodder and Stoughton; 2011.  
574.  Judd HL, Judd GE, Lucas WE, Yen SS. Endocrine function of the 
postmenopausal ovary: concentration of androgens and estrogens in ovarian and 
peripheral vein blood. J Clin Endocrinol Metab. 1974 Dec;39(6):1020–4.  
  
 490. 
575.  Shuster LT, Gostout BS, Grossardt BR, Rocca WA. Prophylactic oophorectomy in 
premenopausal women and long-term health. Menopause Int. 2008 
Sep;14(3):111–6.  
576.  Guo SW. Recurrence of endometriosis and its control. Hum Reprod Update. 
2009;15(4):441–61.  
577.  AAGBI. Pre-operative assessment and patient preparation: the role of the 
anaesthetist AAGBI SAFETY GUIDELINE. 2010 [cited 2016 Nov 30]; Available 
from: www.aagbi.org 
578.  EGBERT LD, BATTIT GE, WELCH CE, BARTLETT MK. Reduction of 
postoperative pain by encouragement and instruction of patients. N Engl J Med. 
1964 Apr 16;270:825–7.  
579.  Department of Health. NHS improvement. Enhanced recovery partnership project 
report. London; 2011.  
580.  Kane EO. Phonograph in Operating-Room. J Am Med Assoc. American Medical 
Association; 1914 Jun 6;LXII(23):1829.  
581.  Nightingale F. Notes on nursing: what it is, and what it is not. London: Harrison; 
1859.  
582.  Dobek CE, Beynon ME, Bosma RL, Stroman PW. Music modulation of pain 
perception and pain-related activity in the brain, brain stem, and spinal cord: a 
functional magnetic resonance imaging study. J Pain. 2014 Oct;15(10):1057–68.  
583.  Croom AM. Music, neuroscience, and the psychology of well-being: a précis. 
Front Psychol. Frontiers Media SA; 2012;2:393.  
584.  Salimpoor VN, Benovoy M, Larcher K, Dagher A, Zatorre RJ. Anatomically distinct 
dopamine release during anticipation and experience of peak emotion to music. 
  
 491. 
Nat Neurosci. 2011 Feb;14(2):257–62.  
585.  McCaffrey R, Locsin RC. Music listening as a nursing intervention: a symphony of 
practice. Holist Nurs Pract. 2002 Apr;16(3):70–7.  
586.  Tam WWS, Wong ELY, Twinn SF. Effect of music on procedure time and sedation 
during colonoscopy: A meta-analysis. World J Gastroenterol. 2008;14(34):5336–
43.  
587.  Bradt J, Dileo C, Shim M. Music interventions for preoperative anxiety. Cochrane 
database Syst Rev. 2013;6(6):CD006908.  
588.  Athanasakis E. Ealth cience ournal ®. Heal Sci J. 2012;6(2):773–83.  
589.  Cepeda MS, Carr DB, Lau J, Alvarez H. Music for pain relief. Cochrane database 
Syst Rev. 2013;10(8):CD004843.  
590.  Hole J, Hirsch M, Ball E, Meads C. Music as an aid for postoperative recovery in 
adults: A systematic review and meta-analysis. Vol. 386, The Lancet. Lancet 
Publishing Group; 2015. p. 1659–71.  
591.  Hupkens S. Implementation of complementary interventions in the Netherlands: 
Experiences of pioneers. Patient Educ Couns. Elsevier Ireland Ltd; 
2012;89(3):411–6.  
592.  Centre for Reviews and Dissemination. Systematic reviews: CRD’s guidance for 
undertaking systematic reviews in health care. University of York . 2009.  
593.  Nilsson U. The anxiety- and pain-reducing effects of music interventions: a 
systematic review. AORN J. 2008;87(4).  
594.  Melzack R, Casey K. Sensory, motivational and central control determinants of 
chronic pain: a new conceptual model. In: Kenshalo DR, ed. The skin senses: 
proceedings of the first International Symposium on the Skin Senses. 
  
 492. 
Tallahassee, Florida; 1968.  
595.  White JM. Effects of relaxing music on cardiac autonomic balance and anxiety 
after acute myocardial infarction. Am J Crit Care. 1999 Jul;8(4):220–30.  
596.  Evans C, Richardson PH. Improved recovery and reduced postoperative stay after 
therapeutic suggestions during general anaesthesia. Lancet (London, England). 
Europe PMC Funders; 1988 Aug 27;2(8609):491–3.  
597.  Avidan MS, Mashour GA. The incidence of intra-operative awareness in the UK: 
under the rate or under the radar? Anaesthesia. 2013 Apr;68(4):334–8.  
598.  Allen K, Blascovich J. Effects of music on cardiovascular reactivity among 
surgeons. JAMA. 1994 Sep 21;272(11):882–4.  
599.  Way TJ, Long A, Weihing J, Ritchie R, Jones R, Bush M, et al. Effect of noise on 
auditory processing in the operating room. J Am Coll Surg. 2013 May;216(5):933–
8.  
600.  Moris DN, Linos D. Music meets surgery: two sides to the art of healing. Surg 
Endosc. 2013 Mar;27(3):719–23.  
601.  Kobayashi H, Yamada Y, Morioka S, Niiro E, Shigemitsu A, Ito F. Mechanism of 
pain generation for endometriosis-associated pelvic pain. Vol. 289, Archives of 
Gynecology and Obstetrics. 2014. p. 13–21.  
602.  Sinha IP, Smyth RL, Williamson PR. Using the Delphi technique to determine 
which outcomes to measure in clinical trials: recommendations for the future 
based on a systematic review of existing studies. PLoS Med. 2011 Jan 
25;8(1):e1000393.  
603.  Egan AM, Smith V, Devane D, Dunne FP, Dunne F, Avalos G, et al. Effectiveness 
of prepregnancy care for women with pregestational diabetes mellitus: protocol for 
  
 493. 
a systematic review of the literature and identification of a core outcomes set 
using a Delphi survey. Trials. BioMed Central; 2015 Dec 14;16(1):356.  
604.  Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE 
guidelines: 2. Framing the question and deciding on important outcomes. J Clin 
Epidemiol. 2011 Apr;64(4):395–400.  
605.  Prinsen CAC, Vohra S, Rose MR, Boers M, Tugwell P, Clarke M, et al. How to 
select outcome measurement instruments for outcomes included in a Core 
Outcome Set - a practical guideline. Trials. BioMed Central; 2016 Sep 
13;17(1):449.  
606.  Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et 
al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann 
Intern Med. 2013 Feb 5;158(3):200–7.  
 
